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The development, in recent years, of reproducible assays for TSH
receptor antibodies and of monoclonal antibodies for the study of
lymphocyte subsets has greatly advanced our understanding of the
pathogenesis of Graves' disease.
The aim of this thesis is to consider both humoral and cell-mediated
immunity in thyrotoxic Graves' disease. Particular attention is paid
to the correlation of the immunological changes with clinical
features of the disease and to age-related changes in immune
parameters. Evidence is sought for heterogeneity within the disease
to account for the variable expression of immunological markers.
Spontaneous hyperthyroidism in the domestic cat has recently emerged
as a clinical problem in veterinary practice. This has not been
previously studied immunologically and is considered here as a
potential model for autoimmune thyrotoxicosis in Man.
Methods used include the measurement of autoantibodies by
haemagglutination and by indirect immunofluorescence, of TSH receptor
antibodies by a binding inhibitory assay and of immune complexes
using a C1q solid phase assay. HLA-DR typing has been performed using
a B lymphocyte microcytotoxicity test. A wide range of monoclonal
antibodies was employed in quantifying lymphocyte subsets including
activated T lymphocytes.
TSH receptor antibodies have been measured in over 300 Graves'
patients. They correlate with thyroid microsomal antibodies and their
expression may be age related. The assay is compared using
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immunoglobulin concentrates and neat serum, the latter being more
sensitive. There is a strong relationship between elevations in
antibody levels after radioactive iodine and the development of
hypothyroidism. TSH receptor antibodies may persist for years after
destructive anti-thyroid therapy and this persistence correlates with
the presence of other autoimmune diseases.
Agoitrous Graves' disease is commoner than is widely realised. These
patients are older than the average Graves' patient, they have less
severe thyrotoxicosis and a lower incidence of autoantibodies. A
group of patients with goitre but without grossly elevated
radioactive iodine uptake had a remarkable incidence of non-thyroidal
autoantibodies, particularly parietal cell antibodies. This
heterogeneity is not clearly related to DR types. A possible
association between the DR2 phenotype and thyroid stimulation is
identified and a group of young female patients, positive for DR2 and
resistant to anti-thyroid therapy is described.
Immune complexes have been studied, not only in Graves' and other
autoimmune thyroid diseases, but also in a unique, large series of
patients with Addison's disease. The latter condition, though rare,
is frequently associated with multiple autoimmune disorders. A role
for immune complexes in modulating autoantibody expression is
proposed.
i
Decreased suppressor cells and an increase in helper to suppressor
cell ratio is confirmed using two separate monoclonal antibodies to
suppressor cells. Furthermore, a decline in suppressor cells with age
in normal female subjects is reported. Early activated T cells as
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defined by the monoclonal antibody 4F2 are present in increased
numbers and they show a negative correlation with TSH receptor
antibodies. The expression of class II antigens on activated T
lymphocytes was studied using a panel of monoclonal antibodies. These
antigens could also be demonstrated on Graves' thyroid tissue by
indirect immunofluorescence. Raised levels of killer cells were
detected in the circulation of patients with active disease using a
new monoclonal antibody.
By studying multiple immune parameters in Graves' disease,
potentially important interactions have been found and their
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Theoretical and technical advances in immunology have, in recent
years, revealed the variety of immunopathogenetic mechanisms involved
in the development of an autoimmune disease. Our concept has changed
from the early days of autoimmunity when the emergence of a
self-reactive , "forbidden" clone of antibody producing cells was
thought to be sufficient to produce disease (Burnet, 1961). We now
recognise a complex immunoregulatory system with subsets of lymphoid
cells, antibodies and soluble factors (lymphokines) controlling a
variety of effector mechanisms, both humoral and cellular. These
mechanisms operate against a complicated genetic background which is
still far from completely understood. We have learned much about
immunoregulation and about the genetic factors from the study of
animal models, yet it is not always easy to translate observations on
highly inbred strains of laboratory animals into useful information
about human disease states. The thyroid gland is of particular
importance to the study of human autoimmunity: its diseases are
common, the anatomical accessibility of the gland and the profound
metabolic effects of its hormone products make for early and accurate
diagnosis of diseases, while in different individuals, the nature of
the immunological response varies, producing a variety of hypo- and
hyper-functioning states. This dissertation is largely concerned with
the mechanisms involved in the pathogenesis of'Graves' disease, how
these immunological abnormalities interrelate and how they affect the
presentation of the disease.
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CURRENT THEORIES ON AUTOIMMUNITY WITH SPECIAL REFERENCE TO THYROID
DISEASE
There is, at present, no single explanation which will on its own
explain why some individuals develop autoimmune disease while others
do not. Early work concentrated on the humoral immune system and a
variety of organ specific and non organ specific autoantibodies was
identified. Not all individuals with antibodies, however, developed
disease and in many cases such as Graves' disease a proportion of
individuals with disease had no detectable autoantibody. As
techniques became available, cell-mediated immunity was also shown to
be disturbed, with changes in both effector and immunoregulatory
functions. The characterisation of the Human Leukocyte Antigen (HLA)
system in the 1960s and the subsequent studies on the association
between alleles of this system and disease states allowed us to
identify at risk individuals but did not explain why only a
proportion of the individuals with a disease associated allele were
affected. It may be that newer HLA antigens will be better disease
markers but one still has to explain the influence they have on the
immune system. In briefly reviewing some of the current theories on
autoimmunity, with special reference to thyroid diseases, it is
posssible to delineate, four areas of interest
1) Changes in the target tissue which render it more immunogenic.
2) Increased autoaggression in susceptible individuals.
3) Defects in immunoregulatory mechanisms.
4) The genetic background to the autoimmune diseases.
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CHANGES IN THE TARGET TISSUE
One obvious explanation for the development of an autoimmune disease
would be a change in the antigenic composition of the target tissue,
perhaps by random mutation. The best characterised autoantigen is
thyroglobulin. There is no difference in the thyroglobulin of obese
strain (OS) chickens, which develop spontaneous thyroiditis, and
that of normal chickens (de Carvalho et al, 1982) and the response
to injected thyroglobulin is the same whether it is self or non-self
(Roitt & de Carvalho, 1982).
It is much more likely that changes in the way that antigen is
presented to the immune system are important. It is known, for
example, that viruses such as the inflenza virus can incorporate host
antigens and that cells so infected have increased immunogenicity
(Lindermann & Klein, 1967). There is evidence that viral infections
may be important in some cases of diabetes mellitus (for review, see
Janson, 1980) but the evidence that infection is involved in the
pathogenesis of Graves' disease is very limited (Joassoo et al, 1975;
Shenkman & Bottone, 1976; Bech et al, 1977). Viral antigens may be
synergistic with endogenous antigen in stimulating autoantibody
production in much the same way as the polyclonal B cell activator,
pokeweed mitogen (PWM) can act in the production of plaque-forming
(antibody producing) cells (see Fauci, 1980). A much more likely
explanation for increased antigen presentation to the immune system
in Graves' disease comes from the studies of Bottazzo's group (1983)
who have shown that a high proportion of Graves' thyroids express
class II histocompatibility antigens which are not present on most
normal thyroid cells (Hanafusa et al, 1983). Such Class II antigen
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expression is probably important in the presentation of thyroid
antigen to helper T lymphocytes. These authors further suggest that
the increased reversal of thyroid epithelial polarity which occurs in
Graves' glands leads to greater availability of antigens which are
normally concealed (Hanafusa et al, 1984). Such "aberrant" HLA-DR
expression has also been found on the beta cells in the pancreas of a
diabetic patient' (Bottazzo G. F., personal communication), in acute
graft-versus-host disease (Manson et al, 1981), in the colonic
epithelium of patients with inflammatory bowel disease (Selby et al,
1983) and on the keratinocytes in certain dermatoses (Lampert,
1984).
Work on the Obese Strain chicken suggests that intrinsic thyroid
abnormalities may precede the development of thyroiditis. Sundick et
al ( 1 979) have demonstrated incomplete suppression of 131i uptake
when Ti| is administered and there is an increased uptake of 131j by
glands transplanted to the chorioallantoic membranes of normal
chickens (Sundick & Wick, 1976). The high functional activity of the
thyroid may increase the amount of antigen released and thus
stimulate an immune reaction. In support of this hypothesis, Sanker
et al ( 1 983) have found high levels of thyroglobulin in the
circulation of Obese Strain chickens prior to the development of
thyroiditis and it may well be, therefore, that a stage of thyroid
hyperactivity precedes the initiation of autoimmune thyroiditis.
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INCREASED AUTOAGGRESSION
The presence of hypergammaglobulinaeraia in autoimmune diseases
including Graves' disease (Briones-Urbina et al, 1982) has been taken
as evidence of increased activity of the humoral immune system.
Increased numbers of B cells in the circulation of Graves' patients
have been reported by some authors (Hsu et al, 1976; Mori et al,
1980) although others have found them to be normal (Mulaisho et al,
1975). Although lymphocytes binding the common autoantigens
thyroglobulin and DNA may be found in the circulation of normal
individuals, the number of such cells is greatly increased in thyroid
autoimmune disease and systemic lupus respectively (Bankhurst &
Williams, 1973; Bankhurst et al, 1975). Selective IgA deficiency is
commoner in patients with autoimmune diseases than in the normal
population and may be one factor in predisposing the individual to
polyclonal B cell activation by infectious agents. Increased
spontaneous activity of antibody forming cells has been shown both in
mice prone to autoimmune disease (Izui et al, 1978) and in human
patients with SLE (Budman et al, 1977). In the latter study, the
degree of humoral immune hyperactivity was highest in the patients
with lowest complement C3 levels, who presumably had the most active
disease. Antibody secretion has also been shown to be increased in
vitro in SLE (Morimoto et al, 1977; Kallenberg et al, 1983) - The
primary immune response in the patients studied by Kallenberg was
depressed and it was suggested that the hyperfunctioning of the
immune system in these patients applied only to recall antigens. If
this were the case, then foetal exposure to maternal autoantigens
released in the course of an autoimmune disease and subsequent recall
of the immune response during a time in later life when the
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individual is susceptible to autoimmune disease may explain the
observation that many of these diseases tend to breed true. Slaughter
et al (1978) reported no difference in the total antibody secretion
of lymphocytes from patients with rheumatoid arthritis when
stimulated in vitro with Epstein-Barr virus, although they did
produce much higher levels of IgM-anti-IgG and that antibody was of
higher affinity for IgG than antibody secreted by normal
lymphocytes.
The increased autoaggression in autoimmune diseases is not confined
to the humoral immune system. Calder et al ( 1 973) showed increased
levels of cells cytotoxic to thyroglobulin coated erythrocytes in
autoimmune thyroid disease. The same authors (Calder et al, 1 976)
have reported increased antibody dependent cellular cytotoxicity (K
cell activity) in thyroid disease, although such activity has been
found to be reduced in some autoimmune diseases (Feldman et al, 1976;
Goto et al, 1981) possibly because of immune complexes or
antilymphocyte antibodies binding to the surface of effector cells.
Much recent interest has been in the natural killer (NK) cells which
have particular autoaggressive potential since their cytotoxic
activity is not HLA restricted. Increased levels of these cells are
found in untreated Graves' disease (Kennedy et al, 1985).
DEFECTIVE IMMUNOREGULATION
Over the past 15 years, the concept has evolved of a dynamic
immunoregulatory network with subsets of T lymphocytes having either
helper or suppressor functions. It has been suggested that escape
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from normal suppressor mechanisms may lead to breakdown of immune
tolerance and thus the emergence of an autoimmune disease (Allison et
al, 1961). The ideal method for quantifying suppressors would be not
only reproducible but would assay some aspect of suppressor cell
function and relate to the specificty of the cells involved. Such a
method does not exist (for review of methodology, see Goodwin &
Williams, 1979) and the method in widest use currently relies on
monoclonal antibodies to define cell surface markers. Using these
antibodies, Buschard et al (1983) have found reduced suppressors in
diabetes of recent onset, as have Morimoto et al (1980) in active SLE
and Sridama et al (1982) in Graves' disease and Hashimoto's.
Decreased suppressors in Graves' disease were confirmed by Ludgate et
al ( 1 984) who also showed them to return towards normal with
treatment. In their study of two HLA identical twins, one of whom had
Graves' disease, Balazs et al (1984) showed that both twins had
autoreactive T cells to the thyroid but only the patient had reduced
suppressor cell activity. A possible basis for the reduction in
suppressor cells may be the presence of antilymphocytic antibodies
directed at this cell subset. Such antibodies are well recognised in
SLE (Morimoto et al, 1980) and have been described in myasthenia
gravis (Mishak & Dau, 1981) and more recently have been found in
patients with Graves' disease (Pacini et al, 1983)• However, not all
antilymphocyte antibodies in autoimmune disease react with
suppressor/cytotoxic cells, Morimoto et al (1981) have described
antibodies in the circulation of patients with juvenile rheumatoid
arthritis which react predominantly with helper/inducer cells.
Heterogeneity of these lymphocyte binding antibodies may occur in
-14-
different disease states and may in part underlie the variable
results seen in studies of lymphocyte subsets with monoclonal
antibodies (see chapter 7).
It was Jerne (1973) who first suggested that the immune system may be
subject to regulation by immunoglobulins directed at determinants
(idiotypes) on the variable regions of other antibody molecules. This
idiotype network may influence not only antibody expression but also
the function of immunoregulatory cell subsets through immunoglobulin
bound to their cell surface. One way in which this network could be
involved in the pathogenesis of an autoimmune disease is shown in
FIGURE 1.1. If an antibody to a virus or an antigen released during
tissue damage shared an idiotype with an autoantibody, then induction
of the former by either infection or cell damage might lead to the
latter being expressed.
Shechter et al (1982) have shown that mice immunized with insulin
develop antibodies both to insulin and to the insulin receptor. The
receptor antibodies displaced labelled insulin from its receptor,
stimulated the oxidation of glucose and its incorporation into
lipids as well as inhibiting lipolysis. These receptor antibodies
could be blocked by or bound to the antibodies to insulin and were
therefore thought to be anti-idiotytpes. Similarly, immunization of
rabbits with Bis Q, an agonist at the acetylcholine receptor, led to
the production of antibodies capable of binding to the receptor
(Wasserman et al, 1982). Immunization of rabbits with the purified
anti-Bis Q led to the development of a myasthenic syndrome. Dwyer et
al (1983) have recently demonstrated the existence of a naturally
occurring anti-idiotypic antibody in patients with myasthenia gravis:
-15-
they found that 40$ of over 50 patients had an antibody which bound
to a monoclonal antibody directed at the acetylcholine receptor and
that such antibodies were most likely to be found in patients with
low anti-receptor antibody titres. That antibodies may develop to
receptor agonists and then anti-idiotypic antibodies to these
antibodies may in turn bind to the receptor (see FIGURE 1.2) may be a
concept which is fundamental in the pathogenesis of the receptor
antibody diseases. The recent detection of naturally occurring
anti-TSH antibodies (Kajita et al, 1983; Akamizu et al, 1984; Copping
et al, 1985) is therefore of great interest.
GENETIC
Although a genetic component clearly exists in autoimmune diseases
such as Graves' disease - for example, about 50$ of Graves' patients
have a family history of thyroid disease (for review of the genetics
of Graves' disease, see Friedman & Fialkow, 1978) - but the precise
mode of inheritance has not been worked out. Graves' is not entirely
genetically determined. Only 50$ of sets of monozygotic twins are
concordant for Graves'. The role of the environmental factor remains
to be clarified but may account for the variable timing of onset of
the different diseases in the polyendocrine deficiency syndromes
(Solomon et al, 1975). Most of the work on the genetics of Graves'
relates to the HLA system but the best marker, HLA-DR3, is only
positive in approximately 65$ of patients (Farid & Bear, 1981) and
its precise relationship to the immunopathogenetic mechanisms is
still largely a mystery. Adams (1978) has suggested that the genetic
basis for autoimmune disease may lie in the genes coding for the
-16-






FIGURE 1.2 POSSIBLE ROLE OF ANTI-IDIOTYPIC ANTIBODIES IN THE
PATHOGENESIS OF RECEPTOR ANTIBODY DISEASES
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variable regions of immunoglobulin molecules (V genes). His
hypothesis accounts for the recognised patterns of inheritance
including the female predominance of many autoimmune diseases, the
increased incidence of diseases with age, the association of the
various autoimmune diseases and their link with the HLA system.
THE RECEPTOR ANTIBODY DISEASES
In this group of organ specific autoimmune diseases (see TABLE 1.1),
the major factor in the pathogenesis is the production of antibodies
to cell surface receptors.
TABLE 1.1 THE RECEPTOR ANTIBODY DISEASES
DISEASE RECEPTOR INVOLVED
GRAVES' DISEASE THYROID RECEPTOR FOR TSH
MYASTHENIA GRAVIS ACETYLCHOLINE RECEPTOR ON POST
SYNAPTIC NEUROMUSCULAR JUNCTION
INSULIN RESISTANT DIABETES INSULIN RECEPTOR
ATOPIC ASTHMA BETA ADRENERGIC RECEPTOR
Other immunological abnormalities are present in these diseases and
the ability to measure an antibody which directly affects cell
function allows us to study the effect of immunological control
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mechanisms. Graves' is unique among the receptor antibody diseases in
that the antibody actually stimulates the thyrocyte rather than
blocking or destroying the receptor. Recently, a receptor mechanism
has been proposed for SLE: Bennett et al (1986) have shown that the
receptor on peripheral blood mononuclear cells which binds DNA and
clears it from the circulation is defective in SLE and this defect is
due to antibodies directed at the receptor.
1. GRAVES' DISEASE
The demonstration in the mid 1950s of circulating antithyroid
antibodies in patients with thyroid disease (Doniach & Roitt, 1957)
and, around the same time, the identification of an abnormal
stimulator in the serum of thyrotoxic patients gave birth to the
study of autoimmunity in thyroid disease. Most patients with the
commmon thyroid diseases were found to have autoantibodies (Witebsky
et al, 1957; Roitt & Doniach, 1960, Mori & Kriss, 1971).
Thyrotoxicosis was shown to occur after hypophysectomy (McCullagh et
al, 1 960; McKenzie, 1962; Christensen & Binder, 1962), after
pituitary stalk section (Furth et al, 1962) and after post-partum
pituitary necrosis (Fajans, 1958). The thyroid of normal subjects
would respond to the infusion of Graves' plasma (Arnaud et al, 1965).
The Long-Acting Thyroid Stimulator (LATS) was identified as an
immunoglobulin G (Dorrington et al, 1966) and its specific antigen,
the TSH receptor, has now been characterised (Smith, B. R.et al,
1985). It is an integral membrane protein with a molecular weight of
about 70,000 consisting of two subunits (45,000 and 25,000). Study of
the receptor is hampered by the small amount present on cells (10
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nanograms/gram of wet tissue, equivalent to about 1000 receptors per
cell). Not all patients with Graves' disease have antibodies
detectable by the methods currently in use. There are a variety of
reasons for this but one may be that different populations of
antibodies exist as has been shown for myasthenia gravis (Mittag et
al, 1981).
2. MYASTHENIA GRAVIS
The target for autoimmune attack in myasthenia gravis is the
nicotinic acetylcholine receptor (AchR) on the postsynaptic membrane
of the neuromuscular junction. Patrick and Lindstrom (1973) described
the syndrome in rabbits immunized with AchR, and it is partly because
of such animal models and the fact that the receptor is so well
characterised that myasthenia gravis is the best understood of the
receptor antibody diseases at the cellular level. The receptor
consists of five membrane glycoprotein molecules - two alpha subunits
(MW = 38,000), one beta subunit (MW = 49,000), one gamma ((MW =
57,000) and one delta subunit (MW = 64,000). There are two
acetylcholine binding sites, one on each alpha subunit and binding is
followed by sodium influx and triggering of the action potential.
Although the receptor is remarkably similar in different animal
species, the antibodies apppear to be highly species specific
(Lindstrom et al, 1978).
Autoantibodies to AchR are rare in individuals who do not have
myasthenia gravis, and, in the individual patient, the antibody level
varies with disease activity (Newsom-Davis et al, 1978; Seybold &
Lindstrom, 1981). When cases of myasthenia gravis are divided
according to the pathology of the thymus, there is evidence of
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clinical and immunological heterogeneity (Compston et al, 1980): In
the 10% of patients with thymoma, the sex incidence is equal, onset
is in middle age and the level of AchR antibodies is high.
Anti-striated muscle antibodies are found in a large number of cases
and the condition is not related to HLA-DR3 (although a weak
association with HLA-DR7 has been suggested). Thymic hyperplasia is
usually associated with disease onset before the age of 40 years,
there is a female preponderance of 3:1, it is associated with
intermediate antibody titres and HLA-DR3. A group of patients with
thymic atrophy typically presents in middle to late life, is
predominantly male, has low AchR antibody levels and a possible
association with HLA-DR2.
There are three established mechanisms by which AchR antibodies bring
about changes in the response to acetylcholine at the motor end
plate: Firstly, the binding of divalent antibody cross links two
receptor molecules and this is followed by an increased rate of
internalisation and lysosomal breakdown (Heineman et al, 1977;
Drachman et al, 1978; Fumagalli et al, 1981). Secondly, complement
dependent lysis alters the morphology of the post synaptic folds thus
reducing the surface area for insertion of AchR (Engel et al, 1976,
1979). Thirdly, there is reduced insertion of AchR into the
post-synaptic membrane (Engel & Fumagalli, 1982). The precise
mechanism for this is not clear but if it were not so, then
presumably increased turnover of receptors might compensate for their
loss from the post synaptic membrane. AchR antibody formation
requires the cooperation of helper cells and can be suppressed by
normal lymphocytes suspensions containing 0KT8 positive cells
(Shinomiya et al, 1984). Reduced suppressor cells as defined by
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monoclonal antibodies have been described in the peripheral blood of
patients with myasthenia gravis (Berrih et al, 1981 ; Skolnik et al,
1982) although this has not been a universal finding (Miller et al,
1982). Myasthenia gravis is associated with thyroid disease and such
patients may have circulating TSH receptor antibodies (Kiessling et
al, 1982).
3. INSULIN RESISTANT DIABETES MELLITUS
The insulin receptor consists of four glycoprotein subunits - two
alpha (MW = 135,000) and two beta (MW = 90,000). There are two
insulin binding sites per receptor and these are probably associated
with the alpha subunit. Antibodies to the receptor raised in rabbits
can simulate the effects of insulin in vitro e.g. enhancement of
glucose transport and oxidation, stimulation of lipogenesis and 3h
thymidine incorporation (for review, see Kahn et al, 1982). They have
also been shown to down-regulate the receptor.
The rare syndrome of insulin resistance due to autoantibodies to the
insulin receptor was first described in 1975 by Flier et al. It
typically occurs in non-Caucasian, middle aged females and often in
association with the skin lesion acanthosis nigricans. Patients often
have features of other autoimmune diseases, although these are
generally not organ specific. In vitro, the acute effect of these
antibodies is initially a stimulatory one, and indeed patients with
the syndrome may present with symptomatic hypoglycaemia, but with
time the cells become resistant to the effects of insulin. Carpentier





may cap, internalise and become associated with the
The phenomenon of post-receptor desensitization is also
to occur (Grunfeld et al, 1980).
4. ATOPIC ASTHMA
This condition is associated with changes in autonomic reactivity
with impaired beta2 adrenergic responsiveness and an increase in
reactivity to alpha adrenergic and muscarinic agents. The beta
receptor is a 59,000 molecular weight membrane protein which may
form a dimer and which contains one catecholamine binding site per
molecule. Autoantibodies were first described to this receptor in
1980 by Venter et al (for review, see Parker 1981). They are present
in only a small proportion of asthmatics and their presence may
relate to the severity of asthma (Blecher et al, 1981). They may also
be found in a small proportion of normal subjects (Fraser et al,
1981) and their role, if any, in the pathogenesis of asthma is not
known. Autoantibodies to the thyroid (Hall et al, 1966) and to smooth
muscle (Turner-Warwick et al, 1970) are both found more commonly in
asthmatics than in normal subjects and atopy has recently been
associated with reduced suppressor cell function (Rose-Pleszynski &
Blanchard, 1981).
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THE SPECTRUM OF AUTOIMMUNE THYROID DISEASE
In addition to the classic autoimmune thyroid diseases - Graves'
disease, primary atrophic hypothyroidism and Hashimoto's thyroiditis,
a number of other entities are becoming recognised. The syndrome of
painless thyroiditis with transient thyrotoxicosis (PTTT) may be
associated with circulating thyroid antibodies and is linked to
HLA-DR3 and DR5 (see Farid & Bear, 1981). The coexistence of
Hashimoto's thyroiditis with Graves' disease is well recognised
(Buchanan et al, 1961; Fatourechi et al, 1971) and may have important
prognostic implications (see Chapter 4) while the common genetic
background of the two conditions is demonstrated by the report of
Volpe and colleagues (1974) of Hashimoto's occurring in tne identical
twin and Graves' in the other. Thyrotoxicosis with no goitre may
account for over 20% of new cases and is associated with thyroid
antibodies and ophthalmopathy (Greeenwood et al, 1985) although its
relationship pathogenetically to classic Graves' disease needs to be
clarified. It may be that these patients simply lack a clone of
cells normally present in Graves' which produce thyroid growth
promoting antibodies. It has become necessary to identify the precise
immunological abnormality causing each manifestation of an autoimmune
disease. Thus, antibodies to melanocytes causing vitiligo (Hertz
et al, 1977) and to orbital antigens in thyroid eye disease (Kodama
et al, 1982) have recently been described.
Relatively little is known of the pathogenesis of multinodular goitre
apart from its relationship to iodine deficiency in endemic areas.
Evidence is however accumulating which suggests an overlap with
autoimmune thyrotoxicosis. In addition to the presence of thyroid
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microsomal and anti-thyroglobulin antibodies in multinodular goitre,
changes in immunoglobulins with high IgG and IgA have been reported
along with a positive response to thyroid antigen in the migration
inhibition factor test (Mota et al, 1 980; Kiy et al, 1 981). In the
study of Boukis et al (1983), performed in an endemic region of
Greece, thyroid antibodies only developed after the patients had been
treated with iodised oil. The release of antigen including
thyroglobulin was thought to account not only for the autoantibody
formation but also for the three cases of thyrotoxicosis which
occurred among 58 patients. Unfortunately TSH receptor antibodies
were not measured in this study. One of the major problems in
interpreting epidemiological studies with nodular goitres is the
geographical variation due to iodine status. A recent study in this
country (Greenwood et al, 1985) reported thyroid antibodies in 58% of
cases of nodular goitre and thyrotoxicosis, comparable to the
incidence of antibodies in hyperthyroidism with diffuse glands. Even
within this country however, considerable geographical variation
exists with respect to the presence of thyroid autoantibodies
including TSH receptor antibodies in populations of thyrotoxic
patients (Phillips et al, 1985).
Using the radioreceptor assay for TSH receptor antibodies, most
studies have not found an increased incidence of positive results in
patients with nodular goitres (Bolk et al, 1972; Mukhtar et al, 1975;
Strakosh et al, 1978) and this agrees with the results presented in
Chapter 2. The one exception is the study from New England by Brown
et al (1978) where a high proportion of patients with toxic nodular
goitre were positive along with a smaller proportion of patients with
euthyroid nodular goitre. This difference is hard to explain since
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the patients selected and the assay method were similar to those used
in the other studies cited. Smyth and colleagues ( 1 983) have also
found TSH receptor antibodies in a high proportion of patients with
euthyroid goitre using a sensitive cytochemical section bioassay.
Positivity in their assay correlated with the loss of TSH response to
injected TRH indicating that the thyroid was either functioning
autonomously or was being driven exogenously by immunological
stimulators.
A detailed examination of the histology, including autoradiography to
give some idea of the functioning of individual follicles, was
carried out by Studer et al (1978) and revealed that thyroid autonomy
was not necessarily related to or confined to the nodules in the
gland. In autonomous goitre, scattered hyperfunctioning follicles or
small clusters of such follicles might not be picked up clinically or
scintigraphically. Of interest in this light is the study of
Schleusener et al (1978) who identified a group of thyrotoxic
patients with apparent diffuse goitres but neither ophthalmopathy or
TSH receptor antibodies. This group did not show the expected
association with HLA-DR3 but instead there was an association with
HLA-DR5 and, in this group, possession of this antigen was a marker
for thyrotoxic relapse following drug treatment. The asssociation
with an allele of the major histocompatibility complex makes an
underlying immunological disturbance much more likely.
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THE CLUSTERING OF AUTOIMMUNE DISEASES
Research has thus far failed to reveal entirely why the organ
specific autoimmune diseases tend to be associated in certain
individuals. Genetic factors must be important and are reflected in
the association with HLA - for example, both Graves' and diabetes
have an increased incidence of HLA-DR3. Defects in immunoregulation
may also account for cases of multiple autoimmune disease although
gross changes such as the reduction in overall percentage of
suppressor cells seen in newly diagnosed Graves' disease tend to
return to normal soon after diagnosis (Ludgate et al, 1984).
Defective suppressor T cell function has been documented in patients
with multiple endocrine deficiencies (Arulanantham et al, 1979). The
possibility that target tissues share antigenic determinants has been
raised by the recent finding of monoclonal antibodies which react
with multiple organs (Haspel et al, 1983) while Onodera et al (1982)
have shown that polyclonal B cell activation in SJL mice by virus
infection leads to multiple organ specific antibodies being
expressed.
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AIMS OF THE THESIS
The aim of the work embodied in this dissertation is to consider the
variety of immunopathogenic mechanisms, both humoral and cellular,
which operate in autoimmune thyrotoxicosis and how these mechanisms
interact with one another. An explanation is sought for the variable
expression of immune markers in Graves' disease: whether different
forms of the disease exist or whether variations may be caused by
patients being studied at different stages in the natural history of
their disease. The influence of the patient's age on immune
parameters and on the clinical expression of the disease is
considered. A major part of the work is devoted to how immunological











TSH receptor antibodies (TBII) have been measured using a TSH binding
inhibitory assay in two large series of patients with Graves'
disease. In the first series of 13 8 patients, immunoglobulin
concentratates prepared by polyethylene glycol precipitation of serum
were used for the assay. 84 (61 %) of the patients had detectable TSH
receptor antibodies. In the second series of 150 patients, neat serum
was used in the assay and TBII were found in 121 (81%) of the
patients. When they were used simultaneously on the same sample, the
correlation between the two assays was good (r = 0.882, p < 0.001).
There was a very low incidence of TBII in patients with multinodular
goitres, while patients with simple goitre and Hashimoto's
thyroiditis were consistently negative.
There was a positive correlation in both studies between TBII and
thyroid microsomal antibody titres although this was more marked for
the assay using neat serum (p < 0.001). When immunoglobulin
concentrates were used, a significant (p < 0.01) negative correlation
between TBII and age at diagnosis was found. No such relationship was
found when neat serum was used in the assay. In neither assay was any
correlation found between TBII and biochemical measurements of
thyroid function or four hour 131I uptake.
Fourteen patients with recurrent Graves' thyrotoxicosis were compared
to 28 age and sex matched patients with newly diagnosed Graves' (two
new patients being matched to each recurrent case). There was no
significant difference in thyroid hormone or 1311 uptake values but
the median value for TBII (measured with neat serum) in the new
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patients was 28 (normal: -10 to +9) compared to 16 in the patients
with recurrent thyrotoxicosis (p < 0.02). By contrast, thyroid
microsomal antibodies tended to be higher in the recurrent patients
with 11 out of 13 (85%) having microsomal antibody titres of 402 or
above compared to 9 out of 26 (35%) new patients (p < 0.01).
The TBII assay using neat serum is therefore more sensitive than the
method using immunoglobulin concentrates in the diagnosis of Graves'
disease without loss of specificity. TBII correlate with microsomal
antibodies in newly diagnosed Graves' and the expression of TBII may
be age related. Recurrent Graves' patients differ from new patients
with lower levels of circulating TBII but higher microsomal antibody
titres which may reflect the tendency to develop thyroiditis in
patients with long standing Graves' disease.
INTRODUCTION
The presence, in Graves' disease, of circulating antibodies directed
against the TSH receptor provides the major evidence for an
autoimmune aetiology for the disease. In the past thirty years, a
number of methods have been developed to measure these antibodies
(see TABLE 2.1) While methods which assay some aspect of thyroid
function provide more direct information about the pathogenesis of
the disease, the radioreceptor assay enjoys the widest usage since it
is both convenient and reproducible. The assay may detect either
stimulatory antibodies or those which simply bind to the TSH receptor
making it refractory to the action of circulating TSH. The
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TABLE 2.1 METHODS DESCRIBED FOR TSH RECEPTOR ANTIBODY MEASUREMENT
a) Bioa.ssa.ys
1. Long-acting Thyroid Stimulator (LATS)
(131i release from thyroid of intact mice)
2. Long-acting Thyroid Stimulator Protector (LATS-P)
(Ability to inhibit neutralisation of LATS by human thyroid)
b) Changes in Thyroid Slices
1. Colloid droplet formation - human/mouse thyroid
2. Cytochemical section bioassay - guinea pig thyroid
c) TSH Binding Inhibitory Assays
Inhibit binding of labelled TSH to human or porcine TSH
receptors
d) Assays Based On Aspects Of Thyroid Function
1. Adenylate cyclase activity - thyroid slices
- human thyroid membrane
preparation
- human cell culture
- rat FRTL-5 cells
2. Iodide Uptake rat FRTL-5 cells
3. Thyroid hormone release - porcine thyroid slices
4. NADPH generation - guinea pig thyroid slices
e) Growth Promoting Antibodies
- guinea pig thyroid
- rat FRTL5 cells
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composition of the antibodies measured may thus vary from patient to
patient and this, along with geographical variation, patient
heterogeneity (discussed in Chapter 4) and methodological
differences, accounts for the variable rate of positivity reported in
the literature. In spite of its wide usage over the past 10 years,
much remains unknown about the radioreceptor assay for TSH-receptor
antibodies.
a) The Long Acting Thyroid Stimulator (LATS)
The bioassay for TSH, which relied on the discharge of radio-labelled
thyroid hormone from a guinea pig thyroid when TSH was injected, was
a well-established method in 1956 when Adams and Purves described an
abnormal activity in the sera of thyrotoxic patients. TSH gave
maximal stimulation between 90 minutes and three hours, while the
maximal stimulation with thyrotoxic sera was between 16 and 24 hours.
Furthermore, the magnitude of the maximal response was greater with
the thyrotoxic sera (Adams, 1958). The assay was modified for use
with mice (McKenzie, 1958) - partly for convenience and partly
because human serum was often toxic to guinea pigs. In 1961 the term
"Long Acting Thyroid Stimulator" (LATS) was coined (Adams, 1961) and
the activity was intensively studied in the ensuing years.
LATS activity could be demonstrated when Graves' sera were
administered to hypophysectomised mice and presumably did not
therefore act by stimulating pituitary TSH release. Its half life in
the circulation was considerably longer than TSH, and it was not
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neutralised by antisera to TSH. It not only stimulated thyroxine
production by the thyroid but also increased 131i uptake and induced
TSH-like changes in thyroid histology (for a review of these
properties see Adams, 1965). Shishiba et al (1970) later showed that
LATS stimulated glucose oxidation by the thyroid as well as
intracellular colloid droplet formation, while Levey and Pastan
(1970) demonstrated activation of the membrane bound adenylate
cyclase.
It seemed to many, therefore, that the cause of Graves' disease had
been found - but there were two major objections: firstly, all
Graves' patients were not positive for LATS - typically only about
30$, although Carneiro et al (1966) found LATS in 55 of the 100
patients in their study. This was ascribed to assay insensitivity
and the rate of positivity could be increased to 65$ by using
immunoglobulin concentrates (Adams, 1965). The second objection was
the presence of LATS in patients who were not thyrotoxic - for
example, Major and Munro (1962) found a small amount of activity in
some normal sera and also in patients rendered hypothyroid by
treatment for thyrotoxicosis. Kriss et al (1964) similarly found
LATS in seven subjects with pretibial myxoedema but who were
euthyroid after treatment, and Liddle et al (1965) detected LATS in
five patients with severe exophthalmos but who were euthyroid. The
thyroids of these latter five patients failed to respond to large
doses of injected TSH. This finding was confirmed by Adams et al
(1969) who found high titres of thyroid microsomal antibodies in
three euthyroid patients with exophthalmos and a high LATS titre.
Impaired thyroid reserve due to concurrent thyroiditis may thus be
the reason why some LATS positive patients do not become thyrotoxic.
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One further objection to LATS as the cause of thyrotoxicosis was that
the degree of thyroid dysfunction did not correlate closely with the
LATS titre. Some felt that LATS may simply be TSH bound abnormally to
a serum protein, while others felt that it might be an epiphenomenon
and that changes in cell-mediated immunity were more important (Volpe
et al, 1972).
LATS was soon recognised to be confined to the gamma-globulin
fraction of the serum (McKenzie, 1962a; Meek et al 1964), it had many
of the properties of an antibody and it could be neutralised by
antisera raised to normal IgG (Kriss et al, 1964). It was found to
be an IgG molecule and the Fab fragment of the molecule was the
active moiety (Dorrington et al, 1966). The antibody - like other
IgG molecules - could cross the placenta causing transient neonatal
thyrotoxicosis (Adams et al, 1964). LATS correlated with the presence
of thyroid eye disease (Lipman et al, 1967) although not with its
severity (Major & Munro, 1962). Much higher levels of LATS were
found in patients with localised myxoedema and thyrotoxicosis than in
those with thyrotoxicosis alone (Lipman et al, 1967; Carneiro et al
1968). This was recently confirmed by Hardisty et al (1984a) who
also found a persistent LATS-P in this group after successful
treatment of hyperthyroidism. Levels of these antibodies declined in
some of their patients as the skin lesions resolved. In the 1960s,
therefore, the identification of LATS as an immunoglobulin and its
correlation with other features of the disease provided the major
evidence for an immune aetiology for Graves' disease.
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b) Long-Acting Thyroid Stimulator Protector (LATS-P)
The activity of LATS in the mouse bioassay can be reduced by
preincubation with human thyroid tissue homogenate (Kriss et al,
1964). The antigen responsible is associated with the microsonal
fraction of the cell (El Kabir et al, 1966) and is quite specific for
the thyroid cell. A substance which blocked the neutralisation of
LATS by thyroid extract, presumably by competing for microsomal
antigen binding sites, was described in 1967 by Adams and Kennedy. It
was named the LATS-Protector (LATS-P) and was found in the
gamma-globulin fraction of the serum. It does not interact with the
mouse thyroid, either in vitro or in vivo and is thought to be
highly-specific for human thyroid (Adams & Kennedy, 1971).
LATS-P is present in most patients with Graves' disease - 14 of the
20 patients studied by Adams and Kennedy (1971) showed activity with
neat serum, while the remaining six were all positive when
immunoglobulin concentrates were used. In a series of 50 cases
reported by Adams et al (1974) LATS-P was found in 45 (90$) while
LATS was only present in 15 (30$). All of the LATS positive cases
were also positive for LATS-P. Furthermore, LATS-P showed a good
correlation with the rate of 131i uptake. More recent studies by
Hardisty et al (1981a; 1981b) confirm the high incidence of LATS-P -
90$ of patients relapsing after antithyroid drugs and 81$ of
patients prior to thyroidectomy were positive.
Direct evidence that LATS-P stimulates the human thyroid has been
obtained by Shishiba et al (1983), who showed a strong correlation
between the presence of LATS-P and intracellular colloid droplet
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formation when thyroid tissue was incubated with Graves' serum. When
plasma containing LATS-P was infused into normal volunteers whose
thyroids had been pre-loaded with 1311, there was a discharge of
radioactive iodine into the circulation (Adams et al, 1974b) - a
modification of the McKenzie mouse bioassay!
c) Intracellular Colloid Droplet Formation and the Cytochemical
Section Biossay
Both morphological and cytochemical changes in thyroid slices have
been used to assess the activity of thyroid stimulating antibodies.
The formation of intracellular colloid droplets has been found to
correlate with 1311 release in response to Graves' immunoglobulins
using mouse thyroid slices (Shishiba et al, 1 967). Unlike LATS-P,
the antibody is not highly species specific - it will interact with
both human and mouse, but not with chicken thyroid (Shishiba et al,
1972).
In the cytochemical section bioassay, thyroid stimulators induce a
change in lysosomal membrane permeability to a chromogenic substrate
for lysosomal naphthylamidase (Petersen et al, 1975). The assay has
been adapted for use with cryostat sections of thyroid (Neylan &
Smith, 1982) and stimulatory antibodies are found in a high
proportion of Graves' patients. Antibodies detected by this method
are thought to correlate with thyroid cell growth rather than thyroid
hormone production (Smyth et al, 1985) and positivity in this assay
correlates with lack of response to injected TRH in euthyroid women
with a diffuse goitre (Smyth et al, 1983).
-37-
d) TSH Binding Inhibitory Immunoglobulins (TBII)
Radioimmunoassays have the benefits of reproducibility and a large
sample capacity. It is not surprising, therefore, that the
radioreceptor assay, more than any other assay for TSH receptor
antibodies, has found its way into the routine clinical laboratory.
The assay is based on the ability of immunoglobulins from Graves'
patients to specifically inhibit the binding of labelled TSH to
membrane preparations containing the TSH receptor. It was first
described in 1974 by Rees-Smith and Hall who felt that TSH binding
inhibitory immunoglobulins (TBII) were equivalent to LATS-P and that
they might thus be specific for human thyroid membranes. TBII were
found in 22 out of 25 patients with Graves' disease and produced
linear Scatchard plots for binding to TSH receptor preparations. The
slope of the line and intercepts varied from patient to patient. When
the assay was further characterized (Rees-Smith & Hall, 1981),
porcine thyroid was found to be as effective as human thyroid and
guinea pig thyroid was also suitable. The major objection to this
method has been its lack of sensitivity; usually 50$ - 80$ of Graves'
patients are positive although this varies greatly from one published
seriesto another (see TABLE 2.2). Shinozawa et al (1 986a; 1 986b)
have recently developed an assay based on the binding of Graves'
immunoglobulins to the TSH receptors on guinea pig fat cell membranes
which have the advantage of not containing the thyroid microsomal
antigen. The assay is sensitive and can be used either with
immunoglobulin concentrates or with neat unfractionated serum. The
presence of false positive results with the sera of patients with
rheumatoid arthritis or systemic lupus could not be explained by
these authors and positive results were also obtained in two cases of
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insulin resistant diabetes associated with anti-insulin receptor
antibodies. Enzyme-linked immunosorbent assays (ELISA) are
increasingly replacing radioimmunoassays and Baker et al (1983) have
described such an assay based on the TSH receptors in guinea pig fat
cell membranes.
In a ten year follow up study of Graves' patients, Hensen et al
(1984) have shown that the percentage positivity in the TBII assay
was increased with repeated determinations, particularly in patients
with recurring hyperthyroidism. Two recent modifications of the
binding assay have also shown increased sensitivity: Borges et al
(1982) have preincubated receptor preparations with the IgG being
tested and then washed the membranes prior to adding labelled TSH.
TBII were found in 94$ of the 50 patients studied, the increased
sensitivity having been achieved by reducing binding by
immunoglobulins from normal controls. Furthermore, the degree of
binding inhibition correlated significantly with an assay based on
cyclic AMP (cAMP) accumulation. De Bruin et al (1984) describe an
immunoprecipitation assay in which solubilised receptors
.equilibrated with a small amount of 125i_TSH are incubated with
serum and then precipatated using a rabbit anti-human IgG. The assay
was positive in 26 out of 32 patients (81$) although antibody levels
correlated poorly with those in a standard TBII assay.
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e) Antibodies Affecting Adenylate Cyclase Activity
The recognition by McKenzie & Zakarija ( 1 976) that immunoglobulins
from Graves' patients stimulated the adenylate cyclase in human
thyroid slices, and that this reflected the activity of the disease
during drug therapy (Zakarija et al, 1980) lent further support to a
role for these antibodies in the pathogenesis of the disease. An
assay based on a membrane fraction from a tissue homogenate
(Orgiazzi et al, 1976) proved to be more convenient and was positive
in over 80$ of untreated Graves' (Bech & Madsen, 1978; Karlsson &
Dahlberg, 1981). A sensitive assay based on human thyroid cells in
tissue culture (Etienne-Decert & Winand, 1981) used infractionated
serum and was positive in 55 out of 69 (80$) patients.
Cryopreserved human thyroid cells have also been used (Davies et al,
1983) and a system based on the FRTL-5 rat thyroid cell line was
recently reported (Vitti et al, 1983). Adenylate cyclase
stimulating antibodies are not species specific and can be detected
using thyroid from calf, dog and guinea pig (Zakarija & McKenzie,
1978a; 1978b). Antibodies which block the cAMP accumulation in
response to Graves' immunoglobulins are now well recognised in
patients with primary hypothyroidism (Konishi et al, 1983).
f) Other Metabolic Activities and Thyroid Hormone Production
The uptake of iodide by the rat FRTL-5 cell line has been used to
complement the adenylate cyclase stimulation (Marcocci et al, 1983) -
When these two measurements were combined with 3H-thymidine uptake as
an index of cell growth, thyroid stimulating antibodies were found in
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100% of newly-diagnosed Graves' patients. A quantitative
cytochemical assay, based on measuring the amount of NADPH generated
when the cells are stimulated in guinea pig thyroid slices has been
described (McMullan & Smyth, 1984). Assays based on the production
of thyroid hormones from porcine thyroid slices have been well
described although not widely-used (Laurberg & Weeke, 1975; Atkinson
& Kendall-Taylor, 1981).
g) Antibodies which affect Thyroid Cell Growth
Garry and Hall (1979) found that LATS increased the mitotic rate of a
rat thyroid cell culture. Growth promoting antibodies are now
recognised in other goitrous thyroid diseases (diffuse euthyroid
goitre and Hashimoto's) and can be measured by nucleic acid
cytophotometry or 3n-thymidine incorporation (Drexhage et al, 1980).
Valente et al (1983) have recently confirmed the presence of
growth-promoting antibodies in Graves' disease using rat FRTL-5
cells.
CORRELATION BETWEEN DIFFERENT METHODS FOR MEASURING TSH RECEPTOR
ANTIBODIES
With the advent of different methods for measuring TSH receptor
antibodies, it has become apparent that considerable heterogeneity
exists. There is some confusion about how the different activities
interrelate. A correlation between LATS and adenylate cyclase
stimulating activity has been reported (Macchia et al, 1982),
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although this is in conflict with the findings of Orgiazzi et al
(1976). LATS has not generally been found to correlate with TBII
(Clague et al, 1976; Endo et al, 1978), although this has been
disputed by Ozawa et al (1978). LATS-P is present in nearly all LATS
positive sera (Adams et al, 1974; Hardisty et al, 1981 ) , and
correlates with colloid droplet stimulating antibodies (Shishiba et
al, 1973). Endo et al (1978) found LATS-P and TBII to correlate in
LATS negative sera but Ozawa et al (1978) found a poor correlation in
this group. In examining the two widely used methods for measuring
TSH receptor antibodies, Ginsberg et al ( 1 983) have distinguished
three patterns: some patients exhibit high binding inhibitory and
adenylate cyclase stimulating activities, while in others there is a
predominance of one or other activity. In general when they have
been measured simultaneously, the two activities have been found to
correlate poorly (Kuzuya et al, 1979; Sugenoya et al,1979; Macchia et
al, 1981; Shishiba et al, 1982; Hardisty et al, 1983). Some authors
have however found a positive correlation between the two methods
(Hall et al, 1978; Bliddal et al, 1982; Hensen et al, 1984). In the
modified binding assay of Borges et al (1982) levels of TBII also
correlated with cAMP accumulation in thyroid slices.
There is no doubt that the various methods are measuring different
immunoglobulin populations. When different assays are combined,
circulating TSH receptor antibodies are found in nearly all cases
(Biro, 1982; Marcocci et al, 1983; Hardisty et al, 1983). The study
by Biro combined TBII, adenylate cyclase stimulation and colloid
droplet formation. All 104 patients were positive in at least one
assay but only 29 were positive in all three.
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In routine laboratories, it is impractical to use several different
methods simultaneously and, of the established methods, the TSH
binding inhibitory assay is by far the most convenient and
reproducible.
The aim of the work presented in this chapter is to assess the
radioreceptor assay in the context of a routine clinical laboratory
comparing the use of immunglobulin concentates as described by
Shewring and Smith (1982) with the modified assay using neat serum
(Southgate et al, 1984). Correlation has been sought between the
clinical features of the disease and the expression of TSH binding
inhibitory immunoglobulins. Recurrent Graves' thyrotoxicosis is
compared to that occurring in newly-diagnosed Graves' disease.
RESULTS
A: Measurement of TSH Receptor Antibodies Using Immunoglobulin
Concentrates.
PATIENTS
This study included 138 patients (122 female, 16 male; mean age 45.1
years, SD 13.6) with thyrotoxicosis plus a diffuse goitre and/or
scintiscan. Thyrotoxicosis was diagnosed by raised triiodothyronine
(T-^ normal up to 2.8 nmol/1) and/or raised thyroxine (T^ normal up
to 150 nmol/1) along with a flat TRH test. Thyroid hormone and TSH
measurements were performed in the Department of Clinical Chemistry,
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Royal Infirmary of Edinburgh by in-house radioimmunoassays. The mean
Tg in the thyrotoxic patients was 5.9 nmol/1 (SD = 2.2) and the mean
T4 was 231 nmol/1 (SD = 55). Twenty one patients with Graves' disease
in remission after oarbimazole were studied as well as twelve cases
of subclinical Graves' disease. The latter twelve patients all had
flat TRH tests but high normal thyroid hormones (mean Tg = 2.3
nmol/1, SD 0.46; mean Tj| = 142 nmol/1, SD 24) and mild symptoms. Four
of the twelve had a palpable goitre.
Nineteen normal controls had no evidence of endocrine or autoimmune
disease and the study also included, as disease controls, ten
patients with euthyroid multinodular goitre and twenty with toxic
nodular goitre. Eight hypothyroid patients with Hashimoto's
thyroiditis were also studied.
ASSAYS
TSH receptor antibodies were measured as described in APPENDIX 1,
using immunoglobulin concentrates prepared by precipitation from
serum with polyethylene glycol. The results were expressed as a
binding inhibitory index, the upper limit of normal for which was 10,
in keeping with the published data of Shewring and Rees Smith (1982).
Anti-microsomal and anti-thyroglobulin antibodies were detected by
tanned red cell haemagglutination (Witebsky & Rose, 1956) using
commercially available kits (Wellcome).
STATISTICS
Thyroid hormone and antibody data were compared using Spearman's
coefficient of rank correlation, since the distribution of TSH
receptor antibody measurements in the thyrotoxic patients was not
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normally distributed. For trend analyses, the Jonckheere monotonic
trend test for independent samples was used. This test is a
non-parametric, rank correlation test and therefore suitable either
where the variables are not normally distributed or where the
measurements are discontinuous, as in the case of thyroid microsomal
antibody titres.
THYROID AUTOANTIBODIES IN UNTREATED GRAVES' PATIENTS
TSH receptor antibodies were detected in 84 out of 138 (61$) Graves'
patients with thyrotoxicosis (Median value 14.5). By contrast, none
of the 19 normal controls or the ten patients with euthyroid
multinodular goitre was positive (see FIGURE 2.1). Two out of twenty
patients with toxic multinodular goitre were mildly positive (Binding
inhibitory indices of 11.1 and 14.2). The 21 patients with Graves'
disease in remission were all negative and no positive value was
found in the cases of subclinical Graves' disease (see FIGURE 2.2).
None of the eight patients with hypothyroidism secondary to
Hashimoto's thyroiditis was positive.
There was a significant negative correlation between the age of the
patient at diagnosis and binding inhibitory index (p < 0.01) - see
FIGURE 2.3. Thyroid microsomal antibodies were detected in 46 of the
135 patients tested (34$) and there was a positive correlation
between the levels of microsomal antibody and those of TSH receptor
antibodies (p < 0.02) - see FIGURE 2.4. Antithyroglobulin antibodies
were found in 19 of 135 patients (14$) and showed no correlation with
TSH receptor antibodies.
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FIGURE 2.1 TSH RECEPTOR ANTIBODIES IN NEWLY DIAGNOSED




































FIGURE 2.2 TSU RECEPTOR ANTIBODIES IN UNTREATED GRAVES',
























FIGURE 2.3 RELATIONSHIP BETWEEN AGE AT DIAGNOSIS AND TSH





























AGE AT DIAGNOSIS (years)
56-65 66 AND ABOVE
N.B. Horizontal bars on this and other similar charts relating to
TBII measurements represent the median values for the group.
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FIGURE 2.4 RELATIONSHIP BETWEEN MICROSOMAL ANTIBODY TITRES AND































B: Measurement of TSH Receptor Antibodies Using Neat Serum
PATIENTS AND METHODS
This study included' 150 patients with thyrotoxicosis plus a diffuse
goitre and/or scintiscan. There were 115 females and 35 males,
overall mean age 46.8 years (SD 14.8). The diagnosis was established
as for the series already described and the mean T3 for this group
was 5.7 nmol/1 (SD 1.8) and the mean T4 was 228 nmol/1 (SD 46.9). TSH
receptor antibodies were measured as described in APPENDIX 1 using
unfractionated serum. The normal range (established by assaying serum
from 98 controls) was -10 to +9. Data from patients with goitrous
thyroid diseases other than Graves' is presented in APPENDIX 1.
Anti-microsomal and anti-thyroglobulin antibodies were measured by
tanned red cell haemagglutination using commercially available kits
(Fujizoki). Statistical analyses were carried out as for the previous
study.
THYROID ANTIBODIES IN UNTREATED GRAVES' PATIENTS
TSH receptor antibodies were detected in 121 out of 150 patients
(81$) with untreated Graves' thyrotoxicosis (see APPENDIX 1, FIGURE
A1.2). Strongly positive titres of thyroid microsomal antibodies
(402 and above) were found in 57 (38$) while anti-thyroglobulin
antibodies were found in 26 (17$).
As in the previous study, there was a significant positive
correlation between binding inhibitory index and microsomal antibody
titre (p < 0.001) - see FIGURE 2.5. This trend was more marked than
FIGURE 2.b CORRELATION BETWEEN MICROSOMAL ANTIBODY TITRE
AND TS11 RECEPTOR ANTIBODIES (NEAT SERUM)
MICROSOMAL ANTIBODY TITRE
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in the study using immunoglobulin concentrates. In contrast to the
previous study, however, there was no significant correlation between
age at diagnosis and binding inhibitory index (see FIGURE 2.6). It
is possible that the TBII assay using neat serum is also measuring to
some extent microsomal antibody, but this does not account for the
lack of age correlation: the mean age for patients in this study with
microsomal antibody titres above 402 was 48.8 years (SD 15.0)
compared to 47.4 years (SD 14.7) for patients with low or
undetectable microsomal antibodies (not significant). Once again,
there was no correlation between thyroid antibody measurements and
biochemical tests of thyroid function.
C: Comparison of TSH Receptor Antibody Measurements P3ing
Immunoglobulin Concentrates and Onfractionated Serum
For this study, TSH receptor antibodies were measured simultaneously
by the two methods already described in 44 patients with untreated
thyrotoxic Graves' disease. The mean T^ in these patients was 6.3
nmol/1 (SD 2.17), the mean Tij was 234 nmol/1 (SD 50.8) and all had
flat TRH tests.
The results are shown in FIGURE 2.7. Overall, the correlation
coefficient was 0. 882 (p < 0.001). In 34 out of the 44 cases, the
actual value for the binding inhibitory index was higher when neat
serum was used in the assay. 28 patients (64$) were positive in both
assays, while 9 (20$) were negative in both assays. Discrepancies
existed in seven cases and, in all of these, the sample was negative
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FIGURE 2. 6 RELATIONSHIP BETWEEN AGE AT DIAGNOSIS AND TSH
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FIGURE 2.7 COMPARISON OF TSH RECEPTOR ANTIBODY MEASUREMENTS
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in the assay using immunoglobulin concentrates but positive in the
assay using neat serum, confirming the greater sensitivity of the
latter method.
D: Thyroid Autoantibodies in Recurrent Graves' Disease.
Graves' is a disease of relapses and remissions where a proportion of
the patients ultimately develop spontaneous hypothyroidism (Doniach,
1 980). This study was undertaken to see if patients with a
recurrence of their thyrotoxicosis differed immunologically from
patients at first diagnosis. Fourteen patients with recurrent
thyrotoxicosis were matched for age and sex with 28 newly diagnosed
Graves' patients (each recurrent being matched to two new patients) .
The mean age in both groups was 44 years, the recurrent group
consisting of 13 females and one male. The mean T3 in the recurrent
group was 5.18 compared to 5.45 in the new patients, while the four
hour 1311 uptake in the two groups was 53.0$ and 50.3$ respectively.
Neither of these two differences nor the difference in T^ values was
significant. TBII were measured using neat serum and microsomal
antibodies using commercial kits (Fujizoki).
The difference in binding inhibitory index between the two groups is
shown in FIGURE 2.8. In newly diagnosed Graves', the median value was
28 compared to 16 for the recurrent patients (p < 0.02). There was
also a significant difference in microsomal antibody titres (p <
0.01) - see FIGURE 2.9. In the newly diagnosed patients, 17 out of 26
(65$) had undetectable or low levels of microsomal antibody compared


























FIGURE 2.9 THYROID MICROSOMAL ANTIBODIES IN RECURRENT
GRAVES' DISEASE
DISCUSSION
Part of the variability in early assays for TBII was undoubtedly due
to differences in the preparation of particulate thyroid membrane
fractions. The use of solubilised TSH receptors was described in
1981 by Kotulla & Schleusener. Uniform preparations of thyroid
membrane could be obtained and stored long-term for standardisation
of the assay. The value of solubilised receptors was confirmed by
Iida et al (1982) who found it to increase assay sensitivity, largely
by decreasing the inhibition of labelled TSH binding by normal serum.
Shewring and Rees-Smith (1982) used an assay based on
Lubrol-solubilised receptors to show that 83$ of newly diagnosed
Graves' patients were positive. In this study, immunoglobulin
concentrates were prepared using polyethylene glycol which eliminates
the dialysis step required when ammonium sulphate precipitation is
used. More recently, their assay has been modified for use with
unfractionated serum (Southgate et al, 1984) . This modification to
the assay not only makes it more convenient to apply but was also
said by the authors to increase assay sensitivity. The use of the
radioreceptor assay has been studied here with two large series of
patients with untreated thyrotoxic Graves' disease, TBII being
measured in one with immunoglobulin concentrates prepared by
polyethylene glycol precipitation from serum and in the other series
the measurement was performed with neat serum. The published normal
ranges for these assays were confirmed. In the assay based on
polyethylene glycol precipitates, 61$ of patients were positive
compared to 81$ when neat serum was used, thus confirming the
previous observation that the assay is more sensitive when neat serum
is used. This may relate to the amount of immunoglobulin applied to
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the receptor preparation. TSH receptor antibodies have generally been
found to correlate with the presence of clinical features of Graves'
disease rather than with their severity or with biochemical measures
of thyroid function. This was also confirmed in the present study.
Goitre size, assessed clinically, correlated well with TBII (data not
shown) but patients with exophthalmos did not differ in terms of
thyroid antibodies from other patients with untreated Graves'
disease.
There are several possible reasons for the relatively low and
variable positivity found in assays for TBII:-
1) Patient selection: patients who clinically and
scintigraphically have a diffuse goitre may in fact have disseminated
thyroid autonomy due to microscopic nodules (Schleusener et al,
1983). Subclinical forms of Graves' may be associated with
incomplete expression of immunological markers. Patient heterogeneity
is discussed further in Chapter 4.
2) Thyroid membrane preparations: solubilised TSH receptors have
generally been found to be more sensitive than particulate membrane
preparations (See Table 2.2). TBII are not highly species
specific; porcine thyroid will bind TBII with high affinity while
guinea pig and sheep thyroid bind with lower affinity (Rees-Smith &
Hall, 1981; Davies, 1981). However, even with different human
thyroids there may be a variation in immunoglobulin binding to TSH
receptor preparations (Gossage et al, 1981).
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3) Immunoglobulin preparations: there is a small amount of TBII
activity in normal serum (Brown et al, 1983) and assay sensitivity
is partly determined by how well this can be separated from the
specific TBII in Graves' serum. The amount of immunoglobulin
applied to the receptors may influence sensitivity (Endo et al,
1978), as may the method of preparing the IgG. For example,
ammonium sulphate precipitation, which has been the most widely
used method, may not always reflect accurately the TBII activity of
serum (De Bruin et al, 1982).
4) Circulating thyroglobulin: this is elevated in patients with
Graves' disease (Van Herle et al, 1973)> it can interfere with TSH
binding to its receptor (Hashizume et al, 1978), co-precipitates with
IgG when ammonium sulphate is added to serum, and has been
considered a possible source of interference in the TBII assay
(Fenzi et al, 1978).
5) Immune complexes: these are present in a proportion of patients
with Graves' disease and a reciprocal relationship with TBII has
been suggested (Van der Heide et al, 1980). The possible role of
immune complexes in modulating autoantibody expression is discussed
in Chapter 5.
6) Autoantibodies to TSH: Akamizu et al (1984) have described, in
two out of 154 Graves' patients, a circulating autoantibody to TSH.
The antibody-TSH complex co-precipitated with the TSH receptors
giving a falsely high value for TBII. A similar antibody was
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reported in Graves' patients by Kajita et al (1983) and also in a
normal individual (Copping et al, 1985), the latter causing a
spurious positive result in the TBII assay.
7) Geographical variation: Phillips et al (1985) have recently
demonstrated that the incidence of TSH receptor antibodies in
thyrotoxic patients differs markedly from area to area and that
there is an inverse correlation with the previous incidence of iodine
deficiency. Patients with disseminated thyroid autonomy may be
included in series of Graves'disease if thyroid nodules are not
clinically or scintigraphically detectable.
Surprisingly little comment is made in the published literature on
the correlation between TSH receptor antibodies and thyroid
microsomal antibodies. Gossage et al (1983) recently reported no
correlation between the two. In both assays used here, a positive
correlation between TBII and thyroid microsomal antibody titre was
found, although this was more marked in the assay based on neat serum
(p < 0.001). The negative correlation between age at diagnosis and
TBII found when immunoglobulin concentrates were used was not found
with unfractionated serum. The latter method may have been picking up
a population of antibodies to components of thyroid other than the
TSH receptor. It is conceivable that such antibodies might become
more frequent with age. This effect did not appear to be due to the
microsomal antibodies detected by passive haemagglutination since
these were not increased in frequency in patients who were older at
diagnosis.
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Recurrent Graves' disease differed immunologically from newly
diagnosed thyrotoxic Graves' although the clinical and biochemical
features of the patients compared were very similar. Fourteen
patients with recurrent disease had lower TBII (p < 0.02) but higher
microsomal antibody titres (p < 0.01) than age and sex matched new
patients. This may reflect an increased amount of thyroiditis in
patients with disease of long standing. The production of TBII by
intrathyroidal lymphocytes may be sufficient to stimulate the thyroid
but localisation of the immune reaction to the thyroid may account
for the decreased levels of TBII.
In conclusion, the studies presented here agree with the published
data on the incidence of TSH receptor antibodies in untreated Graves'
thyrotoxicosis and with the observation of Southgate et al (1984)
that the assay is more sensitive when unfractionated serum is used.
TBII correlated with microsomal antibodies and their expression may
be age related. Humoral immunity is different in recurrent Graves'
compared with newly diagnosed disease.
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Chapter Three





TSH receptor antibodies (TBII) and other thyroid antibodies were
studied before and after treatment of thyrotoxic Graves' disease
with carbimazole, radioactive iodine and surgery.
A) Of 24 patients treated with carbimazole, 18 (73%) were positive
for TBII at diagnosis and 17 (71$) for thyroid microsomal antibodies.
While biochemical control of thyrotoxicosis was achieved within one
to two months in all cases, levels of thyroid antibodies did not
decline until later and were often still high at the end of a nine
month follow-up period.
When TBII is normal at the end of a course of drugs, thyrotoxic
relapse is usually associated with a return of TBII towards
pre-treatment values. Persistent TBII at the end of a course of
drugs is not invariably associated with thyrotoxic relapse (two
cases are presented) and this may be due to concurrent thyroiditis.
Similarly, episodes of relapse in TBII negative patients who become
TBII positive may be self limited.
B) Eighteen patients were followed up after $311 therapy (mean dose
7.7 mCi, range 5 - 15). The median TBII at diagnosis was 35 and, by
three or four months, this rose to over 55 and did not reach normal
levels until two years after therapy, although some patients still
had high TBII at this stage.
TSH receptor antibody titre at diagnosis was related to the thyroid
status six months after therapy in 52 patients with mild to moderate
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thyrotoxicosis. In the six patients not responding to a single dose
of 1311, the mean TBII was 6.5, compared to 10 for the 19 euthyroid
cases and 18 for the 27 hypothyroid cases (p < 0.01). Furthermore,
antithyroglobulin antibodies appeared to have a protective role with
seven of the nine patients positive for these antibodies euthyroid at
six months (p < 0.01). Patients rendered hypothyroid also tended to
show an increase in TBII after therapy (p < 0.05) while the euthyroid
patients either decreased or showed small increases within the normal
range.
24 unselected patients were tested for TBII long after 1311 therapy
(mean period, 56.8 months, range 27 to 156). Significant levels of
TBII were found in 10 cases and were strongly correlated with the
presence of exphthalmos. The median TBII for the non-exophthalmic
group (n=l4) was 1.5 compared to 33.5 for the patients with
exophthalmos (n=10, p < 0.01).
C) After surgery, TBII declined progressively in all eight patients
tested sequentially during the first year. Persistent TBII in
euthyroid patients was uncommon but two such cases were found and
both had marked bilateral exophthalmos.
These studies confirm that TSH receptor antibodies have a bearing on
the prognosis of Graves' treated with drugs, 131i or surgery. The
time course of actions with the former favours a primary antithyroid
rather than an immunosupppressive action although the latter is
clearly important in maintaining remission. Persistence of TBII after
destructive antithyroid therapy is associated with other autoimmune
diseases, particularly Graves' eye disease.
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INTRODUCTION
Thyrotoxicosis in Graves' disease may be treated in one of three
ways: antithyroid drugs, radioactive iodine, or surgery.
Immunological tests may have a role in predicting the ultimate
response to all three treatment modalities, although they have been
most widely used in relation to antithyroid drug therapy. Patients
with persistent evidence of the underlying immunological abnormality
are much more likely to relapse after treatment, even if the
biochemical control of their thyrotoxicosis is good. The aim of the
work presented in this chapter is to consider the changes in thyroid
autoantibodies during therapy, particularly radioactive iodine, since
there is very little published work on predicting the response to
this treatment.
A: ANTITHYROID DRUGS
The treatment of thyrotoxicosis with thiourea and thiouracil drugs
was introduced in 19^3 by Astwood, who showed a prompt response of
both symptoms and basal metabolic rate in three patients. Recent
evidence (Davidson et, 1 978) suggests that these drugs may act by
trapping oxidised iodine rather than directly inhibiting the thyroid
peroxidase. The structure of the common antithyroid drugs
(carbimazole, its metabolite methimazole, and propylthiouracil) is
shown in FIGURE 3.1. Carbimazole is the most widely used antithyroid
drug in the United Kingdom. Drugs are now the treatment of choice for
young patients with mild to moderate thyrotoxicosis. Antithyroid
drugs will control the biochemical and clinical features of
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thyrotoxicosis in over 95$ of cases, but only 45/S to 70$ of patients
will achieve a lasting remission after a single course of drugs
(Solomon et al, 1953; Manson, 1953; Trotter, 1961; Astwood, 1963;
Hersham et al, 1 966). There is no reliable feature at first
presentation which will predict the patients most likely to relapse.
Most of the recurrences are within one year of stopping therapy with
a steady decline in the rate thereafter (Solomon et al, 1953; Goodwin
et al, 1954; Hershman et al, 1966). Hershman ( 1 966) suggested that
the duration of symptoms prior to starting therapy may be of some
relevance, with patients who have had symptoms for longer being more
likely to relapse. This does not, however, agree with the studies of
Manson (1953) or Goodwin (1954).
Patients with larger goitres are much more likely to relapse after
therapy (McCullagh et al, 1951; Manson, 1953). A decrease in goitre
size during therapy has been associated with a low rate of relapse
(Solomon et al, 1953; McCullagh and Cassidy, 1 953; Hershman et al,
1966). The nodularity of the goitre may also help predict relapse:
in the study of McCullagh et al (1951) 62$ of patients with diffuse
goitre remained in remission after a course of drugs while only 34$
of patients with nodular goitre did so. Aspenstrom (1953), however,
in a study from an endemic goitre region, found no difference in the
relapse rate between nodular and diffuse goitres. In practice, very
few patients with Graves' disease have nodular goitres and
undoubtedly many patients included in these studies did not have
Graves' disease, which is now much easier to diagnose with the advent
of scanning techniques and immunological tests. Reveno and Rosenbaum
(1964) identify the patients most likely to respond to a single
course of antithyroid drugs as being younger, with smaller goitres
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and mild thyrotoxicosis of short duration. Patients with pure T3
toxicosis also have a low rate of relapse (Greer et al, 1977).
Another influence may be the iodine content of the diet: the relative
deficiency induced by antithyroid drugs has been suggested to protect
against early relapse and there may be an inverse relationship
between iodine intake and the remission rate after treatment
(Alexander et al, 1965: Wartofsky, 1973).
Thyroid Hormone Suppressibility and the Prediction of Thyrotoxic
Relapse
In a study to determine whether or not thyrotoxicosis was pituitary
dependent, Werner (1952) showed that the administration of thyroid
hormone did not suppress thyroid activity. The thyroid was however
suppressible in normal subjects and in patients who were in remission
after a course of antithyroid drugs (Morgans et al, 1952; VanderLaan,
1957). Suppression of radioactive iodine uptake by the thyroid
develops progressively after antithyroid drug therapy is instituted
(Slingerland and Burrows, 1979) although this is not found in all
patients. For example, in the study by Alexander et al (1966), only
half the patients developed suppressibility. Furthermore, continuing
disease activity was apparent in spite of adequate control of thyroid
hormones (Alexander et al, 1973). There was no difference in terms
of age, sex or thyroid hormone levels at diagnosis between patients
who suppressed and those who did not (Alexander et al, 1967) but
suppressibility did correlate with a small goitre at diagnosis and a
decrease in goitre size with therapy (both factors known to influence
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ultimate prognosis). Loss of suppressibility has also been
documented in Graves' patients relapsing after having apparently
returned to normal after a course of drugs (Alexander et al, 1968).
It was first suggested in 1960 by Cassidy and Vanderlaan that thyroid
suppressibility might be useful in predicting the outcome after a
course of drugs. In their study, the average 24 hour 1311 uptake
after thyroid hormones in patients remaining in remission was 25.4$
compared to 66.2$ in those patients who suffered a recurrence.
Alexander et al (1969) found, in a follow up study involving 93
patients ( 1970), that 32 out of 42 patients lacking suppressibility
relapsed, compared to 16 out of 51 patients who did suppress. Similar
findings were reported by Lowry et al (1971). Not all studies have
confirmed the usefulness of the thyroid suppression test: although
Hales et al (1969) did find a relationship with relapse, they found
that only half the patients who did not suppress actually relapsed.
This technique not only gives an imperfect prediction of the outcome,
but also has the disadvantages of being time consuming both for the
patient and for the investigator, and of requiring multiple doses of
isotope to give a clear picture of trends in the underlying disease.
The Optimal Duration of Antithyroid Drug Therapy
Treatment with antithyroid drugs is generally continued for one year
or more, although the rationale for this is not entirely clear. Greer
et al (1977) suggested that short term therapy, i.e. treating the
patients until they were symptomatically and biochemically normal
(generally about four to five months) was adequate, and gave
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comparable results to long term therapy. Their later study (Bourma
et al, 1982) did not confirm the low incidence of relapse but pointed
out that it may be a useful strategy in selected patients, while
Slingerland and Burrows (1979) have demonstrated that long term
therapy is not associated with an increased incidence of side
effects. The original study of Greer was criticised because the
basis for patient selection was not stated and there was a high
incidence of T3 toxicosis (De Groot, 1977; Burr et al, 1979). De
Groot suggested that, by temporarily depleting the thyroid gland of
hormone, short term therapy may produce temporary relapse without
influencing the underlying disease process. Burr et al (1979) found
a very high relapse rate after short term therapy. Tamai et al
(1980) showed that the more prolonged the treatment, the more likely
was the patient to achieve lasting remission and Sugrue et al (1982)
reported a 91$ relapse rate at five years in patients treated for a
mean period of eleven months compared to 49$ in patients treated for
3.8 years. It would seem certain then that long term therapy is
generally required to ensure a high remission rate.
Beta blockade has been used as the sole agent in treating the
thyrotoxicosis of Graves' disease. For example, Pimstone et al
(1969) treated 27 cases and found that 13 had an adequate response
clinically. This is clearly inferior to antithyroid drugs and
further studies have also suggested beta blockers to be unsuitable as
first line therapy except as preparation for surgery or radioactive
iodine (McLarty et al 1973; Mazzaferri et al, 1976). It has been
suggested by various groups of workers that antithyroid drugs may
influence the natural history of Graves' disease; Lowry et al
(1973) found that radioactive iodine uptake did not change at the
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time of thyrotoxic relapse in patients who had already had a course
of drugs, and concluded that factors other than the iodine trapping
mechanism might be important. Wise and his colleagues (1973, 1979)
have designed a "block-replace" regime where patients are maintained
on high doses of carbimazole supplemented with triodothyronine once
the toxicosis is controlled. They feel that the decrease in 131j
uptake with therapy is not explicable entirely by the inhibition of
iodination and that antithyroid drugs affect thyroid hyperstimulation
at a pre-biosynthetic level. Wilkin et al (1979) also point out that
fluxes in thyroid hyperstimulation appear to occur independently of
symptoms.
TSH Receptor Antibodies and the Prediction of Thyrotoxic Relapse
TSH receptor antibodies decline progressively during treatment with
antithyroid drugs and their persistence usually indicates that the
underlying disease continues to be active. Thus, Hardisty et al
( 1984b) demonstrated a fall in LATS-P with treatment in patients who
remained in remission, and recurrence of thyrotoxicosis after
treatment was associated with a return of LATS-P towards
pre-treatment levels. In the study of Chiovato et al (1978), there
was a progressive fall in thyroid microsomal antibody titres with
therapy with a later increase towards pre-treatment levels in
patients who relapsed. The prognostic value of these antibodies has
not been generally confirmed although these authors were using a
highly sensitive radioimmunoassay, as opposed to passive
haemagglutination which is less sensitive but more widely used. A
progressive decline in adenylate cyclase stimulating antibodies with
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drug therapy has been reported by several groups (Beck & Madsen,
1980; Karlsson & Dahlberg, 1981; Feldt-Rasmussen et al, 1982). In the
first of these three studies, the rate of disappearance of antibodies
was related to the age of the patient, with antibodies becoming
undetectable faster in younger patients. The level of binding
inhibitory immunoglobulins (TBII) also falls progressively during
treatment (Chiovato et al, 1978; Fenzi et al, 1979) and this is
parallelled by a fall in 1311 uptake (Gossage et al, 1983).
Two studies have compared changes in TSH binding inhibitory
immunoglobulins and adenylate cyclase stimulating antibodies during
therapy: in the first, Kuzuya et al (1979) showed a poor correlation
between the two at diagnosis, the stimulatory antibodies tended to
disappear faster with treatment and ultimately became undetectable in
all patients. Of eight patients whose thyroids remained
non-suppressible during treatment, four were persistently positive
for TBII, while none of the nine suppressible patients had persistent
TBII. In the second study, Bliddal et al (1982a) found that the two
activities generally declined in parallel.
The concept that persistence of TSH receptor antibodies indicates
that the underlying disease is still active and that patients will
probably relapse on stopping therapy has led to many studies
attempting to predict the ultimate response to antithyroid drugs.
Although Long- Acting Thyroid Stimulator (LATS) relates well to
disease activity (McKenzie & Kakarija, 1977), its use in predicting
relapse may be limited since it tends to persist in many patients
with exophthalmos but without continuing thyrotoxicosis (McKenzie,
1961). LATS-P is probably a better predictor of relapse (Hardisty et
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al, 1982): 21 out of 24 patients with LATS-P at cessation of therapy
relapsed within one year, compared to eight out of 28 patients who
were LATS-P negative on stopping drug therapy.
Anti-microsomal and anti-thyroglobulin antibodies often decline
during drug therapy, and fluctuations with disease activity have been
reported but these antibodies have been found to be of little value
in predicting the response to treatment (Wilkin et al, 1980). HLA-B8
is associated with recurrent thyrotoxicosis in Graves' disease as
well as with persistence of thyroid microsomal antibodies (Irvine et
al, 1977) and it would not be surprising, therefore if some
relationship were to exist between microsomal antibodies and
relapsing disease but this is certainly not marked enough to be of
use in routine clinical practice. Zakarija, McKenzie and Barovac
(1980) have measured adenylate cyclase stimulating antibodies in 28
patients after therapy: 13 patients remained in remission and all
were negative for antibodies while 12 out of 15 relapsing cases were
positive.
Early reports suggested that TBII were highly accurate in predicting
relapse after antithyroid drugs were stopped: Davies et al (1977)
found that all 16, out of a total of 30 patients, with a high TBII
relapsed, while eight out of nine such patients in the study of
O'Donnell et al (1978) did so. By combining HLA-DR typing with TBII
measurement, McGregor et al (1980) were able to predict the ultimate
outcome in 62 out of 65 cases. Since 27 out of 29 patients positive
for HLA-DR3 relapsed, TBII were most useful in the DR3-negative
patients. The value of TBII in predicting thyrotoxic relapse has been
further confirmed (Schleusener et al, 1978; Schernthaner et al, 1980)
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although the latter study did not find any difference in DR3
positivity between the relapse and remission groups. Teng and Yeung
( 1980) found once more that all of their patients with persistent
TBII relapsed as did the patients who had become TBII negative but
subsequently became positive again. A number of patients who were
TBII negative relapsed, however, and this decreased the overall rate
of successful prediction in this study. Docter et al (1980) found
TBII to be of no value whatsoever in predicting thyrotoxic relapse.
Their study was a small one, and while at odds with other published
data, it does serve to underline that prediction with TBII is
inconstant and therefore may be of limited use for the individual
patient. A recent report by Bliddal et al (1983) has suggested that
the combined use of TBII and stimulatory antibodies may give more
reliable prediction.
The Immunosuppressive Action of Antithyroid Drugs
In addition to their inhibition of the organification of iodine,
antithyroid drugs may directly affect the immune system
(Kendall-Taylor, 1984). This action of these drugs is potentially
important for several reasons. Firstly, in the planning and
monitoring of drug therapy, should we be guided by the patient's
biochemical status or should we be aiming to normalise immunological
parameters? Secondly, if a thyroid-specific immunosuppressive
action influences the natural history of the disease - and the data
discussed above suggests it might - then perhaps we should be
looking for more effective immunosupppressive agents. Thirdly, the
potential use of antithyroid drugs, with appropriate hormone
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replacement, in euthyroid or hypothyroid patients with thyroiditis
may influence their ultimate prognosis as far as thyroid function is
concerned.
TSH receptor antibodies, and other thyroid antibodies, decline in the
course of drug therapy, their persistence indicates activity of the
underlying disease and a high chance of relapse on stopping the
drugs, as discussed above. A decrease in the proportion of
circulating suppressor cells is well described in untreated Graves'
disease (see Chapter 7) and this similarly returns to normal with
therapy except in patients who relapse on drug withdrawal (Ludgate et
al, 1984). Both these lines of evidence suggest that antithyroid
drugs may influence the immune system and the presence or absence of
this action affects prognosis. The first direct evidence was provided
by Michie et al (1967), who not only confirmed that both Graves' and
Hashimoto's thyroiditis were associated with an increase in thymic
size but also that the size of the thymus decreased during long-term
antithyroid drug treatment. Beck et al (1973) followed this up by
showing that there was less lymphoid tissue in the thyroids of
patients prepared for surgery with carbimazole than in those treated
with propranolol alone. They also pointed out the structural
similarity between carbimazole and uracil, a drug with well
documented immunosuppressive actions. More recently, it has been
shown that methimazole influences the degree of thyroiditis and the
amount of anti-thyroglobulin antibody production in August rats
immunized with thyroglobulin and that this effect is not due to
changes in thyroid hormones (Keast et al, 1981; Weetman et al, 1982;
Rennie et al, 1983).
-77-
Wall and his colleagues (1976) have shown that low concentrations of
propylthiouracil can inhibit the mitogenic response of normal
lymphocytes to the mitogens phytohaemagglutinin (PHA), concanavalin A
(con A) and pokeweed mitogen (PWM) as assessed by tritiated thymidine
uptake after prolonged incubation. Their findings were not, however,
confirmed by Hallengren et al (1980) who found only mild inhibition
of con A- and PHA- stimulated mitogenesis and only then at high doses
of propylthiouracil. There was actually an enhancement of PWM
stimulation and and methimazole exerted no inhibitory action with any
mitogen. A direct action of methimazole, inhibiting thyroid antibody
production by lymphocytes in culture has been demonstrated by
McGregor et al (1980) and they estimate that this occurred at doses
of the drug which may prevail in the thyroid. These authors later
showed that the imunosuppressive action might be specific for thyroid
antibodies since it had no influence on parietal cell antibody levels
(McGregor et al, 1982). A haemolytic plaque-forming assay using
protein A coated sheep red blood cells and a specific plaque-forming
assay using thyroglobulin coated red cells has been used by Weiss et
al (1981) to assess total and specific immunoglobulin formation
respectively. They found no influence of methimazole and
propylthiouracil on fresh lymphocyte incubations, but on prolonged
culture both exerted a significant immunosuppressive effect.
Methimazole did not influence immunoglobulin production in the study
of Pinchera et al (1969) when they immunized intact mice with sheep
red blood cells.
Antithyroid drugs can clearly influence antibody production but this
is probably not due to a direct action on lymphocytes which do not
have a peroxidase and are therefore unlikely to concentrate the
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drugs, unlike monocytes and polymorphonuclear leukocytes (Lam &
Lindsay, 1979). It has therefore been suggested that their
immunosuppressive action is mediated by an effect on accessory cells
(Weetman et al, 1983). When Hashimoto lymphocytes are incubated
with thyroglobulin primed accessory cells, antibody production is
inhibited by the addition of methimazole. The basis for this effect
may be the inhibition of oxygen radical production by monocytes which
may, in turn, affect antibody presentation by these cells (Weetman et
al, 1984).
Other aspects of cell-mediated immunity may also be affected by
antithyroid drugs: an inhibition of antibody- dependent cellular
cytotoxicity was demonstrated by Pozzilli et al (1982) when
lymphocytes from eleven normal subjects were incubated with
51-chromium labelled Chang liver cells. They also showed, in six
subjects, a decrease in low affinity sheep red cell rosetting cells
(which possess a receptor for the Fc portion of IgG and are
cytotoxic). Interleukin-2 (formerly T Cell Growth Factor) is a
soluble 15,000 to 20,000 molecular weight glycoprotein found in the
supernatant of stimulated lymphocyte cultures (Morgan et al, 1976) It
can stimulate, for months on end, the growth of T cells in culture. A
receptor for this molecule is expressed on activated lymphocytes
(i.e. cells which have been exposed to an antigen in association with
a major histocompatibility antigen: Larsson & Continho, 1979). This
receptor, which can be detected using the monoclonal antibody TAC, is
an intermediate activation antigen - it is expressed on activated T
cells after the 4F2 antigen but before they express class II
histocompatibility antigens (Lotner et al, 1 983). Lymphocyte
activation is discussed in detail in Chapter 8. Signore et al (1985)
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have shown that, in lymphocyte cultures from 19 healthy volunteers,
the expression of interleukin-2 receptor is inhibited by carbimazole.
This was found to be a true effect on diminished production of
receptor rather than a blocking effect of the drug on the
interleukin-2 receptor.
Evidence against an immunosuppressive action of antithyroid drugs has
been presented by Wengel and Lente (1984) who demonstrated that
treatment with perchlorate produced similar changes in thyroid
stimulating immunoglobulins to antithyroid drugs. Data from in vitro
studies is however convincing as are observations from numerous other
clinical studies: these drugs have been shown to diminish antibody
production in the thyroid and this may be mediated by a metabolic
action on antigen presenting cells. An effect on killer cell activity
is also described as are changes in lymphocyte activation antigens.
PATIEHTS AND METHODS
A follow-up study from the time of diagnosis was undertaken with
twenty four unselected thyrotoxic Graves' patients (six male,
eighteen female; mean age 31.6 years, SD 11.6). Venous blood was
withdrawn from all patients prior to starting carbimazole therapy and
at intervals thereafter for up to nine months (at least four samples
were taken from each patient). 19 samples were studied at one month,
17 at two months and then 16, 19, 12, 13, 7, 6 and 9 samples in
successive months. Thyroid hormones were measured in the Department
of Clinical Biochemistry, Royal Infirmary of Edinburgh by in-house
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radioimmunoassay. The upper limit of normal for T3 was 2.8 nmol/1 and
for Ti|? 150 nmol/1. Thyroid microsomal antibodies were measured by
tanned red cell haemagglutination using commercially available kits
(Fujizoki) and TSH receptor antibodies by the radioreceptor assay on
neat serum as described in APPENDIX 1. Carbimazole (Neomercazole,
Nicholas Laboratories Limited) was started at an initial dose of 30
to 45 milligrams per day in divided doses and the dose was
subsequently reduced according to the clinical and biochemical
response to a maintenance dose of five to ten milligrams per day. No
patient developed worsening of their thyrotoxicosis or hypothyroidism
and all were established on the maintenance dose within the first six
months from diagnosis.
RESULTS
Of the 24 patients in the study, 18 (73%) were positive for TSH
receptor antibodies (TBII) and 17 (7150 for thyroid microsomal
antibodies at diagnosis. Thyroid hormone and antibody data on
follow-up is shown in FIGURE 3.2. The mean Tg at diagnosis was 7.1
nmol/1 and the mean T4 was 263 nmol/1. These had fallen to 3.0 nmol/1
and 138 nmol/1 respectively by the end of the first month of therapy
and, by the second month to 2.4 nmol/1 and 109 nmol/1. In spite of
this rapid biochemical control and good symptomatic relief,
immunological tests were abnormal for considerably longer. The
initial median value for TBII was 22.6 and this was not significantly
changed after one or two months of treatment with levels of 28.4 and
26.7 respectively. It was only after this point that TBII gradually
declined, reaching normal by five months and remaining low for the
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FIGURE 3.2 THYROID HORMONES AND AUTOANTIBODIES IN THE COURSE OF
CARLSIMAZOLE THERAPY
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rest of the follow-up period. The modal value for microsomal antibody
titre at diagnosis was 402 and, in most patients, showed no
consistent change until after three months of therapy by which time
titres were and remained lower than they had been at diagnosis.
Carbimazole treatment was generally continued for between one year
and eighteen months. Recurrent thyrotoxicosis following cessation of
therapy was usually accompanied by a persistence of high TBII during
therapy or, in cases where the TBII had responded to treatment, by a
return of TBII to values approaching those at initial diagnosis.
Data from two patients, both apparent HLA-DR3 homozygotes is shown
in FIGURE 3.3. Despite the normal TBII on stopping the drug, there
was a fairly rapid biochemical relapse in both patients and this was
associated with an increase in their TBII back into the abnormal
range. Data on HLA-DR typing of Graves' patients is presented in
Chapter 6. TBII usually remained negative in patients who were
euthyroid after carbimazole therapy, but in two cases (see FIGURE
3.4) persistent or recurrent TBII was not associated with thyrotoxic
relapse during a seven month period of follow-up. Nearly all
patients in long-term remission, however, have a normal TBII as
discussed in Chapter 2, but in patients with immunological
recurrence the response of the thyroid may be limited by concurrent
thyroiditis.
Episodes of recurrence, as shown by positive TBII, may be self
limited and do not necessarily require further antithyroid therapy
as demonstrated by the following case:-
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FIGURE 3.3 TSH RECEPTOR ANTIBODIES AND THYROTOXIC RELAPSE IN TWO
HLA-DR3 HOMOZYGOTES
u
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FIGURE 3.4 TSH RECEPTOR ANTIBODIES IN PATIENTS EUTHYROID AFTER
A COURSE OF CARBIMAZOLE
TABLE 3.1 BIOCHEMICAL AND IMMUNOLOGICAL DATA ON A PATIENT WITH A
SELF-LIMITED RELAPSE OF THYROTOXICOSIS AFTER CARBIMAZOLE
MONTHS AFTER STOPPING CARBIMAZOLE
0 2 4 6 7 8 7 10 18
T3 (nmol/1) - 2.5 - 5.2 4.3 3.2 2.6 2.7 2. 1
Tij (nmol/1) - 122 125 150 160 143 130 125 135
MICROSOMAL Ab. 102 102 402 402 202 402 <\JOCO 402 -
TBII 3-1 12.1 25.4 31.9 26.1 25.1 18.2 19.8 5.2
TABLE 3.2 BIOCHEMICAL AND IMMUNOLOGICAL DATA ON A PATIENT RELAPSING
AFTER LONG-TERM CARBIMAZOLE TREATMENT
MONTHS AFTER TREATMENT STOPPED
0 2 5 9 11
T3 (nmol/1) 1.7 1.8 3.1 2.5 4.7
Ti| (nmol/1) 90 115 150 150 240
MICROSOMAL Ab. 402 - 802 402 402
TBII -1.6 -2.3 17.3 31.6 19.7
OTHER Abs. PC/ANF - PC/ANF PC/ANF PC/ANF
PC = Parietal cell antibody
ANF = Antinuclear factor
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CASE HISTORY 1.
A 27 year old lady presented in October 1981 with mild symptoms of
thyrotoxicosis and a small goitre but no exophthalmos. Her thyroid
hormones were elevated (T3 5.2 nmol/1; Tij 184 nmol/1) and the TRH
test was flat. She was taking no medications and there was no family
history of autoimmune disease. Technetium scanning confirmed a
diffuse goitre and the four hour 131I uptake was elevated at 70%
(normal up to 30%). Thyroid microsomal antibodies were detected at a
titre of 2C)2 and TBII was 35.0. She was HLA-DR 3+7. Carbimazole was
started using the regime described above and treatment was continued
until March 1983 (a total of 15 months). On stopping therapy, she was
both biochemically and clinically euthyroid. Her hormone and
immunological data on follow-up thereafter is shown in TABLE 3.1. Her
TBII rose gradually to nearly pre-treatment levels and she suffered a
mild biochemical relapse although she had no real symptoms during
this and antithyroid drugs were not therefore restarted.
The controversy surrounding the duration of antithyroid therapy was
highlighted in the introduction to this chapter. The case history
below demonstrates that, even with prolonged therapy, where
thyrotoxicosis was readily controlled by a small maintenance dose of
carbimazole, relapse may still occur promptly on stopping therapy
CASE HISTORY 2.
A twelve and a half year old girl presented in February 1979 with
symptoms and signs of hyperthyroidism. She had a small diffuse goitre
and mild bilateral exophthalmos. Thyrotoxicosis was easily controlled
with carbimazole and she was rapidly established on a maintenance
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dose of 5 mg. per day. Because of her age, this treatment was
continued until after puberty. Treatment was stopped in September
1983 (a total of four years and six months). Immunological data is
not available from her first presentation. She was homozygous for the
HLA-DR3 phenotype. Data in TABLE 3.2 shows her course after stopping
carbimazole. She ultimately underwent subtotal thyroidectomy.
B: THYROID ANTIBODIES AFTER DESTRUCTIVE ANTITHYROID THERAPY
I) RADIOACTIVE IODINE THERAPY
The treatment of thyrotoxicosis with radioactive iodine was
introduced in the late 1940s. While it will control the
thyrotoxicosis in over 97$ of cases, it has the disadvantages of
occasionally temporarily worsening the thyrotoxicosis biochemically,
there is often a delay in its onset of action and there is a high
incidence of hypothyroidism following treatment. With conventional
therapeutic doses of 1311, hypothyroidism is commonest in the first
year (Dunn & Chapman, 1 964) and the incidence of this early
hypothyroidism is dose dependent (Smith & Wilson, 1967). Thereafter,
there is a steady cumulative rise in the prevalence of hypothyroidism
amounting to about 1 - 6$ per year and this does not appear to
diminish, even with prolonged follow-up (Belling & Einhorn, 1961;
Dunn & Chapman, 1964; Nofal et al, 1966). Temporary changes in
thyroid function are common following therapy, with either a low Ti|
alone or in association with elevated TSH (Bellarba, Benard &
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Langlois, 1972). These changes do not necessarily herald permanent
hypothyroidism. A high TSH is common long after therapy, even in
apparently euthyroid patients (Slingerland et al, 1972; Gordin, 1973;
Gordin et al, 1973) and, while this obviously does help to predict
permanent hypothyroidism, it may take many years to develop (Toft et
al, 1975).
In view of the high incidence of hypothyroidism, attempts have been
made to reduce the dose of radiation while still controlling the
thyrotoxicosis. The incidence of hypothyroidism in the early years
after therapy is undoubtedly reduced (Hagen, Ouelette & Chapman,
1967; Smith & Wilson, 1967) but there may be a marked decrease in the
proportion of patients responding to a single dose of 131i (Goolden
& Fraser, 1969; Rapoport, Caplan & DeGroot, 1973). It may be a
reasonable strategy to treat selected patients where rapid control is
not crucial with low dose therapy, but the response rate of Rapoport
et al, for example, where 46 out of 85 patients required at least one
further dose is clearly unacceptable. Also, it is by no means clear
that low dose therapy alters the long-term prognosis as far as
hypothyroidism is concerned: Glennon et al (1972) found 48% of their
patients to be hypothyroid 17 years after low dose therapy (3 mCi)
while Cevallos et al (1974) showed that the annual incidence of late
hypothyroidism may actually be increased with low dose therapy
(presumably because fewer of the cases develop in the immediate
post-treatment period). Roudebush, Hoyle and Degroot (1977) have
described a compensated low dose regime where the dose of radiation
is closely matched to the mass of tissue in the gland. 66$ of their
patients were euthyroid at one year with only 10$ being hypothyroid.
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It has been suggested that two mechanisms may operate in
post-irradiation hypothyroidism (Malone & Cullen, 1976): In the early
months, direct damage to the thyroid cells occurs and the extent of
this is related to the dose of radiation. The iodine trapping
capacity of the normal gland is not, in fact, unduly sensitive to
irradiation but the high mitotic index of toxic glands may render
them more sensitive (Greig et al, 1965). By contrast, late
hypothyroidism is not so clearly related to the dose of 131i and may
relate more to the natural history of Graves' with autoimmunity
playing a part. It is by no means certain however, that early
hypothyroidism is only due to irradiation changes which are often
unimpressive when the glands are examined histologically (Dailey,
Lindsay & Miller, 1953) and immunological factors may again be
important. Certainly, increases in the titres of antithyroid
antibodies after ^ 31j are well documented and may influence the
ultimate prognosis.
Increased levels of thyroid cytoplasmic antibodies after 131I therapy
have been documented by several groups (Buchanan et al, 1 962;
O'Gorman, Staffurth & Ballentyne, 1964; Einhorn et al, 1965). the
latter authors found no difference in the titre of anti-thyroglobulin
antibodies, although this has been reported by at least two other
groups (Burke, 1967; Kriss et al, 1967). Thyroid antibodies did rise
after therapy in the study of Jonsson et al (1968), there was no
increase in parietal cell antibodies, antinuclear factor or
antibodies to gamma globulin and irradiating the uterus produced no
change in antithyroid antibodies. In the study by Irvine et al
(1964), the major rise in the average titre of antithyroid antibodies
in a series of thyrotxic patients treated with 131i was due to those
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patients who were already thyroid antibody positive before therapy.
The toxic gland may be more sensitive to the effects of irradiation
but rises in both anti-cytoplasmic and anti-thyroglobulin antibodies
were found when euthyroid subjects were given ^311 for nodular
goitre, cardiac disease or residual carcinoma after surgery (Einhorn,
Fagraeus & Jonsson, 1966). In an in vitro study, Einhorn et al (1971)
have shown that lymphocyte stimulation by thyroglobulin is enhanced
at six to twelve weeks after 131i. When lymphocytes from Hashimoto
patients are cultured with previously irradiated lymphocytes, there
is an enhanced antibody production, even though the irradiated cells
on their own show diminished antibody secretion (McGregor et al,
1979b; 1979c). This may be due to selective depletion of suppressor
lymphocytes by the radiation.
Several groups have reported increases in LATS after radioactive
iodine therapy (Pinchera et al, 1965; Kriss et al, 1967; Pequegnat et
al, 1967) although these rises are usually transient (Lipman, 1967)
and are not found in patients treated for toxic adenomas (Pinchera et
al, 1969). Wasnich et al ( 1 969) reported seven patients developing
exophthalmos after external neck irradiation for non-thyroidal
neoplasms. All had residual thyroid function, indeed four became
thyrotoxic and all developed thyroid autoantibodies (including LATS
in three cases). None of these patients had previous evidence of
thyroid dysfunction. Volpe et al (1969) did not detect any increase
in LATS in thirteen patients treated with large doses of radioactive
iodine, but they had all been treated with 1311 one to eight years
previously and were selected for the study because of their
persistently elevated LATS following this first treatment. Martin et
al ( 1972) similarly did not find any difference in LATS after
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therapy, in agreement with studies by McKenzie (1965; McKenzie &
McCullagh, 1968) although in the latter studies persistent LATS long
after therapy was found to be quite common. Increases in both the
level and the incidence of TSH binding inhibitory antibodies have
been shown to occur after 1311 therapy (Fenzi et al, 1979; Teng et
al,1980), while Beck & Madsen (1980) showed that adenylate cyclase
stimulating antibodies increased, with some patients who were
initially negative becoming positive.
Compared to the work done on predicting the response to antithyroid
drug therapy, relatively little has been published relating the
relapse or hypothyroid rate after 131x to immunological tests. Greer
and Wilson (1964) found no correlation in their large series between
the ultimate outcome and serological tests or their changes with
therapy. Einhorn et al (1965), on the other hand, did find a
relationship between the expression of thyroid cytoplasmic antibodies
after therapy and the occurrence of permanent hypothyroidism. In
1973, Lundell and Jonsson reported that, in a follow-up study of 188
patients, hypothyroidism occurred in 52$ of patients with cytoplasmic
antibodies compared to only 21$ of those without antibodies. An
increase in cytoplasmic antibodies was frequently recorded at two to
twelve months after treatment but this did not apparently relate to
the development of hypothyroidism except in those patients who were
initially negative for antibodies. Anti-thyroglobulin antibodies were
also associated with hypothyroidism after 1311 but hypothyroidism was
not more common in those who only expressed these antibodies after
treatment. A survey of thyroid function in over 5000 adults in east
Finland actually suggested thyroglobulin antibodies may be protective
as far as the efects of 131i on the thyroid are concerned (Einhorn et
-92-
al, 1966), since in euthyroid patients after treatment, the mean TSH
was lower in patients with anti-thyroglobulin than in those without.
This was not however borne out by a later study published by the same
authors (Einhorn et al, 1966b) where 72 patients were examined at one
to ten years after therapy: five out of nine patients with a raised
TSH were anti-thyroglobulin antibody positive compared to only nine
of the remaining 63 with normal TSH.
Direct evidence that TSH receptor antibodies are related to the
prognosis after ^ 31 x was provided by the study of McGregor et al
(1979a). Most of their patients showed an increase in TBII after
therapy and also responded biochemically within three months. The
three patients who had increased TBII and were still toxic at three
months were controlled without further treatment by six months. Of
the five cases still toxic at six months, four showed a decrease in
TBII while the level was unchanged in the fifth. Beck et al (1982)
demonstrated that the binding inhibitory antibodies produced after
13might be non-stimulatory to the thyroid by showing that a
dissociation existed after therapy between TBII and adenylate cyclase
stimulating activity. TBII were higher both before and after
treatment in patients developing hypothyroidism. Davies, Platzer and
Farid (1982) found a strong relationship between TBII and the
response to 1311 with HLA-DR typing also helping to predict the
response: 23 out of 43 patients studied were TBII positive and
eighteen of them had responded to therapy by three months, compared
to only 4 out of 20 TBII negative patients. Ten of the 16 (62%) TBII
negative patients who failed to rspond were HLA-DR3 positive compared
to 25% of the general polulation.
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If autoantibody production can be causally linked to the response to
radioactive iodine, then pretreatment with antithyroid drugs might be
expected to reduce the response rate in view of their
immunosuppressive actions. Early studies with methylthiouracil did
indeed show a reduced one dose cure rate even though the effect on
iodide trapping by the gland was similar to that which could be
achieved with potassium perchlorate although the latter drug did not
affect the response rate. This effect was not seen with carbimazole
pretreatment (Goolden & Fraser, 1969) and it was suggested that the
SH group in methylthiouracil might act as a free radical scavenger.
However, propylthiouracil which does not contain a sulphydryl group
also reduces the response rate when it is given prior to ^ 311
(Einhorn & Saterborg, 1962). In spite of the reduction in the one
dose cure rate with some antithyroid drugs, their use has not been
associated with a reduction in the incidence of hypothyroidism and
the effect of antithyroid drugs given after radioactive iodine on the
response would make an interesting study.
II) SURGERY
Partial thyroidectomy is an acceptable form of treatment for many
patients with Graves' disease. There is a low incidence of
complications and a low recurrence rate (Michie, 1975; Blichert-Toft
et al, 1977; Toft et al, 1 978). The most important factor in the
development of post-operative hypothyroidism is the amount of
functioning thyroid tissue left after surgery, the incidence of
hypothyroidism after partial thyroidectomy varies in published series
between 6% and 17% (McNeill & Thompson, 1968; Griffiths et al, 197^;
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Evered et al, 1975; Michie, 1975; Toft et al, 1978). A higher
incidence has been reported in two series, however: Hedley et al
(1970) found 36$ of their patients to be hypothyroid after surgery
while Michie, Pegg and Brewster (1972) reported an incidence of 49$.
The former study was a retrospective one covering a long period of
time and many of the operations had been performed before the
importance of remnant size was recognised. In the second study, this
factor became obvious in the course of the project and clinical
practice was modified accordingly.
Thyroid histology also has an influence on the outcome after
operation. Patients with nodular goitres have less tendency to become
hypothyroid. For example, Lundstrom et al (1977) found a negligible
incidence of hypothyroidism after surgery for nodular goitre,
compared to 15$ in patients with diffuse goitre, while Heiman et al
(1962) had reported the incidence of post-operative hypothyroidism in
these two groups to be 1$ and 5$ respectively. Presumably areas of
the gland which are suppressed in the presence of autonomous nodules
respond to the high TSH after operation and recover functionally.
Temporary hypothyroidism in the months after operation is extremely
common (Toft et al, 1978). Even if the patient is not clinically
hypothyroid, elevation of the TSH and decrease of thyroid hormones is
frequently found. Evered et al (1975) discovered 65$ of their
euthyroid patients after operation to have a high TSH. These changes
usually resolve and relate poorly to the development of permanent
hypothyroidism (Lundstrom et al, 1978) although the high TSH may
persist for many years in clinically euthyroid patients (Hedley et
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al, 1971). There is not a cumulative increase in the prevalence of
hypothyroidism in the years after treatment as is found with
radioactive iodine therapy.
There is a well recognised association between inflammatory changes
in the thyroid and post-operative hypothyroidism (Whitesell & Black,
19*19). In an impressive study, Green (1950) demonstrated lymphocytic
infiltration in 44 out of 161 thyroidectomy specimens. Twenty of
these patients became hypothyroid after operation while none of the
117 patients with no lymphocytic infiltration did so. Similar
findings have been reported by Levitt (1951) and by Young, Beck and
Michie (1975). It is well known that lymphocytic infiltration of the
thyroid, particularly when germinal centres have formed, is
associated with circulating anti-thyroid antibodies (Goudie et al,
1959; Schade et al, 1960). Irvine and his colleagues ( 1962; 1967)
have reported on the value of circulating antithyroid antibodies in
predicting post-operative hypothyroidism even though they appear to
have no comparable value after 131i. Finally, van Welsum et al (1974)
also found circulating cytotoxic antithyroid antibodies to be more
common in those patients who became hypothyroid after surgery and
their presence related to plasma cell infiltration of the gland but
there was no difference in the extent of lymphocytic infiltration of
the gland in hypothyroid and euthyroid subjects following
thyroidectomy. They concluded that B cells and the humoral immune
response were important in the development of post-operative
hypothyroidism.
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Although both anti-cytoplasmic and anti-thyroglobulin antibodies may
persist in the serum after operation, they both generally decline
within one year of treatment (Einhorn et al, 1965; Gordin, 1973)-
LATS may persist for many years after surgery (McKenzie, 1965) but
this is probably related to underlying disease activity, with
thyrotoxicosis being prevented by the reduced mass of functioning
thyroid tissue, rather than to destruction of tissue caused by the
operation. LATS-Protector usually declines to normal within one year
of operation and rises in this activity are not seen following
operation (Hardisty, Talbot & Munro, 1981). The incidence of binding
inhibitory antibodies in the year following operation is low (17% in
the series of Mukhtar et al, 1975) when compared to the incidence in
untreated cases or those in the months after radioactive iodine
therapy. This finding was confirmed by Teng et al (1980) who found
three out of seven TBII-positive patients developed recurrent
thyrotoxicosis. Clearly, TSH receptor antibodies after surgery
better reflect the activity of underlying disease than they do after
^ 31 j an(j can thus be reliably used to predict the recurrence of
thyrotoxicosis.
RESULTS
A: CHANGES IN TBII FOLLOWING RADIOACTIVE IODINE THERAPY
Eighteeen patients with Graves' disease were followed up at intervals
after 131x therapy for up to two and a half years. There were two men
and sixteen women in the study and the mean age was 46.8 years (SD
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7.1). Mean T3 was 6.9 nmol/1 (SD 2.18) and the mean was 236 nmol/1
(SD 61.1). Blood was withdrawn from each patient prior to radioactive
iodine therapy and thereafter at least five sequential samples were
collected from each patient. TSH receptor antibodies were measured
with the radioreceptor assay on neat serum. The dose of *• 31 x varied
from patient to patient depending on goitre size, radioactive iodine
uptake and the severity of thyrotoxicosis, the mean dose for the
group being 7.7 mCi (range 5 to 15 mCi).
The results are shown in FIGURE 3.5 along with the number of samples
collected at each time interval. The median TBII at diagnosis was
35.0, and this was not markedly different at 1 - 2 months (37.5) but
had risen to over 55 by 3 - 4 months from treatment. This rise in the
median TBII was sustained until after eight months when it began to
decline although it did not reach normal levels until two years after
treatment.
B: TSH RECEPTOR ANTIBODIES AND THE RESPONSE TO RADIOACTIVE IODINE
A study was undertaken of 52 consecutive patients with mild to
moderate hyperthyroidism who were treated with 1311 to see whether
immunological tests performed at diagnosis had any bearing on the
ultimate outcome. All patients had a diffuse goitre and/or
scintiscan. Radioactive iodine uptake was measured four hours after
an oral dose of five microCuries 1311. Blood was withdrawn in all
cases prior to treatment. Thyroid hormones were measured by in-house
radioimmunoassay, TBII by the radioreceptor assay on immunoglobulin
concentrates as described in APPENDIX 1 and other thyroid antibodies
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FIGURE 3.5 CHANGES IN TSH RECEPTOR ANTIBODY LEVEL FOLLOWING
RADIOACTIVE IODINE THERAPY
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MONTHS AFTER TREATMENT
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were assayed by tanned red cell haeraagglutination using commercially
available kits (Wellcome). Six patients were excluded from the study
because they had severe thyrotoxicosis (mean T3 8.4 nmol/1), large
goitres and a high uptake of "• 311 (mean uptake 77%). The criterion
for exclusion was a four hour radioactive iodine uptake above 70%.
Such patients are well known to respond less well to radioactive
iodine, and since they would in any case be closely followed up
prediction of their outcome is of less importance. For the 52
patients included in the study, only their thyroid status at the end
of the six month follow up period was considered. Temporary
hypothyroidism occurring in the few months after therapy was
disregarded and only biochemically confirmed hypothyroidism after six
months was deemed to be permanent. Where patients did not respond to
the initial dose of ^311 ^ they were treated with a further dose but
their subsequent response was not included in the study. The dose of
radioactive iodine varied from patient to patient as described above
and depending on the need for other medical reasons to control
thyrotoxicosis urgently. The dose varied between five and fifteen
milliCuries.
Of the 52 patients in the study, six did not respond to their initial
dose of 1311 and required further treatment, while 19 of the
remainder were euthyroid and 27 hypothyroid at the end of six months.
The mean dose of 1311 in the three groups was 8.75 mCi, 7.0 mCi and
7.1 mCi respectively (none of these differences was statistically
significant). The mean T3 for the responders was 4.8 nmol/1 compared
to 5.8 nmol/1 for the euthyroid patients and 5.4 nmol/1 for the
hypothyroid patients (nil significant) , while the Tjj in the three
groups was 232, 237 and 208 nmol/1 (p < 0.05 for the euthyroid Vs
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hypothyroid). Four hour 131I uptake for the three groups was 50$, 51$
and 46$ respectively (nil significant). The levels of TSH binding
inhibitory immunoglobulins in the non-responders, euthyroid and
hypothyroid patients is shown in FIGURE 3.6. The median value for the
six non-responders was 6.5, compared to 10 for the euthyroid cases
and 18 for the hypothyroid cases. Only the difference between the
euthyroid and the hypothyroid cases was significant (p < 0.01,
Wilcoxon Rank Sum Test) and there was a significantly progressive
rise of TBII with increasing response to radioactive iodine (p <
0.01, Jonckheere Monotonic Trend Test for Independent Variables).
Thyroid microsomal antibodies were found in all six of the patients
who did not respond to their first dose of ^ 311 ? in 14 of the 19
patients who were euthyroid at the end of six months and in 15 of the
27 patients hypothyroid after six months (not significant). All of
the eight hypothyroid patients who were TBII negative were also
negative for thyroid microsomal antibody (p < 0.001, Chi Squared Test
with Yates' Correction). Anti-thyroglobulin antibodies were found in
nine patients overall, and seven of them were euthyroid at the end of
the six month follow up period (p < 0.01). Of the six patients
excluded from the study because of the severity of their
thyrotoxicosis, three were euthyroid after six months, two
hypothyroid while one required yet a further dose. All three
euthyroid patients had circulating antithyroglobulin antibody but
none of the other three patients was positive.
The difference in the response of TBII to 131l between nine
consecutive patients becoming hypothyroid and seven who were
euthyroid after six months was studied. The hypothyroid group
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FIGURE 3.6 TSH RECEPTOR ANTIBODIES AND THE RESPONSE TO
THERAPEUTIC DOSES OF RADIOACTIVE IODINE
-102-
consisted of eight women and one man, mean age 45.2 years (SD 5.9)
with a mean T3 at diagnosis of 5.9 nmol/1 (SD 0.7) and a mean T4 of
213 nmol/1 (SD 40.4). The euthyroid group were two men and five
women, mean age 46.0 years (SD 10.7) and a mean T3 of 5.2 nmol/1 (SD
1.2) and a T4 of 218 nmol/1 (SD 46.8). Samples of serum were studied
before treatment and at two to four months after therapy. All
measurements were performed as described above.
The changes in the two groups with therapy are shown in FIGURE 3.7.
In the euthyroid patients, the median TBII at diagnosis was 13.4
decreasing to 8.6 after 1311 (not significant). Three patients showed
a marked decrease in TBII, two increased but not outwith the normal
range and the other two did not change substantially. The median TBII
in the hypothyroid group was 26.7 at diagnosis rising to 33-1 after
) 311 (p < 0.05, Wilcoxon Rank Sum Test for Paired Samples). Six of
these patients showed a marked increase in TBII and the other two did
not change although they had initially been very high. After therapy,
the titre of microsomal antibodies increased in seven of the
hypothyroid patients and was the same in two as it had been before
treatment. The euthyroid group's response was much more variable with
two increasing, three decreasing and two staying the same.
Two patients who had previously been treated with carbimazole but
developed a recurrence were treated with radioactive iodine. Both
had high levels of TBII at diagnosis but remained euthyroid after
^311, thus not conforming to the pattern described above for newly
diagnosed Graves' patients
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FIGURE 3.7 TSH RECEPTOR ANTIBODIES FOLLOWING RADIOACTIVE IODINE
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CASE HISTORY 3.
A 42 year old lady was treated with carbimazole between June 1979 and
May 1981. She was euthyroid thereafter until August 1 982 when she
developed recurrent thyrotoxicosis with a Tg of 4.2 nmol/1, a T4 of
164 nmol/1 and a flat TRH test. She had a large goitre and the four
hour 1311 uptake was markedly elevated at 63?. Ten milliCuries of
1311 were administered and she became biochemically and clinically
euthyroid and remained so until June 1983 when she was lost to follow
up. At the time of her recurrence, TBII was 10.9 and microsomal
antibodies were detected at a titre of 402. Three months after
therapy, TBII had risen to 50.2 and microsomal antibodies to 1602.
CASE HISTORY 4.
A 43 year old lady reieved carbimazole between June 1978 and June
1979. In January 1980, she had a mild recurrence of thyrotoxicosis
and was treated with 5 mCi of 131j. she was euthyroid after this
until September 1982 when thyrotoxicosis again developed (Tg 4.1
nmol/1, Tj| 200 nmol/1 and ^311 uptake 68?). At the second recurrence
she had a small goitre and moderately severe bilateral exophthalmos,
the TBII was 69.7 and the microsomal antibody titre was 802. Four
months later, the TBII was 63.8 and the microsomal antibodies 3202.
She was still euthyroid and had high TBII in October 1984, 25 months
after the second dose of radioactive iodine.
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C: PERSISTENCE OF TSH RECEPTOR ANTIBODIES LONG AFTER 131I THERAPY
It is clear from the data presented in FIGURE 3.5 that TSH receptor
antibodies not only rise after radioactive iodine therapy but may
persist in the circulation for a considerable time. TBII were
measured on neat serum from 24 unselected patients followed up long
term after 1311 therapy for Graves' thyrotoxicosis (mean period 56.8
months, range 27 to 156 months). Significant levels of TBII were
found in ten cases and the persistence of TBII was strongly
correlated with the presence of exophthalmos at the time of follow-up
(see FIGURE 3-8). Ten patients in the study had clinically detectable
exophthalmos (two men and eight women treated an average of 52 months
previously with a mean dose of 7.0 mCi, range 5 to 15 mCi). The
fourteen patients without exophthalmos consisted of four men and ten
women treated on average 60.1 months before with a mean dose of 10.5
mCi (range 5 to 30 mCi).
TSH receptor antibodies were detected in eight of the ten
median
exophthalmic patients with a value of 33-5 while only two of the
patients without exophthalmos had TBII, the median value for this
group being 1.5 (p < 0.01, Mann-Whitney U Test). The two patients who
were TBII positive but did not have exophthalmos both had evidence of
other autoimmune disease: the first was a man in his late 50s who was
treated with 15 mCi in November 1980 and followed up until 1984 by
which time he had developed seropositive rheumatoid arthritis and had
a TBII of 12.7. The second was a lady treated with 5 mCi in January
1976 (then aged 52) and was followed up until June 1983 (TBII 74.1).
During the follow-up period she developed an illness with
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FIGURE 3.8 PERSISTENCE OF TSH RECEPTOR ANTIBODIES LONG





























N.B. Filled circles in patients without exophthalmos indicates
the presence of other autoimmune disease (see text).
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polyarthralgia and severe Raynaud's phenomenon, associated with high
ESR and high levels of circulating immune complexes (C1q solid
phase).
D: TSH RECEPTOR ANTIBODIES FOLLOWING PARTIAL THYROIDECTOMY
TBII data from eight female patients (mean age 29.1 years, SD 5.95,
range 18 to 40 years) following partial thyroidectomy is shown in
FIGURE 3-9. In all eight cases there was a decline in TBII from
pre-operative levels within a few months. All patients had been
rendered euthyroid prior to operation with carbimazole and all were
treated with potassium iodide and propranolol in the immediate
pre-operative period. They were all euthyroid during the nine month
follow-up period shown in Figure 3.9. One further patient (a twenty
year old female discussed in detail in Chapter 6) was negative for
TBII prior to operation but TBII appeared in the serum subsequently
and was associated with thyrotoxic relapse. Where data was available,
TBII declined to normal usually within one to two years after
operation but persistent TBII were found in two cases:-
CASE HISTORY 5.
A 39 year old lady presented in September 1981 with thyrotoxicosis
having had a small diffuse goitre for five years previously.
Carbimazole was started, but the goitre increased markedly in size
and she therefore underwent thyroidectomy in January 1982. Six months
later she developed severe bilateral exophthalmos and TBII was
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FIGURE 3.9 TSH RECEPTOR ANITBODIES IN THE MONTHS AFTER
PARTIAL THYROIDECTOMY
X3QNI AHOLiaiHNI 0NIGNI3 HSX
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positive at 52.1 (immunological tests had not been performed at
initial diagnosis). TBII was still positive two years after operation
at 10.9. She is HLA-DR 2 positive.
CASE HISTORY 6.
A 41 year old lady had a partial thyroidectomy in November 1976
having been treated with carbimazole for fourteen months previously,
there was a moderate sized diffuse goitre before surgery and marked
bilateral exophthalmos. TBII was 40.8 prior to operation and she was
HLA-DR 3+4. Over eight and a half years later in February 1984, she
was still TBII positive at 33.5 and her severe exophthalmos
persisted.
DISCUSSION
Carbimazole treatment for Graves' thyrotoxicosis produces symptomatic
and biochemical control within one to two months. It also lowers TSH
receptor antibody and thyroid microsomal antibody levels although the
time course of this is much slower, suggesting that the primary
action of the drug is antithyroid rather than immunosuppresssive.
One of the problems in accepting that the immunosuppressiive action
is important in vivo relates to the concentration of the drug
required to produce these effects. The thyroid is the major site of
thyroid autoantibody production (McLachlan et al, 1979) and
antithyroid drugs are concentrated in the thyroid. When 35s_iabelled
carbimazole is administered, its metabolite methimazole accumulates
in the thyroid (Marchant et al, 1972) and, similarly, methimazole
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itself and propylthiouracil accumulate in the thyroid when given
systemically (Lazarus et al, 1975). These studies showed a fairly low
plasma to tissue ratio of the drug, but in an even more recent study
using a highly sensitive gas chromatography-mass spectroscopic
analysis which showed that the ratio could be as high as 60:1
(Jansson et al, 1983), the estimated concentration in the thyroid was
not as high as that required to produce some of the in vitro
immunosuppressive effects. The major effect of antithyroid drugs on
the immune system may be mediated via accessory cells which could
become depleted in the preparation of mononuclear cells for in vitro
studies. The effect of these drugs on antigen presentation by the
thyroid itself, which is after all the major site of drug
accumulation, has not yet been considered in the published
literature.
By the end of a twelve to eighteen month course of drug treatment,
TBII is usually normal and if thyrotoxicosis recurs it is generally
associated with a further increase in TBII. Persistently high TBII in
the months after a course of carbimazole is not invariably associated
with thyrotoxic relapse - two such cases have been presented where
they remained euthyroid. The response of the thyroid to stimulatory
antibodies may have been limited by concurrent thyroiditis causing
destruction of functioning gland tissue or, alternatively, the
antibodies detected in the radioreceptor assay in these patients'
sera may have been receptor blocking antibodies rather than
stimulatory ones. A patient was described with a self-limited
recurrence of thyrotoxicosis which did not require therapy. The TBII
were very high in this case, yet the response of the thyroid was
clearly limited. The optimal duration of drug therapy is
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controversial, but in one case treated for four and a half years,
thyrotoxicosis recurred immediately carbimazole was stopped. This
patient was a DR3 homozygote and such patients frequently require
definitive treatment in the form of thyroidectomy or radioactive
iodine although the role of HLA typing in predicting the likelihood
of relapse has recently been challenged (see Chapter 6). It seems
however that immunological factors are certainly important in
determining the natural history of Graves' even if DR phenotype is a
poor marker: in toxic multinodular goitre, where the thyrotoxicosis
is probably not immunologically mediated, the therapeutic response to
antithyroid drugs is good but there is a high relapse rate on
stopping the drug in contrast to cases of thyrotoxic Graves' disease
where the immunological abnormalities have normalised during drug
treatment.
After therapeutic doses of radioactive iodine there was a transient
rise in TBII, in keeping with published data. The median value for
TBII in a follow up study of eighteen patients took two years to
return to normal and, even then, some patients still had high values.
Persistent TBII was found in ten out of 24 patients tested at random
27 to 156 months after therapy although none of these patients was
thyrotoxic. The persistence of TBII after 1311 therapy strongly
correlated with the presence of exophthalmos or other autoimmune
diseases. In untreated Graves' patients, the levels of TBII do not
correlate with the presence or severity of eye disease although
persistent LATS after 1311 therapy has previously been associated
with exophthalmos (Lipman, 1967). A role for LATS in the pathogenesis
of Graves' eye disease has been suggested: for example, the study of
Wasnich et al (1979) where seven pateints became exophthalmic and
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developed LATS after external neck irradiation for non-thyroidal
neoplasms. Generally, however, thyroid stimulating antibodies are not
thought to have any direct role in the production of eye changes in
Graves' disease. In spite of the rise in TBII after 1311, there is no
difference between the incidence of exophthalmos after this form of
therapy and that after surgery (Hamilton et al, 1967).
TBII may have a part to play in predicting the response to
radioactive iodine. In a six month follow-up study of 52 patients
after therapeutic doses of 1311, the median TBII was 6.5 in six non
responders compared to 10 in 19 euthyroid patients and 18 in 27
hypothyroid patients. TBII positive patients are more likely to
respond to 131 x and are more likely to develop hypothyroidism. TBII
negative patients who became hypothyroid were also negative for
microsomal antibodies suggesting that factors other than autoimmunity
are involved or that these patients may have had a
non-immunologically mediated thyrotoxicosis. Seven out of the nine
patients with anti-thyroglobulin antibodies remained euthyroid after
therapy (p < 0.01). This may reflect higher levels of thyroglobulin
in these patients - thyroglobulin can interfere with the binding of
TSH to its receptor as discussed in Chapter 2, this may prevent a
pathogenetic effect of receptor antibodies in post-iodine
hypothyroidism.
The response of TBII to 131i was different in patients becoming
hypothyroid to those who remained euthyroid, the former patients
showing a greater rise in TBII after therapy, suggesting that
autoantibodies to the TSH receptor might cause hypothyroidism.
Radioactive iodine therapy thus might be an important model for the
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study of immunologically mediated thyroid damage. Where the
thyrotoxicosis treated with radioactive iodine was recurrent, having
been previously treated with carbimazole, TBII was high in two
patients after 131i although both remained euthyroid after 131i. TSH
receptor blocking antibodies would be of interest to study in these
patients since such antibodies might protect the thyroid cell from an
immunological reaction directed at the TSH receptor.
After surgery, TBII declined in all eight patients studied during a
nine month follow-up period. Values for TBII were nearly always
normal in patients studied within one to two years after operation
(data not presented) but two cases are reported where persistent TBII
long after operation were associated with Graves' eye disease. It
would seem that patients with multiple autoimmune diseases are more
likely to become sensitised immunologically to thyroid cell damage







A series of 139 consecutive thyrotoxic patients with Graves' disease
(flat TRH test, raised T3 and/or T 4 y diffuse goitre and/or
scintiscan) was subdivided as follows: Group A - 89 patients with
goitre and high 131i uptake (over 40$ at four hours). Group B - 21
patients with goitre butlower 131i uptake (under 40%). Group C - 29
patients with no detectable goitre. The mean age in Group A was 41.0
years at diagnosis compared to 51.6 and 52.6 years respectively for
Groups B and C. The mean T3 for Group A was 6.6 nmol/1 compared with
4.2 nmol/1 (p < 0.001) for Group B and 5.4 nmol/1 (p < 0.001) for
Group C. The four hour 131I uptake was lower for the patients without
a goitre (Group C) than for those patients with goitre (Groups A and
B together) with values of 45% and 56% respectively (p < 0.001).
TSH receptor antibodies were detected using the binding inhibitory
assay in 64/89 (72%) of Group A, 9/21 (43$) of patients in Group B
and 9/29 (31$) of Group C. The median inhibition index in the three
groups was 24.8, 12.0 and 8.4 respectively. Titres of thyroid
microsomal antibody were significantly lower in Group C (no goitre)
than in group A (p < 0.02). In Group B, 9/21 patients had parietal
cell antibodies (42.9$) compared to only 4/89 (10.1$) of group A (p <
0.001). The total number of patients in group B with non-thyroidal
antibodies was 12/21 (57$) as against 14/89 (15.7$) for group A.
It is concluded that patients with Graves' disease but no goitre
differ from the majority of Graves' patients in that they are older,
they have less severe thyrotoxicosis and lower titres of thyroid
antibodies including TSH receptor antibodies. Patients with lower four
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hour 1311 uptake but with a goitre are also older and less toxic but
have a remarkable incidence of non-thyroidal autoantibodies. These
subgroups may represent different disease states or simply an
incomplete expression of Graves' disease, possibly due to age-related
changes in autoimmune phenomena.
INTRODUCTION
There is evidence for clinical and immunological heterogeneity in a
number of autoimmune diseases and in the polyendocrine deficiency
syndromes. For example, in Addison's disease (primary adrenocortical
failure) due to autoimmune destruction of the adrenal glands, not
all patients have circulating anti-adrenal antibodies and not all
patients show the recognised association with the HLA B8/DR3 axis
(see Chapter 6). On the basis of the association with other organ
specific autoimmune diseases, it has been suggested that two
different subgroups of Addison's patients may exist (Neufeld et al,
1979) and from this observation has developed the classification of
the polyendocrine deficiency syndromes (for review, see Loriaux,
1985). In Type I syndrome, adrenocortical failure is associated with
hypoparathyroidism and mucocutaneous candidiasis and, in a lesser
proportion of patients, with alopecia, pernicious anaemia,
malabsorption and chronic active hepatitis. The syndrome typically
begins in late childhood and has no recognised HLA association. In
Type II syndrome (Schmidt's syndrome), Addison's disease is found in
association with autoimmune thyroid disease and insulin dependent
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diabetes mellitus. Patients show an increased incidence of HLA-B8
(Eisenbarth et al, 1978). Gonadal failure and vitiligo may occur in
both types of polyendocrine deficiency syndrome.
The clinical syndrome of myasthenia gravis occurs in patients with
differing thymic pathologies and this relates to the expression of
autoantibodies and to the presence of HLA markers (Newsom-Davis et
al, 1982). The small group of patients with thymoma typically
presents in the fourth or fifth decade of life and there is an equal
sex incidence. High circulating levels of acetylcholine receptor
antibody are found and there is antibody to striated muscle in 90% of
cases but no clear HLA association exists. Amongst patients with
thymic hyperplasia, females predominate and the disease usually comes
on before the age of forty years, there are moderately high levels of
acetylcholine receptor antibody and an association with the
HLA-B8/DR3 axis (Pirskanen, 1976). Patients with thymic involution
usually present in later life, with males and females equally
affected, low levels of acetyulcholine receptor antibody in the
circulation and a possible association with HLA-DR2.
In type I diabetes mellitus, there is no definite evidence for
disease heterogeneity based on HLA typing studies (for review, see
Farid & Bear, 1981) except that those patients with coincident
thyroid disease show a stronger than expected asssociation with
HLA-B8, marked female preponderance, onset in later life and a strong
family history of autoimmune disease (Bottazzo et al, 1978). Cudworth
suggested that heterogeneity may exist with respect to aetiology:
Patients with purely virus induced insulitis would be younger, with
equal sex distribution and only transient islet cell antibody
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production around the time of onset, while those with a predominant
autoimmune aetiology who would have a wider age distribution at
diagnosis, be mainly female, tend to have persistent islet cell
antibodies and have a strong association with other autoimmune
diseases (Cudworth et al, 1980). Undoubtedly there is a spectrum with
some patients having entirely virus induced disease at one end and,
at the other end, patients in whom the islet cell damage is due
entirely to a primary autoimmune attack. In many patients it may
well be a combination of the two which gives rise to diabetes
mellitus.
There is only very limited evidence for environmental factors being
important in the induction of Graves' disease. Joassoo et al (1975)
have found an increased incidence of antibodies to influenza B and
mumps viruses in Graves' patients and Yersinia enterocolitica type 3
infection has also been suggested as a possible trigger for the
disease (Shenkman & Bottonne, 1976; Bech et al, 1977). It has been
postulated by Volpe's group that environmental stress, by decreasing
suppressor cell activity may, initiate some cases of autoimmune
thyroid disease (Strakosh et al, 1982). Doniach ( 1960) has reported
three cases of thyroiditis developing after mumps. If aetiological
or genetic heterogeneity were to exist in Graves' disease, it may
account for the variable expression of immunological markers and
recognition of this could increase the usefulness of immunological
tests in choosing the most appropriate therapy for a given patient
and in monitoring the response to that therapy.
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Two recent studies have suggested that heterogeneity may indeed
exist in Graves' disease: Schleusener et al (1983) have divided 150
consecutive patients with thyrotoxicosis and a diffuse goitre into
two groups. Group A consisted of 101 patients with either
ophthalmopathy or circulating TSH receptor antibodies, while Group B
had 49 patients with neither. Within Group A, there was the expected
aassociation with HLA-DR3 particularly in those patients with
relapsing hyperthyroidism. Group B patients, however, had no
increased incidence of HLA-DR3 but did have increased DR5 and in this
group DR5 was found particularly in patients with a tendency to
relapse after medical therapy. HLA antigens and TSH receptor
antibodies may thus be completely independent markers for Graves'
disease and there may be a genetically predisposed subgroup of
Graves' for which TSH receptor antibodies as detected by the
radioreceptor assay do not serve as a disease marker.
Stenszky et al (1983) used the mathematical technique of cluster
analysis to look at 49 clinical and immunological characterisics in
196 patients with Graves' disease. They did not measure TSH receptor
antibodies and only performed HLA-A and B typing but they did have
information from thyroid biopsies. Patients in this study could be
divided into three groups: the first group consisted of 79 patients
with small goitres, low indices of autoimmunity including lymphocyte
proliferative responses to thyroglobulin and a tendency to remit with
medical therapy. The second group was of 29 patients with
"Hashitoxicosis", having lymphocytic infiltration of the thyroid and
high titres of anti-thyroglobulin antibodies. The third, and largest
group, was of 84 patients with high indices of autoimmunity, high
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incidence of ophthalmopathy, strong familial tendency and a high rate
of relapse after medical therapy. The incidence of HLA-B8 in these
three groups was 9%, 21% and 87% respectively.
The relationship between Graves' disease and Hashimoto's thyroiditis
is a complex one. Both occur in patients with a similar genetic
background and both share many immunological features (for review,
see Kidd et al, 1982). Autoimmune ophthalmopathy may occur in
Graves', in pure Hashimoto's thyroiditis or indeed in patients with
entirely normal thyroids (Solomon et al, 1977). It may well be wrong,
in fact, to regard Hashimoto's and Graves' as separate disease
entities and perhaps they should be seen as different aspects of the
same disease process causing a spectrum of clinical conditions with
pure thyroid stimulation at one end and thyroid destruction by
cytotoxic antibodies and T cells at the other end. In terms of
treatment, it may be important to recognise the presence of
thyroiditis in a patient with Graves' thyrotoxicosis since it may
affect the response to radioactive iodine (Lundell & Johnson, 1973)
and to surgery (Whitesell & Black, 1949; Green, 1950; van Welsum et
al, 1974).
The coexistence of thyroiditis with LATS positivity has been
postulated to account for those patients with exophthalmos or
dermopathy and who have circulating LATS but do not become
hyperthyroid (Kriss et al, 1964; Liddle et al, 1965; Adams et al,
1969). Thyroiditis was demonstrated histologically in three
thyrotoxic patients with high levels of circulating antithyroid
antibodies by Buchanan and colleagues (1961). These authors also
described five patients with goitres and mildly elevated radioactive
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iodine uptakes who were biochemically euthyroid and had chronic
lymphocytic thyroiditis. Another possible source of confusion in
diagnosis is subacute thyroiditis with a presumed viral aetiology
where patients may develop transient mild thyrotoxicosis but soon
return to euthyroidism and occasionally ultimately become
hypothyroid. The 131i uptake in these cases is characteristically
very low. Fatourechi et al (1971) studied 24 Graves' patients with
histological Hashimoto's thyroiditis and found them to be older than
the average Graves' patient and they also had a particularly high
incidence of post-operative hypothyroidism. Ten of these patients had
either a personal or a family history of diabetes mellitus. The
identification of a subgroup of Graves' associated with HLA-DR5 by
Schleusener is relevant here since this marker is also known to be
associated with Hashimoto's thyroiditis (Farid et al, 1980).
That hypothyroidism may develop spontaneously in Graves' disease was
first recognised as long ago as 1895 by Baldwin, while Eason in 1928
demonstrated histologically that the two conditions can coexist in
the same gland. The possibility of progressive thyroiditis as an
important factor in the natural history of Graves disease was well
demonstrated in a pathological study of over 2000 thyroids by Levitt
in 1951. It is currently thought that, without destructive
antithyroid therapy, about 10% of Graves' patients will become
spontaneously hypothyroid (Doniach, 1981). Primary hypothyroidism is
generally a permanent state but spontaneous remission has been
described (Nelson & Palmer, 1975; Yamamoto & Sakamoto, 1978) and
there are now a number of cases reported where primary hypothyroidism
has been succeeded by thyrotoxicosis. In 1959, Joplin & Fraser
reported a case in which hyperthyroidism developed in a patient with
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focal thyroiditis but the first cases of thyrotoxicosis following
biochemically confirmed hypothyroidism were reported in 1971 (James,
1971; Goolden et al, 1971). Since then further case reports have
appeared in the literature (Gavras & Thomson, 1972; Williams et al,
1974; Bremner & Griep, 1976; Olczak et al, 1978). In some of these
cases, for example, the two reported by Irvine and his colleagues,
the thyrotoxicosis was quite resistant to therapy. Presumably where
hypothyroidism remits spontaneously or progresses to thyrotoxicosis
there is either regeneration of destroyed thyroid tissue under a
trophic stimulus or the hypothyroidism was in the first place due to
TSH receptor blocking antibodies rather than to autoimmune tissue
destruction.
It is well recognised that thyrotoxicosis may occur in the absence of
a goitre but standard textbooks of endocrinology usually state this
to be a relatively uncommon occurence although its frequency may
increase with age. (Burgi & Labhart, 1974; Montgomery & Wellbourn,
1975; Ingbar, 1985). Hegedus et al (1983a) have developed the use of
ultrasound to determine thyroid gland volume and have found it to
relate to age, sex and body weight in normal subjects. When they
studied 90 consecutive thyrotoxic patients (Hegedus et al, 1 983b),
they found the gland to be impalpable in 28 (31%) and normal thyroid
volume was confirmed by ultrasound in 21 (23%) • Thyroid volume in
this study did not correlate with any measure of thyroid function or
with the age of the patient. The high frequency of thyrotoxicosis
with an impalpable thyroid gland has recently been confirmed by
Greenwood et al (1985) who reviewed 594 consecutive cases of
thyrotoxicosis. A diffuse goitre was found in 374 (63%), a nodular
goitre in 110 (19%) and no goitre in 96 C\6%) . The proportion of
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patients with nodular goitres or impalpable glands increased with
age. The frequency of antithyroid antibodies was similar in all three
groups and patients with no goitre had the same incidence of
exophthalmos as those with diffuse goitre although there was a very
low incidence in patients with nodular goitre. The frequency of post¬
partum thyrotoxicosis and hypothyroidism in women with subclinical
autoimmune thyroid disease has recently become appreciated and many
of these patients do not have goitre at the time of presentation
(Amino et al, 1982). Some patients, at least, with thyrotoxicosis but
no goitre therefore have evidence of an underlying autoimmune disease
although they clearly lack the usual stimulus to thyroid cell growth
which is found in classic Graves' disease.
The aim of the work presented in this chapter is to consider humoral
immune changes in a large consecutive series of patients with
thyrotoxic Graves' disease in the light of possible disease
heterogeneity. In addition to patients with classical Graves' disease
(goitre plus high 1311 uptake), two possible subgroups have been
considered: Firstly, those patients without grossly elevated four
hour 1311 uptakes since this group may include patients with
coincident thyroiditis which could be of considerable prognostic
importance. Secondly, patients with no palpable goitre, a
presentation of Graves' disease which is now considered to be
relatively common. These patients need to be included in
epidemiological studies of thyrotoxicosis, and some clearly have
autoimmune disease since they have an appreciable incidence of
exophthalmos (Greenwood et al, 1985) but they are often excluded from




The study included 139 consecutive patients presenting to the Royal
Infirmary, Edinburgh with thyrotoxicosis and a diffuse uptake of
isotope on a technetium scintiscan. There were 124 females and 15
males with ages ranging from 15 to 78 years (mean 44.9 years).
Graves' disease was diagnosed on the basis of raised T^ and/or Ti|> a
flat TRH test and a diffuse goitre and/or scintiscan. Rectilinear
scanning was performed twenty minutes after the injection of one
microCurie of 99tc sodium pertechnetate. 1311 uptake was measured
four hours after an oral dose of five microCuries. The presence of
goitre was assessed clinically and all patients without goitre
irrespective of their ^ 31 j uptake were assigned to Group C.
Radioactive iodine uptake was also measured in 41 controls who were
unselected clinic patients in whom endocrine and autoimmune disease
had been excluded.
AUTOANTIBODY MEASUREMENT
Thyroid microsomal and anti-thyroglobulin antibodies were measured
using standard, commercially available haemagglutination kits
(Wellcome). For the former, a titre of 202 was considered to be
weakly positive, 402 ancj above to be definitely positive and for the
latter a titre of 320 or above was positive. Indirect
immunofluorescence assays were performed on seven micrometer sections
of human thyroid, rat stomach and kidney. TSH receptor antibodies
were measured by the radiorecpeptor assay on immunoglobulin
concentrates as described in APPENDIX 1.
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STATISTICS
Data on radioactive iodine uptake, age at diagnosis and thyroid
hormone levels were analysed using Student's t test. TSH receptor
antibody values were clearly not normally distributed and were
therefore compared using the Wilcoxon rank Sum Test. All other
probability values were derived using the Chi-squared test with
Yates' correction.
RESULTS
The series of 139 patients with thyrotoxicosis were divided into
three groups
Group A - 89 patients (64%) with goitre and high
radioactive iodine uptake (over 40$)
Group B 21 patients (15$) with goitre but low
radioactive iodine uptake (below 40$)
Group C - 29 patients (21$) with no detectable goitre
FOUR HOUR 1311 UPTAKE
Data for the four hour radioactive iodine uptake in the three groups
is shown in FIGURE 4.1 along with results from 41 normal controls.
The mean four hour uptake for the controls was 16.8$ (SD 5.1, range
10 to 30). The mean 131i uptake in the high and low uptake groups of
toxic patients with goitre was 61.9$ (SD 11.1, range 43 to 89) and
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FIGURE 4.1 FOUR HOUR UPTAKE OF RADIOACTIVE IODINE IN NORMAL


































































31.9% (SD 5.9, range 16 to MO) reepectively. The mean uptake for the
patients with no goitre (Group C) was M6.M$ (SD 12.9, range 25 to 77)
and this differed significantly from the means of normal controls and
that of both groups of thyrotoxic patients with goitre (all p <
0.001).
AGE AT DIAGNOSIS
The mean age in group A at diagnosis was MO.9 years (SD 12.M)
compared to 51.6 years (SD 11.6) in Group B (p < 0.001) and 52.6
years (SD 12.2) in Group C (p < 0.001) - see FIGURE M.2. There was no
significant difference between Groups B and C.
THYROID HORMONES
The values for Tj are shown in FIGURE M.3. Patients in Group A had a
mean T^ level of 6.6 nmol/1 (SD 2.M) compared to M.2 nmol/1 SD 1.1, p
< 0.001) for Group B and 5.M nmol/1 (SD 1.3, P < 0.001) for Group C.
The mean Tjj in the three groups was 2M0.8 nmol/1 (SD 56.3), 205.3
(SD M0.3) and 223.0 (SD 39.5) respectively for Groups A, B and C. The
only significant difference was between Groups A and B (p < 0.01).
AUTOANTIBODIES
TSH receptor antibody levels are shown in FIGURE M.M. The mean
inhibition index for Group A was 2M.8 as against 12.0 (p < 0.001) for
Group B and 8.M (p < 0.001) for group C. In group A 6M/89 (72$)
patients were positive compared to 9/21 (M3$, P < 0.05) in Group B
and 9/29 (31$, P < 0.001) in Group C - see TABLE M.1.
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TABLE 4.1 AUTOANTIBODIES AGAINST THE THYROID AND OTHER TISSUES IN
THREE GROUPS OF PATIENTS WITH GRAVES'DISEASE
GROUP A GROUP B GROUP C
(n = 89) (n = 21) (n = 29)
No. (50 No. (50 No. (50
TBII POSITIVE 64 (72) 9 (43)* 9 (3D**
MICROSOMAL Ab. 43 (34) 10 (48) 8 (28)
THYROGLOBULIN Ab. 9 (10) 3 (14) 1 (3)
PARIETAL CELL 9 (10) 9 (43)** 2 (7)








14 (16) 12 (57)** 3 (10)
= p < 0.05 compared with Group A
**
= p < 0.001 compared with Group A
Mitochond. = Mitochondrial antibody positive
Group A = High uptake + goitre
Group B = Low uptake + goitre
Group C = No goitre
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The titres of other autoantibodies are also shown in TABLE 4.1. There
was no significant difference in the numbers of patients in the three
groups positive for anti-microsomal or anti-thyroglobulin
antibodies. However, when the actual titres of thyroid microsomal
antibodies were analysed using a rank correlation test, significantly
lower values were found in the group of patients with no goitre when
compared to the rest of the patients (p < 0.01).
There was an unusually high incidence of parietal cell antibodies in
group B with nine out of 21 patients positive (43%) as opposed to
9/89 (10%) of Group A (p < 0.001) and 2/29 (7%) of Group C. The
total number of patients in Group B with non-thyroidal
autoantibodies was 12/21 (57%) compared to 14/89 (16%) of group A
and 3/29 (10)5) of group C.
DISCUSSION
Using the four hour radioactive iodine uptake and clinical
observation on the presence or absence of a goitre, it has been
possible to identify three putative subgroups of Graves' patients in
a series of 139 patients. The first group (89 patients) had goitre
and high 311 uptake and may be regarded as having classical Graves'
disease. The second group was of 21 patients with goitre but without
grossly elevated ^311 uptake (less than 40$ at four hours), while the
third group was of 29 patients with no detectable goitre.
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The patients with low radioactive iodine uptake and goitre (Group B)
were older than the patients with high uptake and less severely
thyrotoxic as judged by their thyroid hormone levels. They were
studied as a separate group since minor degrees of elevation of the
radioactive iodine uptake may occur in thyroiditis and multinodular
goitre both of which may have some clinical and immunological overlap
with Graves' disease. TSH receptor antibodies were detected in fewer
of this group and the levels of TBII were lower than in the patients
with goitre but with a high 131i uptake. They also had a remarkably
high incidence of non-thyroidal autoantibodies (mainly parietal cell)
with 12/21 (57$) positive compared to 14/89 of the high uptake group.
This group of patients may be analagous to the "Hashitoxicosis "
patients in the study of Stenzsky et al (1983). The association of
Hashimoto's thyroiditis with HLA-DR5 (Farid et al, 1980) is of
interest in the light of the high incidence of parietal cell antibody
since pernicious anaemia is also associated with HLA-DR5. The
coexistence of Graves' disease with other autoimmune diseases in this
sort of patient was also noted by Fatourechi et al (1971) who found
five out of 24 patients with Graves' and histological thyroiditis to
have diabetes mellitus and a further five to have close relatives
with diabetes.
Patients with "Hashitoxicosis" may differ prognostically with a
higher proportion becoming hypothyroid, either spontaneously or after
destructive antithyroid therapy. Of the 57 patients studied in
Chapter 3 after 131i therapy, 31 had high uptake and goitre (Group
A), 11 had low uptake and goitre (Group B) and 15 patients had no
goitre (Group C). In all, six patients did not respond to their
initial dose of radioactive iodine and required further therapy
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(three in group A and three in Group B). Of the 28 patients who
responded to a single dose in Group A, 15 patients were euthyroid
after six months while 13 had become hypothyroid. In Group C, nine
out of the fifteen patients, all of whom responded to a single dose,
became hypothyroid. In Group B, there were eight responders and seven
of them became hypothyroid in the six months following treatment.
While no statistically significant differences were found, there is
some indication that Group B patients are more likely to become
hypothyroid after therapeutic doses of radioactive iodine.
Patients with no goitre are also older than patients in Group A and
have less severe thyrotoxicosis. Since such patients may account for
up to 20$ of cases of thyrotoxicosis, it is clearly of importance to
decide whether they are suffering from true Graves' disease or
whether some other pathology is involved. The relatively high
incidence of exophthalmos in patients with no goitre reported by
Greenwood et al (1985) and the appreciable incidence of TSH receptor
antibodies reported here support the hypothesis that some, at least,
of these patients have true Graves' disease. In the diagnostic index
for thyrotoxicosis devised by Crooks et al (1959) before
sophisticated thyroid hormone measurements were available, the
absence of goitre weighed heavily against the diagnosis. These
authors did however, cite the case of a 63 year old man who had no
goitre but did have a high diagnostic index supporting the diagnosis
of thyrotoxicosis. Although the diagnosis of hyperthyroidism is now
made much more readily, it is not always easy to substantiate a
diagnosis of Graves' disease as the underlying cause since no single
marker is always positive and it is possible for patients with early
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disseminated thyroid autonomy to have a diffuse thyroid scan because
individual thyroid follicles may begin to function autonomously
before discrete nodules form (Studer et al, 1978).
Heterogeneity may therefore exist within Graves' disease and it may
possible
become^in time to devise a classification analagous to that for
diabetes mellitus. Apparent heterogeneity may exist because of the
variable expression of autoantibodies such growth promoting
antibodies or cytotoxic antibodies or there may be an incomplete
expression of some of the features of the disease in some patients








Immune complexes were studied using the C1q solid phase assay in the
serum of patients with autoimmune thyroid disease and in patients
with Addison's disease. Particular attention was paid to the
relationship between circulating immune complexes (CICs) and the
expression of organ specific autoantibodies. The Addison's patients
were of special interest in this light because of the high frequency
of associated autoimmune endocrine diseases found in this condition.
CICs were detected in 12 out of 55 (22%) patients with untreated
Graves' disease. Only one of the patients with CICs was also positive
for TSH receptor antibodies compared to 28 out of 42 (67%) patients
with no CICs (p < 0.001). The mean value for TBII in the IC positive
group was 5.4 as opposed to 22.2 in the IC negative group (p < 0.02).
The presence of ICs at diagnosis may relate to the prognosis after
radioactive iodine therapy. None of seven IC positive patients became
hypothyroid within six months of treatment while seven of fifteen IC
negative patients did so (p = 0.056, Fisher Exact Test). Four out of
eleven (36%) patients with Graves' disease in remission after
medical treatment had CICs as did four out of eleven patients with
subclinical Graves' (flat TRH test, normal or slightly elevated
thyroid hormones, diffuse thyroid scan and relatively few symptoms).
In the patients in remission and in the subclinical group, there was
an association between exophthalmos and IC positivity (all four
exophthalmic patients positive) but none of the seven patients with
untreated Graves' thyrotoxicosis who had documented exophthalmos was
IC positive.
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Of 40 patients with Hashimoto's thyroiditis, CICs were detected in
ten out of 19 patients (53$) who were euthyroid and in 14 out of 21
(67%) who were hypothyroid. CIC positivity showed a biphasic
distribution with respect to age at first diagnosis with the first
peak corresponding mainly to euthyroid cases (mean age 32 years),
followed by a trough in the incidence of IC positivity between the
ages of 35 and 50 years and a further peak of patients presenting in
later life and who were mainly hypothyroid (mean age 52 years).
Thyroid microsomal antibodies were strongly positive in 15/19 (79$)
euthyroid and 19/21 (90%) hypothyroid patients. Immune complex
positivity and increasing titres of microsomal antibody were
negatively associated in the euthyroid group but positively
associated in the hypothyroid group. Anti-thyroglobulin antibodies
were detected in five patients from each group. All five of the
hypothyroid anti-thyroglobulin positive patients were also positive
for CICs with a mean C1q-SP value of 7.7 while only one of the five
corresponding euthyroid patients was IC positive and the mean C1q-SP
value in this group was 5.4 (p < 0.05).
In primary atrophic hypothyroidism (PAH) CICs were detected in 69
out of 105 patients at the time of diagnosis. Once more there was a
variation in IC positivity with age at diagnosis, but where there
had been a trough incidence in middle life for the Hashimoto
patients , the peak incidence of IC positivity in PAH was between 36
and 45 years (79$ of patients positive). There was a significant (p
< 0.01) trend towards IC positivity with increasing titre of thyroid
microsomal antibody. CICs were found in seven out of eleven (64$)
patients with subclinical hypothyroidism and in two patients with
spontaneous hypothyroidism following Graves' throtoxicosis.
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Addison's disease is relatively uncommon and ICs have not been
previously studied extensively. CICs were found in 122 out of 210
cases (58%) - 170 idiopathic, 38 tuberculous, one sarcoid and one
post-septicaemia. Serum from the time of diagnosis, before
replacement therapy was commenced, was available in 79 cases. Of the
fourteen patients with tuberculous Addison's (nine male and five
female), eight were IC positive. In this group, but not in the
autoimmune group, there was a negative correlation between C1q-SP and
age. In the 65 idiopathic cases, CICs were found in 41 (63%)• There
was no difference between the adrenal antibody negative cases (n =
31, 15 male and 16 female) and the adrenal antibody positive cases (n
= 34, 9 male and 25 female) either in the incidence or level of CICs.
However, in the antibody negative group, 11 out of 13 patients with
non- adrenal autoantibodies or autoimmune diseases were positive
compared to eight of the remaining 18 patients (p = 0.02).
Thirteen out of 24 (58%) patients with established tuberculous
Addison's disease (one to 22 years from diagnosis) and 57 out of 105
(54%) with idiopathic disease (one to 30 years) were IC positive.
While the proportion of patients with adrenal antibodies declined
with time from diagnosis the IC positivity did not - but the
incidence of other autoantibodies and other autoimmune diseases
increased. Only 49$ of patients with no extra-adrenal antibodies or
autoimmune diseases were IC positive, compared to 58$ of those with
non-pathogenic antibodies, 67$ of those with at least one other
diagnosis and 79$ of those patients with at least two other
autoimmune diseases.
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In conclusion, thyroid autoimmune diseases and Addison's diseease
(tuberculous and idiopathic) are associated with a high incidence of
immune complexes. CICs may affect the detection of organ specific
autoantibodies, both in untreated Graves' disease and in Addison's
disease. In the latter condition, their presence on long term follow
up is related to the incidence of other organ specific autoimmune
diseases. In primary hypothyroidism, CICs are age related but show a
different distribution with age in PAH and Hashimoto's. In
Hashimoto's thyroiditis, the association of CICs with thyroid
antibodies depends on thyroid status.
INTRODUCTION
Immune complexes are the result of non-covalent bonding between
antigens, both endogenous and exogenous, and their specific
antibodies. They form in the tissues and in the circulation of
patients with a wide variety of infectious, malignant and autoimmune
diseases (Lambert et al, 1978; Theofilopoulos, 1980; Poskitt &
Poskitt, 1985). The nature and size of the complex depends on the
antigen involved and the number of potential antibody binding sites
as well as the type of antibody and its valency. The scope for
variety is virtually unlimited although, in practice, there may be
fairly simple rules governing the structure of immune complexes (ICs)
which are actually formed and relatively small complexes tend to be
found in the circulation (Steensgaard & Johansen, 1980). While the
formation of ICs is the inevitable result of a humoral immune
reaction, their detection in the circulation in disease states is
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variable. This variability is partly due to differences in detection
methods and particular methods or combinations of methods may be
suitable for some disease states but not for others (Lambert et al,
1978; Migliorini et al, 1974) - Also the clearance of ICs from the
circulation depends, to a large extent on their size and composition
(Mannick et al, 1974) with smaller complexes being cleared by the
kidneys and larger ones by circulating lymphocytes, mononuclear and
polymorphonuclear phagocytic cells and the fixed phagocytic cells of
the reticuloendothelial system. In cutaneous vasculitic conditions,
the clearance of ICs by the reticuloendothelial system is greatly
accelerated (Dambuyant et al, 1984) and if this were to be generally
applicable to immune complex-associated autoimmune diseases, then
this might add to the difficulty experienced in detecting CICs. A
possible role for red blood cells in clearing CICs has come to light
recently: Inada et al (1982, 1983) have demonstrated defective
erythrocyte C3b receptor function in SLE and have found that this
relates to the presence of CICs and is associated with increased
fragility of the red cells. Not only does the level of CICs decline
with disease remission, but the C3b receptor function and the changes
in osmotic fragility also return towards normal.
The variety of methods which have been developed to detect and
quantify ICs is summarised in TABLE 5.1, a list which is by no means
exhaustive. For reviews on methodology see - Lambert et al, 1978;
Theofilopoulos, 19 8 0; Williams, 1981; Ritzman & Daniels, 1982.
Generally speaking, the physical methods have found limited usage:
Analytical ultracentrifugation is relatively insensitive and is in
any case too cumbersome for routine use. Polyethylene glycol
precipitation may be a useful screening test but is subject to
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TABLE 5.1 METHODS USED TO DETECT IMMUNE COMPLEXES
A. PHYSICAL METHODS
- Analytical Ultracentrifugation
- Polyethylene glycol Precipitation
- Laser Nephelometry
B. DETECTION IN TISSUES
- Immunofluorescence
- Immunoperoxidase
C. INTERACTION WITH ANTIGLOBULINS
- Polyclonal or Monoclonal Rheumatoid Factor Assay
(fluid or solid phase)
- Latex Agglutination Inhibition
D. INTERACTION WITH COMPLEMENT FACTORS
- C1q Binding Assay (fluid phase)
- C1q Solid Phase Assay
- Inhibition of C1q Binding (by radioimmunoassay or by [cr]
inhibition of latex agglutination)
- Conglutinin Solid Phase Assay
E. INTERACTION WITH CELLS
1) via complement receptors:
- Raji Cell Radioimmunoassay
- Inhibition of EAC-lymphocyte Rosetting
2) via Fc receptors
- Platelet Aggregation Test
- Inhibition of Antibody Dependent Cellular Cytotoxicity
F. BINDING TO STAPHYLOCOCCAL PROTEIN A
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interference from a large number of factors including the presence of
large amounts of monomeric IgG. Laser nephelometry measures the light
scatter from a diluted serum sample, is highly sensitive but again
strongly dependent on the physical state of the serum and many other
variables. Results correlate poorly with those obtained using the C1q
binding assay (Izzard et al, 1983). Assays based on antiglobulins
rely on the inhibition of rheumatoid factor binding to aggregated or
insolubilised IgG (bound to Sepharose or Latex particles) by immune
complexes.
C1q is an 11S heat-labile protein which contains the immunoglobulin
binding site of the first component of complement. It is widely used
in the assay of immune complexes, either as a fluid phase assay
(Zubler et al, 1976) where binding to labelled C1q is followed by
polyethylene glycol precipitation, or as a solid phase assay where
the C1q is immobilised on the surface of a plastic tube and bound
complexes are detected using a labelled anti-IgG. The latter method
is the one employed in this thesis. Conglutinin is a soluble protein
found in the serum of bovine species which binds avidly to fixed
complement components, particularly C3d (Lachman, 1967). It can be
used in a solid phase assay analagous to that used with C1q and this
asay proves to be both sensitive and reproducible (Casali et al,
1977).
Raji cells are a lymphoblastoid B cell line derived from a patient
with Burkitt's lymphoma. They lack surface immunoglobulin and have
few receptors for the Fc portion of IgG but have a large number of
high affinity receptors for complement components including C1q. A
radioimmunoasssay for immune complexes bound to their surface is the
_1£|4_
most reliable of the cell based techniques for measuring CICs. Fresh
platelets will aggregate when cell surface receptors interact with
immune complexes but a number of other agents including viruses and
antiplatelet antibodies may also aggregate platelets. Antibody
dependent cellular cytotoxicity is inhibited by ICs because they
compete for the Fc receptors on effector cells. Staphylococcal
protein A binds the Fc portion of IgG1, IgG2 and IgG4 and can be used
directly as an assay for immune complexes or used as an
anti-immunoglobulin in tests such as the C1q solid phase assay.
The precise role of immune complexes in the pathogenesis of
autoimmune diseases is not clear. There are however a number of
possible ways in which they might contribute to the autoimmune
process. They can activate complement both by the classical and
alternative pathways and thereby induce immune adherence via C3b
receptors, chemotaxis of leukocytes via the C5a component or
macrophage activation by the Bb fragment of factor B. They can
interact with cellular complement or Fc receptors causing, for
example, platelet aggregation with release of nucleotides or
vasoactive amines, neutrophil degranulation with consequent release
of proteolytic enzymes. Indeed ICs have the potential to interact and
thus modulate the function of any cell with an Fc receptor. These
include suppressor/cytotoxic T lymphocytes, K cells and activated T
lymphocytes. Samurat and Revillard (1979) have shown that both IgG
and IgM complexes will reversibly inhibit the formation of rosettes
between peripheral blood lymphocytes and red cells sensitised with
IgM. The inhibition with IgG complexes was not seen when the cell
preparation was depleted of lymphocytes with receptors for IgG,
indicating an immunoregulatory role for the latter cells. In
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addition to an effect on immunoregulation, they may also block the
antigen receptors on plasma cells and effector T cells. The effect
of ICs on K cells is potentially twofold. In antibody excess, they
may arm K cells against a specific antigen and ICs have been shown
to stimulate lymphokine production by K cells (Neville & Lischner,
1981). On the other hand, they can cause irreversible loss of Fc-IgG
receptors (Moretta et al,1978) and this may account for the loss of
K cell activity in some patients with systemic lupus erythematosus
(Schneider et al, 1975), diabetes mellitus (Pozzilli et al, 1981)
and Graves' disease (Endo et al, 1983). In the latter two studies,
an inverse relationship between CICs and K cell activity was
actually demonstrated. That immune complexes are detected in the
circulation may be due to impaired phagocytic function in the
autoimmune diseases. This has been documented in diabetics with
severe microangiopathy (Iavicoli et al, 1982) and in Sjogren's
syndrome with associated C4 deficiency (Hersey et al, 1983) • It has
been suggested by Lewis and Roberts ( 1980) that ICs could have a
central role in the induction of autoimmune disease. Tissue
inflammation, from any cause, will release into the circulation
antigens such as DNA which, when cleaved into smaller fragments by
circulating enzymes might form small ICs on binding with their
appropriate anbtibodies. Such complexes, if they were of such a size
to be cleared relatively slowly, could become deposited, for
example on vascular endothelium, and hence initiate tissue damage.
Many of the diseases in which immune complexes are thought to be
important have an HLA association and the expression of ICs may thus
have a genetic basis. Probably the best evidence for a disease state
being caused by ICs is in glomerulonephritis. Goodpasture's syndrome,
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where nephritis is due to antibodies to the glomerular basement
membrane is strongly associated with HLA-DR2 (Rees et al, 1978) and
idiopathic membranous nephropathy has been linked to HLA-DR3 (Klouda
et al, 1979). The renal lesions in strains of mice susceptible to
autoimmune disease may be related to previous viral infection,
particularly with retroviruses, and the formation of virus-antivirus
immune complexes in (NZB x NZW) F1 hybrid mice is genetically
determined (Maruyame et al, 1983) as is the formation of C1q binding
complexes in mice persisently infected with the lymphocytic
choriomeningitis virus (LCMV, Oldstone et al, 1983). Random
terpolymers of L-glutamine, L-alanine and L-tyrosine have been used
to characterise the immune response genes in guinea pigs (Bluestein
et al, 1972) and, since these synthetic antigens are similar to many
bacterial and virus coat antigens, the hypothesis has been advanced
that the IC response to infection may be genetically determined and
may, in part, underlie the association between HLA and autoimmune
disease (Vickerman, 1979).
In terms of clinical application, immune complexes have been most
extensively studied in the connective tissue diseases. They are found
in the sera and synovial fluids of a high proportion of patients with
rheumatoid arthritis (Halla et al, 1979a) and particularly in
patients with circulating rheumatoid factor (Gupta et al, 1979). Both
the studies of Halla and of Gupta employed three different methods to
quantify CICs - one based on their binding to monoclonal rheumatoid
factor, the C1q binding assay and the Raji cell radioimmunoassay.
Both studies reported a poor correlation between the three methods
in keeping with the findings of Reeback et al (1985) who used
different methods but again found the results of them to correlate
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poorly. The results in the C1q binding assay may correlate with some
measures of disease activity (Halla et al, 1 979b; McDougal et
al,1982) and relate to systemic features in juvenile rheumatoid
disease (Possen et al,1977) but methods based on polyethylene glycol
precipitation and the C1q solid phase assay show no such correlations
(Reeback et al, 1985).
CICs have been found in a small proportion of patients with
progressive systemic sclerosis using assays based on C1q and
conglutinin (Siminovitch et al, 1982) and their presence correlated
with disseminated organ involvement, particularly lung disease.
Certain serological markers correlate with the severity of the
disease and with the extent of organ involvement. The centromere
pattern of staining on immunofluorescence is found typically in the
CREST syndrome (calcinosis, Raynaud's phenomenon, oesophageal
dysmotility, sclerodactyly and telangectasia) , a benign variant of
the disorder, while the marker anti-Scl-70 is found particularly in
those patients with pulmonary involvement (Cattogio et al, 1983).
Recently, French et al ( 1985) have found immune complexes using the
Raji cell radioimmunoassay in about a third of patients and they
correlated strongly with the presence of anti-Scl-70 which is a
highly specific marker for systemic sclerosis. CICs have also been
correlated with disease activity in eosinophilic fasciitis, a
disorder related to scleroderma where inflammation and thickening of
the deep fascia is associated with hypergammaglobulinaemia and
eosinophilia (Seibold et al, 1982).
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In systemic lupus erythematosus (SLE), there are frequently CICs
although there is some controversy surrounding their relationship to
the activity and the extent of the disease, and hence their
usefulness in monitoring therapy (for review, see Inman, 1982).
Complexes detected by the C1q binding assay have been reported to
correlate with disease activity, DNA binding capacity and the
consumption of complement components (Nydegger et al, 1974; Zubler et
al, 1976). By contrast, Abrass et al (1980) found this assay to be of
little use but reported that complexes detected using the C1q solid
phase assay correlated with disease activity and the presence of
renal or articular manifestations. It has been suggested by Tung et
al (1981) that the size of ICs may relate to the pathological changes
they cause, with larger complexes (greater than 19S) being found in
patients with membranous glomerulonephritis, small complexes (around
7S) in patients with cerebral involvement and a mixture of the two in
patients with proliferative glomerulonephritis or no renal changes at
all. As already discussed, the size or composition of CICs determines
which assay is most appropriate for their detection. There is also
evidence that ICs are frequently found and relate to disease activity
in mixed connective tissue disease (Halla et al,1979b) and in
polymyalgia rheumatica with giant cell arteritis (Espinoza et al,
1982).
In diabetes mellitus, CICs may be detected in over half the patients
tested at diagnosis depending on the method used and their presence
correlates with that of islet cell antibodies (Irvine et al, 1977,
1980). Generally IC positivity decreases with time from diagnosis in
parallel with islet cell antibody positivity and persistent
antibodies are associated with persistent ICs (Irvine et al, 1980).
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There is in fact a bimodal distribution of IC positivity with time
from diagnosis (Irvine 1980) and this may in part relate to
insulin-anti-insulin complexes which, it has been suggested, may be
involved in the pathogenesis of microvascular complications (for
review see Di Mario et al, 1984). Anderson (1976) did find serum
insulin binding capacity to be slightly but not significantly
increased in patients with complications and patients with very high
titres of anti-insulin antibodies were especially likely to have
complications. Generally, however, anti-insulin antibodies and
complexes have been found to correlate poorly with microvascular
disease (Botansky et al, 1982; Di Mario et al, 1983). There is an
overall correlation between ICs and diabetic complications but these
could clearly be secondary to vascular disease and their role in
pathogenesis, if any, is not established (Andreani et al, 1982;
Botansky et al, 1982).
Immune complexes have been demonstrated in tissue by
immunofluorescence (Dixon et al, 1961) and can be found thus in a
variety of IC-related diseases (Penner et al, 1982) . They are
demonstrable in the thyroid in animal models of thyroiditis - both in
mice (Clagget et al, 1974) and in obese strain (OS) chickens (Katy et
al, 1981). In both cases the deposition of ICs is age related,
although it can be found as early as hatching in OS chickens, and
precedes cellular infiltration (Kofler et al, 1983)- Immune complexes
have been found using electron microscopy in human patients with
Hashimoto's thyroiditis or Graves' disease. They are seen in
association with the follicular basement membrane and often occur
near areas of lymphocytic or plasma cell infiltration (Werner et al,
1972; Kalderon et al, 1973; Kalderon & Bogaars, 1977)-
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Thyroglobulin-antithyroglobulin ICs have been shown to bind to
extraocular muscle membrane where they may have a role in the
production of Graves' exophthalmos (Konishi et al,1974). A case of
glomerulonephritis has been reported following radioactive iodine
therapy where thyroglobulin was demonstrated in the IC deposits in
the basement membrane of the kidney (Ploth et al, 1978).
Immune complexes have been found in the circulation of patients with
thyroid disorders by a number of authors. Using an anticomplementary
assay, Calder et al (1974) found CIC in 59$ of Hashimoto patients,
29$ of patients with atrophic hypothyroidism and 17$ of Graves'
patients. McKenzie & Zakarija (1977) cited a study where 11 out of 24
(46$) Graves' patients were positive in an assay where the binding of
C1q to sheep red blood cells was inhibited by the presence of CICs
(the red cells having been previously sensitised with
subagglutinating doses of rabbit anti-sheep haemolysin). Barkas et al
(1976) used the inhibition of ADCC to quantify ICs, and found K cell
activity to be reduced in the presence of sera from patients with
Hashimoto's and from those with atrophic hypothyroidism as well as to
a lesser extent with the sera from patients with thyrotoxicosis. The
Raji cell radioimmunoassay was used by Al Khateeb et al ( 1978) to
demonstrate CIC in 78$ of Hashimoto's, 36$ of atrophic hypothyroidism
and 20$ of thyrotoxic patients. CIC have been detected in a
proportion of Graves' patients using the C1q fluid phase assay (van
der Heide et al, 1980): 17/57 (30$) patients were positive and there
was a negative correlation between CIC and TSH receptor antibodies.
CIC appeared in many patients early in the course of drug treatment,
just as TSH receptor antibodies were disappearing from the
circulation. The possibility arises from this study that assays for
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TSH receptor antibodies may not be positive in some Graves' patients
because the antibody is complexed in the circulation with its
specific antigen. Bogner et al (1979), however were unable to
demonstrate thyroid antigens in Raji cell bound ICs when they were
incubated with fluorescein conjugated antibodies against the TSH
receptor, microsomal antigen or thyroglobulin.
The C1q solid phase assay is the one used in the studies reported in
this dissertation and extensive studies of this method in autoimmune
thyroid disease have not been previously reported. Endo et al (1983)
found 34% of 41 Graves' patients to be positive but included in their
study patients already on drug treatment. Brohee et al (1979) applied
the assay to the serum of 171 patients with thyroid disease and found
an overall positivity of 26$. They did, however, include patients
with non-autoimmune thyroid disease and did not take into account the
metabolic state of the patient or the time from diagnosis. C1q-SP was
positive in 7/25 (28$) Graves' patients, 15/37 (40$) of those with
asymptomatic thyroiditis and 5/29 (17$) with goitrous thyroiditis.
CIC correlated with the presence but not with the titre of thyroid
microsomal antibody and not with anti-thyroglobulin or the age or sex
of the patient.
The aim of the work presented in this chapter is to investigate
immune complexes as measured by the C1q solid phase assay in primary
hypothyroidism, Graves' disease and Addison's disease. The latter
condition was of particular interest, not only because of its
relative rarity but also because of the high frequency of other organ
specific autoantibodies and autoimmune disease found in association
with the disease. Evidence was sought for the differential expression
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of immune complexes in putative subgroups of the autoimmune endocrine
diseases and for a possible reciprocal relationship between immune
complex positivity and the expression of organ specific
autoantibodies in the circulation which may prevent these antibodies
being detected in standard tests.
NOTE: The limits of positivity for the C1q solid phase assays used
here varies from one section to another. This is due to the use of
different C1q preparations and to differences in the times for
preincubation, the C1q binding being higher the longer the incubation
period. Each assay is standardised using a bank of normal and
abnormal serum and, for each set of experiments, the assay conditions
were identical.
IMMUNE COMPLEXES IN GRATES' DISEASE
I) Untreated Graves' disease
PATIENTS AND METHODS
The study included 55 patients (eight male, 47 female), a random
selection from one of the series studied in Chapter 2. The mean age
at diagnosis was 45.4 years (SD 14.3, range 15 to 70), the mean Tg at
diagnosis was 5.94 nmol/1 (SD 2.31) and the mean T^ was 231.5 nmol/1
(SD 60.4). Thyroid microsomal and anti-thyroglobulin antibodies were
assayed by passive haemagglutination using commercially available
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kits (Wellcome). Other autoantibodies were detected by indirect
immunofluorescence and TSH receptor antibodies were assayed using
immunoglobulin concentrates as described in APPENDIX 1. Immune
complexes were measured by the C1q solid phase assay as detailed in
APPENDIX 2.
RESULTS
Positive results in the C1q solid phase assay were obtained in 12 out
of the 55 patients (22%). Thyroid microsomal antibodies were detected
in 37 (67%) and anti-thyroglobulin in eight (15%). Parietal cell
antibodies were found in nine (16%), antinuclear factor in four (756)
and smooth muscle antibodies in one patient. The value obtained in
the C1q-SP assay did not correlate with the presence or titre of any
of these antibodies, with any measure of thyroid function or with the
sex of the patient. The mean age of IC positive patients was 55.5
years compared to 42.8 years for the IC negative patients (p < 0.01).
TSH receptor antibodies were found in 29 out of 54 (54%) patients.
Only one of the twelve patients positive for immune complexes was
also positive for TBII compared to 28 out of 42 (67%) patients with
no immune complexes (p < 0.001, Chi Squared test). The mean value for
TBII in the IC positive group was 5.4 as opposed to 22.2 in the IC
negative group (p < 0.02, see FIGURE 5.1). Overall, there was a
slight but non-significant negative correlation between C1q-SP and
TBII.
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FIGURE 5.1 TSH RECEPTOR ANTIBODIES IN 1MMUNO COMPLEX POSITIVE AND

































When the patients were divided, as in Chapter 4, into three groups -
one with no goitre, one with goitre but low four hour 1311 uptake
and one with goitre and high 1311 uptake, there was a slight
association between the former two groups and immune complex
positivity (see TABLE 5.2) although this did not reach statistical
significance.
II) Graves' Disease in Remission
Of eleven patients tested while in remission after drug therapy for
thyrotoxic Graves' disease, four (36$) were positive in the C1q solid
phase assay. Two of the four IC positive patients had exophthalmos
(C1q-SP = 8.3$ and 9.1$), one had vitiligo (C1q-SP = 8.8$) and the
other had rheumatic heart disease (C1q-SP = 11.1$). None of the seven
IC negative patients had exophthalmos although one did have both
Addison's disease and insulin dependent diabetes mellitus. Among the
55 patients tested for ICs prior to therapy, seven had documented
exophthalmos, one had pernicious anaemia and another had both
diabetes and vitiligo. None of these nine patients was IC positive
using the C1q solid phase assay.
Ill) Subclinical Graves' Disease
Eleven patients were tested who
Graves' disease: The mean T3 in
range 1.5 to 3.1) and the mean
112 to 193) and all had flat TRH
were considered to have subclinical
this group was 2.3 nmol/1 (SD 0.46,
Tij was 145.8 nmol/1 (SD 26.0, range
tests. Four had palpable diffuse
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goitres and exophthalmos was present in two oases. None had more than
very mild symptoms of thyrotoxicosis. A thyroid scintigram showed a
diffuse uptake of isotope in all cases and the mean four hour uptake
of 131I was 25.7% (SD 11.2). Thyroid microsomal antibodies were
detected in the serum of four cases but none was positive for either
anti-thyroglobulin or TSH receptor antibodies. Immune complexes were
found in four of these eleven patients, and three of the four IC
positive patients were also positive for microsomal antibodies. Both
patients with exophthalmos were IC positive and one IC positive
patient went on to develop florid thyrotoxic Graves' disease eleven
months after her initial presentation and was subsequently treated
with carbimazole.
IV) Immune Complexes and the Response to Radioactive Iodine
The outcome after therapeutic doses of radioactive iodine may relate
in part to the presence of ICs in the circulation prior to treatment
(see TABLE 5.3). Of 17 IC negative patients, treated with a mean dose
of 6.4 mCi, seven were hypothyroid within six months. By contrast,
none of seven IC positive patients treated with a mean dose of 7.8
mCi, developed hypothyroidism within six months of treatment (p =
0.056, Fisher Exact Test).
Immune complexes, TSH receptor antibodies and thyroid microsomal
antibodies were tested sequentially in six patients following
therapy. Immunological data from these patients is shown in TABLE
5.4. Patient details are given below
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TABLE 5•2 IMMUNE COMPLEX POSITIVITY IN DIFFERENT GROUPS OF
PATIENTS WITH UNTREATED GRAVES* DISEASE
No. PATIENTS IC POSITIVE $ POSITIVE










U/T = Four hour 1311 uptake













TABLE 5.4 IMMUNE COMPLEXES AND THYROID AUTOANTIBODIES FOLLOWING
RADIOACTIVE IODINE THERAPY FOR GRAVES' THYROTOXICOSIS
MONTHS AFTER RADIOACTIVE IODINE THERAPY



















































































































































MICROSOMAL = Titre of thyroid microsomal antibodies
TBII = TSH receptor antibodies, Limit of positivity = 9.0
C1q-SP = ICs by C1q-solid phase assay, positive > 10.9
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PATIENT 1 44 year old female, Tg 5.1 nmol/1 and T4 183 nmol/1. No
goitre and no eye signs. Diffuse scintigram, uptake 25% at four
hours. Treated with 7 mCi and became hypothyroid at three months.
PATIENT 2 38 year old male with moderate goitre marked exophthalmos
and severe myopathy. T4 320 nmol/1, diffuse thyroid scan, uptake 80$.
HLA-DR 3+6. Tretaed with 7 mCi and still euthyroid at six months.
PATIENT 3 52 year old female, Tg 6.8 and T4 157 nmol/1. No goitre
or eye signs, diffuse thyroid scan and uptake 47$. HLA-DR 2. Treated
with 5 mCi and hypothyroid at six months.
PATIENT 4 54 year old female, Tg 7.0 nmol/1 and T4 340 nmol/1. No
goitre and no eye signs, diffuse scan and uptake 40$. Treated with 5
mCI and euthyroid at six months.
PATIENT 5 55 year old female, Tg 6.3 nmol/1 and Tij 216 nmol/1.
Small goitre but no exophthalmos, diffuse scan and uptake 50$.
Treated with 5 mCi and hypothyroid at five months.
PATIENT 6 42 year old female, Tg 5.1 nmol/1 and T4 230 nmol/1.
Small goitre and no eye signs. Diffuse scan, uptake 50$. HLA-DR 6+7.
Treated with 6 mCi and hypothyroid at six months.
From the data shown in TABLE 5.4, immune complexes were found in only
one patient of the six at diagnosis, they remained positive in this
patient until five months after treatment but did not increase in
parallel with TBII. Transient IC positivity in the months following
therapy was seen in a further two patients but they were only
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slightly positive and bore no relation to changes in other
immunological tests. Both TSH receptor antibodies and thyroid
microsomal antibodies showed significant increases after therapy in
five out of the six patients.
IMMUNE COMPLEXES IN HASHIMOTO'S THYROIDITIS
The study included 19 patients who were biochemically and clinically
euthyroid (18 female and one male) and 21 patients who were
hypothyroid (all female). The mean age in the euthyroid group was
32.3 years (SD 14.7, range 14 to 63 years) while it was 51.6 years
(SD 15.4, range 23 to 75 years) in the hypothyroid group. This
difference was significant at the 0.001 level. In the euthyroid
group, the mean Tjj at diagnosis was 78.6 nmol/1 (SD 16.8, range 49
to 105, normal range 70 - 150) and the mean basal TSH was 15.7 mU/1
(SD 15.4, range 3.8 to 68.6, normal less than 5.7 mU/1). The ten
patients with low or borderline TSH (between 3.8 and 12.2 mU/1) all
had exaggerated response to 0.2 mg of TRH intravenously with a mean
basal TSH of 7.38 mU/1 rising to a mean of 50.4 mU/1 twenty minutes
after injection of TRH. The mean Tij in the hypothyroid patients was
43.3 nmol/1 (SD 14.3, range 20 to 64) and the basal TSH was 65.4 mU/1
(SD 53-5, range 6.5 to 233).
Of the 19 euthyroid patients, ten (52.6%) were positive for immune
complexes with a mean value of 6 . 5455 of the maximal radioactivity
bound in the C1q solid phase assay (SD 2.23, limit of positivity
5.950. Fourteen of the 21 (67%) hypothyroid patients were positive
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for immune complexes with a mean value of 6.39$ (SD 1.43). FIGURE 5.2
shows the values for the C1q solid phase assay in all 40 patients
with Hashimoto's thyroiditis plotted against age at first diagnosis.
The figure illustrates the younger age of diagnosis in the euthyroid
patients, but also suggests an overall biphasic distribution of
immune complex positivity with respect to age at diagnosis with a
peak for those patients diagnosed before the age of 35 years of age,
a trough between 35 and 55 years and a further peak for those
patients (mainly hypothyroid) diagnosed in later life. This data is
also shown in TABLE 5.5. There are two very high values in patients
diagnosed between the ages of 35 and 55 years. The first was in a 38
year old euthyroid lady with a strong family history of autoimmune
disease, her mother having both pernicious anaemia and primary
hypothyriodism and her sister having been treated for Graves'
thyrotoxicosis (C1q-SP = 15-3) - The second was a 44 year old
hypothyroid lady whose serum was also strongly positive for
antinuclear factor and anti-thyroglobulin.
ANTITHYROID ANTIBODIES AND OTHER AUTOANTIBODIES
Thyroid microsomal antibodies were detected at a titre of 402 or
above in 15 out of 19 (79$) euthyroid patients and in 19 out of 21
(90$) hypothyroid patients. The modal value for both groups was 802.
There was no significant correlation in either group between the
value obtained in the C1q-SP assay and the titre of thyroid
microsomal antibodies. However the distribution of immune complex
positivity with respect to microsomal antibody titre differed in the
two groups - see FIGURE 5.3- In the euthyroid group, all four
patients with low or undetectable microsomal antibodies were IC
positive, and, with increasing titre of antibodies, there was a
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figure 5.p relationship between age at diagnosis and immune complexes
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FIGURE 5.3 RELATIONSHIP BETWEEN IMMUNE COMPLEX POS1T1V1TY AND
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decreasing proportion of patients with immune complexes. By contrast,
hypothyroid patients with high antibody titres were more likely to be
positive for immune complexes.
Anti-thyroglobulin antibodies were detected in five (26%) of the
euthyroid patients only one of whom was also positive for immune
complexes. Five of the hypothyroid patients (24/5) had circulating
anti-thyroglobulin antibodies and all were positive for immune
complexes. The mean value in the C1q-SP assay for the euthyroid
patients with anti-thyroglobulin was 5.4;5 compared to 7.7% for the
five hypothyroid patients with anti-thyroglobulin (p < 0.05). In the
hypothyroid group, the mean C1q-SP binding was 6.07% for the patients
with no anti-thyroglobulin which was significantly different to that
of the patients with antibodies to thyroglobulin (p < 0.05, see
FIGURE 5.4).
Parietal cell antibodies were detected in two of the 19 euthyroid
Hashimoto's (11%) and in five of the 21 (24%) hypothyroid cases. The
mean C1q binding in the seven parietal cell antibody positive cases
was 5.85 compared to 6.6/6 for the antibody negative cases (not
significant). Antinuclear factor was found in five cases (two
hypothyroid and three euthyroid) but once more there was no
significant association with C1q-SP.
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FIGURE 5.4 IMMUNE COMPLEXES AND ANT1THYROGLOBUL1N ANTIBODIES IN


































TABLE 5.5 RELATIONSHIP BETWEEN IMMUNE COMPLEX POSITIVITY AND AGE
AT DIAGNOSIS IN HASHIMOTO'S THYROIDITIS
AGE AT DIAGNOSIS (YEARS)
UP TO 25 26-35 36-M5 46-55 56-65 OVER 65
No. PATIENTS 9 7 7 6 7 5
No. POSITIVE 6 5 3 2 4 5
$ POSITIVE 67$ 71$ 43$ 33$ 57$ 100$
TABLE 5.6 AGE AT DIAGNOSIS AND IMMUNE COMPLEX POSITIVITY IN
PRIMARY ATROPHIC HYPOTHYROIDISM
AGE AT DIAGNOSIS (YEARS)
UP TO 25 26-35 36-45 46-55 56-65 OVER 65
No. PATIENTS 5 13 14 29 21 23
No. POSITIVE 3 8 11 18 14 16
$ POSITIVE 60$ 62$ 79$ 62$ 67$ 70$
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PRIMARY ATROPHIC HYPOTHYROIDISM
In this study, 105 patients (eleven male and 94 female) were included
and the mean age at diagnosis was 52 years (SD 15.2, range 14 to 85
years). The mean T^ at diagnosis was 36.0 nmol/1 (SD 16.8, range 12
to 77) and the mean TSH was 59.1 mU/1 (SD 47.2, range 7.3 to 330).
Immune complexes were detected in 69 (66%) patients with a mean
C1q-SP value of 6.5% (SD 1.26, range 4.8 to 10.8, normal less than
5.9%). There was no significant difference between male and female
patients.
There was no significant overall correlation between age at diagnosis
and C1q-SP values but, as with Hashimoto patients, there was a
variation in the proportion of patients positive with age (see TABLE
5.6). Immune complexes were most commonly found in patients aged 36
to 45 years at the time of diagnosis.
THYROID MICROSOMAL ANTIBODIES AND OTHER AUTOANTIBODIES
Microsomal antibodies were detected by haemagglutination in in 90 of
the 98 (92%) patients tested and by indirect immunofluorescence in 89
of the 105 patients (85$). Immune complexes were found in five of
the eight 63$) patients negative by haemagglutination and in nine of
the 15 (60%) negative by immunofluorescence. The mean C1q SP in
patients with no or very low levels of microsomal antibody was 6.38$,
in patients with a titre of 40^ it was 6.26% compared to 6.61% in
patients with a titre of 80^ and 7.00% in patients with a titre of
1602 or above. This trend did not reach statistical significance but
there was a significant trend (p < 0.01) towards increasing numbers
of patients positive in the C1q solid phase assay with increasing
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titres of microsomal antibody (see TABLE 5-7). This trend was even
more marked when patients with antibodies against the stomach were
excluded (the presence of other autoantibodies may affect the
relationship between ICs and thyroid antibodies).
Anti-thyroglobulin antibodies were detected by passive
haemagglutination in 20 out of 101 patients tested. Sixteen of these
patients (80$) were immune complex positive and the mean C1q-SP value
was 6.92$. Of the 81 patients negative for anti-thyroglobulin, 50
(62$) had detectable ICs and the mean C1q-SP was 6.42$ (no
significant difference). Of 22 patients positive for parietal cell
antibodies, 12 (55$) were also positive for ICs and the mean C1q-SP
binding was 6.42$.
SUBCLINICAL HYPOTHYROIDISM
Eleven patients, all female were studied. The mean age at diagnosis
was 51.5 years (SD 15.2, range 28 to 76), the mean T4 was 81 nmol/1
(SD 16.1, range 63 to 116) and the mean TSH was 7.2 (range 3.4 to
30.2). All had an exaggerated TSH response to injected TRH. None had
a palpable goitre or marked symptoms of hypothyroidism.
Microsomal antibodies were detected in ten of the eleven patients
(91$), anti-thyroglobulin in one (10$) and parietal cell antibodies
in five (45$). Immune complexes were found in seven cases (64$) and
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TABLE 5.7 CORRELATION BETWEEN POSITIVITY IN THE C1q-SP ASSAY AND
TITRE OF MICROSOMAL ANTIBODY IN PRIMARY ATROPHIC HYPOTHYROIDISM
MICROSOMAL ANTIBODY TITRE
202 402 802 1602
No. PATIENTS 32 27 22 17
ALL PATIENTS No. POSITIVE 20 18 15 13
(N = 98) $ POSITIVE 63% 67$ 68$ 76$
EXCLUDE No. PATIENTS 31 21 18 13
PC POSITIVE No. POSITIVE 19 14 14 11
onCOIIS
V
/ $ POSITIVE 61$ 67$ 78$ 85$
EXCLUDE ALL No. PATIENTS 31 21 17 12
STOMACH Abs. No. POSITIVE 19 14 14 11




This group excludes all patients with either parietal cell or
anti-smooth muscle antibodies (both detected using rat
stomach as tissue substrate)
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the mean C1q-SP value was 6.48%. No correlation was found between
the results of the C1q-SP assay and the presence of thyroid or
non-thyroid antibodies.
SPONTANEOUS HYPOTHYROIDISM IN GRAVES' DISEASE
Two patients were found, both strongly positive for immune complexes,
who had been previously treated for thyrotoxic Graves' disease with
antithyroid drugs many years before the diagnosis of hypothyroidism.
Neither had recieved destructive antithyroid therapy:
CASE 1
A 62 year old lady presented with mild hypothyroidism (Tij = 70
nmol/1, TSH = 9.6 mU/1). She had been treated with a full course of
antithyroid drugs over twenty years previously. There was no goitre
or eye signs when she developed hypothyroidism. Microsomal antibodies
were positive by passive haemagglutination at 402 and also positive
by immunofluorescence. Parietal cell antibody was also found and the
C1q-SP binding was strongly positive at 8.9$.
CASE 2
A 54 year old lady developed symptoms of hypothyroidism developed
symptoms of hypothyroidism (T4 56 nmol/1, TSH 28.2 mU/1). She had
been treated with antithyroid drugs in her late teens for a single
episode of Graves' thyrotoxicosis. She had no goitre or eye signs at
her second presentation. Microsomal antibodies were weakly positive
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at 202 (negative by immunofluorescence). Parietal cell antibodies
were found in the circulation and C1q-SP was strongly positive at
7.2%.
IMMUNE COMPLEXES IN ADDISON'S DISEASE
PATIENTS AND METHODS
Serum was available for study from 210 patients. In 79 cases this
serum was from the time of diagnosis, before steroid replacement
therapy was commenced. 14 of these cases were of tuberculous origin
and 65 idiopathic. Serum from follow up was available from 24
tuberculous cases (one to 22 years from diagnosis) and 105 idiopathic
cases (one to 30 years) as well as one case where sarcoidosis was
thought to have caused adrenal failure and another case following
septicaemia. Where tuberculous Addison's disease was diagnosed, there
had been evidence of disseminated tubercle and most cases had adrenal
calcification on a plain abdominal X ray.
The diagnosis of Addison's was made on the basis of symptoms and
signs (pigmentation and hypotension) and supported by steroid
measurements and ACTH stimulation tests although the latter were
clearly not available from those patients followed up long after the
diagnosis had been made. Associated autoimmune diseases were also
diagnosed on the basis of clinical histories and were confirmed by
appropriate biochemical tests in all cases.
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All sera were stored in aliquots, continuously frozen at -20°C and
only thawed prior to assay for immune complexes. The C1q assay was
performed as detailed in APPENDIX 2. The limit of positivity for this
assay was 13.8/6 of the maximal counts bound and was set using sera
from 50 normal blood donors. The use of Addison's sera which had been
stored long term was validated by testing 40 control sera which had
been stored with the Addison's sera for comparable periods of time
see FIGURE 5.5. None of these storage controls had evidence of
endocrine or autoimmune diease. The 90^h centile for the C1q assay in
these 40 controls was 13.75? i.e. virtually identical to that for the
normal blood donors used to set the limit of positivity.
Autoantibodies were measured by indirect immunofluorescence on five
micrometer sections of adrenal, thyroid, pancreas, ovary and stomach.
Statistical analyses were performed using linear regression,
Student's t test and the Wilcoxon Rank Sum Test as appropriate.
A: ADDISON'S DISEASE AT DIAGNOSIS
Fourteen tuberculous cases were studied (nine male and five female,
mean age 42.4 years). Immune complexes were detected in eight of
these cases (575?) with a mean C1q-SP value of 15.45? but none of these
patients had adrenal autoantibodies.
Of the 65 idiopathic cases studied at diagnosis, adrenal
autoantibodies were found in 34 (25 female, nine male, mean age 31.8
years). Immune complexes were found in 22 out of these 34 cases
( 655?) with a mean C1q-SP of 16.95? for the whole group. Adrenal
autoantibodies were not detected in 31 of the 65 idiopathic patients
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FIGURE 5.5 STORAGE CONTROLS FOR ADDISON'S EXPERIMENTS
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(17 male, 14 female, mean age 40.2 years) and 19 of these eases (61%)
were immune complex positive. The mean C1q-SP for this group was
17.9%- The results of the C1q solid phase assay in the different
groups of Addison's disease at diagnosis are shown in FIGURE 5.6.
Neither the incidence nor the C1q-SP level differed significantly
between the adrenal antibody positive and negative idiopathic cases.
In tuberculous Addison's disease, there was a negative correlation
between age at diagnosis and the results obtained in the C1q-SP assay
(see FIGURE 5.7, r = -0.67, P < 0.01). No such relationship was found
for the idiopathic cases.
In the idiopathic group with no adrenal autoantibodies (31 patients),
18 had no autoantibodies of any sort while the remaining 13 had
autoantibodies to tissues other than the adrenal. Of the former group
of 18 patients, eight (44%) were positive for immune complexes and
the mean C1q-SP value for these patients was 15-6%. Eleven of the 13
patients with non adrenal autoantibodies were IC positive and the
mean C1q binding for this group was 21.1% (p = 0.02, see FIGURE 5.8).
B: ADDISON'S DISEASE ON FOLLOW-UP
Thirteen out of 24 (54$) tuberculous patients were positive for
immune complexes but none had adrenal autantibodies. ICs were not
found in the patient with sarcoidosis (male, 32 years old at
diagnosis and tested two years later) nor in the patient with
Addison's following septicaemia (33 year old female tested three
years after diagnosis).
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CONTROLS TUBERCUL. ANTIBODY ANTIBODY
POSITIVE NEGATIVE
(N = 29) (N = 1A) (N k 34) (N = 31)
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FIGURE 5.7 NEGATIVE CORRELATION BETWEEN AGE AND IMMUNE COMPLEXES
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In idiopathic Addison's disease, there was a progressive decline in
adrenal antibody positivity with time from diagnosis (see FIGURE
5.9): 51$ of 65 patients at diagnosis were positive, 53$ of 36
patients tested at one to four years from diagnosis had antibodies,
50$ of 32 patients five to nine years from diagnosis, 39$ of 24
patients ten to 14 years from diagnosis and 32$ of 13 patients at 15
years or more from the time of diagnosis. This decline in adrenal
antibody positivity was not however paralleled by a decrease in IC
positivity (see FIGURE 5.10) - 54$ of patients were still IC positive
15 years from diagnosis. There was a progressive increase from the
time of diagnosis of Addison's in the incidence of other
autoantibodies or autoimmune diseases (see FIGURE 5.11). 55$ of
patients at diagnosis of Addison's had evidence of other autoimmune
disease, either clinical or subclinical. This was 56$ at one to four
years, 69$ at five to nine years, 67$ at ten to 14 years and 85$ at
15 years or more from the time of diagnosis of Addison's.
The incidence of non-adrenal autoimmune diseases in this series of
idiopathic Addison's is shown in TABLE 5.8 along with the immune
complex positivity associated with each disease. Evidence that the
increase in the incidence of autoimmune diseases with time from
diagnosis of Addison's is related to increasing immune complex
positivity is shown in FIGURE 5-12. Of 66 patients with no other
autoantibody or autoimmune disease, 32 (48$) were immune complex
positive. 43 patients had subclinical diseases (autoantibodies with
no clinical features of the associated disease) and 25 of them (58$)
were IC positive. Of 61 patients with at least one other autoimmune
disease, 41 (67$) were IC positive compared to 19 out of 24 (79$)
patients with at least two other diseases.
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FIGURE 5.9 DECLINE IN ADRENAL ANTIBODY POS1T1V1TY WITH TIME FROM
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FIGURE 5.11 INCREASE IN THE INCIDENCE OF NON-PATHOGENIC AUTO¬
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TABLE 5.8 THE INCIDENCE OF IMMUNE COMPLEXES IN AUTOIMMUNE
DISEASES ASSOCIATED WITH ADDISON'S DISEASE
























FIGURE 5.12 INCIDENCE OF IMMUNE COMPLEXES IN IDIOPATHIC ADDISON'S



















A NO OTHER AUTOANTIBODY OR AUTOIMMUNO DISEASE
B NON-PATHOGENIC AUTOANTIBODIES BUT NO OTHER AUTOIMMUNE DISEASE
C AT LEAST ONE OTHER AUTOIMMUNE DISEASE
D AT LEAST TWO OTHER AUTOIMMUNE DISEASES
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DISCUSSION
Immune complexes have been sought using the C1q solid phase assay in
large series of patients with Graves' disease, Hashimoto's
thyroiditis, primary atrophic hypothyroidism and Addison's disease.
Immune complexes (ICs) were found in 12/55 (22%) patients with
untreated Graves' disease, 10/29 (53%) patients with euthyroid
Hashimoto's, 14/21 (67%) with hypothyroid Hashimoto's, 69/105 (66%)
with primary atrophic hypothyroidism at diagnosis and in 41/65 (63%)
patients with idiopathic Addison's disease at dignosis. The finding
of a small, but significant, percentage positivity in Graves' disease
is in keeping with the findings of Brohee et al (1979) and Endo et al
( 1983) while ICs have been reported in primary hypothyroidism by a
number of authors (Calder et al, 1974; Al Khateeb et al, 1978; Brohee
et al, 1979). Addison's disease has not been extensively studied
previously.
The relationship of ICs to the expression of autoantibodies was
explored because of the variable positivity of organ-specific
antibodies in the various autoimmune endocrine diseases. For example,
in large series of patients with Graves' disease, TSH receptor
antibodies are only detectable by the radioreceptor assay in up to
80$ of patients (Biro et al, 1982; see also results presented in
Chapter 2), while only about a half of patients with idiopathic
Addison's disease are positive for adrenal autoantibodies (Blizzard
et al, 1967). Although this may in part reflect a relative
insensitivity of the assay methods, clearly the autoantibodies might
not be detected if they were complexed with antigen in the
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circulation. In Graves' disease, a negative correlation was found
between TSH receptor antibodies and ICs, in agreement with the
results of van der Heide et al (1980), although ICs did not correlate
with other thyroid autoantibodies. Only 1/12 IC positive patients was
also positive for TSH receptor antibodies compared to 28/42 (67%) IC
negative patients (p < 0.001). A posssible role for ICs in modifying
autoantibody expression was also apparent in those idiopathic
Addison's patients negative for adrenal antibodies. Eight out of
eighteen (44$) patients with no non-adrenal antibodies were positive
for ICs compared to eleven out of thirteen (85$) patients with
autoantibodies to organs other than the adrenal. The existence of
associated autoimmune disease in the latter group makes it virtually
certain that their Addison's is autoimmune in origin despite the lack
of antibodies to the adrenal.
In their study of 171 patients with various thyroid diseases, Brohee
et al (1979) found a positive correlation between IC positivity and
thyroid microsomal antibodies. In the patients with newly diagnosed
Graves' disease studied here, there was no such relationship, nor did
ICs correlate with anti-thyroglobulin antibodies, parietal cell
antibodies or antinuclear factor. The relationship between thyroid
microsomal antibodies and ICs in Hashimoto's depended on thyroid
status. All four patients who were euthyroid and had low microsomal
antibody titres were IC positive, with increasing titre of antibodies
there was a decreasing proportion of patients with ICs. In
hypothyroid Hashimoto's, on the other hand, patients with high
antibody titres were most likely to be IC positive. It is possible
that all patients with euthyroid Hashimoto's produce comparable
amounts of microsomal antibody but that these are not expressed in
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some patients because they form immune complexes. The positive
correlation in hypothyroid Hashimoto's may relate to the degree of
tissue destruction, the amount of residual tissue or the degree of
lymphocytic infiltration. A similar relationship existed between
anti-thyroglobulin antibodies and ICs: Significant levels of
anti-thyroglobulin were found in five euthyroid patients, only one of
which was also positive for ICs, while all five anti-thyroglobulin
positive hypothyroid patients were also IC positive. In primary
atrophic hypothyroidism, there was a significant (p<0.01) trend
towards increasing numbers of patients positive in the C1q solid
phase assay with incresing microsomal antibody titre. The presence of
ICs may thus mask the expression of organ specific autoantibodies in
Graves' disease, idiopathic Addison's disease and in euthyroid
Hashimoto's but in primary hypothyroidism, whether atrophic or
goitrous, ICs correlate with indices of thyroid destruction.
In the normal population, the prevalence of immune complexes
increases with age (di Mario et al, 1981). A relationship between IC
positivity and age at diagnosis was seen in some of the autoimmune
diseases studied here. The mean age of 12 untreated Graves' patients
with immune complexes was 55.5 years compared to 42.8 years for the
43 IC negative patients (p<0.01). This may be of relevance to the
groups of patients with Graves' disease identified in the previous
chapter - patients without a palpable goitre were older and had
lower levels of TSH receptor antibodies while patients with a low
1311 uptake were also older and had less severe thyrotoxicosis but
showed a remarkable incidence of non-thyroid autoantibodies. Of the
14 patients in this study with no goitre, 5 (36%) were IC positive
and three out of seven patients (4355) with goitre but low radioactive
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iodine uptake were positive. By contrast, only four out of 34 (12%)
patients with goitre and high 131i uptake were positive for ICs.
Although these results do not reach statistical significance, they
would tend to support the hypothesis that immune complexes have a
role in the age-related change in the presentation of Graves'
disease.
In Hashimoto's thyroiditis, the distribution of IC positivity with
age at diagnosis was a biphasic one. Eleven out of 16 (69%) patients
presenting at 35 years or younger were IC positive and most of these
patients were euthyroid at the time of presentation. By contrast,
only 5/13 (38%) of patients presenting in middle life (36 to 55
years) were IC positive, but 9/12 (75%) of cases above the age of 55
at diagnosis had circulating ICs and most of these patients were
hypothyroid at presentation. This distribution was not seen with
primary atrophic hypothyroidism and, if anything, IC positivity was
most common in middle life with 11/14 (79%) of patients presenting
between the ages of 36 and 45 being IC positive. No relation between
age at diagnosis and IC positivity was seen in idiopathic Addison's
disease.
The increase in thyroid autoantibodies following 1311 therapy for
thyrotoxicosis in Graves' disaease was discussed in Chapter 2. There
was, however, no indication of a parallel increase in IC positivity
in the six patients tested sequentially here. The C1q assay measures
complexes with a relative antigen excess and the presence of greatly
increased levels of autoantibodies may suggest that a method such as
the Raji cell radioimmunoassay, which detects complexes with a
relative antibody excess could be more appropriate. IC positivity
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prior to radioiodine treatment appeared to influence the prognosis:
7/17 IC negative patients were hypothyroid six months after treatment
but none of seven IC positive patients became hypothyroid (p =
0.056, Fisher Exact Test). One possibility is that ICs prevent the
expression of blocking antibodies to the TSH receptor since, although
TSH receptor antibodies rise after 1311 therapy, these antibodies are
not stimulatory.
The incidence of ICs in patients with subclinical Graves' disease or
Graves' disease in remission was comparable to that of thyrotoxic
patients. All four exophthalmic patients in these two groups (two in
each group) were IC positive but none of the seven patients in the
group with frank thyrotoxicosis who had documented exophthalmos was
IC positive. It may be that IC positivity is associated with multiple
autoimmune diseases (infiltrative exophthalmos and Graves' thyroid
disease) but, as thyrotoxicosis develops, the release of antigen
including thyroglobulin changes the characteristics of ICs in the
circulation, preventing them being detected by the C1q solid phase
assay. Both the patients with spontaneous hypothyroidism in Graves'
disease were strongly IC positive.
The study of patients with Addison's disease is of particular
interest, not only because of the presence of organ-specific
autoantibodies to the adrenal (Anderson et al, 1957; Goudie et al,
1966; Irvine & Barnes, 1972) which occur particularly in female
patients (Irvine et al, 1967) but also because of the high frequency
of other organ-specific autoantibodies for example, to steroid
secreting cells in the gonads (Anderson et al, 1968) and to the
thyroid (Blizzard et al, 1968). There is also an increased incidence
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of organ specific antibodies in first degree relatives of these
patients (Wuepper et al, 1969). The association between idiopathic
Addison's disease and other autoimmune diseases is well documented
(Morse et al, 1961; Kenny & Holliday, 1964) and this has led to the
description of polyendocrine deficiency syndromes (Loriaux, 1985). In
the patients tested in this study, the incidence of adrenal antibody
positivity declined with time from diagnosis but this was not
paralleled by a decrease in IC positivity. This may be due to an
increase with time from diagnosis of the prevalence of other
autoimmune diseases. The high incidence of associated autoantibodies
and autoimmune diseases in patients with idiopathic Addison's disease
was confirmed in this study and there was direct evidence for
increasing IC positivity with increasing organ involvement.
In conclusion, ICs are detectable by the C1q solid phase method in a
large proportion of patients with Hashimoto's thyroiditis, primary
atrophic hypothyroidism and idiopathic Addison's disease but in a
lesser proportion of patients with Graves' disease. Their presence
may prevent circulating organ-specific autoantibodies being detected
and they may be particularly common in multiple disease states. The
information available from IC studies is at present limited until
more information is available about the antigens involved. Only in
the case of thyroglobulin have antigen-specific ICs been studied
(Takeda & Kriss, 1977). However, the microsomal antigen and the TSH
receptor have both been solubilised and the combination of physical
methods of separation and the use of monoclonal antibodies (Kohn et







HLA-DR typing was performed by a standard B lymphocyte microcyt-
otoxicity test on 82 patients with thyrotoxic Graves' disease. 53 of
the patients (65%) were positive for the DR-3 allele in keeping with
data from the published literature. There was no significant
difference between DR-3 positive and DR-3 negative patients in terms
of age at first diagnosis, thyroid hormones or four hour 131i uptake.
Thyoid microsomal antibodies were found particularly in patients who
were DR-3 homozygotes or those who had the phenotype DR-3+4 (such
patients may be specially susceptible to autoimmune endocrine
disease): Ten out of eleven (91$) of these patients were positive for
thyroid microsomal antibodies compared to 23 (55$) of the remaining
42 patients tested (p = 0.05).
TSH receptor antibodies (TBII) were found in 44/53 (83$) patients
tested. The median value for TBII in DR-2 positive patients was 25.2
compared to 17.5 in non DR-2 positive patients (p < 0.05). The median
TBII in seven DR-2 homozygotes was 36.2 compared to 19.9 in the 15
other DR-2 positive patients (p < 0.01).
Of 24 patients followed up after starting carbimazole, eight were
DR-2 positive. The median TBII was not only higher at diagnosis in
these patients but but it also took six months to return to normal
after starting treatment despite adequate biochemical control of
their thyrotoxicosis. By contrast, in sixteen other patients studied
TBII was normal in two months. 26 DR typed patients were tested for
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TBII at least 18 months after 131I therapy. DR-3 was found in 12/15
(80%) patients with persisting TBII compared to 5/11 (4550 with no
TBII.
These results suggest that autoimmune thyroid stimulation and thyroid
destruction might be under separate genetic control and that HLA-DR2
may be a marker for the former. HLA-DR3, although strongly associated
with Graves' disease, does not appear to be a useful marker for any
particular aspect of the disease.
INTRODUCTION
The Human Leukocyte Antigen (HLA) system is a complex of some 1000
genes on the short arm of chromosome six. Its discovery arose from
the observation of antibodies in the sera of parous women or multiply
transfused patients which would agglutinate white blood cells
(Dausset, 1954; Payne, 1 957). Very quickly, a polymorphism became
apparent in the system whereby the serum from a particular patient
would agglutinate the cells of some patients but not of others. This
polymorphism became relatively easy to study after Terasaki and
McClelland (1964) introduced a microcytotoxicity assay based on
complement-mediated lysis of leukocytes in microwell plates. The HLA
system is now known to code for glycoproteins on the surface of all
nucleated cells in the body and comprises four loci (A, B, C and D).
One haplotype is inherited from each parent and the alleles at each
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locus are expressed in a codominant fashion. Because the gene complex
is relatively small, recombination is quite uncommon and the
haplotypes are generally inherited intact.
The structure of the human Major Histocompatibility Complex (MHC) is
shown in FIGURE 6.1. Products of the A, B and C loci are known as
Class I antigens and are expressed on the surface of all nucleated
cells and blood platelets. Class II antigens include the ten (eighth
histocompatibilty workshop) recognised alleles of the DR locus and
are expressed on the surface of B lymphocytes, accessory cells of the
immune system (monocytes, macrophages and Langerhans cells),
activated T lymphocytes and some endothelial cells. Until recently
typing for alleles of the D locus could only be performed by a mixed
lymphocyte reaction whereby stimulator cells treated either by
irradiation or with mitomycin would induce transformation in HLA
non-identical responder cells. A microcytotoxicity assay on B cells,
similar to that used for alleles of the A, B, and C loci, is now
widely employed and specificities thus identified are known as DR
(D-related). Other Class II antigens are coded for in the DQ and DP
loci (formerly SB and DC respectively) and, in addition, two systems
- MB and MT - are recognised each with three alleles in linkage
disequilibrium with those of the DR locus. The complex also codes for
three complement components - C2, C4 and properdin factor B (Bf) of
the aternative pathway, as well as two enzyme systems -the red cell
glyoxylase (Glo) and the adrenal 21-hydroxylase.
The gene product of the HLA -A, B, and C loci is a 43,000 molecular
weight glycoprotein found at the cell surface in association with a
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I antigens are thought to restrict the action of cytotoxic T cells
i.e. antigen bearing cells need to be similar in their HLA complement
to that of the cytotoxic T cells for the latter to be active
(McMicheal et al, 1 977; Dickmeiss et al, 1 977). Class II (DR)
antigens differ in structure: They consist of two similar chains, an
alpha chain of 32,000 Daltons and a beta chain of 28,000 Daltons,
both of which are coded for at the DR locus. These antigens are
thought to restrict helper cell function and are therefore important
in the relationship between immunoregulatory T cell subsets and
effector cells. For example, Thorsby et al (1983), in studying the T
cell response to purified protein derivative of tuberculin and herpes
simplex virus, showed that the T cell response to these antigens was
reduced by about a half if the effector cells and antigen presenting
cells shared only one DR determinant, while it was very poor indeed
if they were completely non identical for Class II antigens. The
function of Class II antigens is discussed in detail in Chapter 8.
The importance of HLA typing in clinical practice lies in the
association between certain HLA alleles and disease states,
particularly those with an autoimmune aetiology. The assocciation
betwen histocompatibility antigens and disease was first appreciated
in the mid 1960s when susceptibility to virus-induced leukaemia in
the mouse was shown to be related to the major histocompatibility
complex (Lilly et al, 1964). The susceptibility to a disease is
quantified in terms of relative risk (RR) which is defined as the
ratio of the particular antigen frequency in patients with the
disease to the allele frequency in control subjects (Svejgaard et al,
1974). In the autoimmune diseases, early reports of associations with
the HLA-A, B and C alleles have largely been superceded by
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associations with the DR locus which are generally more marked. The
recognised associations between HLA-DR loci and autoimmune diseases
are summarised in TABLE 6.1.
The mechanism underlying these HLA asociations with autoimmune
diseases is not clear. One of the problems is the incomplete
association between particular disease states and HLA alleles
although this may become less of a problem as new specificities
become characterised. For example, coeliac disease has recently been
shown to be more closely linked to the DC3 phenotype than it is to
HLA-DR3 (Tosi et al, 1983). Hypotheses that the HLA system restricts
the range of antigens to which the individual is capable of
responding or that the glycoprotein gene products act as receptors
for viruses or chemically modified antigens remain largely unproven.
The main research thrust has been towards identifying genes in the
major histocompatibility complex which control the immune response
such as those described in the mouse or the guineas pig (McDevitt and
Chinitz, 1969; Benacerraf and McDevitt,1972). Unfortunately, the
experimental evidence for a direct role of the histocompatibility
complex in determining individual differences in immune response in
Man is sparse. Sasazuki et al (1978) have shown in normal Japanese
subjects, that the response to tetanus toxoid is under the influence
of HLA-B5, and to a greater extent of an HLA-D determinant. A similar
effect with the response to influenza A and vaccinia has been
reported (for review see Sasazuki et al, 1983). These authors have
further studied the antigen-specific T cell response to streptococcal
cell wall antigen in normal families which were HLA typed. The
correlation between the level of response in HLA identical sibs was
very high, but was less marked in sibs sharing only one haplotype and
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TABLE 6.1 ASSOCIATIONS BETWEEN HLA-DR AND AUTOIMMUNE DISEASES
DISEASE PHENOTYPE RELATIVE RISK
Goodpasture's syndrome DR2 15.9
Multiple sclerosis DR2 4.1
Dermatitis herpetiformis DR3 15.4
Coeliac disease DR3 10.8
Systemic lupus erythematosus DR3 5.8
Sicca syndrome DR3 9.7
Idiopathic membranous nephropathy DR3 12.0
Myasthenia gravis DR3 2.5
Addison's disease (idiopathic) DR3 6.3
Graves' disease DR3 3-7
Type I diabetes DR3 3.3
Rheumatoid arthritis DR4 4.2
Hydralazine-induced SLE DR4 5.6
IgA nephropathy DR4 4.0
Type I diabetes DR4 6.4
Juvenile rheumatoid (pauciarticular) DR5 5.2
Pernicious anaemia DR5 5.4
Hashimoto's thyroiditis DR5 3.2
* Data from Svejgaard, Platz and Ryder (1983).
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very low in HLA non-identical sibs. The response to the antigen in
vitro could be abolished by the addition of monoclonal anti-DR
indicating that the reaction between antigen presenting cells and T
cells was restricted by Class II antigens. The mechanism for the
HLA-mediated control of response to streptococcal antigen was thought
to be the generation of Leu-2a positive suppressor cells and a
linkage between this response and the MT1 allele was proposed. Some
direct evidence that HLA phenotype might affect lymphocyte subsets
has recently accumulated: Lawley et al (1981) have shown decreased
numbers of cells with Fc receptors for IgG in HLA B8/DR3 positive
patients with dermatitis herpetiformis and also in normal subjects
with this phenotype. This subset of cells contains those lymphocytes
with suppressor cell activity (see Chapter 7). In the study of Caruso
et al (1984), the DR1 phenotype was associated with increases of both
T-gamma and T-mu cells, while both subsets were decreased, although
not significantly, in DR3 positive normal subjects. These authors
(Caruso et al, 1985) have recently extended their study to include
the use of monoclonal antibodies to define T cell subsets. Both 0KT4
and 0KT8 positive cells were increased in association with DR1 while,
once more there was a non-significant decrease in DR3 positive
subjects.
The association between HLA-B8 and Graves' disease was first
recognised in 1973 by Grumet et al and has been confirmed in many
subsequent studies (Farid et al, 1975; Thorsby et al, 1975;
Whittingham et al, 1975; Balazs et al, 1978; Mather et al, 1980). In
a further report by Grumet et al (1974), the association with HLA-B8
was confirmed but was not found in patients with Graves' disease
following external neck irradiation. In the study by Farid et al
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( 1976), not only was the B8 allele frequency increased but so too
was the incidence of homozygosity compared to the general population.
An association with HLA-DR3 is now recognised and this is more marked
than that with B8 (Bech et al, 1977; Farid et al,1979; Allanic et al,
1980; Farid et al, 1980a; Dahlberg et al, 1981; McKenna et al, 1982).
HLA-B8 and DR3 are in linkage disequilibrium and the latter is more
closely linked to the gene or genes which confer suscepibility to
Graves' disease while the association of the former may only be due
to the linkage disequilibrium with DR3. These associations only apply
to Caucasians with Graves' disease: For example, Grumet et al (1975)
found no association with HLA-B8 in Japanese patients while, more
recently, an increase of HLA-Bw35 has been reported (Kawa et al,
1977; Nakao et al, 1978). A recent study in a Chinese population
(Hawkins et al, 1985) found an increase in HLA-Bw46 in early onset
Graves', and of B5 in late onset disease. A younger age of onset in
DR3 positive Caucasian patients was reported by Farid et al (1980a)
but this finding has not been a universal one (Balazs et al, 1978).
There is therefore no doubt that, in Caucasian populations, the
B8/DR3 axis relates to the development of Graves' disease, but does
it relate to the clinical features of the disease? An association
between HLA-B8 and thyroglobulin antibodies and in vitro lymphocyte
transformation was found by Balazs et al (1 978) but, generally, no
correlation between HLA alleles and thyroid microsomal antibodies or
anti-thyroglobulin has been found (Whittingham et al, 1 975; Bech et
al, 1977; Mather et al, 1980; Dahlberg et al, 1981). Similarly, the
B8/DR3 alleles do not correlate particularly with the presence or
titre of TSH receptor antibodies (McGregor et al, 1980a; Mather et
al, 1980; Schernthaner et al, 1980). In a family with multiple cases
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of Hashimoto's disease, no correlation was found between HLA
haplotype and the expression of antithyroid antibodies (Gordin et al,
1979). By contrast, in systemic lupus erythematosus, Ahearn et al
(1982) have found the DR2 and DR3 phenotypes to correlate with
circulating autoantibodies. Briones-Urbina et al (1982) have reported
high levels of immunoglobulins in patients with Graves' disease and
that the IgG level was higher in DR3 positive patients than in those
without this phenotype. Exophthalmos has been associated with HLA-B8
(Balazs et al, 1978) and with HLA-DR3 (Farid et al, 1980b) although
Bech et al (1977) found no such association.
In patients euthyroid after antithyroid drugs, Irvine et al (1977)
found the persistence of thyroid microsomal antibodies to correlate
with HLA-B8, a relationship which was confirmed by Schernthaner et al
(1979) although the latter study found no correlation with the
presence of TSH receptor antibodies. Indeed, after drug therapy,
McGregor et al (1980a) found TSH receptor antibodies to be higher in
patients negative for DR3. When Stenszky et al (1983) attempted to
divide Graves' patients into subgroups, those pateints with eye
disease, high levels of autoantibodies, strong family history and a
tendency to relapse after medical therapy had a particularly high
incidence of HLA-B8. Thyroid abnormalities are common in the first
degree relatives of patients with Graves' disease (for example,
thyroid antibodies and abnormal responses in the TRH test) but these
do not necessarily correlate with HLA (Chopra et al, 1977). It seems
therefore, that HLA B8/DR3 may relate to susceptibility to disease
and to the persistence of autoantibodies but not to the clinical
features of the disease.
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HLA-B8 has also been associated with primary atrophic hypothyroidism
but not with Hashimoto's thyroiditis (Irvine et al, 1 978; Moens et
al, 1979). Similarly, in polyglandular autoimmune disease, the
incidence of B8 is increased in diabetic patients with Graves' but
not in patients with Hashimoto's and diabetes (Farid et al, 1980).
When an early report of increased HLA-DR3 in Hashimoto's was
re-examined the apparent increase was found to be due to patients
with atrophic hypothyroidism (Moens & Farid, 1978; Farid et al,
1981). Goitrous thyroiditis is now known to be associated with
HLA-DR5 (Farid et al, 1980c; Weissel et al, 1980; Farid et al,
1981). The overlap between Graves' disease and Hashimoto's
thyroiditis and the possibility of a DR5 related subgroup of Graves'
was discussed in Chapter 4 - Schleusener et al (1983) have identified
a group of thyrotoxic patients with a diffuse goitre but no
ophthalmopathy or TSH receptor antibodies where the incidence of DR5
was increased. The syndrome of painless thyroiditis with transient
thyrotoxicosis (PTTT) has only recently been recognised and an
association with HLA-DR3 documented, although cases which occur in
the post partum period also have an increased incidence of DR5
(Farid et al, 1983). TSH receptor antibodies have been detected in
patients with Hashimoto's thyroiditis by Bliddal et al (1982b):
Positivity in the radioreceptor assay was associated with DR5 while,
in an assay based on the stimulation of human thyroid adenylate
cyclase, it was the negative patients who tended to be DR5 positive.
These two subpopulations of antibodies may thus be under independant
genetic control.
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The presence of genetic influences other than DR3 is also shown by
family studies. For example, Farid et al ( 1 980d) looked at two
families with multiple cases of Graves' disease and showed that
disease susceptibility was not necessarily related to B8/DR3. In
another family reported by these authors (Farid et al, 1979), Graves'
disease was strongly associated with a maternal haplotype containing
HLA-DR2. Reviewing 14 pairs of sibs with Graves' disease, they (Farid
et al, 1980) found nine of them to be HLA identical suggesting that a
contribution from both parental haplotypes might be important. These
cases did not show an increase in B8, although this allele was
frequently found in the parental haplotype which did not relate to
disease susceptibility.
The value of HLA typing in predicting the response to therapy in
Graves' disease is controversial. Early reports suggested that B8 and
DR3 were markers for relapsing disease (Irvine et al, 1977b; Bech et
al, 1977). By combining the measurement of TSH receptor antibodies
after drug therapy with DR typing, McGregor et al (1980a) were able
to successfully predict the ultimate outcome in 95% of cases. HLA-DR3
has also been reported to relate to the outcome after radioactive
iodine (Davies et al, 1 982) - in this study, there was a high
incidence of the allele in TSH receptor antibody negative patients
who did not respond to therapy. The consensus from recent follow up
studies after drug therapy is that HLA-B8 or -DR3 is not an accurate
predictor of relapsing disease (Schernthaner et al, 1980; Dahlberg et
al, 1981; McKenna et al, 1982; Young et al, 1985). The benefit of DR
typing in clinical practice is, at best, marginal and since it is so
technically demanding, it probably has no place in routine patient
management.
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The aim of the work presented in this chapter was firstly to confirm
the high incidence of HLA-DR3 in thyrotoxic Graves' disease which is
reported in the literature and thus to validate the inclusion of
patients studied in other studies described in this dissertation.
Secondly, to seek correlations between HLA markers and clinical or
immunological features of the disease and evidence to support the
hypothesis of disease heterogeneity put forward in Chapter 4. The
role of HLA-DR typing in predicting the response to antithyroid drugs
and to radioactive iodine therapy was re-examined in limited clinical
studies.
PATIENTS AND METHODS
HLA-DR typing was performed by a lymphocyte microcytotoxicity test as
described in APPENDIX 3 on 82 unselected patients with thyrotoxic
Graves' disease. The study comprised 14 male and 68 female patients
with a mean age at diagnosis of 38.3 years (SD = 13.1, range 10 to 69
years). The diagnosis was made, as before, on the basis of symptoms
and signs, raised T3 and/or T4, flat TRH test and diffuse goitre
and/or scintiscan. Also typed were three patients with pure
ophthalmic Graves' disease (two men aged 48 and 49, one woman aged 61
at diagnosis). All three of these patients had a flat TRH test but
none was clinically or biochemically thyrotoxic. It was not possible
in three patients to obtain a definite tissue type. Only one
antiserum was available for HLA-DR1 and therefore results for this
allele may not reflect the true incidence in Graves' disease.
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Thyroid hormone assays were performed by in-house radioimmunoassay
(Department of Clinical Chemistry, Royal Infirmary, Edinburgh). Anti-
thyroglobulin and anti-microsomal antibodies were detected by
passive haemagglutination using commercially available kits
(Wellcome) and TSH receptor antibodies were assayed using neat serum
as described in APPENDIX 1.
STATISTICS
Thyroid hormone and age data were compared using Student's t Test and
TSH receptor antibody values were analysed with the Mann-Witney U
Test. Other data were subjected to the Fisher Exact Test.
RESULTS
The DR phenotypes of 82 patients with thyrotoxic Graves' disease are
shown in TABLE 6.2 and the frequency of the individual alleles
compared to that in the normal United Kingdom population is shown in
FIGURE 6.2. The only allele showing a significant difference is DR-3
with 65% of Graves' patients positive compared to 27% of the normal
population.
AGE AT DIAGNOSIS
The mean age of the 82 patients at diagnosis was 38 years and no
group of patients with any one allele differed significantly from
this. The mean age for DR-3 homozygotes (n = 7) was 35.2 years
compared to 37.6 years for other DR-3 positive patients (n = 46) and
40.3 years for non DR-3 positive patients (n = 29). The mean age at
diagnosis for all DR-5 positive patients (n = 15) was 43-9 years
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DR-3 10 7 DR-1
DR-4 8 12 1 DR-5
DR-5 H 7 1 1 DR-6
DR-7 1 10
Figures given refer to the number of patients with each phenotype
(total number = 81, one patient who was DR-1+1 is not included in
this table).
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compared to 36.4 for DR-3 positive patients (excluding those who were
also DR-3 positive, n = 46, p = 0.07, Fisher Exact Test).
THYROID HORMONES AMD RADIOACTIVE IODINE UPTAKE
There was no difference in triiodothyronine, thyroxine or four hour
radioactive iodine uptake between groups of patients with different
HLA-DR phenotypes.
THYROID MICROSOMAL AND ANTI-THYROGLOBULIN ANTIBODIES
Microsomal antibodies were detected at a titre of 20^ or above in 33
out of 53 (62%) patients at diagnosis. Of eleven patients who had
DR-3 only or DR-3+4, ten were positive (91%) compared to 23 of the 42
(55%) other patients (p = 0.05, Fisher Exact Test).
Anti-thyroglobulin antibodies were found in six out of 52 (12$)
patients at diagnosis and showed no association with HLA DR type.
TSH RECEPTOR ANTIBODIES
In the 53 patients tested at diagnosis, there was no difference in
the incidence or level of TSH receptor antibodies between DR-3
positive (n = 32)and DR-3 negative (n = 21) patients. The twelve
patients with DR-3 only or DR-3+4 did not differ significantly from
other patients. HLA DR-2 was, however, associated with increased TBII
with 20 out of 22 DR-2 positive patients (91$) having TBII compared
to 24 out of 31 (77$) other patients and the median TBII in the two
groups was 25.2 and 17.5 respectively (p < 0.05, see FIGURE 6.3). The
median TBII in seven DR-2 homozygotes was 36.2 compared to 19.9 in
the 15 other DR-2 positive patients (p < 0.01, see FIGURE 6.4).
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The change in TBII in the six months after starting carbimazole
treatment was studied in eight DR-2 positive patients and compared to
that in sixteen other patients. The DR-2 positive patients were five
females and three males with a mean age at diagnosis of 35.6 years
(SD 16.8, range 16 to 69 years). The other patients, ten of whom were
HLA typed, consisted of 13 females and three males with a mean age at
diagnosis of 29.7 years (SD 7.1, range 15 to 42 years). The response
of TBII during carbimazole treatment is shown in FIGURE 6.5. The
median TBII at diagnosis in the DR-2 positive patients was 48.8
compared to 19.3 in the others (p < 0.05). TBII had reached normal
levels in the latter group by two months after therapy was initiated
but took six months to do so in the DR-2 positive group.
HLA DR-2 AND RESISTANCE TO THERAPY IN GRAVES' DISEASE
Consistent with the above observations, several patients were
encountered where the DR-2 phenotype was associated with a resistance
to medical therapy. Three such examples are reported below:-
CASE HISTORY 1
A 24 year old female (DR-2 + 3) presented with symptoms and signs of
thyrotoxicosis in August 1982. She had a moderate diffuse goitre but
no ophthalmopathy. Tg at diagnosis was 6.6 nmol/1, T4 was 230 nmol/1
and the TRH test was flat. TBII were strongly positive at 75.2 and
thyroid microsomal antibodies were detected weakly at 102. After four
months of carbimazole therapy with which she complied well, she was
still requiring 30 milligrams to keep her clinically euthyroid and
even then here Tg and Tjq were mildly elevated at 3-0 and 158 nmol/1
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FIGURE 6.5 RESPONSE OF TSH RECEPTOR ANTIBODIES TO CARBIMAZOLE IN
respectively. She was therefore submitted to subtotal thyroidectomy
after which she became biochemically euthyroid.
CASE HISTORY 2
An 18 year old girl (DR-2+4) was treated for thyrotoxicosis in late
1975 with carbimazole. She had a large diffuse goitre and severe
bilateral exophthalmos. Because of poor response to drugs, she
underwent subtotal thyroidectomy in March 1976. She remained
euthyroid until April 1979 when she again developed symptoms of
hyperthyroidism (Tg 5.3 nmol/1, 196 nmol/1). She was recommenced
on carbimazole but her thyroid hormones remained marginally elevated.
In July 1981, she therefore recieved 15 milliCuries of 131i and four
months later became hypothyroid. In October 1984, TBII was still
elevated at 14.5.
CASE HISTORY 3
A 20 year old lady (DR-2) was referred in January 1983 having been
taking 30 milligrams of carbimazole per day intermittently since
September 1982. She was eight weeks pregnant at presentation and
therapy was reinstituted with atenolol 100 mg. per day in addition to
carbimazole 30 mg. The response of thyroid hormones was poor and in
March 1983, when Tg was 5.2 nmol/1 and T4 was 162 nmol/1 underwent
subtotal thyroidectomy. TBII prior to operation was 24.4. Throughout
her pregnancy, the thyroid hormones remained towards the upper limit
of normal and the TBII was consistently raised. On the 18th July
1983, she gave birth to a normal female child by Caesarean section.
Two months later TBII had risen from the pre-delivery value of 29.4
to 44.4 and Tg was borderline high at 2.8 nmol/1 with a normal Tij of
136 nmol/1. By June 1984, these values had risen to 5.4 and 299
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nmol/1 respectively and she restarted carbimazole, following which
she became euthyroid.
OPHTHALMOPATHY
The three patients with isolated Graves' eye disease had HLA types
DR-3+4 (two cases) and DR-2+3. In the 82 thyrotoxic patients,
ophthalmopathy was found in 35 of which 22 (6355) were DR-3 positive.
Neither this nor any other allele differed significantly in frequency
between patients with and without exopthalmos. In four of the above
cases, the exophthalmos only occurred after treatment for
thyrotoxicosis and three of these patients were DR-2 positive.
RADIOACTIVE IODINE THERAPY
Of ten consecutive patients rendered hypothyroid in the six months
after therapy, three were DR-3 positive compared to eight out of ten
patients who were euthyroid at the end of six months ( not
significant). HLA DR-3 was found in 12 out of 15 (80/5) patients with
TBII persisting long after radioactive iodine therapy (mean 42
months, range 24 to 71) compared to five out of eleven (4555) patients
with normal TBII (mean period of follow up 58 months, range 18 to
147). Microsomal antibodies were detected in eight out of 14 ( 5755)
patients with persistent TBII and in four out of eleven (3655) of
those with no TBII on long term follow up.
DISCUSSION
The HLA-DR3 allele has been found in 53 out of 82 (65%) patients with
thyrotoxicosis and a diffuse goitre and or scintiscan confirming the
incidence which is already recognised in Graves' disease (Bech et al,
1977; Farid et al, 1977; Allanic et al, 1980; Dahlberg et al, 1981;
McKenna et al; 1982). In keeping with these studies, there was no
difference in the thyroid hormone values or in the radioactive iodine
uptake of the thyroid gland between DR-3 positive and DR-3 negative
patients. The age of the patient at diagnosis similarly showed no
significant correlation with HLA although a trend was seen with the
mean age for apparent DR-3 homozygotes of 35.2 years, 37.6 years for
other DR-3 positive patients and 40.3 for DR-3 negative patients.
Farid et al (1980a) did find a younger age of onset for DR-3 positive
patients although this was not seen in the study by Balazs et al
(1978).
No correlation was found between any DR allele and circulating
anti-microsomal or anti-thyroglobulin antibodies and this is in
agreement with the reports of Whittingham et al (1975), Bech et al
(1977), Mather et al (1980) and Dahlberg et al (1981) . HLA-B8 has
been reported to be associated with higher levels of
anti-thyroglobulin and lymphocyte transformation in response to
thyroid antigen by Balazs et al (1978). DR-3 homozygotes and those
with DR-3+4 might be expected to have a particular tendency towards
autoimmune endocrine destruction: The DR-3 phenotype is associated
not only with Graves' disease but also with primary atrophic
hypothyroidism, Addison's disease and diabetes mellitus while over
95% of Type I diabetics possess either this allele or DR-4 and
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DR-3/DR-4 heterozygosity has been associated with a higher than
anticipated risk of diabetes (Thomsen et al, 1979). Of eleven
patients who were either DR-3 only or DR-3+4, ten (91%) were positive
for anti-microsomal antibody compared to 23 out 42 (55%) other
patients (p = 0.05) .
HLA-DR3 is not generally found to correlate with the presence or
titre of TSH receptor antibodies within a group of patients with
Graves' disease (McGregor et al, 1980a; Mather et al, 1980;
Schernthaner et al, 1980) and this has been confirmed by the present
study. A surprising correlation between DR-2 and TBII was, however
noted. The median TBII in 22 DR-2 positive patients was 25.2 compared
to 17.5 for 31 other patients (p < 0.05). In seven apparent DR-2
homozygotes the value was 36.2 as opposed to 19-9 for the other 15
DR-2 positive patients (p < 0.01). This observation clearly needs to
be confirmed with a larger series of patients but it does fit with
our present knowledge that TSH receptor antibody secretion is not
directly under the control of DR-3. Genetic influences other than
DR-3 have previously been indicated from family studies (Farid et al,
1980d) and indeed one family has been described where the
susceptibility to Graves' disease was linked to DR-2 (Farid et al,
1979) It is noteworthy that two of the DR-2 positive patients in the
present study were sisters, both with the phenotype DR-2+3.
The response to carbimazole was also different in DR-2 positive
patients: After starting the drug, the median TBII for eight DR-2
positive patients took six months to return to normal despite
adequate biochemical control of their thyrotoxicosis while, in
sixteen other patients, the TBII was normal in two months. In the
-216-
study by McGregor et al ( 1980a), TBII were higher after therapy in
DR-3 negative patients than they were in DR-3 positive patients.
The response to radioactive iodine therapy may relate to HLA status:
Three out of ten patients hypothyroid at six months were DR-3
positive compared to eight out of ten euthyroid patients. If
hypothyroidism, euthyroidism and persisting toxicosis are regarded as
part of a continuum in the response to therapy, these results are in
agreement with those of Davies et al ( 1982) who showed that poor
response to therapy at three months related to DR-3 positivity. 131 j
therapy is not only of interest because it is frequently used in the
treatment of thyrotoxicosis but also because of the autoimmune
reaction it initiates which makes it a potentially useful model.
The production of non-stimulatory TSH receptor antibodies after 131j
therapy (Bech et al, 1982) and their persistence long after treatment
was discussed in Chapter 3. This persistence may relate to HLA with
12 out of 15 (80$) patients with persistent antibodies being DR-3
positive compared to five out of eleven (4550 of those in whom
antibodies did not persist. A similar trend was noted with
anti-microsomal antibodies.
For the study described in Chapter 4, a large series of patients with
thyrotoxic Graves' disease was divided into three groups - one with
goitre and high 131x uptake, the second with goitre but low 131 x
uptake and the third group with no goitre. Patients in the latter two
groups were not only older but had less severe thyrotoxicosis while
those in the second group had a very high incidence of autoantibodies
including parietal cell antibodies. Since pernicious anaemia is
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associated with DR-5 and patients with high thyroid antibody titres
may have coexisting Hashimoto's thyroiditis which is also DR-5
associated, it was of interest to examine this apparent disease
heterogeneity with respect to DR typing. However the twelve patients
with low uptake and goitre and the 21 patients with no goitre did not
show any deviation from the incidence of HLA alleles seen in the
majority of Graves' patients. Nor was there any difference in
patients with ophthalmopathy although Balazs et al (1978) have
previously reported an association with HLA-B8 and Farid et al
(1980b) showed DR-3 to be increased in patients with eye disease.
In conclusion, no correlation was found between HLA-DR3 and any
clinical or biochemical feature of the disease, as expected. TBII
were higher in DR-2 positive patients and in DR-2 homozygotes
compared to heterozygotes. These patients were also less susceptible
to the specific immunosuppressive effects of carbimazole. Microsomal
antibody secretion and the persistence of TBII after 131 therapy
-both measures of thyroid autoaggression - may be under the influence
of DR-3. There may therefore be separate genetic control of thyroid
stimulation and destruction by the immune system and this could in









Lymphocyte subsets were studied in Graves' disease using monoclonal
antibodies. There was an increase in the absolute lymphocyte count
in untreated Graves' (2.33 x 109/i) compared to controls (1.80 x
109/1, p < 0.05). Total T lymphocytes, as measured by the monoclonal
antibody 0KT3, did not differ significantly. There was a reduction in
the percentage of 0KT8 positive cells in untreated Graves' (17.2% vs.
22.b% in controls, p < 0.001), which was not present in patients
rendered euthyroid after treatment. The OKT4/OKT8 ratio in untreated
Graves' was 2.53 compared to 1.95 in controls (p < 0.001). The
absolute count of 0KT8 positive cells did not, however, differ in the
two groups and, indeed, there was a moderate increase in the absolute
0KT4 positive cell count in the Graves' patients (9.82 x 10^/1
vs.7.62 x 10^/1 in controls, p = 0.05).
The decrease in the percentage of suppressor cells was also
demonstrated with the antibody UCHT4. Overall, the correlation
between 0KT8 and UCHT4 was good (r = 0.763, P < 0.001) but this was
largely due to the nine controls (r = 0.933, P < 0.001), while the
correlation between the results with the two antibodies was poor in
the Graves' patients (r = 0.096, not significant).
In normal female subjects, the proportion of 0KT8 positive cells in
peripheral blood declined with age (r = 0.641, p < 0.001) with an
increase in the OKT4/OKT8 ratio (r = 0.696, p < 0.001). The absolute
0KT8 count did not change significantly with age.
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In conclusion, data on lymphocyte subsets needs to be interpreted
with caution since changes in the proportion of a subset might not
reflect changes in absolute numbers of cells. Measurements using
different monoclonal antibodies may not be wholly comparable in
disease states. The influence of age means that controls for studies
should be carefully selected.
INTRODUCTION
A: PERIPHERAL BLOOD T AND B LYMPHOCYTE SUBSETS IN GRAVES' DISEASE
Lymphocytosis is a well recognised feature of Graves' thyrotoxicosis
but it is by no means clear whether this is due to an overall
increase in lymphocytes or only to an increase in particular
subsets. Non-thymus derived, B lymphocytes are responsible for
antibody secretion and constitute up to 15$ of circulating
lymphocytes, they may be identified by their surface immunoglobulin
or by receptors on their surface including the CR2 receptor which
forms the basis for the EAC rosetting test. Increased numbers of B
lymphocytes have been reported in untreated Graves' disease using
this method (Hsu et al, 1976; Mori et al, 1980). Lundell et al
(1976), however, found no alterations in B cells in Graves'
patients, in keeping with the findings of Mulaisho et al (1975) who
also found no alterations in goitrous or non goitrous
hypothyroidism. Urbaniak et al (1974) point out that differences in
separation procedures for lymphocytes may give rise to variations in
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the yield of T lymphocytes and therefore produce apparent changes in
the ratios of T to B cells. Using two different methods, however,
they did not find alterations of either subset in Graves' or
Hashimoto's diseases compared with normal controls. An increase in
cells staining with the monoclonal antibody OKIa (anti-DR) has been
attributed to an elevated B cell count (Wall et al, 1983), although
such cells may equally well represent activated T cells (Jackson et
al, 1983, see Chapter 8). The published literature is thus rather
ambiguous with respect to changes in B cells in Graves' disease.
Cell mediated immunity is much harder to study than is humoral
immunity but there is now good evidence that it is disturbed in
conditions such as systemic lupus erythematosus, diabetes mellitus
and Graves' disease. Much of the recent work in autoimmunity has
been concerned with subsets of thymus derived lymphocytes. T cells
can be distinguished by their proliferative response to certain
soluble mitogens and are classically enumerated by a rosetting
technique with sheep red blood cells. There are conflicting reports
on T lymphocyte numbers in Graves' disease: Early studies suggested
that they may be increased (Farid et al, 1973; Aoki et al, 1973)
presumably reflecting a state of activation of the cell mediated
immune system. It was even suggested by Farid et al (1974) that the
E rosette test may be useful in predicting the response to
antithyroid drug therapy since it was shown in 13 subjects to
correlate well with T3 suppression of radioactive iodine uptake.
Later work did not, however confirm this and other workers have
found the proportion of T cells to be normal in Graves' disease
(Mulaisho et al, 1975; Calder et al, 1976; Hsu et al, 1 976; Lundell
et al, 1976 ). In one study, Marciel et al ( 1 976 ) showed the
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percentage of T cells to be normal but the absolute number of T
cells was elevated.
These studies all used the red cell rosetting technique and their
findings have been confirmed recently by Okabe et al (1983) but most
recent work suggests that, if anything, T cells are reduced in
active Graves' disease (Wall et al, 1977; Grinblat et al, 1979; Mori
et al, 1980). The monoclonal antibody 0KT3 has been used by Wall et
al (1983) and these authors found about 46% of peripheral blood
mononuclear cells to be 0KT3 positive compared to 52% in controls. A
similar finding using another monoclonal antibody has been reported
by Iwatani et al (1983). Not all studies with monoclonal antibodies
show reduced T cells - Sridama et al (1982) and Ludgate et al
(1984) found them to be normal.
There is uncertainty therefore, concerning changes in T and B
lymphocyte numbers in untreated Graves' disease but clearly gross
changes in cell numbers are not a prerequisite for an autoimmune
disease. Experimental differences, including lymphocyte separation
methods may underlie part of this controversy but even where the
method is fairly standard as with the use of monoclonal antibodies,
the results have proved to be conflicting.
B: HELPER AND SUPPRESSOR SUBSETS OF T LYMPHOCYTES
Two subpopulations of lymphocytes with major immunoregulatory roles
are now recognised - helpers (T^) and suppressors (Ts). The former
are important in promoting the immune response by cooperating with B
lymphocytes and other subsets of T lymphocytes with effector
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functions. The latter limit the immune response and may be important
in the prevention of autoimmune disease, which may be achieved as
much by the presence of an active immunoregulatory process as by the
absence of "self-reactive" clones of cells. Thus, a relative
deficiency of Ts may permit both humoral and cell-mediated immune
attack on organs such as the thyroid. These cell subsets have been
studied both in animals (for a review of Th and Ts in animal models
of thyroiditis, see Rose et al, 1981) and in a variety of autoimmune
disease states affecting Man.
Several approaches have been used to study these lymphocyte subsets:
Firstly, using in vitro systems, attempts have been made to reverse
changes in humoral and cell mediated immunity by the addition of
normal lymphocytes which are presumed to contain the suppressors
deficient in the patient's cells. Secondly, they may be estimated
qualitatively by using certain properties of Ts in culture - they are
rapidly activated by the mitogen concanavalin A and they are
selectively depleted on long term incubation of the culture. Thirdly,
Fc receptors on the surface of T lymphocytes allow helpers and
suppressors to be distinguished - Ts mainly have receptors for IgG
while the receptors on Th are mainly for IgM. Finally, monoclonal
antibodies have proved to be powerful tools in the investigation of
lymphocyte subsets. They give no direct information on the activity
of the cells nor on their specificty but the assays are reproducible
and readily applied to large numbers of samples.
Early evidence linking autoimmune thyroid disease to changes in
cell-mediated immunity came from studies on the migration inhibition
factor (MIF, Lamki et al, 1973): The normal migration of peripheral
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blood mononuclear cells in a culture chamber is inhibited when they
are exposed to an antigen to which they have been previously
sensitized. Kovalczyk and Zembala (1978) have shown that the
migrating cells are mainly T lymphocytes and have refined the test by
using a T cell enriched fraction as both the indicator cells and
MIF-producing cells. Using this test, Okita et al (1981) have
provided further evidence of T lymphocyte sensitization in Graves'
disease and Hashimoto's thyroiditis. They have gone on to show that
the migration inhibiting activity of these two patient groups could
be abolished by the addition of normal T lymphocytes and this was
thought to be due to their suppressor cell content (Okita et al,
1981). Furthermore, the Ts defect may be organ specific - the same
group (Topliss et al, 1983) have demonstrated that the migration
inhibition by lymphocytes from Graves' and diabetic patients is
specific for thyroid and pancreatic antigens respectively. Migration
inhibition by diabetic lymphocytes could be reversed by the addition
of Graves' lymphocytes and vice versa. While it has been possible in
the MIF test to reverse the abnormality in patients cells by the
addition of normal cells, this has proved difficult in systems
involving humoral immunity. Beall (1972) has cultured B lymphocytes
from patients with autoimmune thyroiditis and found them to produce
anti-thyroglobulin antibody. Antibody production was not inhibited by
the addition of normal lymphocytes. Similarly, McLachlan et al (1980)
have shown that neither mitogen- nor antigen-stimulated antibody
production by lymphocytes from thyroiditis patients was inhibited by
normal lymphocytes. A recent report by Shinomiya et al (1984) tells
of the inhibition of acetylcholine receptor antibody formation by the
addition of culture supernatant of normal lymphocytes to B cells from
patients with myasthenia gravis.
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A subset of lymphocytes which is preferentially activated by
concanavalin A has been shown to have suppressor cell activity
(Sakane & Green, 1977). They will suppress the response of B cells to
mitogen and antigen as well as antibody-dependent cellular
cytotoxicity and natural killer activity (Hallgren et al, 1977; Nair
et al, 1981) and they are present in the peripheral blood of normal
subjects (Shou et al, 1976). The activity of such cells is
selectively lost after 24 hours of incubation (Dutton et al, 1972).
These two properties have been used to qualitatively assess Ts in
autoimmune disease. Thus, a decrease in suppressor activity has been
found in newly diagnosed diabetics (Buschard et al, 1980), returning
to normal with treatment. Horowitz et al (1 977) and Lederman et al
(1981) reported similar findings, although Slater et al (1980) found
no difference in diabetics of long standing. A decrease in Ts
measured by this method has also been demonstrated in SLE (Bresnihan
& Jasin, 1977) and in active multiple sclerosis (Gonzalez et al,
1979). Balazs et al (1979) have found a reduced con A-activated and
short lived suppressor cell function in patients with untreated
Graves' disease. These increased with treatment but not to normal
levels. Aoki et al (1979) reported similar results but there was no
change in Hashimoto's thyroiditis or in thyroid cancer. A more recent
study by Jones et al (1982) showed no change in con A-activated
suppressor cell activity in untreated Graves' disease. Although Ts
activity has generally been found to be reduced in autoimmune disease
when studied by this method, it may not correlate well with
suppressor cell numbers as measured by monoclonal antibodies:
Schandene et al (1983), in a series of patients with various
immunological disorders found a poor correlation between con
-226-
A-activated suppressor activity and percentage 0KT8 positive cells
although a significant correlation with the OKT4/OKT8 ratio was
noted.
Distinctive cell surface markers allow us to enumerate subsets of
lymphocytes. T cells bearing Fc receptors for IgG (Tg cells) and for
IgM (Tm cells) differ in function - Tg cells posssessing suppressor
activity and Tm cells having helper activity (Moretta et al, 1977).
Tg cells are reduced in active SLE (Moretta et al, 1979) but normal
levels have been reported in Hashimoto's thyroiditis (Canonica et al,
1982). It may well be, however, that the diagnosis of Hashimoto's is
made long after the autoimmune process is initiated. Increased Tg
cells are described in subacute thyroiditis (Wall et al, 1981) and
reduced levels have been found in Graves' disease in association with
increased numbers of activated lymphocytes (Canonica et al, 1 983).
Tg cells returned to normal following radioactive iodine therapy and
were not elevated in patients with toxic adenoma. By contrast, Okabe
et al (1983) found no change in active Graves' disease using this
method.
The availability of monoclonal antibodies to cell surface antigens
has transformed research into lymphocyte subsets and is the method
reported in this thesis. A variety of autoimmune diseases has been
associated with a decrease in suppressor cells with a consequent
increase in the ratio of helper to suppressor cells. Thus, Buschard
et al (1983) have investigated patients with Type I diabetes mellitus
with the antibodies 0KT3 (pan T cell), OKT1! (helper/inducer cells)
and 0KT8 (suppressor/cytotoxic cells). At diagnosis patients showed no
change in absolute lymphocyte numbers or total T cells but had
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increased 0KT4+ as well as decreased 0KT8+ cells. Diabetics of long
standing also had reduced 0KT8+ cells but this was not as marked as
in the new patients. Morimoto et al (1980) have reported reduced
0KT8+ cells in active SLE and similar changes have been found in
multiple sclerosis - particularly in the acute phase and in
progresssive forms (Bach et al, 1980). Pernicious anaemia has
recently been added to the list of conditions associated with a
reduced percentage of 0KT8+ cells (Imamura et al, 1984).
A reduced proportion of suppressor cells in thyroid diseases has been
shown in a number of studies: The reduction in total T lymphocytes
found by Thielemnas et al (1981) in 25 patients with Graves',
atrophic hypothyroidism and Hashimoto's was attributed to a decrease
in 0KT8+ cells. These authors found no correlation between thyroid
hormone status and suppressor cell numbers. Sridama et al (1982) also
report a decrease in 0KT8+ cells in untreated Graves' and Hashimoto's
thyroiditis although treated Graves' patients did not differ from
controls. Lymphocyte subsets were investigated in a spectrum of
thyroid disorders by Bonnyns et al (1983) who found a negative
correlation between 0KT8+ cells and thyroid hormone levels. Thus,
Graves' patients had a low 0KT8$ but a high free thyroxine and the
converse was true of Hashimoto's. A direct influence of thyroid
hormones on the immune system was suggested. A different set of
monoclonal antibodies was used by Iwatani et al (1983): Leu2+
(cytotoxic/suppressor) and Leu3+ cells (helper/inducer) were present
normal numbers in Graves' but there was a qualitative difference in
that the fluorescence peak on the cell sorter was shifted in the
Graves' patients. One recent study has shown normal levels of helper
and suppressor cells using the OKT series (Wall et al, 1983). Ludgate
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et al (1984) showed not only that 0KT8+ cells were reduced in active
Graves' and that these returned to normal with treatment, but also
that they remained low in patients whose thyrotoxicosis relapsed
after antithyroid drug therapy.
There is good evidence, therefore, for reduced suppressor cell
activity in untreated Graves' disease although this has not been
confirmed in all published studies. The work presented here was aimed
at finding out whether the reduction in the proportion of 0KT8+ cells
was the result of a decrease in the absolute number of these cells or
whether it may be secondary to an increase in the levels of another
cell subset. Two separate monoclonal antibodies defining the
suppressor cell subset are compared and further support for the
hypothesis that age-related changes in the immune system might be
important in the genesis of autoimmune disease is sought.
PATIENTS AND METHODS
PATIENTS The study included 21 consecutive cases of untreated
Graves' disease. The diagnosis was made on the basis of an elevated
Tg and/or T4, flat TRH test and a diffuse goitre and/or scintigram.
TSH receptor antibodies were detected in neat serum as already
described and were found in 18 of the 21 new cases. The other three
all had exophthalmos. Seven cases were studied while clinically and
biochemically euthyroid six to nine months after starting carbimazole
(maintenance dose 5 to 15 mg.) . A further nine cases were in
remission and were recieving no antithyroid therapy (five had
previously been treated with carbimazole and the others had been
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treated with radioactive iodine) . Subclinical Graves' disease was
diagnosed in seven cases: Two were TSH receptor antibody positive,
the total ranged from 2.6 to 3.8 nmol/1 (normal upper limit = 2.8)
and the Tfrom 121 to 162 nmol/1 (normal upper limit = 150). All
seven had flat TRH tests and all had a diffuse scintigram but none
had severe symptoms or signs of thyrotxicosis.
Controls were selected from staff of the Royal Infirmary, Edinburgh
and were matched approximately to the age and sex of the patients.
None had a history of autoimmune disease or any other intercurrent
illness.
METHODS Venous blood was collected in preservative-free heparin at
the same time each day (9 to 11 A.M.) since lymphocyte subsets may
show a diurnal variation (Bertouch et al, 1983; Ritchie et al, 1983).
At least one control was processed with each patient sample. Absolute
lymphocyte counts were supplied by the Department of Haematology,
Royal Infirmary, Edinburgh using a Coulter counter followed by a 200
cell manual differential count. TSH receptor antibodies were analysed
on neat serum as described in APPENDIX 1.




The study included 24 controls (20 female, four male), 21 patients
with thyrotoxic Graves' disease prior to starting carbimazole (16
female and five male), seven patients who were taking carbimazole but
who were euthyroid, nine patients in remission following therapy and
seven patients with subclinical Graves' disease. The following
monoclonal antibodies were used to enumerate lymphocyte subsets




0KT8 POSITIVE CELLS There was a significant reduction in the
percentage of 0KT8 positive cells in untreated Graves' disease (mean
0KT8 = 17.2/0 compared to controls (mean = 22.4$, p < 0.001) - see
FIGURE 7.1. The mean 0KT8 in the seven patients euthyroid on
carbimazole was 20.3$ with a value of 21.7$ for the patients in
remission and 21.9$ for the patients with subclinical disease. None
of these values differed from controls.
OKT4 POSITIVE CELLS These values are illustrated in FIGURE 7.2 The
mean percentage of 0KT4 positive cells in controls was 42.6$ compared
to 42.4$ in untreated Graves', 42.8$ in those euthyroid on
carbimazole, 40.6$ in the group in remission and 42.9$ in the
subclinical group. There was no significant difference between the
various groups.
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CONTROLS UNTREATED EUTHYROID REMISSION SUBCLINICAL
GRAVES' (ON CARB.)
(n = 24) (n = 21) (n =7) (n = 9) (n = 7)
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OKT4/OKT8 RATIO See FIGURE 7.3. The mean ratio in controls was
1.95 while that in untreated Graves' was 2.53 (p < 0.001). Patients
euthyroid on carbimazole had a mean ratio of 2.14, those in remission
after treatment 1.90 and the subclinical cases 2.09 - none of which
differed from controls.
0KT3 POSITIVE CELLS In 29 controls, the mean percentage of T cells
was 58.4% (SD = 6.52) compared to 51.3% in 20 patients with untreated
Graves' disease (SD = 5.55, not significant).
COMPARISON OF THE MONOCLONAL ANTIBODIES 0KT8 AND UCHT4
Suppressor/cytotoxic cells were measured with these two antibodies in
nine controls and in nine patients with untreated Graves' disease.
The correlation between the two is shown in FIGURE 7.4. The overall
correlation coefficient was 0.763 (p < 0.001), but this correlation
was largely due to the controls (r = 0.933, P < 0.001). The
correlation in the nine Graves' patients between 0KT8 and UCHT4 was
poor (r = 0.096). Like 0KT8, however UCHT4 was significantly reduced
in the Graves' patients (18.4%) compared to controls (23.1$, p <
0.05).
ABSOLUTE LYMPHOCYTE NUMBERS Untreated Graves' disease was
associated with a mild lymphocytosis - the absolute lymphocyte count
in 13 cases was 2.33 x 109/1 compared to 1.80 x 109/1 in 22 controls
(p < 0.05). In 13 patients in remission (five on carbimazole, eight
post-treatment), the mean lymphocyte count was not elevated at 2.06 x
10 9/i.
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A B C D E
CONTROLS UNTREATED EUTHYROID REMISSION SUBCLINICAL
GRAVES' (ON CARB.)
(n = 24) (n = 21) (n =7) (n = 9) (n = 7)
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ABSOLUTE SUBSET NUMBERS See TABLE 7.1. The absolute count of 0KT8
positive cells in 22 controls averaged 4.10 x 108/i compared to 4.21
x 108/i in 13 untreated Graves'. These were not significantly
different although the percentage 0KT8 positive cells in the patients
was 18.6 compared to 22.5% for the controls (p < 0.01) and the
OKT4/OKT8 ratios were 1.95 and 2.32 respectively (p < 0.05). There
was a slight increase in the number of 0KT4 positive cells in the
untreated cases - 9.82 x 108/1 as against 7.62 x 108/1 for the 22
controls (p = 0.05).
The absolute 0KT8 count for the euthyroid Graves' cases was 4.24 x
108/1 which is similar to the control value and the count of 0KT4
positive cells was 8.89 x 108/1 which again is comparable to the
control value.
CHANGES WITH AGE IN NORMAL FEMALE CONTROLS In the 20 female
controls used in this study, there was a significant negative
correlation between age and the percentage of 0KT8 positive cells (r
= -0.641, p < 0.01 - see FIGURE 7.5). There was a consequent positive
correlation between age and OKT4/OKT8 ratio which is illustrated in
FIGURE 7.6 (r = 0.696, p < 0.001). 0KT4 did not change with age and
there was no relationship between absolute subset numbers and age.
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TABLE 7.1 ABSOLUTE LYMPHOCYTE SUBSET NUMBERS IN THYROTOXIC AND
EUTHYROID GRAVES' PATIENTS AND IN CONTROLS
0KT8 0KT4 RATIO LYMPHOCYTE ABSOLUTE ABSOLUTE
(*) (*) 4/8 COUNT 0KT8 0KT4
CONTROLS 22.5 42.6 1.95 00o X O vo cooX—Xo 7.62 x 108
(N = 22)
EUTHYROID 20.6 42.0 2.06 2.06 X 109 4.24 x 108 8.89 x 108
GRAVES'
(N = 13)
UNTREATED 18.6 42.0 2.32 2.33 x 109 -fcr r\) X o 00 9.82 x 108
GRAVES'
(N = 13) ** * * *
* = p < 0.05
** = p < 0.01
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FIGURE 7.5 CORRELATION BETWEEN AGF AND PERCENTAGE OKT8 POSITIVE
CELLS IN NORMAL WOMEN
r-~ f\ on
cm CM *—
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Helper and suppressor lymphocyte subsets were quantified in Graves'
disease using monoclonal antibodies. Untreated Graves' was associated
withumild lymphocytosis with a peripheral blood count of 2.33 x
109/1 in 13 patients compared to 1.8 x 109/1 in 22 controls. The
proportion of total T lymphocytes (0KT3 positive cells)was, however,
normal, in keeping with the findings of Mulaisho et al (1975), Hsu et
al (1976), Calder et al (1976) and Lundell et al (1976). All of these
authors employed rosetting techniques to enumerate T cells but normal
T cells have also been found with monoclonal antibodies by Sridama et
al ( 1982) and Ludgate et al (1984). By contrast, Wall et al (1983)
found 0KT3 positive cells to be reduced in active Graves'.
The percentage of 0KT8 positive cells was reduced in the peripheral
blood of 21 patients with untreated Graves' disease (17.2$) compared
to 24 controls (22.4$) in agreement with the findings of Thielemans
et al (1981), Sridama et al (1982) and Ludgate et al (1984). 0KT8
percentage was normal in patients euthyroid on carbimazole and in
patients who were in remission after therapy. Not all published
studies with monoclonal antibodies have found suppressor cells to be
reduced; both Wall et al (1983) and Iwatani et al ( 1 983) found the
proportion of these cells to be normal although the latter authors
did report a qualitative change in the fluorescence of suppressor
cells in Graves' patients.
Since other subsets of cells are undoubtedly raised in Graves' and
other autoimmune diseases (see below and Chapter 8), the reduction in
the percentage of 0KT8 positive cells may result and it was therefore
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of interest to measure the absolute count of 0KT8 positive cells. In
22 controls the count of 0KT8+ cells was 4.10 x 10^/1 and this did
not differ significantly from that of 13 untreated Graves' patients
whose average count was 4.21 x 108/1. While the evidence for a
functional suppressor cell deficit in autoimmune thyroid disease is
good, both in animal and human studies (Rose et al 1981; Okita et al
1981b), this need not necessarily be reflected in cell numbers.
Topliss et al ( 1 983) have suggested that the suppressor defect in
autoimmune endocrine disease is organ specific and that such a
defect may therefore only affect a proportion of the total suppressor
cells. It may also be that changes in the proportion of a cell subset
in peripheral blood do not accurately reflect what is happening at
the actual site of the autoimmune reaction. For example, in
autoimmune thyroid disease, both Wall et al (1983) and Warford et al
(1985) have found differences in proportion of lymphocyte subsets in
the thyroid compared to the peripheral blood.
The proportion of 0KT4 positive (helper/inducer) cells was normal in
Graves' patients although there was a modest increase in the absolute
number of 0KT4 + cells (9.82 x 10®/1 in Graves' patients compared to
7.62 x 10^/1 in controls). This increase may account for some of the
reduction in the percentage of 0KT8+ cells. It may be that the
relative reduction in suppressor cells in relation to inducer cells
is sufficient to allow the autoimmune reaction to proceed. 0KT4$ has
generally been reported as normal in Graves' although Buschard et al
( 1983) did find 0KT4$ to be increased in newly diagnosed diabetes.
Newer monoclonals may contribute to the study of helper cells. The
antibody 5/9, for example, reacts with 15 to 20$ of peripheral T
cells and this subset contains the cells which promote pokeweed
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mitogen-driven B cell differentiation and increase the activity on
killer cells (Corte et al, 1982; Moretta et al, 1982). 5/9+ cells are
known to be increased in patients with active Graves' disease
(Canonica et al, 1983).
When the two monoclonal antibodies 0KT8 and UCHT4 (both of which
identify the suppressor/cytotoxic cell subset) were compared in nine
Graves' patients and nine controls, the overall correlation in the
percentage of positive cells was good (r = 0.763, p < 0.001). This
was, however, almost entirely due to the correlation in controls (r =
0.933) while the two sets of values for the Graves' patients
correlated poorly, although both antibodies confirmed a reduction in
the percentage of suppressor cells. This phenomenon has not
previously been reported and clearly requires further study. It does
demonstrate that caution is necessary when comparing results of
studies which use different monoclonal antibodies. Changes in the
cell surface chemistry may occur during the development of an
autoimmune disease and this could affect the reaction of cells with
monoclonal antibodies. Pincus et al (1985) showed that some activated
lymphocytes in patients with rheumatoid arthritis expressed both the
0KT4 and 0KT8 markers. Other methods of quantifying suppressor cells
are laborious to apply and difficult to reproduce. There are,
however, problems associated with the use of monoclonal antibodies
and each antibody must be evaluated for use in individual disease
states.
In 20 normal female controls, there was a negative correlation
between age and OKT856 (r = -0.641, p < 0.01) with a corresponding
positive correlation between age and OKT4/OKT8 ratio. Absolute subset
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numbers showed no such correlation and the percentage reduction may
reflect an increase in another cell subset. The onset of autoimmune
disease is well known to be age-related (Burch and Rowell, 1963) and
this might be a reflection of age-related changes in immunological
functions which could be exaggerated in those individuals genetically




Killer/Natural Killer Cells and




Subsets of peripheral blood mononuclear cells have been investigated
using monoclonal antibodies in patients with either newly diagnosed
or recurrent Graves' disease. T cells with early activation antigen
were studied with the antibody 4F2 while those with late activation
antigens were quantified using three separate monoclonal antibodies
to class II histocompatibility antigens. Cells with killer/natural
killer activity were measured as were helper and suppressor subsets
of lymphocytes.
0KT8 positive cells were reduced in both new and recurrent Graves'
with 16.2% and 15.9$ respectively compared to 22.4$ in controls (both
p < 0.05). 4F2 positive cells were increased in new Graves' with 14
out of 28 patients having increased numbers of positive cells (p <
0.01) but they were normal in patients with recurrent Graves'
disease. There was a negative correlation between TSH receptor
antibodies and 4F2 positive cells in newly diagnosed Graves' disease
(r = -0.603, P < 0.05).
Class II antigen positive T cells were increased in both new and
recurrent Graves' - 12 out of 21 (58$) new and five out of eight
(63$) recurrent cases having increased numbers of positive cells.
Many patients showed increased levels of positive cells with one
antibody but not with the others. Overall, increased numbers of
activated T cells were seen in 15/21 (71$) new cases and in 6/8 (75$)
patients with recurrent thyrotoxicosis.
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Using the antibody H366, cells with natural killer activity were
found to be increased in untreated Graves' (10.6% of peripheral blood
mononuclear cells compared to 6.0$ for controls) but normal levels
were found in recurrent disease. Class II antigen expression on the
surface of thyroid cells was confirmed in three Graves' thyroids.
In conclusion, changes in cell-mediated immunity are present in
Graves' disease with reduced percentage of suppressor cells,
increased activated T cells and increased cytotoxic cells. Class II
antigen expression both on thyrocytes and on T lymphocytes may be
involved in initiating and maintaining the autoimmune response. The
negative correlation between 4F2 positive cells and TBII may account
for some of the heterogeneity seen in the expression of immunological
markers. Recurrent Graves' disease differs immunologically from new
disease by being associated with normal K/NK cells and early
activated T cells in the peripheral blood although changes in
immunoregulatory T cell subsets and late activated T cells are
comparable to those found in new disease.
INTRODUCTION
The use of new monoclonal antibodies has much to offer for the study of
cell-mediated immunity in Graves' and other autoimmune diseases. A
sequence of antigen expression on the surface of T lymphocytes as they
become activated is now apparent, while novel antibodies readily allow
us to study cells with effector functions such as killer (K) and
natural killer (NK) cells. Monoclonal antibodies have also revealed the
aberrant expression of class II histocompatibility antigens on the
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surface of tissues which are the target for autoimmune attack. Studies
of these phenomena will tell us much about the early events in the
development of diseases such as Graves' and further reveal the
multi-facetted nature of the autoimmune response.
EARLY ACTIVATION ANTIGENS ON T CELLS.
By using monoclonal antibodies to study the appearance of cell surface
antigens relative to DNA synthesis when T cells are stimulated, Cotner
et al (1982) have defined a sequence of activation antigens. Thus,
early activation antigens include the transferrin receptor, Tac (T
cell activation antigen), and that defined by the monoclonal antibody
4F2 while, most notable amongst the late activation antigens are the
DR specificities of the major histocompatibility complex (class II
antigens). 4F2 is a mouse monoclonal developed and characterised by
Eisenbarth's group in Boston, USA (Eisenberth et al, 1980; Haynes et
al, 1981). Although primarily a monocyte antigen, it is expressed on
the surface of about 70% of activated T cells. It has been widely
used to study these cells and is included in the panel of monoclonal
antibodies used for the work presented in this chapter. It binds to a
cell surface component of 120,000 Daltons, is not related to HLA
antigens and does not block killer or natural killer activity.
Increased circulating mononuclear cells bearing the 4F2 antigen have
been reported in Crohn's disease (Fais et al, 1985) but Jackson et al
(1982, 1984) did not find increased levels of such cells in either
untreated Graves' disease or in patients with recently diagnosed type
I diabetes. Raised levels of 4F2 positive cells were found in
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Hashimoto's thyroiditis by Canonica et al (1982) and, more recently,
Kennedy et al (1985) have reported increased numbers in thyrotoxic
Graves' patients (see Note 1 at the end of introduction).
CLASS II ANTIGENS ON ACTIVATED LYMPHOCYTES
Class II antigens are normally detected on the surface of B
lymphocytes, monocytes and other antigen presenting cells such as the
Langerhans cells of the skin, endothelial cells and haematopoietic
precursors. Resting T cells do however express a small quantity of
class II antigen which can be detected using the highly sensitive
technique of flow microfluorometry with a fluorescence-activated cell
sorter (Mann & Sharrow, 1979). The amount of la antigen on the
surface of T cells can be greatly increased by stimulation with
antigen, mitogen or in a mixed lymphocyte reaction (Zimmerman et
al,1979; Yu et al, 1980; Charron et al, 1980). The latter authors
further showed that the electrophoretic pattern of the class II
antigen so produced was similar to that on the B cells of the same
individual. That the antigen is actively synthesized by the T cells
rather than being passively absorbed, was shown by Evans et al (1978)
using 35s-methionine added to lymphocyte cultures and was later
confirmed by by Pincus et al (1985) by RNA hybridisation studies with
a cloned HLA-DR alpha chain gene probe. It is also known that
physical changes in the cell membrane induced by cross linking cell
surface antigens can unmask DR antigens without the need for de novo
synthesis (Mittler et al, 1983).
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In normal individuals, only a small proportion of the circulating T
cells are usually found to express class II antigens (Fu et al, 1978).
The number of these "activated cells" is greatly increased after
infection, in autoimmune diseases (SLE and rheumatoid arthritis) and in
response to immunization with tetanus toxoid or purified protein
derivative of tubercle (Yu et al, 1 980). In the peripheral blood of
rheumatoid patients, for example, 16.7% of T cells were found to be
class II antigen positive compared to 2.4$ in controls (Pincus et al,
1985). Ia positive cells are also found in the synovial fluid and
tissues of some patients (Burmester et al, 1981 ) and, although some
were of the "blastoid" type described by Yu et al (1980), more were
typical of the T lymphocytes seen in the peripheral blood. Increased Ia
positive T cells have also been found in the circulation of patients
with Sjogren's syndrome (Sanvezie et al, 1982) and in a young patient
with a primary autoimmune disease similar to acute graft-versus-host
disease (Reinherz et al, 1979).
Increased class II antigen positive T cells were found in the
circulation of nine out of eleven patients with diabetes of recent
onset by Jackson et al (1982). The same applied to all 33 of the
thyrotoxic Graves' patients studied by these authors, while other
thyrotoxic patients and patients euthyroid after antithyroid therapy
for Graves' had normal levels of activated T cells (Jackson et al,
1984). These findings were similar to those of the previous study by
Canonica et al ( 1983). In their study of a series of patients tested
sequentially after starting drug treatment, Ludgate et al (1984)
confirmed the elevated Ia cells at diagnosis and reported a progressive
decrease during treatment except in those patients whose disease
remained active. In a recent report by Kennedy et al ( 1985) where Ia
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positive T cells were again increased, the importance of using more
than one antibody was stressed since many patients had increased levels
of cells staining with one antibody but not with another. There is some
overlap betwween the results in this report and the work presented in
this chapter and the panel of monoclonal antibodies used was the same
for both (see Note 1 at the end of introduction). Some heterogeneity in
the expression of antigens on lymphoblastoid cells bound by two of the
monoclonal antibodies used had already been reported (Van Heyningen et
al, 1982). The class II molecules on B cells and activated T cells have
at least one epitope which is not expressed on haematopoietic
precursors or monocytes (Torok-Storb et al, 1983) and differences in
the binding of anti-DR antibodies by la positive cells are well
recognised to occur (Lampson & Levey, 1980; Hurley et al, 1982) and
it thus seems better, where possible, to employ more than one
monoclonal in the search for activated T cells.
The expression of class II antigens on the surface of activated T
lymphocytes is undoubtedly important in the interaction with other cell
types including antigen presenting cells. It also gives rise to the
phenomenon of restriction: for example, Rodey et al (1979) have shown
that, when accessory cells and antigen are added to T cells in culture,
a proliferative response if the former cell type shares an HLA region
determinant with the T cells. Similarly, the antigen production of
spleen cells in response to antigenic stimulation can be inhibited by
adding an anti-la specific for the la type of the cells but not with an
antibody against another la type (Hodes et al,1980). Class II antigens
are thus crucial to the cooperation which exists between antigen
presenting cells, B cells and helper T cells, a relationship which
must be central in the production of an autoimmune disease. Examining
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the cell infiltrates in the synovial tissue of rheumatoid patients,
Klareskog et al ( 1 982) found that the bulk of the T cells were
helper/inducer cells and were mostly found in close proximity to cells
expressing HLA-DR. Pincus et al (1985) found that the activated T cells
expressed the T6 (thymocyte-related) antigen suggesting that they may
be young cells released from the thymus in response to an immune
challenge. Most of the activated T cells in the circulation share
surface markers with suppressor cells - thus they are enriched in Tg
fractions and can be stained with the monoclonal antibody 0KT8
(Speares et al, 1979; Yu et al, 1980; Burmester et al, 1981). Direct
evidence of their suppressor activity comes from the study of
Sauvezie and colleagues (1982) who, by depleting lymphocyte
suspensions of la positive cells, showed enhancement of both the
autologous and the allogeneic mixed lymphocyte reactions (MLR).
KILLER (K) AND NATURAL KILLER (NK) CELLS.
Not all effector cells in the immune system are either B cells or
typical T cells. A subset of cells with spontaneous cytolytic activity
are now recognised, the natural killer (NK) cells (for review of
their properties, see Herberman & Ortaldo, 1981; and summary in TABLE
8.1). These cells circulate in normal individuals and are thought to
be important in immune surveillance. Most NK cells have Fc receptors
for IgG and are therefore capable of antibody-dependent cellular
cytotoxicity (i.e. K cell activity). Morphologically, they are
somewhat larger than T cells with a higher ratio of cytoplasm to
nucleus, they are thus often identified as "large granular
lymphocytes". Although they do not depend on the thymus for their
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TABLE 8.1 PROPERTIES OF NATURAL KILLER CELLS
1. 12 to 15 micrometers in diameter with a high cytoplasm to
nucleus ratio (large granular lymphocytes).
2. Have spontaneous cytolytic activity against tumour cell lines
but are not phagocytic.
3- Proliferate in response to T cell mitogens and T Cell Growth
Factor.
4. They are non-thymus dependent but share a number of T cell
markers (50% have receptors for sheep red blood cells but NK
cells do not bind 0KT3).
5. Possess receptors for the Fc portion of IgG and may therefore
function as killer cells.
6. Their action is not restricted by MHC products.
7. There is no evidence for immunological memory.
8. They produce interferon and possibly T Cell Growth Factor.
9. They are recognised by the monoclonal antibody H366 which is
directed at a 96,000 molecular weight cell surface protein.
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development, they do express a number of T cell markers. For example,
receptors for sheep red blood cells are found on about half of them
although they do not bind the monoclonal antibodies 0KT3, 0KT4 or
0KT8. They are not phagocytic but share some surface markers with
monocytes (e.g. 0KM1). NK cells will proliferate in response to the T
cell mitogens phytohaemagglutinin and concanavalin A and can also be
stimulated by Interleukin 1 (T cell growth factor) and interferon.
Recently, NK cells have been shown to display activation antigens
similar to those on activated T cells (HLA-DR, 4F2, transferrin and
interleukin 2 receptors) when they are stimulated (London et al,
1985). their activity is not restricted by HLA gene products and, as
a result, they can respond to antigenic challenge much quicker than
cytotoxic T cells (probably less than four hours in vivo). There is
no evidence for immunological memory in this subset of cells.
As with subsets of T lymphocytes, a number of methods have been
developed to study NK cells. By looking at the formation of low
affinity sheep red blood cell rosettes, Pozzilli et al (1979) have
found raised levels of NK cells in 13 out of 23 patients with type I
diabetes and in five out of ten unaffected sibs. Assays which directly
measure ADCC (usually by release of Cr51 fr0m antibody coated target
cells) are more satisfactory than this method although they are
technically much more demanding. Using such a method, Calder et al
(1976) demonstrated raised K cell levels in patients with
Hashimoto's, primary hypothyroidism and Graves' disease. In Graves'
patients, the K cell activity was most marked in those patients with
small or absent goitres and in those woth low titres of circulating
thyroid antibodies. Feldman et al (1976) using the same method,
reported reduced activity of K cells in systemic lupus and in two
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patients with polyarteritis nodosa. The K cells in this study were
inhibited reversibly by some factor in serum. In a similar fashion,
Goto et al (1981) found reduced K cell activity in Sjogren's and
hypothesised that anti-lymphocytic antibodies might have been
responsible although this was not borne out in their experiments. The
negative correlation between ADCC and circulating immune complexes
was discussed in Chapter 5 (Calder et al, 1974) and this may provide
an alternative explanation for the reduced NK activity reported in
some autoimmune diseases. Monoclonal antibodies provide a simpler and
more reproducible way of studying cell subsets although the presence
of a surface marker does not always reflect functional activity of
that subset of cells. Pozzilli and Andreani (1982) used the antibody
3A1 in a cytotoxic assay to show increased K/NK cells in Graves'
patients. The problem with this study was that the K/NK cells were
contained in the 3A1-negative cell population and could only therefore
be deemed to be increased by inference. Two mouse monoclonals have
recently been described which will bind to cells active in both K and
NK cell assays. H25 (an IgG-|) binds to a 96,000 Dalton subunit of a
cell surface polypeptide, while H366 (an IgG2b) binds to the other,
53,000 Dalton subunit. Increased levels of K/NK cells was reported
recently (Kennedy et al, 1985; see Note 1 at the end of introduction)
using one of these monoclonals (H25) and the other antibody (H366)
has been used for the work presented in this chapter.
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ABERRANT HLA-DR ANTIGEN EXPRESSION ON TISSUES
On the basis of their studies with thyroid cells in culture, follicular
suspensions and cryostat sections of thyroidectomy specimens, Bottazzo
and his colleagues (1983) at the Middlesex Hospital in London have
developed one of the most intriguing hypotheses to come out of
immunological research in recent years. They suggest that the
expression of DR antigens on the surface of diseased thyroid
epithelium, coupled with increased antigen availability because of
reversed epithelial polarity exposing microsomal and other antigens
might be responsible for initiating autoimmune atteck on the gland. DR
expression on thyroid cells in culture can be induced by the lectins
phytohaemagglutinin, concanavalin A and pokeweed mitogen as well as
gamma interferon which is much more potent (Pu jol-Borrell et al,
1983; Todd et al, 1984). When cryostat sections of normal thyroid are
stained with appropriate monoclonal antibodies, no DR staining and
only weak HLA-A,B and C staining are seen. By contrast, the Middlesex
group (Hanafusa et al, 1983) found 16 out of 20 Graves' thyroids to
have patchy HLA-DR staining at the vascular pole of the thyrocytes. The
amount of HLA-A, B, and C staining was greatly increased and the
capillary endothelium showed particularly strong HLA-DR staining.
Thyrocyte staining could also be demonstrated in follicular suspensions
and on cultured monolayers of cells from these thyroids. The thyroid
from a patient with Hashimoto's was even more strongly positive than
the Graves' thyroids and one out of five euthyroid multinodular goitres
was also positive and an increase in capillary staining was also seen
in the latter thyroids. By changing the concentration of foetal calf
serum in the thyroid cell cultures, it is possible to produce a gradual
movement of microvilli from the colloid edge to the vascular pole of
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the thyrocyte (Hanafusa et al, 1984). The tendency for this to happen
is much greater in Graves' glands and it has been suggested that this
may increase the exposure of microsomal antigen which is normally
concentrated at the colloid edge.
The expression of HLA-DR on the surface of thyrocytes in Graves' glands
has been confirmed by Jansson et al (1984) who also found thyroids from
patients with nodular goitres to be positive. In contrast to the
studies of Bottazzo's group, in this study the DR expression was found
in relation to infiltrating lymphocytes (particularly those of the
helper/inducer phenotype) and the extent of DR staining correlated
with the degree of lymphocytic infiltration implying a pathogenetic
relationship between the two. HLA-DR staining has also been found on
the surface of the beta cells in the pancreatic islets in a patient
with diabetes mellitus (G.F. Bottazzo, personal communication) and is
recognised to occur in acute graft-versus-host disease and in the
colonic epithelium of patients with inflammatory bowel disease (Mason
et al, 1981; Selby et al, 1983). While in normal skin the HLA-DR
staining is confined to the antigen presenting dendritic cells, it
has been detected on the keratinocytes of patients with dermatoses
such as eczematous dermatitis and discoid lupus (Lampert, 1984). DR
expression was usually seen in association with keratinocyte damage
and lymphocytic infiltration. Eczematous skin also showed a marked
increase in the number of DR-positive Langerhans cells. Weetman et al
(1985) have recently published studies on factors affecting the DR
expression on cultured thyrocytes: DR could be induced, even in
non-diseased thyroids, by culture supernatant containing T
cell-derived lymphokines and, more potently, by gamma interferon
which could also induce DQ expression. Phytohaemagglutinin would
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induce DR on thyrocytes only in the presence of T cells. Unlike the
induction of DR on monocytes, DR expression on thyrocytes could not
be inhibited by the addition of prostaglandin E2 or dibutyryl cyclic
AMP.
There are however several problems which have to be overcome before
aberrant HLA-DR expression can be accepted as an initiating event in
the pathogenesis of autoimmune diseases: 1) growth factor as well as
B cell growth and differentiation factors. Weetman et al (1985) were
unable to detect IL-1 production from DR positive thyrocytes in
culture. Keratinocytes, on the other hand, are known to be capable of
producing IL-1 (Oppenheim & Gery, 1982) and this may account for the
association of lymphocytes with DR-expressing keratinocytes observed
by Lampert in human dermatoses. 2) The DR expression may simply be
secondary to cell damage. For example, perturbation of the cell
membrane by cross linking cell surface antigens can unmask DR (Mittler
et al, 1983). In the dermatoses, DR expression was only seen in
damaged areas of skin, while, in Jansson's study of Graves' thyroids
the lymphocytes associated with DR-expressing cells may have caused
thyrocyte damage by producing autoantibodies or by cell-mediated
cytotoxicity. 3) The aberrant DR expression is not confined to
thyroids with established autoimmune diseases. Both Jansson and
Bottazzo have found euthyroid nodular goitres which are positive.
However, immunological abnormalities are relatively common in patients
with multinodular goitre and some role for autoimmunity in the
pathogenesis of this condition cannot be ruled out. 4) Bottazzo has
argued that the change in antigen availability due to reversed
epithelial polarity is important. He notes that in the only six
completely DR negative thyroids in their study, there was no
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circulating thyroid microsomal autoantibody. This antibody is not
however the major pathogenetic antibody in Graves' disease and its
correlation with DR expression may simply reflect cell damage by these
cytotoxic antibodies. All Graves' patients probably have antibodies
directed towards the TSH receptor (see Chapter 2) although these are
not always picked up by the standard assays. Since the TSH receptor
exists to interact with circulating TSH, it would seem highly likely
that it is expressed mainly at the vascular pole of the thyroid
follicle rather than at the colloid edge. A change in antigen
availability therefore seems unlikely for this antigen although, no
doubt DR expression may markedly alter its immunogenicity.
NOTE 1 : The work on lymphocyte subsets presented in this chapter
was performed as part of a cooperative project between the
Endocrine/Immunology Unit, Royal Infirmary, Edinburgh and the
Department on Endocrinology in the University of Rome, Italy. Data
from the Italian patients is contained in the report by Kennedy et al
(1985) while that from the Edinburgh patients is presented here. The
combined results of the two parts of the study, including the
relationship of activated lymphocytes with humoral immune markers has
been presented both to the British Endocrine Societies (4th joint
Meeting, Oxford, March 1985; see Kadlubowski et al, 1985) and to the
Italian Endocrine Society (Pisa, May-June, 1985; see Scardellato et




The study included 28 patients with newly diagnosed Graves' disease
(six male and 22 female, mean age 40 years) and nine patients (three
male and six female, mean age 42 years) with recurrent Graves'
disease. None of the new patients had recieved any antithyroid
therapy at the time blood was withdrawn for study while the recurrent
cases had all been treated previously with antithyroid drugs although
none had been treated with radioactive iodine or surgery. All
recurrent patients had enjoyed a period of remission prior to their
recurrence. The diagnosis of Graves' disease was made, as before, on
the basis of raised T^ and/or T4, flat TRH test, diffuse goitre
and/or scintigram. The controls were 24 normal subjects of comparable
age and sex distribution to the patient groups.
COLLECTION AND STORAGE OF SAMPLES
For TSH receptor antibody studies, fresh serum was obtained and
stored at -20°C. prior to use. The assay for TBII was performed on
neat serum as described in APPENDIX 1. For cell studies, 20 mis. of
venous blood was collected in a sterile universal container with 20
units per ml. of preservative-free heparin and mononuclear cells were
isolated by gradient centrifugation as described in APPENDIX 3. These
cells were frozen at a concentration of 5 x 106/mi and stored in
liquid nitrogen until used. Control samples were stored under
identical conditions. The cells were thawed in a 37°C. water bath,
washed twice in medium and their viability checked. The concentration
was adjusted to 6 x 106 cells per ml. in RPMI 1640 with 10/6 foetal
calf serum.
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ENUMERATION OF CELL SUBSETS
Suppressor/cytotoxic cells, helper/inducer cells and total T
lymphocytes were enumerated respectively with the antibodies 0KT8,
0KT4 and 0KT3 (Ortho Diagnostics). The other monoclonal antibodies
were used as part of a cooperative study between the Endocrine Unit,
Royal Infirmary, Edinburgh and the Department of Endocrinology,
University of Rome and were donated for use by Dr. Umberto di Mario.
4F2 binds to a 120,000 molecular weight glycoprotein on the surface
of monocytes and activated T lymphocytes (Eisenbarth et al, 1980).
4F2 antibody was a gift of Dr. G. S. Eisenbarth, Joslin Clinic,
Boston, U.S.A. and he also donated the antibody L243 which is against
a determinant of the DR locus and is thus a marker for late
lymphocyte activation (Lampson & Levey, 1980). The antibodies DA6.164
and DA6.231 (Guy et al, 1982; van Heyningan et al, 1982) bind to
different determinants of the non-polymorphic region of the beta
chain of DR molecules. These antibodies were a gift of Dr. K. Guy of
the M.R.C. Clinical and Polpulation Cytogenetics Unit, Edinburgh. The
antibody H366 defines a set of cells with killer and natural killer
activity and was donated by Dr. P. C. L. Beverley, I.C.R.F. Human
Tumour Immunology Group, University College, London.
For the assays, approximately 300,000 cells were incubated in
polystyrene tubes with 50 microlitres of monoclonal antibody
(suitably diluted as determined by previous titration) at 4°c. for 30
minutes. The cells were washed twice with medium and 50 microlitres
of fluorescein conjugated goat anti-mouse IgG (Nordic) at a dilution
of 1:10 was added. The cells were incubated once more for 30 minutes
at 1°C. and then washed twice. For those incubations with the
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antibodies 0KT3, 0KT4, 0KT8, 4F2 and H366, the cells were mounted in
30$ glycerol/PBS and duplicate 200 cell samples were counted. For the
cells stained with anti-DR antibodies, double staining
immunofluorescence was carried out (Di Mario & Guy, 1984); The cell
pellet was resuspended in 50 microlitres of medium with 0.1 mg. of
0KT3 and a previously determined amount of freeze-dried rabbit
complement (Pel Freeze Biologicals). The cells were incubated at
37°C. for 30 minutes and five microlitres of 1mg/ml ethidium bromide
was added for one minute prior to washing. The cells were mounted on
microscope slides and 200 cell samples counted as before. Values
above the 90th eentile of the normal controls were considered to be
high.
CLASS II ANTIGENS ON THYROID CELLS
Three Graves' thyroids were tested for class II antigen positivity
using five micrometer cryostat sections. Monoclonal antibodies were
applied at the appropriate dilutions for 30 minutes at 37°C.. After
washing, goat anti-mouse IgG was applied for 30 minutes and the
sections were washed then read by fluorescent microscopy.
RESULTS
HELPER AND SUPPRESSOR LYMPHOCYTES
The percentage of 0KT4 positive cells in normal controls (n = 24),
new Graves' (n = 28) and recurrent Graves' (n = 9) was 42.3$, 42.1$
and 45.0% respectively (no significant difference). 0KT8 positive
cells in controls were 22.4$ compared to 16.2$ in new and 15.9$ in
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recurrent Graves' (both p < 0.05, see FIGURE 8.1). The corresponding
OKT4/OKT8 ratios were 1.95 for controls, 2.79 for new Graves' and
3.05 for recurrent Graves'.
EARLY ACTIVATED T CELLS
The median percentage of 4F2 positive cells in controls (n = 15) was
8.3? compared to 11.1? in 28 newly diagnosed Graves' patients (p <
0.01, see FIGURE 8.2). 14 (50?) of the Graves'patients had elevated
levels of 4F2 positive cells. By contrast, only two out of nine
recurrent cases had increased 4F2 positive cells and the median value
in this group was 6.4? (not significantly different from normal).
TSH receptor antibodies were measured in 14 of the new patients.
Positive values were obtained in 13 (93?) and there was a negative
correlation between the values in the TBII assay and the percentage
of 4F2 positive cells (r = -0.603, P < 0.05 - see FIGURE 8.3).
LATE ACTIVATED T CELLS
The percentage of class II antigen positive T cells in normal
controls, new and recurrent Graves' patients is shown in TABLE 8.2.
In the normal controls, the 90th centile for the antibodies DA6.164,
DA6.231 and L243 were 2.9, 3.1 and 3.1 respectively.
Increased class II positive T cells were seen in 12/21 (58?) new
Graves' (see TABLE 8.3) and in five out of eight (63?) recurrent
Graves'. Taking results for 4F2 and class II antigen positive T cells
together, increased activated T lymphocytes were seen in 15 out of 21
(71?) new Graves' and six out of eight (75?) recurrent Graves'.
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FIGURE 8.1 SUPPRESSOR/CYTOTOXIC (OKT8 POSITIVE) CELLS IN NEWLY

















































































































FIGURE 8.3 CORRELATION BETWEEN 4F2 POSITIVE CELLS AND TSH RECEPTOR
ANTIBODIES IN NEWLY DIAGNOSED GRAVES' DISEASE
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TABLE 8.2 CLASS II ANTIGEN POSITIVE T CELLS IN NORMAL CONTROLS AND
IN PATIENTS WITN NEWLY DIAGNOSED OR RECURRENT GRAVES' DISEASE
MONOCLONAL ANTIBODY
L 243 DA6.164 DA6.231
CONTROLS 1.6% 0.5$ 1.1$
(No.) (18) (23) (23)
NEW GRAVES' 5.1 $ 1.8$ 2.7$
(No.) (19) (21) (21)
RECURRENT 2.4$ 1.9$ 2.5$
(No.) (8) (8) (8)
The figures given in the table refer to the percentage of peripheral
blood mononuclear cells which are HLA-DR positive T lymphocytes.
Absolute numbers of these cells were not calculated because of the
small percentages involved.
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N.T. = Patient's cells not tested against this antibody.
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KILLER/NATURAL KILLER CELLS
Percentages of H366 positive cells with characteristic small
lymphocyte appearance in controls and the two groups of Graves'
patients are shown in FIGURE 8.4. The mean value for the 16 controls
was 6.01% compared to 10.6% for 28 patients with untreated Graves' (p
< 0.05). The value for recurrent Graves' was 6.24% which did not
differ from normal controls.
CLASS II ANTIGENS ON THYROCYTES
The monoclonal anti-DR antibodies were tested on cryostat sections of
three Graves' thyroids. Similar results were obtained for all three
glands, the fluorescence being seen as a thin rim round the vascular





FIGURE B.I l'ERCENTAGE UL;' KILLER/NATURAL KILLER CELLS IN NEWLT










































Activated T cells and cells with killer/natural killer activity were
enumerated in the peripheral blood mononuclear cell preparations of
patients with thyrotoxic Graves' disease. A distinction was made
between patients at first presentation and those in whom the
thyrotoxicosis was recurrent. A sequence of T cell activation
antigens is recognised (Cotner et al, 1983 ). Early activation
antigens include that recognised by the antibody 4F2 which binds to a
120,000 molecular weight glycoprotein on the surface of 70% of
activated T cells (Haynes et al, 1981) while late activation antigens
include class II histocompatibility determinants.
Jackson and colleagues (1982) found the proportion of 4F2 positive
cells to be normal in the peripheral blood of Graves' patients and in
newly diagnosed diabetics. Subsequently, however, increased 4F2
positive cells were found in Hashimoto's patients by Canonica et al
(1982) and in Graves' patients by Kennedy et al (1985). In the study
presented here, the mean percentage 4F2 positive cells in controls
was 8.3$ compared to 11.1% in newly diagnosed Graves' patients (p <
0.01). In patients with recurrent thyrotoxicosis, only 6.4$ of cells
were 4F2 positive. The early stages of activation of the
cell-mediated immune system may have been superceded in these
patients by memory phenomena or may have become confined to the
thyroid gland. In newly diagnosed patients, there was a negative
correlation between 4F2 positive cells and TBII. The possibility that
TBII were masking the 4F2 antigen and thus preventing the antibody
from binding was investigated (data not presented) by culturing
normal lymphocytes with and without TSH receptor antibody
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preparations and in the presence and absence of mitogens. TBII did
not per se affect the expression of the 4F2 antigen and it is
concluded that early activation of the cell mediated immune system
and TSH receptor antibody formation may represent different stages in
the pathogenesis•of Graves' disease.
The percentage of T cells bearing class II antigens was raised in 12
out of 21 (58$) new Graves' patients and in five out of eight
recurrent cases. The comparable incidence of increased cell numbers
in new and recurrent disease is in contrast to the data for early
activation antigen. Class II antigen positive T cells may be
important in antigen presentation to other components of the immune
system and the expression of these antigens could thus be regarded as
an end point of cell activation. The work of Ludgate et al (1984)
showing that activated T cells decline with antithyroid drug therapy
would suggest that increases of these cells are related to recurrence
of the disease rather than persistence of an underlying immunological
abnormality. The work presented here shows the importance of using
antibodies against different determinants of the DR molecules. Class
II antigen expression at the vascular pole of the thyroid follicle
has been confirmed although only one of the three antibodies tested
gave consistently positive results.
Cells with K/NK activity as defined by the antibody H366 were
elevated in new but not in recurrent Graves'. This again may be
because the immune reaction is confined more to the thyroid in
advanced disease. It is not clear why some patients have elevated
cytotoxic cells in the circulation while others do not but one reason
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may be the presence of circulating immune complexes which can
decrease K cell numbers (as discussed in Chapter 5).
These studies with monoclonal antibodies provide further evidence for
the role of the cellular immune system in the pathogenesis of
autoimmune thyroid disease. The inverse relationships between K cells
and immune complexes and between activated T cells and TSH receptor
antibodies may underlie some of the heterogeneity which exists in the







Thyroid autoantibodies have been demonstrated by indirect
immunofluorescence in the sera of ten out of 29 (3^.556) oats with
hyperthyroidism. Antinuclear factor, rare in normal cats, was found
in a further four cats. 28 of the cats had a palpable goitre at first
presentation - in 16 cases this was unilateral while in the others
the goitre was bilateral. Lymphocytic infiltration was present in
nine of the 27 (33%) thyroids examined histologically.
Five of the sera gave a particularly strong reaction on
immunofluorescence for thyroid antibodies. Four of these cases had
bilateral goitres and lymphocytic infiltrates were found in four of
the five thyroids (p < 0.05). 21 of the cats were followed up for a
mean period of 10.3 months after operation, during which time three
cats developed recurrent hyperthyroidism: Two of them had bilateral
goitres with lymphocytic infiltration at first presentation and the
serum was strongly positive in both for thyroid autoantibodies. The
third recurrence was in a cat with unilateral goitre and lymphocytic
infiltration and the serum in this case was positive for antinuclear
factor, the recurrence involving the same lobe which had been
previously operated on.
Some cases of feline hyperthyroidism may be immunologically mediated
and the condition is thus a potential model for some aspects of
autoimmune thyrotoxicosis in Man.
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INTRODUCTION
The study of animal models of thyroiditis has greatly contributed to
our knowledge not only of this condition but that of autoimmune
disease in general. However, no satisfactory model exists either for
Graves' disease or for toxic nodular goitre. Attempts to induce the
former condition in animals have been unsuccessful while the
pathogenesis of the latter condition is poorly understood.
Spontaneous hyperthyroidism is uncommon in the animal kingdom and,
when it does occur, it is usually due to malignant neoplasms of the
thyroid. The one exception is the domestic cat in which
hyperthyroidism has been found recently to be a relatively common
occurrence. Although the lesion is more akin histologically to toxic
nodular goitre, a role for autoimmunity in the pathogenesis of the
condition has not yet been ruled out.
Feline hyperthyroidism was first described in 1979 by Cotter and by
Peterson et al. The common occurence of benign thyroid lesions in the
cat was previously well recognised (Lucke, 1964) and, in reviewing 52
cases of enlarged thyroid, Leav et al (1976) found 22 to have typical
benign adenomas while a further 17 had multinodular adenomatous
goitres. Over 90$ of palpable neoplasms in the cat thyroid are benign
in contrast to, for example, the canine thyroid where 90$ of
clinically apparent tumours are carcinomas and 25$ or less produce
hyperthyroidism (Kirk, 1982). Hyperthyroidism is equally common in
male and female cats and shows no particular breed predisposition.
The clinical presentation is entirely comparable to the human
condition with weight loss, hyperactivity, increased temperature and
heart rate, cardiac failure, anorexia, vomiting, diarrhoea with bulky
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stool, thirst polyuria, hyperaemia of the skin and mucous membranes
and muscle weakness. The feline thyroid consists of two separate
lobes which are not usually joined by an isthmus (Lucke, 1964).
Goitre in the cat may thus be unilateral or bilateral.
Radioisotope scanning using 99m technetium as pertechnetate is a
useful adjunct to diagnosis and to assess the extent of thyroid
involvement prior to surgery (Hoenig et al, 1982). With the use of
scintiscans, many cases which were thought to be unilateral initially
turn out to have bilateral involvement: In Peterson's review (1984)
of 135 cases which had been scanned, 38 (27$) had unilateral
involvement while the remaining 97 (73$) were bilateral. The
treatment of choice for hyperthyroidism in the cat is, of course,
surgery with complete removal of the affected lobe or lobes. After
operation, the thyroid hormone levels return to normal within 24
hours (Peterson et al, 1980). Propylthiouracil has also been shown to
be an effective treatment (Peterson, 1981) but, apart from obvious
difficulties of administration, side effects are quite common and, in
particular a syndrome with autoimmune haemolytic anaemia and
thrombocytopenia has been described in nine out of 105 cats treated
(Peterson et al, 1984).
Animal Model3 of Hypothyroidism
It seems appropriate here to discuss the contribution that the study
of animal models of thyroiditis has made to our understanding of the
pathogenesis of autoimmune thyroid disease in Man. Of particular
interest are the studies on murine thyroiditis and the disease which
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occurs in Obese Strain chickens and these are both discussed in
detail below. Thyroiditis in the dog is also of interest because it
occurs naturally in a domestic animal. These three models are not
however the only ones: Thyroglobulin administration to guinea pigs in
appropriate dosage schedules may induce thyroiditis and a similar
disease can be induced in the Rhesus monkey injected with crude
thyroid extract (Kite et al, 1966). Rats may also be induced to
develop thyroiditis by immunization with thyroglobulin although
certain strains such as the BUF strain will develop the disease
spontaneously. The genetic influence has been studied in the rat to
some extent and the antibody response to thyroglobulin is not thought
to be linked to the major histocompatibility complex (Lillehoj et al,
1981). An influence of genes on the X chromosome has been postulated
to account for the enhanced response to thyroglobulin in female
animals. The T cell proliferative response correlates better with the
severity of the lesions than does antibody level suggesting that
there may be separate genetic influences on the humoral and cell
mediated immune abnormalities (Lillehoj & Rose, 1975). Microsomal
antigen as well as thyroglobulin may induce thyroiditis in the rabbit
and, indeed this was the first animal model of thyroiditis to be
described (Witebsky & Rose, 1956; Mangkornkanok et al, 1972).
Susceptibility to murine thyroiditis is known to be related to the
major histocompatibility complex of the mouse and, in particular,
to the H-2K locus (Vladutiu & Rose, 1971) although an influence of
the H-2D end of the gene complex is also recognised and may be
related to the control of suppressor cell function (Kong et al,
1979)- Although B lymphocytes are clearly required for autoantibody
production and thence the induction of thyroiditis - indeed the
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thyroid lesions may be induced by the passive transfer of immune
serum (Tomazic & Rose, 1975) - the susceptibility to thyroiditis
following immunisation with thyroglobulin is transferred with T
lymphocytes rather than B lymphocytes (Vladutiu & Rose, 1975).
Evidence for the role of immunoregulatory T cell subsets in the
induction of thyroiditis also comes from other animal models (for
review of T cell regulation in murine and Obese Strain chicken
thyroiditis, see Rose et al, 1981). For example, the thymectomised,
irradiated rat has been used as a model (Penhale et al, 1975).
Thyroiditis is much less common in rats subjected only to sublethal
total body irradiation but not thymectomised (Penhale et al, 1973)
and the autoallergic response may be suppressed by reconstituting the
animals with normal lymphoid cells (Penhale et al, 1976). In the
Obese Strain chicken, thymectomy also greatly enhances the
development of thyroiditis (Wick et al, 1970; Welch et al, 1973).
Inhibition of suppressor cells with cyclophosphamide has been shown
to convert low responder mice to high responders (Vladutiu, 1982)
while activation of suppressors by appropriate immunization schedules
may induce tolerance to thyroglobulin (Okayasu et al, 1980; Kong et
al, 1982).
Although the production of autoantibodies and the formation of
complement fixing immune complexes are early and necessary events in
the evolution of thyroiditis (Clagget et al, 1974), they are not the
only mechanisms involved: Poor responder strains may produce very
high levels of autoantibody with little evedence of tissue damage and
no reason to suspect deficiency of a complement fixing subclass of
immunoglobulin (de Carvalho & Roitt, 1982). Good responder strains
have T cells reactive to thyroglobulin (Esquivel et al, 1978) and
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stimulation with polyadenylic: polyuridylic acid shows them to have
helper function which may be important in the development of
thyroiditis. In experiments with thyroid cell monolayers, depletion
of T cells from the lymphocyte suspensions reduces the degree of
sensitisation to the thyrocytes (Charriere, 1982) whereas there is
enhanced reactivity with a T cell enriched fraction and, indeed, a
pure T lymphoblast suspension can be immunologically sensitised to
the thyrocytes (Charriere & Michel-Bechet, 1982). More recently, a
direct cytotoxic effect of T lymphocytes has been demonstrated and is
specific for the inducing antigen (thyroglobulin) and is also H-2
restricted (Creemers et al, 1983).
Obese Strain (OS) chickens develop severe thyroiditis, circulating
anti-thyroglobulin antibodies and hypothyroidism within a few weeks
of hatching. Three factors are thought to be important in the
development of the lesion in these animals (Wick et al, 1982):
Firstly, genetic susceptibility related to the major
histocompatibility complex, although this is less well characterised
than for the mouse. Secondly, abnormal thymic maturation with a
relative deficiency of suppressor cells and thirdly, intrinsic
abnormalities of the thyroid gland. The genetic influence is related
to the b locus of the MHC (Bacon et al, 1974) although this is not
the only genetic factor involved (Bacon et al, 1981). Further recent
evidence for the role of non-MHC genes has come from the work of Boyd
et al ( 1983) who have compared two inbred strains of chicken which
are identical as far as the MHC is concerned but one was selected for
only on the basis that it developed hypothyroidism while the other
strain was specifically bred because it had high levels of
circulating anti-thyroglobulin and this strain also had high levels
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of thyroid-specific cytotoxic T cells and antibody dependent cellular
cytotoxicity. The role of thymic maturation of T cells in the
pathogenesis of the disease is apparent from the enhancing effect of
thymectomy in the development of thyroiditis (Wick et al, 1970; Welch
et al, 1973). However, in this model too, T cells are clearly
necessary for the development of the thyroid lesion since combination
of thymectomy with treatment with anti-T cell serum (which completely
depletes the animal of T cells) prevents the thyroiditis evolving (de
Carvalho et al, 1981). Furthermore, the disease may be produced in T
cell depleted normal animals by reconstitution with T cells from
histocompatible OS chickens (Livezey et al, 1981). The conclusion is
that a relative defect in suppressor cells in these animals allows
helper and cytotoxic T lymphocytes to initiate the autoimmune
response.
The disease is, however, multifactorial and abnormalities are not
confined to the immune system. Incomplete suppression of ^31j uptake
by administered thyroxine has been shown (Sundick et al, 1979) as has
increased thyroid uptake of 131i when glands are transplanted to the
chorioallantoic membranes of normal chickens (Sundick & Wick, 1976).
Susceptible chickens may thus go through an initial stage of
hyperthyroidism before thyroiditis is initiated and this is supported
by the observation that thyroglobulin levels are high in the early
weeks of life prior to the onset of thyroiditis (Sanker et al, 1983).
The release of antigens from an overactive gland may stimutate an
immune reaction in genetically susceptible animals and, in keeping
with this would be the observed temporary suppression of
anti-thyroglobulin antibody synthesis when thyroxine is adnministered
in doses sufficient to suppress endogenous thyroid activity (Sanker
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et al, 1983). The possibility that this effect may not be due to
reduction in antigen release but to a direct effect on the immune
system must be borne in mind. Long and Shewell (1955) showed that Ti|
administration enhanced the immune response to injected diphtheria
toxin and, more recently, work on experimentally hyperthyroid animals
has suggested that T4 may specifically inhibit suppressor cell
function while retaining normal B cell function (Wall et al, 1979).
The presence of a generalised autoimmune disturbance in OS chickens
has been confirmed by the demonstration that some animals have
antibodies not only to thyroid components but also to the
proventricular glands of the stomach (analagous to parietal cells)
and occasionally to pancreas and adrenal glands (Khoury et al, 1982).
Naturally occurring canine thyroiditis is well described (Mueller et
al, 1983). It has an equal sex incidence and may affect practically
any breed of dog although some breeds are particularly predisposed
Two types of pathology are recognised to lead to thyroid failure in
the dog (Gosselin et al, 1981): Firstly, idiopathic follicular
atrophy, where the functioning thyroid tissue is replaced by fatty
fibrous tissue. It appears to be a degenerative condition with no
immunological component. Secondly, lymphocytic thyroiditis which is
an autoimmune condition similar to human Hashimoto's thyroiditis.
Here, infiltration of the gland by lymphocytes, plasma cells and
macrophages precedes fibrosis and is associated with circulating
antithyroid antibodies. The condition was first described in 1968 by
Beierwates and Nishiyama in a colony of purebred beagles where
thyroiditis occurred in over 10% of animals. Only dogs with the most
severe thyroid lesions showed evidence of low PBI on a low iodine
diet, low 1311 uptake and lack of response of uptake to injected TSH.
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Antibodies against thyroid microsomes, thyroglobulin and a
non-thyroglobulin colloid antigen have been demonstrated in these
dogs (Micejewski et al 1971). Systemic lupus erythematosus has also
been well characterised in the dog and produces a spectrum of
clinical abnormalities similar to the human condition. It is
asociated with circulating antinuclear antibodies and there is often
a family history of other autoimmune disease including lymphocytic
thyroiditis (Grinden & Johnstone, 1983). The overlap between
autoimmune thyroid disease in Man and non-organ specific autoimmune
disease is also documented (Hijmans et al, 1961).
ANIMAL MODELS FOR GRAVES' DISEASE
There is at present no animal model for human Graves' disease. One
experimental approach which has been tried involves the use of
transplanted tissue. Gittes (1966) used transplanted isologous
thyroid tissue to study thyroiditis in inbred strains of guinea pig
and found that the lesion produced in transplanted tissue was
identical to that in the in situ thyroid when the animals were
immunized with thyroid antigen. The use of athymic (nude) mice has
been suggested by Smeds et al (1981) as a suitable recipient for
transplanted Graves' tissue but, although transplanted thyroid
tissue survives in this animal, it does not continue to hyperfunction
(Leclare et al, 1984). Part of the problem is undoubtedly the lack of
T cells in these animals, particularly helper T cells which are
necessary for the immune reaction and thus autoantibody production to
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continue. In support of this, Wick et al (1978) found that
thyroiditis did not develop in homozygous nude mice when injected
with thyroid antigen but did develop in Nu/+ heterozygotes.
The work presented in this chapter is concerned with the search for
autoantibodies to the thyroid gland in a series of 29 hyperthyroid
cats which were investigated, treated and followed up in the
Department of Veterinary Medicine of the University of Edinburgh. It
was hypothesised that immunological abnormalities might be found
especially in cats with bilateral goitre and particularly if this was
associated with lymphocytic infiltration of the thyroid.
MATERIALS AND METHODS
The study comprised 29 consecutive cases of feline hyperthyroidism
presenting either directly to the University of Edinburgh's
Department of Veterinary Medicine or to veterinary surgeons in
private practice who agreed to take part in the study. The diagnosis
was made on the basis of history and clinical findings and confirmed
by the presence of elevated total thyroid hormone levels. The
clinical assessment of the patients, their treatment, follow up and
thyroid hormone measurements were all carried out by Mr. Keith Thoday
of the above department.
Thyroxine (Tij) and tr iiodothronine (T 3) were measured by double
antibody radioimmunoassays optimised and validated for use with cat
serum as described by Thoday et al (1984). Normal ranges were
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established by the nonparametric method of percentile estimates,
using measurements from 318 normal cats for T4 and 299 normal cats
for T3. For T4 this was 8.5 to 46.2 nmol/1 (Mean + SD = 26.1 + 10.1)
and for T3 0.13 to 1.26 nmol/1 (Mean + SD = 0.69 + 0.29).
Two cats died soon after diagnosis was made. Euthanasia was
requested by the owners in two further cases. One cat was treated
medically with propylthiouracil and one cat was lost to follow up.
The remaining 23 cases were treated surgically by unilateral or
bilateral thyroidectomy after one week's treatment with potassium
iodide (ten milligrams, three times daily) and propranolol (2.5
milligrams, three times daily). Because radionuclide imaging
facilities were not available, the decision whether to perform
unilateral or bilateral thyroidectomy was a clinical one based on
the distribution of goitre and the appearance of apparently
uninvolved lobes at operation. Affected lobes were removed, taking
care to preserve at least one parathyroid gland and excised tissue
was preserved in 10% formal saline for histological examination.
Tissue for immunological studies was snap frozen in liquid nitrogen
and subsequently stored at -40. Where possible, animals were followed
up at regular intervals after the operation.
AUTOANTIBODY MEASUREMENTS
Thyroid microsomal and antinuclear antibodies were measured by
indirect immunofluorescence on normal cat thyroid. The tissue was
removed from a normal cat after euthanasia using intravenous
injection of 20% pentabarbitone sodium, and frozen in liquid
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nitrogen. For the assay, sera were diluted 1:4 with phosphate
buffered saline pH 7.2 (PBS) and applied to five micrometer sections
of thyroid for 30 minutes at room temperature. These sections were
then washed in PBS for 30 minutes with two changes of buffer. Goat
anti-cat IgG conjugated with fluorescein isothiocyanate (Miles-Yeda)
was then applied at a dilution of 1:8 for 30 minutes after which
slides were washed for two hours with several changes of buffer.
The sections were coded and read under ultraviolet light. The
intensity of fluorescence was scored as follows:
0 = No fluorescence.
+ = Borderline fluorescence (not counted as positive).
+ = Definite positive.
++ = Strong positive.
Sera from fifteen healthy cats acted as controls and autoantibodies
were not detected in any of their sera. TSH receptor antibodies were
sought using the radioreceptor assay with neat serum as described in
Southgate et al (1984). The non-organ specific nature of the
antinuclear factor detected in some cases was confirmed by repeating
the experiment using rat kidney as a substrate.
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STATISTICS
Continuous variables were analysed using the Student's t test (T^ and
age). The Wilcoxon Rank Sum test was used for T4 since two of the
very high values were not precisely quantified, and for TSH receptor
antibodies. All other data was analysed using the Fisher Exact test.
RESULTS
There were 28 domestic short haired and one domestic long haired cats
in the study. Thirteen (45/5) were male (one intact and 12 castrated)
and fifteen were female (three intact and 13 ovariohysterectomised) .
The mean age was 12.8 years with a range of six to seventeen years.
The symptoms and signs at presentation were as follows: Weight loss
(92/5), polyphagia (81%), polydipsia and polyuria (78%), hyperactivity
(58/5), diarrhoea (57%), polypnoea 39/5), tachycardia (39%), skin
changes (mats, scaling and hyperaemia - 3855), increased faecal bulk
( 3555), vomiting (24/5), elevated temperature (18%) , reduced activity
( 1 755 ), cardiac murmur (14$), dyspnoea (8$) and anorexia (8$). Twenty
eight cats had a palpable goitre and 16 of these were unilateral
while the remaining 12 were bilateral.
Thyroid antibodies were detected in ten cases - five of which were
strongly positive. Antinuclear factor was found in a further four
cats. Clinical and laboratory data from the fifteen antibody negative
cats is shown in TABLE 9.1 and that for the fourteen antibody
positive cats in TABLE 9.2. In all cases, the total Ti| was elevated,
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TABLE 9.1 CLINICAL AND LABORATORY DATA ON ANTIBODY NEGATIVE CATS
NO. SEX AGE t3 T4 GOITRE LYMPH0. FOLLOW-
(years) (nmol/1) (nmol/1) INFILT. UP
1 M (c) 12 5.57 297.6 UNILAT NONE 30 mths.
2 M (c) 12 CM 71.6 BILAT NONE died
3 F (o) 15 2.40 150.0 UNILAT NONE 11 mths.
4 F (o) - 3.60 145.0 UNILAT NONE 9 mths.
5 F (o) 11 4.00 241.0 UNILAT NONE 10 mths.
6 F (o) 15 2.50 152.0 UNILAT PRESENT 4 mths.
7 M (c) 10 1.73 160.0 UNILAT PRESENT died
8 M (c) - oo 440.0 BILAT PRESENT euth
9 F (o) 10 6.20 168.0 BILAT - euth
10 F (o) 17 5.80 299.0 UNILAT NONE 8 mths.
11 F 9 1.65 COE^-OT— BILAT NONE 12 mths.
12 M 13 6.70 338.0 NONE - -
13 F 16 1.70 92.0 UNILAT NONE 3 mths.
14 F 15 - 136.0 BILAT NONE 3 mths.
15 F (o) 15 9.00 654.0 BILAT NONE died
M = Intact male
F = Intact female
M (c) = Castrated male
F (o) = Ovarohysterectomised female
died = Death in immediate pre- or post-operative period
euth = Euthanased
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TABLE 9.2 CLINICAL AND LABORATORY DATA ON ANTIBODY POSITIVE CATS
No. SEX AGE t3 T4 GOITRE LYMPH0. FOLLOW-
(years) (nmol/1) (nmol/1) INFILT. UP
A: THYROID ANTIBODY +
16 M (c) 13 1.91 146.3 UNILAT NONE 9 mths.
17 M (c) 13 4. 70 250.0 UNILAT NONE 3 mths.
18 M (c) 11 2.10 86.0 UNILAT NONE 9 mths.
19 M (c) 15 3.80 109.0 BILAT NONE died
20 F (o) 14 4.20 205.0 BILAT NONE 3 mths.
B: THYROID ANTIBODY ++
21 F (o) 12 7.41 > 200 BILAT PRESENT 24 mths.*
22 M (o) 15 1.40 86.0 BILAT NONE 5 mths.
23 M (c) 16 1.06 65. 1 UNILAT PRESENT 9 mths.
24 F (o) 14 o-=rC\J 159.0 BILAT PRESENT 19 mths.
25 F (o) 9 10.30 388.0 BILAT PRESENT 7 mths.*
C: ANTINUCLEAR FACTOR ++
26 F (o) 6 6.57 > 200 UNILAT NONE 24 mths.
27 F (o) 7 2.00 121.0 UNILAT PRESENT -
28 M 17 2.20 206.0 UNILAT PRESENT 10 mths.*
29 M (c) 11 2.20 70.0 UNILAT NONE 3 mths.-
= Recurrent hyperthyroidism
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while the T3 was elevated in all but one cat. The T4 was not
precisely quantified in two cats with very high levels and was
reported at >200 nmol/1. In the remainder, the Tij ranged from 65.1 to
654.0 nmol/1 (mean 197-9) and the T3 ranged from 1.06 to 10.3 nmol/1
(mean 3.87).
THYROID ANTIBODIES
Cat thyroid incubated with normal serum and serum positive for
thyroid antibodies is shown in FIGURES 9.1 and 9.2 respectively. The
ten thyroid antibody positive cats consisted of six castrated males
and four ovarohysterectomised females. The mean age was 13.3 years at
diagnosis compared to 12.5 years for the other seventeen cats. The
mean T3 and Tij in the thyroid antibody positive cats was 3.93 nmol/1
and 166 nmol/1 respectively compared to 3.84 nmol/1 and 213 nmol/1 in
the thyroid antibody negative cats. None of these differnces was
statistically significant. Thyroid tissue from thyrotoxic cats could
also be used to detect thyroid antibodies although the background
staining was much higher making it harder to distinguish negative
from weakly positive reactions.
Of the five cats scored ++ for thyroid antibodies, four had bilateral
goitres compared to only eight of the other 24 cats and lymphocytic
infiltrates were found in four of the five thyroids. Lymphocytes were
seen in only five out of the remaining 22 thyroids examined
histologically (p<0.05) and two of these cats were positive for
antinuclear factor.
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FIGURE 9.1 CAT THYROID INCUBATED WITH NORMAL CAT SERUM
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TSH receptor antibodies were not detected in any of the twelve sera
tested in the radioreceptor assay nor in any of the sera from twelve
control cats.
ANTINUCLEAR FACTOR
Four cats were positive for antinuclear factor, an example of which
is shown in FIGURE 9.3. All of these cats had unilateral goitres and
lymphocytic infiltrates were found in two of the thyroids. The two
youngest cats in this series, aged six and seven and a half years,
are in this group. The mean Tg and T4 in these four cats did not
differ from that in the antinuclear factor negative cats. The
non-organ specific nature of the antinuclear factor was demonstrated
by using rat kidney as a tissue substrate.
FOLLOW UP
Twenty one cats were followed up for a mean period of 10.3 months.
During this time, three cats developed recurrent hyperthyroidism
which was confirmed biochemically in all cases. Two of these had
bilateral goitre at initial presentation and the thyroid contained
lymphocytic infiltrates. The serum of both cats was strongly positive
for thyroid microsomal antibodies. The third recurrence was in a cat
with unilateral goitre, with lymphocytic infiltration in the gland
and the serum was positive for antinuclear factor. The recurrence
involved the lobe which had already been operated on. Further
resolution of thyrotoxicosis followed surgery in all cases.
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FIGURE 9.3 REACTION OBTAINED WITH ANE POSITIVE SERUM
Figures 9.1, 9.2 and 9.3 are reproductions of photomicrographs




The 29 cats described in this study have clinical features comparable
to other series reported in the literature. Using normal cat thyroid
as a tissue substrate, autoantibodies have been detected in 14 (48%)
of these cats. Ten showed thyroid antibodies with a pattern of
staining similar to that of the microsomal antibody seen in human
thyroid diseases and four had antinuclear antibodies. The non organ
specific nature of the latter was demonstrated by incubating the
positive sera with rat kidney.
The five sera with strong reactions for microsomal antibody included
four cats with bilateral goitre and four of the five thyroidectomy
specimens contained lymphocytic infiltrates which were found in only
five of the other 22 thyroids examined (and two of these cats were
positive for antinuclear factor). The correlation between lymphocytic
infiltration of the gland and circulating antibodies to the thyroid
is well recognised in human disease (Goudie et al, 1959; Schade et
al, 1960) and the presence of both correlates with the development of
post-operative hypothyroidism which presumably, therefore has an
autoimmune basis (Whitesell & Black, 1949; Greene, 1950; Young et al,
1975). Despite adequate surgical therapy with removal of affected
thyroid lobes, thyrotoxicosis recurred in three cases during a follow
up period ranging from three to thirty months (mean 10.3 months). Two
of the cases which recurred had bilateral goitres with lymphocytic
infiltrates at the initial presentation and their sera were both
strongly positive for thyroid microsomal antibodies. Autoantibodies
may thus have prognostic significance as they do in human thyroid
disease. The third cat with recurrence had a unilateral goitre but
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there was lymphocytic infiltration and the recurrence involved the
side which had been previously operated on (remnants of the thyroid
gland may have been left with the parathyroid glands). The serum in
this case was strongly positive for antinuclear factor.
Antinuclear factor is rare in normal cats but may occur in systemic
lupus, feline leukaemia virus infections and liver disease. Two of
the antinuclear factor postive cats in this series (aged six and
seven and a half years) are amongst the youngest cases of feline
hyperthyroidism reported. If thyroid autoantibody production is
secondary to thyroid damage rather than part of a primary
immunological disturbance, the formation of non-organ specific
antibodies would perhaps not be surprising although ANF is also found
in human autoimmune thyroid diseases.
Histologically, the changes in the thyroids of hyperthyroid cats are
usually described as adenomas or adenomatous hyperplasia and the
condition has been proposed as a potential model for the toxic
nodular goitre of Man. Autoantibodies to the thyroid are found in a
high proportion of cases of nodular goitre in Man, and although they
may simply reflect thyroid damage or overactivity, a variety of other
immunological disturbances has been described in the condition (see
Chapter 1). An autoimmune aetiology is not necessarily excluded by
the finding of a nodular goitre and one case of particular interest
was reported by Benezu et al (1977) where radioactive iodine
treatment of an adenoma was succeeded by thyrotoxicosis associated
with a diffuse goitre. Tissue damage by the therapy may have
stimulated autoantibody production including TSH receptor antibodies.
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The equal sex incidence in feline hyperthyroidism, unlike the female
predominance in Graves' disease, again does not preclude an
autoimmune pathogenesis. Neither systemic lupus or primary
hypothyroidism in the dog have a particular sex predisposition
(Muller et al, 1983; Scott, 1981) while diabetes in the dog has only
a slight female preponderance (Feldman, 1983). The fact that feline
hyperthyroidism is a disease of older cats makes it more like toxic
nodular goitre with respect to age but autoimmune diseases in general
tend to become more common with advancing years. The absence of TSH
receptor antibodies is not surprising since the assay used in this
study has been developed for use with human serum and even so is not
positive in all human patients with Graves'.
The observation that many cases of feline hyperthyroidism have
autoantibodies may indicate the presence of an underlying
immunological disturbance. Pathologically the condition is not
similar to Graves' but the role of the immune system in its





A: IMMUNOLOGICAL CHANGES IN AUTOIMMUNE THYROTOXICOSIS
The work presented in this dissertation has confirmed the variety of
immunological mechanisms which may operate in the pathogenesis of
Graves' disease and these are summarised in FIGURE 10.1. Both humoral
and cellular mechanisms are involved and interaction between the
various components of the immune system may alter the presentation of
the disease.
I) HUMORAL IMMUNE MECHANISMS
Hypergammaglobulinaemia has been demonstrated in the autoimmune
diseases including Graves' disease (Briones-Urbina et al, 1982) and
has been taken as evidence of altered humoral immunity. Indeed,
changes in B lymphocyte function have been documented in both
systemic lupus erythematosus and in rheumatoid arthritis (Budman et
al, 1977; Kallenberg et al, 1983; Slaughter et al, 1 978). However,
when complement and immunoglobulin G, A and M levels were
investigated by radial immunodiffusion in patients with Graves' or
nodular goitres (data not presented), no difference was found from
normal controls. Similarly B lymphocyte numbers are generally normal,
and the major evidence of disturbed humoral immunity is the presence
of circulating autoantibodies. The pathognomonic change in Graves' is
the presence of antibodies to the TSH receptor. When different assays
for these antibodies are combined, they can be detected in most
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Functional assays for TSH receptor antibodies are too demanding for
routine clinical laboratories and the method which measures TSH
binding inhibitory immunoglobulins (TBII) has found wide usage. TBII
were found in 84 out of 138 (61%) patients when immunoglobulin
concentrates were used for the assay and in 121 out of 150 (81$)
patients when neat serum was used, in keeping with other large
series (Schleusener et al, 1978 ; Teng et al, 1980; Bliddal et al,
1982; Biro, 1980). The greater sensitivity of the assay using neat
serum was reported by Southgate and colleagues (1984). TBII were not
found in other goitrous thyroid diseases except for a low incidence
in multinodular goitre - in all, one out of 57 patients with
euthyroid, and five out of 60 patients with toxic nodular goitre were
mildly positive. It is not clear whether these are true Graves'
patients with nodular goitres or whether there is, in fact,
autoimmune thyroid stimulation in some cases of multinodular goitre
as suggested by Brown et al (1978).
That the level of TBII does not correlate with thyroid hormone or
radioactive iodine uptake values shows that other factors both in the
thyroid and in the immune system (such as coincident thyroid damage
from thyroiditis) affect the response of the gland to stimulatory
immunoglobulins. In fact, not all antibodies detected by the TBII
assay are stimulatory: For example, non-stimulatory antibodies
develop after 7 311 therapy. Indeed, TBII correlate poorly with the
level of thyroid stimulators measured in vivo by the LATS assay
(Clague et al 1976; Endo et al, 1978) and in vitro by cyclic AMP
accumulation (Kuzuya et al, 1979; Sugenoya et al, 1979; Macchia et
al, 1981 ; Shishiba et al, 1982; Hardisty et al, 1983) - TBII assay is
not, therefore, a useful means of gauging the degree of thyroid
-300-
stimulation but is useful in confirming the diagnosis of Graves'
although multiple determinations may be necessary (Hensen et al,
1984) and immune complexes may interfere with the expression of TBII.
Thyroid microsomal antibodies and anti-thyroglobulin antibodies are
found in a proportion of Graves' patients (38% and )7% respectively
in the series of 150 patients reported here) and, while immune
reactions to these antigens may be important in initiating the
disease and determining its prognosis, they are not specific markers
for any aspect of Graves' disease. Their presence does serve to
illustrate the polyclonal nature of the autoimmune response. That
over 90% of patients with primary hypothyroidism had these antibodies
testifies to their role in mediating thyroid destruction. A positive
correlation (p < 0.001) was found between TBII level and microsomal
antibody titre in untreated Graves'. This may either be an indicator
of the degree of the immune response or because of a cross reation
between the two assays.
Immune complexes (ICs) were detected with the C1q solid phase assay
in patients with autoimmune thyroid disease and Addison's disease and
their relationship to circulating pathogenetic antibodies was
explored. In untreated Graves' disease, ICs were found in 12 out of
55 (22%) and this low incidence is in keeping with the findings of
Brohee et al (1979) and Endo et al ( 1983). A similar incidence was
found when ICs were measured with the conglutinin binding assay (data
not presented). There was a negative correlation between TBII and ICs
- one out of twelve IC positive patients was also positive for TBII
compared to 28 out of 42 (67%) IC negative patients (p < 0.001). Van
der Heide et al ( 1980) reported a similar phenomenon with the C1q
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fluid phase assay. ICs did not correlate with other autoantibodies. A
negative correlation between ICs and microsomal antibodies was seen
in euthyroid patients with Hashimoto's thyroiditis. In idiopathic
Addison's disease, ICs were found in 41 out of 65 (63$) patients at
diagnosis and a similar incidence was seen with the conglutinin assay
(data not shown), the correlation between the two assays being good.
There was no difference in ICs between adrenal antibody positive and
negative cases. However, in the 31 antibody negative cases studied,
only eight out of 18 (44$) without non-adrenal antibodies were
positive compared to 11 out of 13 (85$, p < 0.05) patients with
other antibodies or autoimmune diseases. It seems, therefore, that in
Graves' disease, euthyroid Hashimoto's and Addison's with multiple
autoimmune diseases that ICs may prevent circulating antibodies from
being detected.
The situation is different in patients with primary atrophic
hypothyroidism and in those hypothyroid with Hashimoto's thyroiditis
where the level of ICs showed a positive correlation with microsomal
antibody titre. Five out of 21 hypothyroid patients with Hashimoto's
were positive for anti-thyroglobulin antibodies and all had ICs
while, in euthyroid patients with Hashimoto's, only one of the five
anti-thyroglobulin antibody positive patients also had circulating
ICs. The mean C1q binding in the two groups of anti-thyroglobulin
antibody positive patients was 7.7$ and 5.4$ respectively (p < 0.05).
This is comparable to the relationship between anti-microsomal
antibodies and ICs in Hashimoto's thyroiditis. In Addison's patients
tested on follow up, ICs did not decline in parallel with adrenal
antibodies with time from diagnosis but persistence of autoantibodies
correlated with the presence of non-adrenal autoantibodies or
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autoimmune diseases. The correlation between pathogenetic antibodies
and ICs in autoimmune endocrine diseases is illustrated in FIGURE
10.2.
In the early stages of the diseases, a relative excess of antigen may
lead to the formation of complexes with antigen excess which the C1q
solid phase assay is particularly useful for detecting. The relative
lack of free antibody in this situation may prevent its detection by
insensitive methods such as immunofluorescence. Thus, in Graves'
disease and the early phase of Hashimoto's or polyendocrine disease
associated with Addison's, a negative correlation exists between the
antibody marker and ICs detected by the C1q solid phase assay. With
prolonged autoimmune attack on the thyroid and other endocrine
glands, a predominance of antibodies may exist, both in the
circulation and in ICs. A positive correlation was found between ICs
and antibodies in these circumstances. A study of circulating immune
complexes using different methods to take account of the relative
antigen and antibody composition and to relate this to the natural
history of the diseases would be of relevance. ICs are not therfore,
simple antigen-antibody combinations but are dynamic structures, the
changing nature of which may underlie the presentation of an
autoimmune disease and its relationship with other diseases.
II) CELLULAR IMMUNE MECHANISMS
The major evidence for disordered immunoregulation has come from
studies on the helper (T^) and suppressor (Ts) subsets of T
lymphocytes. There is good evidence from animal studies and from
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FIGURE 10.2 THE RELATIONSHIP BETWEEN IMMUNE COMPLEXES AND

























limited work on human patients that the function of Ts is defective
in autoimmune thyroid disease (Rose et al, 1981; Balazs et al, 1984).
In recent years, it has become possible to quantify these cells by
using monoclonal antibodies. However, there are two notes of caution
in interpreting these studies. Firstly, the reduction in Ts is in the
proportion of cells (Thielemans et al, 1981; Sridama et al, 1982;
Ludgate et al, 1984) rather than in their absolute numbers. This may
be due to changes in the numbers of other subsets of peripheral blood
mononuclear cells. For example, a mild increase in 0KT4
(helper/inducer) cells was found (9.28 x 10^/1 in Graves' patients
compared to 7.62 x 10&/1 in controls, p = 0.05). It may be that the
relative deficiency of Ts is sufficient to allow effector mechanisms
to become activated, or the defect may be qualiative rather than
quantitative (Iwatani et al, 1983). Alternatively, the defect may be
specific for a particular antigen or organ and might have little
effect on the overall cell numbers in this subset. The second caution
relates to comparing work with different monoclonal antibodies. The
antibodies 0KT8 and UCHT4 gave a good correlation in cell numbers
measured in normal individuals, but the correlation was poor in
Graves' patients although both antibodies showed reduced proportions
of Ts.
Other potentially important immunoregulatory mechanisms include the
network of anti-idiotypic antibodies and the regulation of lymphocyte
function by antibodies against these cells. The capacity of the
former to regulate the expression and function of other components of
the immune system, both humoral and cellular, is only just becoming
appreciated. Anti-lymphocytic antibodies are recognised to occur in
systemic lupus erythematosus (Morimoto et al, 1980), myasthenia
-305-
gravis (Mishak & Dau, 1981), juvenile rheumatoid arthritis (Morimoto
et al, 1981) and in Graves' disease (Pacini et al, 1983) - They have
mainly been found to be directed at the suppressor/cytotoxic subset.
It is not clear whether this phenomenon is part of the normal
immunoregulatory mechanism or whether it represents part of a
polyclonal response in individuals susceptible to autoimmune disease.
Immune complexes may also have an immunoregulatory role. They may
bind via Fc receptors to TS) K cells and activated T lymphocytes.
Complexes with an antibody excess can arm K cells thus initiating
antibody dependent cellular cytotoxicity (ADCC), while other
complexes might be responsible for the reduced numbers of K cells
detected in some cases of systemic lupus (Schneider et al, 1975),
diabetes mellitus (Pozzilli et al, 1981) and Graves' disease (Endo et
al, 1983). ICs may reduce Ts although such a correlation was not seen
here using the C1q solid phase assay (data not presented) - possibly
because complexes with a relative antibody excess would be much more
likely to bind to cells expressing Fc receptors. ICs may also have a
part to play in the initiation of the disease since their deposition
is known to precede cellular infiltration (Kofler et al, 1983) . The
potential interactions between the humoral and cellular immune
systems are summarised in FIGURE 10.3.
Evidence for increased activation of the cellular immune system comes
from the presence of raised numbers of self-reactive,
antigen-specific cells found in SLE and thyroid disease (Bankhurst &
Williams, 1973; Bankhurst et al, 1975). Using monoclonal antibodies
against early activation (4F2) and late activation (class II)
antigens, increased numbers of activated lymphocytes have been
demonstrated in over 70% of new Graves' patients. All patients
studied had either increased activated T lymphocytes or TSH receptor
-306-
FIGURE 10.3 INTERACTIONS BETWEEN HUMORAL AND CELLULAR IMMUNITY IN
THE PATHOGENESIS OF AUTOIMMUNE ENDOCRINE DISEASE
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antibodies (TBII). There was a negative correlation between TBII and
4F2 positive cells which was not due to TBII masking the expression
of the 4F2 antigen. It was concluded that the two abnormalities might
represent different stages in the immunopathogenesis of Graves'
disease. Enhancement of cellular effector mechanisms was shown using
an antibody directed at a determinant on the surface of K/NK cells.
There was no relationship between the numbers of these cells and
circulating autoantibodies or immune complexes.
Both humoral and cellular immune abnormalities exist in Graves'
disease. Their interactions may promote or limit the autoimmune
reaction. The system is subject to a dynamic regulatory process and
not all abnormalities need be present simultaneously.
B: THE NATURAL HISTORY OF GRAVES' DISEASE
Immunological changes in the circulation are useful in diagnosis and
in monitoring the progress of an autoimmune disease but they do not
necessarily tell us much about the lesion which initiates the
disease. In type I diabetes, a pathological heterogeneity exists with
some cases being induced by viral infection and others being purely
of autoimmune origin. The relative contribution of the immune system
in the pathogenesis of the condition may be genetically determined
(Cahill & McDevitt, 1981). The evidence for virus infection as a
triggering factor is good, both from pathological studies of
individual patients who have died soon after diagnosis was made and
from epidemiological studies. There is only very limited
epidemiological evidence to suggest a viral trigger for Graves'
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disease (Joassoo et al, 1975) although, by causing local increases in
the concentration of interferon, viral infection may contribute to
the increased expression of class II antigens on the surface of
thyrocytes seen in the disease. Class II antigen expression on
thyrocytes was confirmed here by immunofluorescent studies on three
Graves' thyroids. Other variable features in the pathogenesis include
iodine status and the relative contributions of autoimmune thyroid
stimulation and destruction.
Both thyroid autoantibodies and thyrotoxicosis may develop after
iodine refeeding in an iodine deficiency region (Boukis et al, 1983)
although it is not at all clear whether the pathological entity which
arises is true Graves' disease. Indeed, the recent study by Phillips
et al ( 1985) in the United Kingdom showed an inverse correlation
between TSH receptor antibody positive thyrotoxicosis and previous
endemic iodine deficiency. The balance between thyroid stimulation
and destruction may be crucial in determining the presentation of the
disease. The response of the gland to thyroid stimulators may be
limited in patients with significant thyroiditis, while it is
possible that hyperstimulation with Graves' immunoglobulins may
increase microsomal antibody expression and thus ultimately increase
the tendency for thyroiditis to develop - it is known, for example,
that TSH stimulation increases the expression of microsomal antigen
on the surface of rat FRTL5 thyroid cells (Chiovato et al, 1985). The
expression of histocompatibility antigens on the thyrocyte in
response to thyroid stimulators requires full study and may be an
important determinant of the subsequent immunological reaction.
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Graves' is a disease of relapses and remissions with approximately
10$ of patients developing hypothyroidism spontaneously in the
absence of destructive anti-thyroid therapy (Doniach, 1980). In an
attempt to obtain some information on the natural history of the
immune changes in Graves' patients with subclinical disease have
been studied as have those in remission and those with recurrent
Graves' thyrotoxicosis. The information obtained from the different
patient groups is summarised in TABLE 10.1. In subclinical disease
(flat TRH test, high normal levels of thyroid hormones and mild
symptoms) - a group of patients difficult to define clinically or to
study epidemiologically - TBII were not found in any of the twelve
patients studied, confirming that this is a highly specific marker
for the onset of true Graves' although a low level of thyroid
stimulation must be present within the thyroid gland. Other
immunological abnormalities were present with microsomal antibodies
in four cases and immune complexes in four cases. Both exophthalmic
patients and three of the four with microsomal antibody were ICs
positive. This relationship between ICs and the presence of other
autoantibodies and autoimmune diseases may explain the reduced
expression of autoantibodies in IC positive patients as was found in
newly diagnosed Addison's disease. T^ and Ts were only studied in a
few cases (data not presented) and were normal. Other lymphocyte
subsets were not studied. It is not known whether there is a large
pool of patients with subclinical disease with only a small number,
under the appropriate gentetic or environmental influences, going on
to develop the full blown syndrome. One group which is of interest is
the first degree relatives of patients with thyroid disease. These
individuals have an increased incidence of thyroid autoantibodies
(Mather et al, 1980) and biochemical thyroid abnormalities (Tamai et
-310-
TABLE 10.1 IMMUNOLOGICAL ABNORMALITIES AT DIFFERENT STAGES IN THE
NATURAL HISTORY OF GRAVES' DISEASE
SUBCLIN. ACTIVE REMISSION RECURRENT
MICROSOMAL ANTIBODY ++ ++ + +++
TSH RECEPTOR Ab. NEGATIVE ++ NEGATIVE +
IMMUNE COMPLEXES + + + ?
SUPPRESSOR CELLS NORMAL REDUCED NORMAL REDUCED
EARLY ACTIVATED T CELLS 7 RAISED NORMAL NORMAL
LATE ACTIVATED T CELLS ? RAISED NORMAL RAISED
K/NK CELLS 7 RAISED NORMAL NORMAL
HLA MARKER ? E8 DR3 (65%) - DR3 (77%)
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al, 1979). One study has found an increased incidence of HLA-B8 (and
from this we may infer DR-3: Mather et al, 1980) in contrast to the
work by Chopra et al (1979) where a normal HLA distribution was
found.
TBII were not generally found in patients who were in remission after
a course of drug therapy although persistent microsomal antibodies
and immune complexes are frequent (data not presented). Lymphocyte
subset abnormalities are also not present apart from a slight, but
non significant, reduction in the proportion of Ts.
The immunological abnormalities in patients suffering a relapse of
thyrotoxicosis were impressively different to those of new Graves'
patients. TBII were found in 64% of 14 recurrent cases compared to
82? of age and sex matched new cases , the median TBII in the two
groups being 16 and 28 respectively (p < 0.02). Strongly positive
titres of microsomal antibody were found in 35$ of new and 85% of
recurrent cases (p < 0.01). The percentage reduction in 0KT8 positive
cells was comparable in the two groups but 4F2 (early activated) T
cells were not increased in recurrent disease. There was, however,
the expected increase in T cells bearing class II antigens. K cells
were elevated in new but not in recurrent disease. The incidence of
HLA-DR3 was only slightly higher (77%) in recurrent disease than in
new cases (65%) confirming recent observations that the marker is of
limited use in predicting recurrence (Schernthaner et al, 1980;
Dahlberg et al, 1981; McKenna et al, 1982; Young et al, 1985). Thus,
while an underlying immunoregulatory defect is still present in
recurrent disease, the lower levels of circulating TBII and cytotoxic
cells may indicate that the immunological reaction is becoming
-312-
confined to the thyroid. The higher levels of microsomal antibody may
represent the greater tendency to develop thyroiditis and
hypothyroidism in long standing disease.
Class II antigen expression, both on the thyrocyte and on activated T
lymphocytes, may be important in the pathogenesis of Graves' disease.
The immunological markers associated with the disease are largely a
feature of the active thyrotoxic phase of its natural history.
Recurrent disease shows marked immunological differences to newly
diagnosed disease and these patients should be considered separately
in studies on the immunopathogenesis of Graves' disease.
C: AGE-RELATED CHANGES IN IMMUNOLOGICAL PARAMETERS
The prevalence of many autoantibodies and thus of autoimmune diseases
increases with age (Doniach & Bottazzo, 1983). Graves' is one
exception where the disease most commonly affects young to middle
aged women. The incidence of TBII in Graves' patients fell off with
age when the assay was performed using IgG concentrates (p < 0.001).
The negative correlation between ICs and TBII has already been
alluded to. The mean age in IC positive Graves' patients was 55.5
years compared to 42.8 for the IC negative patients (p < 0.01). The
increasing incidence of ICs with age in the normal population is well
recognised (Di Mario et al, 1981) and could account for the decline
in TBII positivity with age in Graves' patients. Age related changes
in suppressor cell function are documented in animals (De Kruyff et
al, 1980). While no correlation between age and 0KT8+ cells was seen
in Graves' patients, there was a negative correlation between age and
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0KT8+ cells in normal female subjects (r = 0.64, p < 0.001). It has
been suggested that the decrease in suppressor cells in autoimmune
disease may relate to the presence of the DR-3 allele (Lawley et al,
1981) and one may therefore expect that DR-3 positive patients would
develop Graves' at a younger age than those without this allele. The
mean age of onset in seven DR-3 homozygotes was 35.2 years compared
to 37.6 in 46 DR-3 heterozygotes and 40.3 years in 29 DR-3 negative
patients - a trend in the expected direction although it did not
reach statistical significance.
There are changes in immune parameters with age (TSH receptor
antibodies, immune complex formation and the proportion of suppressor
cells) which may affect the onset of Graves' disease. The age of
onset is not clearly related to ht.a status.
D: HETEROGENEITY WITHIN GRATES' DISEASE
It has been suggested in two previous published studies (Schleusener
et al, 1983; Stenszky et al, 1983) that different forms of Graves'
disease may exist. The former study confirmed the expected high
incidence of HLA-DR3 in patients with either ophthalmopathy or TSH
receptor antibodies but also identified another group of patients
with goitrous thyrotoxicosis who had neither eye disease or receptor
antibodies and had a high incidence of HLA-DR5. Stenszky's study used
a complex mathematical technique to identify three possible
subgroups. The first of these had low indices of autoimmunity, a
tendency to remit with medical therapy and a low incidence of HLA-B8
(9%). The second group had high antibodies and marked lymphocytic
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infiltration of the gland but again a relatively low incidence of
HLA-B8 (21/0. They proposed that this group had a combination of
Hashimoto's thyroiditis and Graves' disease. The third group had high
titres of antibodies, a high incidence of ophthalmopathy and relapse
after drug treatment, a strong family history and a high incidence of
HLA-B8 (87*).
In this dissertation, three putative subgroups have been studied.
Their clinical and immunological data is shown in TABLE 10.2. It was
hypothesised that patients with a low four hour uptake of radioactive
iodine might have limited thyrotoxicosis because of the presence of
thyroiditis and may therefore be similar to Stenszky's second group.
Patients with no goitre have recieved some attention in recent
literature and they were also considered as a possible
immunologically distinct subgroup.
It is well known that Graves' and Hashimoto's may coexist in the same
gland (Eason, 1928) and it has been suggested that patients with this
combination have a strong personal or family history of other
autoimmune disease (Fatourechi et al, 1971). Patients studied here
with a low 131I uptake and goitre had less severe thyrotoxicosis than
the majority of patients with classic Graves' disease and they also
had a later age of onset. These patients showed a decreased incidence
of TBII but had a slight increase in the level of microsomal antibody
and a marked increase in the incidence of non-thyroidal
autoantibodies (particularly parietal cell antibodies). The
prevalence of immune complexes was also slightly increased. Because
of the potential overlap with Hashimoto's thyroiditis and the
possible risk of pernicious aneimia in this group of patients, an
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TABLE 10.2 CLINICAL AND IMMUNOLOGICAL DATA FROM THREE GROUPS OF
PATIENTS WITH GRAVES' DISEASE
A B C
GOITRE + GOITRE + no goitr:
UPTAKE >4056 UPTAKE < 40$
(N = 89) (N = 21) (N = 2'
AGE (years) 41.0 51.6 52.6
T3 (nmol/1) 6.6 4.2 5.4
1311 UPTAKE 6256 3256 4656
TBII (No. positive) 72% 4356 3156
TBII (median) 24.8 12.0 8.4
MICROSOMAL > 202 34 % 4856 2856
THYROGLOB. > 320 1056 1456 356
PARIETAL CELL Ab. 1056 4356 756
NON-THYROID Abs. 16)6 5756 1056
IMMUNE COMPLEXES 1256 4356 3656
HLA-DR2 4856 2556 3356
HLA-DR3 62% 7556 5756
HLA-DR5 1756 1756 29%
HLA-DR3/3+4 2156 3356 1956
HYPOTHYROIDISM IN
RESPONDERS TO 131I 4656 8856 6056
(No.) (28) (8) (15)
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association with HLA-DR5 was proposed but was not, in fact,
confirmed. The prognosis of this group following 1311 therapy-
differed from other Graves' patients with a high incidence of
hypothyroidism presumably reflecting either pre-existing thyroid
damage or a genetic predisposition to form destructive antibodies
after treatment.
Thyrotoxicosis without goitre is a common and important clinical
entity which has been neglected in immunological studies. Hegedus et
al (1983b) confirmed normal thyroid volume by ultrasound in 23% of 96
consecutive thyrotoxic patients, and a similar incidence was reported
in a large retrospective study by Greenwood et al (1985). The latter
study showed that this group had an incidence of thyroid microsomal
antibodies and ophthalmopathy comparable to that of classic Graves'
disease. Once again the patients in this group who were described in
Chapter 4 were older and had less severe thyrotoxicosis than Graves'
patients with goitre and high 131 x uptake. The incidence of TBII in
this group suggests that some, at least, of these patients are
suffering from true Graves' disease. Growth promoting antibodies can
now be readily measured (Drexhage et al, 1980; Valente et al, 1 983)
but their relationship to TSH binding inhibitory antibodies remains
to be clarified. It may well be that, like other autoantibodies,
their expression is age-related.
Agoitrous Graves' disease may thus be a form of autoimmune
thyrotoxicosis where the immunological stimulus to thyroid growth is
lacking. Studer et al (1978) have, however, shown that thyroid
autonomy can be confined to individual follicles or groups of
follicles in the early stages. Nodules may not, therefore be
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identified either clinically or scintigraphically and an autonomous
thyroid condition could be mistaken for Graves' disease.
Hyperfunction of parts of the gland may increase antigen expression
or release and could account for the appreciable incidence of
thyroid abnormalities including microsomal antibodies in such
patients (Mota et al, 1980; Kuy et al, 1981). TSH receptor antibodies
may be part of a polyclonal autoimmune response in some patients
although they are not usually detected in the serum of patients with
nodular goitres using the TBII assay (Bolk et al, 1972; Mukhtar et
al, 1975; Strakosh et al, 1978). Changes in iodine status may
initiate antibody formation in patients with thyroid autonomy (Boukis
et al, 1983).
It has been proposed, on the basis of HLA-DR typing studies reported
in Chapter 6, that thyroid stimulation by TSH receptor antibodies and
thyroid destruction by cytotoxic antibodies might be under separate
genetic control. Thyroid stimulation may relate to the DR-2 locus.
The median TBII in DR-2 positive patients studied was 25.2 compared
to 17.5 in other patients (p < 0.05). In DR-2 homozygotes, the median
TBII was 36.2 compared to 19-9 in DR-2 heterozygotes (p < 0.01).
Several DR-2 positive patients were encountered with unusual
resistance to therapy and TBII took significantly longer in DR-2
positive patients to decline to normal values on intiating
antithyroid drug therapy. Thyroid autoaggression, on the other hand,
may be more related to the HLA-DR3 locus. The persistence of TBII
after 1311 therapy was commoner in DR-3 positive patients. Patients
who were DR-3 homozygotes or who possessed the DR-3+4 phenotype
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tended to have high titres of thyroid microsomal antibodies. The
possession of DR-3+4 is associated with a high risk of type I
diabetes (Thomsen et al, 1979) -
An interaction between Graves' and related thyroid disorders is
proposed in FIGURE 10.1. The overlap between the various disease
states was suggested in a pathological study by Levitt (1950) on a
large number of thyroidectomy specimens and aspects of this
interaction have been confirmed by many subsequent clinical and
immunological investigations. It is hypothesised that the diseases
can broadly be divided into two groups. The first includes classic
Graves' disease with goitre, high levels of TSH receptor antibodies
and an early age of onset. This group has a high incidence of HLA-DR3
and includes patients with primary atrophic hypothyroidism and
agoitrous Graves' disease. Patients with disseminated thyroid
autonomy overlap clinically and some immune changes may be present
but the condition probably does not have an autoimmune aetiology. The
second group of conditions shows an association with HLA-DR5 although
this is probably not as strong a marker as DR-3 is for the first
group. Recurrent Graves' disease is presented on the basis of data
which has alreeady been discussed and the observation by Schleusener
et al (1983) that some cases of Graves' disease may be associated
with this allele. Genetic factors may determine whether the primary
event in autoimmune thyroid disease is thyroid stimulation or
destruction while environmental factors such as viral infection or
changes in iodine intake may relate to the timing of onset. Age
related changes in immune function could then dictate the nature and
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The primary event in the DR-3 associated group may be thyroid
stimulation by TSH receptor antibodies. It is well known that
hypothyroidism develops spontaneously in Graves' disease (Doniach,
1981) although the natural history is frequently changed by
destructive antithyroid therapy. In the obese strain (OS) chicken, a
phase of subclinical thyrotoxicosis may well precede the development
of thyroiditis (see Chapter 9). The expression of thyroid microsomal
antigen in rat FRTL5 cells is known to be TSH dependant (Chiovato et
al, 1985) and it will be of interest to see whether the antigen
expression is increased during the course of autoimmune thyroid
stimulation. The primary event in the second, DR-5 associated, group
is the development of cytotoxic antibodies. Thyroid stimulation may
develop as part of the polyclonal immune response to thyroid damage.
The existence of cases of thyrotoxicosis succeeding hypothyroidism
was discussed in Chapter M. The relationship between immune complexes
and pathogenetic antibodies has already been discussed. In the early
phases of autoimmune diseases, ICs may decrease the expression of
antibodies and, because of the relative antigen excess in complexes,
they are unable to arm K cells and their interaction with other Fc
bearing cell subsets may be similarly limited. Furthermore, the
clearance of immune complexes may be more effective in young patients
thus limiting the extent of tissue damage. As the immune response
develops with advancing years, complexes of antibody excess may form
and be associated with progressive tissue damage.
Heterogeneity may exist in Graves* disease. It may partly depend upon
age-related changes in the immune system and thyroid function. The
genetic basis is not clear although separate genetic control of
thyroid stimulation and destruction may exist. The recognised thyroid
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autoimmune disease states are part of a complex network of
interacting pathologies and the presentation of individual cases may
vary with time and relate to environmental trigger factors.
E: IMPLICATIONS FOR DIAGNOSIS
Whatever other immunological abnormalities play a part in the
pathogenesis of Graves' disease, the final common pathway is thyroid
stimulation by immunoglobulin molecules binding to the TSH receptor.
However, using standard assay methods, these antibodies are not
always detected in the circulation. The assay in widest use is the
radioreceptor assay. Even with the modified assay proposed by
Southgate et al (1984), only 121 out of 150 unselected Graves'
patients were positive. Although impractical in routine clinical
laboratories, the use of multiple methods to detect TSH receptor
antibodies greatly increases the yield of positive results (Biro,
1982; Marcocci et al, 1983; Hardisty et al, 1983). The development of
reproducible methods for directly measuring thyroid stimulation in
vitro has made an impact already on clinical studies of the disease.
The measurement of iodide uptake by rat FRTL5 cells, for example, is
a convenient assay which has found wide application in the past two
or three years.
The yield of positive tests in assays for TSH receptor antibodies may
also be decreased by including subgroups of patients which have a low
incidence of antibodies. The possibility that the immune reaction
becomes confined to the thyroid gland in cases of Graves' disease of
long standing has already been postulated to account for the lower
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levels of TBII found in the circulation of such patients. In the
series of patients presented in Chapter 4, only 43% of patients with
low uptake of 1311 and goitre were TBII positive and only 3156 of
patients with no goitre had antibodies compared to 72% of patients
with classic Graves' disease with high 1311 uptake and goitre. In
scientific studies on the immunopathogenesis of Graves' disease, the
diagnostic criteria used must be clearly stated and abnormalities
found must be related only to this defined population of patients.
HLA-DR3 was found in 53 out of 82 patients with thyrotoxic Graves'
disease and this is in keeping with other published studies (Bech et
al, 1977; Farid et al, 1979; Allanic et al, 1980; Dahlberg et al,
1981; McKenna et al, 1982) . It is not a marker for any particular
aspect of the disease and its role in predicting the response to
antithyroid drug therapy has now been disputed. Graves' patients are
commonly found who are negative for both TBII and DR-3, and, in view
of the demanding nature of the latter test, it cannot be considered
to have a useful part to play in the routine diagnosis and
management of autoimmune thyroid disorders. It remains to be seen
whether more newly characterised HLA phenotypes will prove to be
better markers - for example, DC-3 has recently been shown to be
present in a high proportion of patients with coeliac disease.
The importance of T cell abnormalities in the pathogenesis of
autoimmune thyroid disease has been amply documented from animal
studies. For example, Vladutiu and Rose (1975) have shown that
susceptibility to murine thyroiditis following thyroglobulin
immunization is transferred with T rather than B lymphocytes. The
changes in T lymphocyte subsets discussed in this dissertation are
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not specific for Graves' disease and are not, therefore, helpful in
diagnosis. The inverse correlation found between 4F2 positive cells
and TBII demonstrates that studying patients in different stages of
the disease may reveal different immunological abnormalities.
The measurement of TSH receptor antibodies is the only true
immunological test for Graves' disease. Assays of functional activity
of these antibodies are now becoming widely available and the use of
multiple tests improves diagnostic yield.
F: IMPLICATIONS FOR THERAPY
The possibility that antithyroid drugs exert an immunosuppressive
action which is specific to the thyroid was discussed in Chapter 3-
The presence, or otherwise, of this action has important implications
for the way drug treatment is monitored. By studying 24 patients
after carbimazole therapy was started, it was clear that different
time courses existed for the reduction in thyroid hormones and for
the decline in thyroid antibodies including TBII. The latter took
much longer to become normal than the former. One conclusion is that
the primary action of these drugs is antithyroid and the secondary
reduction in autoantibody synthesis is brought about by reduced
autoantigen presentation or expression when the thyrocyte is no
longer hyperstimulated.
HLA-DR3 is not particularly helpful in predicting the response to
drug therapy (Schernthaner et al, 1980; Dahlberg et al, 1981; McKenna
et al, 1982; Young et al, 1985). Studies reported in Chapter 6
-324-
suggested that DR typing may help to identify those cases resistant
to therapy. DR-2 positive patients took longer for their TBII to
normalize with carbimazole when compared to other patients, an
observation which needs to be tested in a larger series of patients.
The relationship of immunological changes to the outcome of
radioactive iodine therapy was extensively studied. 18 patients
tested sequentially after treatment showed a rise in the median TBII
from 35 at diagnosis to 55 at four months after 1311. The levels of
antibody steadily declined thereafter to reach normal levels by two
to three years. Persistent TBII beyond this correlated strongly (p <
0.01) with the presence of exophthalmos. Patients with a genetic
predisposition to multiple autoimmune diseases may have a greater
capacity to form autoantibodies after an immune challenge such as
that provided by 1311. Early changes in TBII following treatment
related to the ultimate outcome. Nine patients becoming hypothyroid
showed an increase in TBII from 26.7 (median) at diagnosis to 33-1 at
two to four months (p < 0.05). In eight euthyroid patients, TBII were
not only lower at diagnosis but showed a tendency to decline
following treatment.
Of 52 patients followed up after 131I therapy, six required further
treatment 19 were euthyroid at six months and 27 were hypothyroid.
There was a trend towards increasing TBII with increasing response to
1311 with median values for TBII in the three groups of 6.5, 10 and
18 respectively (p < 0.01). The cytotoxic or TSH receptor blocking
properties of antibodies might be of importance. The sequestration of
-325-
such antibodies in immune complexes could account for the observation
that seven out of 17 IC negative cases became hypothyroid while none
of seven IC positive cases did so.
Feline hyperthyroidism is a recently recognised condition which may
provide a model for some aspects of thyroid disease in Man.
Autoantibodies to the thyroid (microsomal and antinuclear factor)
were found in 14 out of 29 cases. The five cases with high levels of
thyroid microsomal antibody included particularly cats with bilateral
goitres and lymphocytic infiltration of the gland. These cases in
particular may have an underlying immune disturbance. On follow up,
three cats developed recurrent thyrtoxicosis and all three had
circulating autoantibodies and lymphocytic infiltration of the gland.
Immunolgical changes in feline hyperthyroidism may thus influence the
presentation of the disease and its prognosis as they do in human
thyroid disease.
The time courses for thyroid hormone and TSH receptor antibody
reduction during the early months of carbimazole treatment of Graves*
thyrotoxicosis do not support the hypothesis that the drug has a
direct immunosuppressive action. TSH receptor antibodies may help the
prediction of outcome of radioactive iodine therapy. Feline
thyrotoxicosis is associated with a high incidence of anti-thyroid
antibodies and these may be of prognostic importance in the
condition.
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G: PERSPECTIVES FOR FUTURE RESEARCH IN GRAVES' DISEASE
The defects in humoral immunity, cell-mediated immunity and
immunoregulation which occur in Graves' and related diseases are far
from completely understood. The antibody activities which stimulate
the thyroid are being characterised by in vitro assays using cultured
thyroid cells and it is likely that differences in the actions of
different populations of antibodies will account for the varying
presentations of the disease. The genetic basis for the production of
these antibodies will become clearer and this along with the
recognition of further HLA specificities may increase the value of
tissue typing. The cell mediated immune system will be studied
further with monoclonal antibodies and the relationship of cell
surface markers to function of the cells in vivo will undoubtedly
become clearer.
Monoclonal antibodies have not, thus far, elucidated the role of
suppressor cells in the initiation of autoimmune diseases and a
return to assays of functional activity is required. Other
developments in our understanding of immunoregulation may come from
the study of anti-idiotypic antibodies. Their role in animal models
for myasthenia gravis and insulin resistant diabetes mellitus has
been examined (Wasserman et al, 1982; Shechter et al, 1982) and such
antibodies may occur in a high proportion of patients with myasthenia
gravis (Dwyer et al, 1983). Naturally occurring antibodies binding
TSH have been recognised (Kajita et al, 1983; Akamizu et al, 1984;
Copping et al, 1985) and may be of relevance to anti-TSH receptor
autoimmunity.
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While changes in circulating immune parameters are of clinical
importance, the thyroid gland is ideal for the study of a target
organ in autoimmune disease. The discovery of changes in the
expression of histocompatibility antigens on the thyrocyte and the
characterisation of factors controlling this phenomenon is one of the
most fundamental areas of research at present (Hanafusa et al, 1983;
Pujol-Borrell et al, 1983; Weetman et al, 1985). No doubt further
work will reveal much about the interaction of changes in target cell
antigen expression with other components of the immune system.
Clinical and epidemiological studies will help us to define the
condition, its variants and its overlap with other autoimmune
diseases. The contribution from research on other receptor antibody
diseases will increase and, new diseases of this group may be
recognised. For example, a role for recpetor antibodies in some cases
of SLE has recently been proposed (Bennett et al, 1986) and receptor
antibodies have been suggested to account for familial cases of
Cushing's syndrome (van Berkhout et al, 1986).
It is now thirty years since Adams and Purves described the activity
of the Long-Acting Thyroid Stimulator. Nobody could have predicted
the advances which have taken place in our understanding of Graves'
disease during this time. It will be fascinating to see what develops




APPENDIX 1: THE MEASUREMENT OF TSH RECEPTOR ANTIBODIES USING THE
TSH BINDING INHIBITORY ASSAY
The assay was performed using either neat serum or immunoglobulin
concentrates prepared from serum by precipitation with polyethylene
glycol. All haemolysed or grossly lipaemic samples were excluded.
Serum was separated and stored at -20°C prior to use. Reagents
(including the TSH receptor preparation) were obtained in kit form
from R.S.R. Ltd., Cardiff.
A) ASSAY BASED ON IMMUNOGLOBULIN CONCENTRATES
This assay was performed broadly as described in Shewring and Rees
Smith ( 1982): immunoglobulins were precipitated from serum using a
solution of 15% polyethylene glycol (PEG) in water. The precipitate
was harvested by centrifugation at 2000g for 45 minutes after which
0.5 mis. of pre-warmed assay buffer (Tris/sodium chloride containing
1mg/ml bovine serum albumin) was added. The pellet was resuspended
using a vortex mixer and allowed to stand for 15 minutes at room
temperature. Undissolved material was removed by centrifugation at
2000g for 10 minutes.
Duplicate 100 microlitre aliquots of IgG preparation were added to
100 microlitres of a solution containing Lubrol-solubilized TSH
receptors (porcine) and allowed to stand for 15 minutes at room
temperature. 100 microlitres of a solution containing 125i_iabelled
TSH was added and the resulting solution was incubated at 37°C for
one hour, following which 0.7 mis of ice cold assay buffer and 1 ml
of ice cold 30$ PEG in 1M NaCl were added. After mixing, the tubes
were centrifuged for one hour at 2000g, 4°C. The supernatant was
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discarded and the pellet counted. Each assay included positive and
negative control sera.
B) ASSAY BASED ON NEAT SERUM
This uses the same method and reagents as above and its use was
described by Southgate et al (1984): duplicate 50 microlitre aliquots
of serum were added to 50 microlitres of receptors and incubated as
before prior to the addition of labelled TSH. After a further hour at
37°C, 800 microlitres of assay buffer and 1 ml of 30$ PEG in 1M NaCl
(to give a final PEG concentration of 15$) were added. The
precipitate was harvested and counted as before.
EXPRESSION OF RESULTS
Non-specific binding was taken as the amount of labelled TSH
precipitated with 1$ Lubrol in the presence of negative serum,
results were expressed as a binding inhibitory index calculated as
follows
100 X
Labelled TSH specifically bound in
the presence of test sample
1 -
Labelled TSH specifically bound in
the presence of negative serum
-331-
For the assay using immunoglobulin concentrates, the normal range was
-10 to +10 (see Chapter 2, FIGURE 2.1 and Shewring & Rees Smith,
1982).
The normal range of the assay using neat serum was obtained from 98
normal controls in whom endocrine and autoimmune disease had been
excluded (see FIGURE A1. 1) . The mean binding inhibitory index in
these controls was -1.23 with a standard deviation of 4.7. The mean
plus two standard deviations was 8.2 but nine was taken as the upper
limit of normal since none of the controls had a value for TBII
higher than this.
TSH receptor antibodies (TBII) were measured in neat serum from 150
patients with untreated thyrotoxic Graves' disease. The results are
shown in FIGURE A1.2. Positive values were found in 121 (81$)
patients. By contrast, there were very few positives in other
goitrous thyroid diseases (see FIGURE A1.3). None of 16 patients with
simple goitre or 25 patients with hypothyroidism secondary to
Hashimoto's thyroiditis was positive. One out of 47 patients with
euthyroid multinodular goitre was positive as were three out of 40





































FIGURE A 1_ .2 T S H _B INDING INHI BIT OR Y IMMUNOGLOBULINS IN PATIENTS
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FIGURE A1.3 TSH BINDING INHIBITORY IMMUNOGLOBULINS IN GOITROUS
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APPENDIX 2: THE C1q SOLID PHASE ASSAY FOR IMMUNE COMPLEXES
A: THE PURIFICATION OF HUMAN C1q
The first component of complement consists of three subunits, C1q,
C1r and C1s which only function in the presence of Ca++. C1q is a
heat-labile, 11S protein which will precipitate antigen-antibody
complexes. It can be obtained in a highly purified form with a 40 to
60/6 yield by repeated precipitation in the presence of chelating
agents to remove C1r and C1s. The method set out has been developed
in the Department of Endocrinology/Immunology, Royal Infirmary,
Edinburgh from that of Yonemasu & Stroud (1971).
Reagents
The C1q was prepared from 150 millilitres of fresh serum from a
normal blood donor, stored at -40°C pending the procedure outlined
below. The following solutions were required:-
BUFFER 1: 0.026M EGTA1 2.2 litres, pH 7.5
BUFFER 2: 0.75M sodium chloride
0.02M sodium acetate.3H2O
0.02M acetic acid
0.01M EDTA* 500 mis., pH5
BUFFER 3: 0.06M EDTA 4 litres, pH5
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BUFFER 4: 0.005M KH2.PO4
0.005M Na2.HP0i(
0.75M sodium chloride
0.1M EDTA 500 mis., pH 7.5
BUFFER 5: 0.035M EDTA 4 litres, pH 7.5
BUFFER 6: 0.75M sodium chloride
0.02M sodium acetate.3H2O
0.02M acetic acid
0.01M EDTA 500 mis., pH 7.5
*
ABBREVIATIONS
EDTA = Trisodium ethylenediamine tetra-acetate (Sigma).
EGTA = Ethyleneglycol bis-(aminoethyl)-tetra-acetic acid (Sigma).
First Precipitation
1: Fresh serum was dialyzed against 1 litre of buffer for four
hours at 4°C. The buffer was changed and dialysis proceded
for a further eleven hours.
2: Spin 10,000g for 15 minutes.
3: Wash precipitate with 50 mis. of Buffer 1.
4: Spin 10,000g for 15 minutes.
5: Dissolve in 3 mis. of Buffer 2.
6: Spin 5,000g for 5 minutes to remove undissolved material.
Second Precipitation
7: Dialyze solution against 4 litres of Buffer 3 for four hours at
4oc.
-337-
8: Spin at 10,000g for 15 minutes.
9: Wash precipitate with 50 mis. of Buffer 3.
10: Spin at 10,000g for 15 minutes.
11: Dissolve in 32 mis. of Buffer 4, stirring overnight if
necessary.
12: Spin at 5,000g for five minutes.
Third Precipitation
13: Dialyze the above solution against 4 litres of Buffer 5 for
five hours at 4°C.
14: Spin 10,000g for 15 minutes.
15: Wash precipitate with 50 mis. of Buffer 5.
16: Spin 10,000g for 15 minutes.
17: Dissolve with 16 mis. of Buffer 6 and store at -40oC. in
aliquots.
The presence and the approximate concentration relative to reference
solutions of C1q could be checked at each stage by the agglutination
of IgG-coated latex beads (Hoechst, after Elwald & Schubart, 1966).
THE C1q SOLID PHASE ASSAY
The assay was performed according to a modified method of Hay,
Nineham and Roitt (1976). C1q coated polystyrene tubes (Luckhams,
LP3) were prepared by adding 0.5 mis. of a solution of C1q purified
as above and diluted appropriately (see below). These tubes were left
at 4oc. for 24 to 78 hours. The incubation time and the C1q
concentration were standard for each set of experiments. Immediately
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prior to the asay, the tubes were washed three times with 0.5% Tween
20 in phosphate-buffered saline, pH 7.2 (PBS/Tween) and onoe with
0.1$ gelatin in PBS.
In order to determine the working dilution of C1q, a series of
standard curves was constructed with heat aggregated human globulin
(Sigma, Cohn fraction II) using C1q at various dilutions as shown in
FIGURE A2.1. For each curve, heat aggregated globulin (HAG) was added
to a final concentration of 1, 2, 5, 10, 20, 30, 40 and 50
microlitres per ml. The assay was performed as described below. The
total volume of solution added to each tube was 0.5 ml. - 500 mcl. of
PBS for the reagent blank, 475 mcl. of PBS and 25 mcl. of
EDTA-treated normal serum for the control and, for the standard
curve, 375 mcl. of PBS, 100 mcl. of HAG in PBS at various dilutions
and 25 mcl. of treated normal serum. For the experiment shown in
FIGURE A2.1, a dilution of 1:480 was taken as the working
concentration. The curve obtained was similar to that of more
concentrated solutions and it was approximately linear in the range
3 to 20 mcl./ml. of HAG in which most immune complex positive sera
fall. This process was repeated for each new batch of C1q.
All sera, including the normal serum used as a control were
pretreated by incubating 25 mcl. of serum with 50 mcl. of EDTA (0.2M,
pH 7.5) for 30 minutes at 37°C. These were then stored at 4°C until
the start of the assay. 25 mcl. of the solution thus prepared was
added to a C1q coated tube. All incubations were performed in
duplicate. Each experiment included a reagent blank and control as
above as well as a standard curve with heat-aggregated globulin. The
tubes, each containing a total volume of 0.5 ml. were incubated at
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FIGURE A2.1 BINDING CURVES FOR HEAT-AGGREGATED GLOBULIN AT















3Y°C for one hour and then at 4°C for 30 minutes. Each tube was then
washed three times with PBS/Tween. Immune complexes bound to the
surface of the tube were detected using staphylococcal protein A
(Sigma) labelled with 125j using the chloramine T method of McConahey
& Dixon (1966).
The results were expressed as a percentage of the maximum counts
bound on the standard curve and the normal range was calculated for
each batch of C1q by testing the sera from 40 to 50 normal
volunteers. An example of the results thus obtained is shown in
FIGURE A2.2. The 90th eentile was taken as the limit of positivity
since the scatter of results in a normal population conforms to a
skewed normal distribution (Di Mario et al, 1981). This limit of
positivity was checked for each experiment by including at least ten
sera from the normal donors. Also included in each assay were five
positive controls, usually from patients with connective tissue
diseases and ten sera which had already been tested in previous
assays. The only test sera which had been stored long-term were those
from Addison's patients and the limit of positivity was checked in
these experiments by including 50 controls which had been stored with
the test sera under identical conditions.
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APPENDIX 3: METHOD FOR HLA-DR TYPING
A: PREPARATION OF LYMPHOCYTES
Venous blood (20 mis.) was collected in a sterile plastic universal
container with 20 units per ml. of preservative-free heparin.
Separation of peripheral blood mononuclear cells was achieved using a
modified method of Boyum (1966) within two hours. Blood was diluted
with an equal volume of RPMI 1640 medium (Flow Laboratories)
supplemented with 20 units per millilitre of preservative-free
heparin and 20% foetal calf serum. This was divided into three
aliquots of approximately 14 mis., each of which was underlaid with
Ficoll-Hypaque, S.G. 1.077 (Lymphocyte Separation Medium, Flow
Laboratories) and centrifuged at 400g for 30 minutes at 20°C. Cells
were harvested by centrifugation, washed twice at 100g to remove
contaminating platelets and resuspended in 2 mis. RPMI/FCS.
B: PREPARATION OF DESIALATED SHEEP RED BLOOD CELLS
Sheep's blood in Alsever's solution (Gibco) was diluted 1:2 with 2.5
mM MOPS buffer/150 mM sodium chloride (MOPS/Saline, pH 7.3) and white
blood cells were removed by centrifugation over Ficoll-Hypaque. The
red cell pellet was washed twice in MOPS/Saline and resuspended to a
final concentration of 6%. To each 5 mis. of this suspension, was
added 150 raicrolitres of a 1 unit per ml. solution of neuraminidase
(Sigma, type V). After incubation at 30°C for 30 minutes, the cells
were harvested, washed twice with MOPS/Saline and resuspended to a
concentration of 2.5% in 10mM EDTA/100mM sodium chloride/2.5mM MOPS,
pH 7.3 containing 0.156 gelatin. Sheep red blood cells prepared in
this way were stored for up to one week prior to use at 4°C.
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C: SEPARATION OF B LYMPHOCYTES.
One millilitre of a 5% solution of papain (Sigma, type II) was added
to the 2 mis. of lymphocyte suspension prepared as described above
and incubated at 37°C. for three minutes. Cells were harvested and
washed twice in MOPS/saline/20$ FCS and then resuspended to a density
of 3 x 106/mi. This suspension was mixed with an equal volume of
desialated sheep red blood cells containing 0.001 ml. per ml. of 5%
polybrene (Sigma) and agitated gently on a roller mixer for ten
minutes before being left overnight at 4°C. to rosette. The cells
were harvested the next morning by gentle centrifugation
(approximately 500 rpm on a MSE bench centrifuge). Rossetted and
unrosetted cells were separated on Ficoll-Hypaque, the B cell rich
fraction being collected from the interface. The B cells were washed
twice with MOPS/saline and the concentration adjusted to two million
cells per ml.
D: PREPARATION OF PLATES FOR TISSUE TYPING
The antisera used for tissue typing defined the specificities HLA-DR
1, 2, 3, 4, 5, and 7. They included commercially available sera
(Hoechst) and sera donated to the laboratory (Blood Transfusion
Centre Sheffield; Department of Clinical Immunology, Royal Infirmary,
Glasgow and Blood Transfusion Centre, Newcastle). 60 well Terasaki
plates were filled with 10 mis. Liquid paraffin and into each well
was injected one microlitre of antiserum. In all, four antisera were
available to define the DR-4 locus, five for DR-3, two for each of
DR-4 and DR-5, four for DR-7 in addition to one for DR-1, one cross
reacting with DR-1 and DR-4, two cross reacting with DR-4 and DR-7
and one with DR-5 and DR-8. Each plate also included negative control
serum, AB serum as a complement control and anti-lymphocyte serum as
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a positive control. All antisera were preabsorbed with platelets to
remove A, B, and C specificities. Prepared plates were stored at
-40oc.
E: THE LYMPHOCYTOTOXICITY TEST FOR PR-TYPING
The microcytotoxicity assay was performed according to the method of
Bodmer et al (9176). One microlitre of B cell suspension was added to
each well in the Terasaki plate and left at 20°C. for one hour. Five
microlitres of a complement solution specifically marketed for
DR-typing (Pel-Freez Biologicals) was added and incubated for a
further two hours. Three microlitres of 5% eosin was added, followed
three minutes later by five microlitre of a 30 - 40% solution of
formaldehyde, pH 7.0. The plates were allowed to settle and scored
blindly as below. Each plate was reread after a few days and any
discrepant test was repeated.
SCORING OF MICROCYTOTOXICITY TEST
PERCENTAGE DEAD CELLS
UP to 30% NEGATIVE
31 to 50% WEAK POSITIVE
51 to 75% POSITIVE
ABOVE 75% STRONG POSITIVE
Patients and normal volunteers previously typed in the laboratory and
in the regional tissue typing laboratory functioned as controls and
such subjects were typed repeatedly to ensure quality control. Four
patients tested could not be assigned a DR type from the typing as
-345-
described above. Time and resources did not permit a large control
population to be typed although, ideally controls should be typed
from the same geographical location and with the same antisera. Data
for the normal UK population was taken from that issued to transplant
service users and was derived from over 2000 normal controls. The
HLA-DR antigen frequencies in the normal UK population are shown in
TABLE A3-1 -
TABLE A3.1 HLA-DR ANTIGEN FREQUENCIES IN THE NORMAL U.K.
POPULATION.








Data from a report "HLA-A, B and DR antigens in the British Isles"
issued to U.K. Transplant Service users, November 1985 by P.T.




Abrass C.K., Nies K.M., Louie J.S., Border W.A. & Glassock R.J.
(1980) Correlation and predictive accuracy of circulating immune
complexes with disease activity in systemic lupus erythematosus.
Arth. Rheum. 23 p273-282.
Adams D.D. (1958) The presence of an abnormal thyroid-stimulating
hormone in the serum of some thyrotoxic patients. J. Clin.
Endocrinol. J_8 p699-712.
Adams D.D. (1961) Bioassay of long-acting thyroid stimulator
(LATS): the dose-response relationship. J. Clin. Endocrinol. 2A_
P799-805.
Adams D.D. (1965) Pathogenesis of the hyperthyroidism of Graves'
disease. Brit. Med. J. _1_ p1015—1019.
Adams D.D. (1978) The V gene theory of inherited autoimmune
disease. J. Clin. Lab. Immunol. p17-24.
Adams D.D. & Purves H.D. (1956) Abnormal responses in the assay of
thyrotropin. Proceedings of the University of Otago Medical School
34 pi 1-12.
Adams D.D., Lord J.M. & Stevely H.A.A. (1964) Congenital
thyrotoxicosis. Lancet 2 p497-498.
Adams D.D., & Kennedy T.H. (1967) Occurrence in thyrotoxicosis of
a gamma globulin which protects LATS from neutralization by an
extract of thyroid gland. J. Clin. Endocrinol. Metab. 2J_
P173-177.
Adams D.D., Couchman R. & Kilpatrick J. A. ( 1969) Lack of
response to TSH injections in euthyroid patients with high LATS
levels. J. Clin. Endocrinol. 29 P1502-1503-
Adams D.D. & Kennedy T.H. (1971) Evidence to suggest that LATS
Protector stimulates the human thyroid gland. J. Clin. Endocrinol.
Metab. 33p47-51.
Adams D.D., Fastier F.N., Howie J.B., Kennedy T.H., Kilpatrick J.A.,
& Stewart R.D.H. (1974) Stimulation of the human thyroid by
infusions of plasma containing LATS protector. J. Clin.
Endocrinol. Metab. 3£ p826-832.
Adams D.D., Kennedy T.H. & Stewart R.D.H.(1974) Correlation
between Long-Acting Thyroid Stimulator Protector level and thyroid
131-I uptake in thyrotoxicosis. Brit. Med. J. 2 p199-200.
Ahearn J.M., Provost T.T., Dorsch C.A., Stevens M.B., Bias W.B. &
Arnett F.C. ( 19 8 2) Interrelationships of HLA-DR, MB and MT
phenotypes, autoantibody expression and clinical features in systemic
lupus erythematosus. Arth. Rheum. 25 p1031-1040.
Akamizu, T., Ishii, H., Mori, T., Ishihara, T., Ikekubo, K., Imura,
H., Bito, S., & Saiki, Y. (1984). Abnormal thyrotropin-binding
immunoglobulins in two patients with Graves' disease. J. Clin.
Endocrinol. Metab. 5£ p240-255.
-348-
Al-Khateeb S.F. & Irvine W.J. (1978) Detection, quantification and
characterization of soluble immune complexes in sera of patients with
thyroid disorders. J. Clin. Lab. Immunol. J_ p55-58.
Alexander W.D., Harden R.M., Koutras D.A. & Wayne E. (1965) Influence
of iodine intake after treatment with antithyroid drugs. Lancet 2
p866-868.
Alexander W.D., Harden R.M. & Shimmins J. (1966) Thyroidal
suppression as a guide to duration of treatment of thyrotoxicosis
with antithyroid drugs. Lancet 2 p1041-1046.
Alexander W.D., Harden R.M., Shimmins J., McLarty D. & McGill P.
( 1967) Development of thyroidal suppression by triiodothyronine
during six months of treatment of thyrotoxicosis with antithyroid
drugs. J. Clin. Endocrinol. 27 P1682-1689-
Alexander W.D., Harden R.M. & Shimmins J. (1968) Emotion and
non-specific infection as possible aetiological factors in Graves'
disease. Lancet 2 p196—197-
Alexander W.D., Harden R.M., McLarty D. & Shimmins J. (1969)
Thyroidal suppressibility after stopping long-term treatment of
thyrotoxicosis with antithyroid drugs. Metabolism 18 p58-62.
Alexander W.D., McLarty D., Robertson J., Shimmins J., Brownlie
B.E.W., Harden R.M. & Patel A.R. (1970) Prediction of the long-term
results of antithyroid drug therapy for thyrotoxicosis. J. Clin.
Endocrinol. Metab. 30 p540-543.
Alexander W.D., McLarty D.G., Horton P. & Pharmakiotos A.D. (1973)
Sequential assessment during treatment of thyrotoxicosis. Clin.
Endocrinol. 2 p43-50.
Allanic H., Fauchet R., Lorcy Y. , Heirn J., Guegen H., Leguerrier
A.M. & Genetet B. (1980) HLA and Graves' disease: an association
with HLA-DRw3. Ann. Endocrinol. 4J p70-72.
Allison A.C., Denman A.M. & Barnes R.D. (1971) Cooperating and
controlling functions of thymus derived lymphocytes in relation to
autoimmunity. Lancet 2 p135—140.
Amino N., Mori H., Iwatani Y., Tanizawa 0., Kawashima M., Tsuge I.,
Ibaragi K., Kumuhara Y. & Miyai K. (1982) High prevalence of
transient post-partum thyrotoxicosis and hypothyroidism. New
England J. Med. 306 p849-852.
Andersen A.0. (1976) Anti-insulin antibodies and late diabetic
complications. Acta Endocrinol. 83. p329-340.
Anderson J.R., Goudie R.B., Gray K.G. & Timbury G.C. (1957)
Autoantibodies in Addison's disease. Lancet _1_ p1123—1 124.
Anderson J.R., Goudie R.B., Gray K.G. & Stuart-Smith D.A. (1968)
Immunological features of idiopathic Addison's disease: An antibody
to cells producing steroid hormones. Clin. Exp. Immunol. 3.
p107-117-
-349-
Andreani D., Di Mario U., Galfo C., Ventriglia L. & Iavicoli M.
(1982) Circulating immune complexes in diabetics with severe
microangiopathy: evaluation by two different methods. Acta
Endocrinol. £9 p239-244.
Aoki N., Wakisaka G. & Nagata T. (1973) Increase of T cells in
Graves' disease. Lancet £ p49-50.
Aoki N., Pinnamaneni K.M. & De Groot L.J. ( 1979) Studies on
suppressor cell function in thyroid diseases. J. Clin. Endocrinol.
Metab. £8 p803-8l0.
Arnoud C.D., Kneubhuler H.A., Seiling V.L., Wightman B.K. & Engbring
N.H. ( 1965) Responses of the normal human to infusions of plasma
from patients with Graves' disease. J. Clin. Invest. 4j£ p1287—1294.
Aspenstrom G. (1953) Late results with propylthiouracil treatment
of hyperthyoidism in a goiter region. Acta Med. Scand. 147 p63-70.
Astwood E.B. (1943) Treatment of hyperthyroidism with thiourea and
thiouracil. J. American Med. Assoc. 122 p78-80.
Astwood E.B. (1963) Management of thyroid disorders. J. American
Med. Assoc. £86. P585-589
Atkinson, S., & Kendall-Taylor, P. (1981 ) The stimulation of
thyroid hormone secretion in vitro by thyroid-stimulating
antibodies. J. Clin. Endocrinol. Metab. 53_ P1263 - 1266.
Bach M-A., Tournier E., Phan-Dinh-Tuy F., Chatenoud L., Bach J-F.,
Martin C. & Degos J-D. (1980) Deficit of suppressor T cells in
active multiple sclerosis. Lancet 2 p1221-1223.
Bacon L.D., Kite J.H. & Rose N.R. (1974) Relation between the major
histocompatibility (B) locus and autoimmune thyroiditis in obese
chickens. Science 186 p274-275.
Bacon L.D., Polley C.R., Cole R.K. & Rose N.R. ( 1981) Genetic
influences on spontaneous autoimmune thyroiditis in (CS x OS) F2
chickens. Immunogenetics 1_2 P339-349.
Bai Y., Beverley P.C.L., Knowles R.W. & Bodmer W.F. (1983) Two
monoclonal antibodies identifying a subset of human peripheral
mononuclear cells with natural killer activity. Eur. J. Immunol. £_3
P521-52
Balazs C. , Stenszky V., Kozma L. & Leovey A. (1978) The possible
influence of HLA-A1, B8 antigens on the course of Graves' disease.
Biomedicine 29. p263-264.
Balazs C., Leovey A. & Bordan L. (1979) Decrease of concanavalin A
activated and short lived supppressor T cell function in
thyrotoxicosis. Biomedicine £0 p143—147.
Balazs C.S., Stenszky V., Kozma L. & Farid N.R. (1984) Specific
suppressor T cell function in a patient with Graves' disease and her
identical twin. Clin. Endocrinol. 2£ p683-693-
-350-
Baldwin W.W. ( 1895) Some cases of Graves' disease succeeded by
thyroid atrophy. Lancet J_ p145-146.
Balls K.B., Chamberlain R.H., Rose E., Gorson R.O. & Blount H. C.
(1955) The treatment of thyrotoxicosis with radioiodine.
Radiology 6_4 p858-866.
Bankhurst A.D., Torrigiani G. & Allison A.C. (1973) Lymphocytes
binding thyroglobulin in healthy people and its relevance to
tolerance for autoantigens. Lancet _1_ p226-230.
Bankhurst A.D. & Williams R.C. (1975) Identification of DNA-binding
lymphocytes in patients with systemic lupus erythematosus. J. Clin.
Invest. 56 P1378-1385-
Barkas T., Al-Khateeb S.F., Irvine W.J., Davidson N.M. & Roscoe P.
(1976) Inhibition of antibody-dependent cell-mediated cytotoxicity
(ADCC) as a means of detection of immune complexes in the circulation
of patients with thyroid disorders and bronchogenic carcinoma.
Clin. Exp. Immunol. 2j[ p270-279-
Barnett E.V., Knutson D.W., Abrass C.K., Chia D.S., Young L.S. &
Liebling M.R. (1979) Circulating immune complexes: Their
immunochemistry, detection and importance. Ann. Internal Med. 9J_
plJ30-440.
Beall G.N. (1982) Production of human anti-thyroglobulin in vitro.
IV. Specific stimulation by antigen. J. Clin. Endocrinol. Metab. 54
P1-5.
Bech K., Lumholtz B. , Nerup J., Thomsen M., Platz P., Ryder L.R.,
Svejgaard A., Siersbock-Nielsen K., Moholm Hansen J. & Larsen J.H.
(1977) HLA antigens in Graves' disease. Acta Endocrinol. 86
P510-516.
Bech, K., & Madsen, S.N. (1978). Human thyroid adenylate cyclase in
non-toxic goitre: sensitivity to TSH, fluoride and thyroid
stimulating immunoglobulins. Clin. Endocrinol (Oxf) 8_, 457-466.
Bech K. & Madsen S.N. (1980) Influence of treatment with
radioiodine and propylthiouracil on thyroid stimulating
immunoglobulins in Graves' disease. Clin. Endocrinol. _1_3 p4l7-424.
Bech, K., Bliddal, H., Siersbaek-Nielson, K., & Friis, T. ( 1982).
Production of non-stimulatory immunoglobulins that inhibit TSH
binding in Graves' disease after radioiodine administration. Clin.
Endocrinol (Oxf) J7., 395 - 402.
Beck J.S., Young R.J., Simpson J.G., Gray A.S., Nicol A.G., Pegg
C.A.S. & Michie W.J.C. (1973) Lymphoid tissue in the thyroid gland
and thymus of patients with primary thyrotoxicosis. Brit. J.
Surgery 6£ P769-771
Beierwaltes W.H. & Nishiyama R.H. (1968) Dog thyroiditis: Occurence
and similarity to Hashimoto's struma. Endocrinology 8_3 p501-508.
-351-
Beling U. & Einhorn J. (1961) Incidence of hypothyroidism and
recurrences following 1 31 — I treatment of hyperthyroidism. Acta
Radiologica £6 p275-288.
Bellarba D., Benard B. & Langlois M. (1972) Pattern of serum
thyroxine, triiodothyronine and thyrotrophin after treatment for
thyrotoxicosis. Clin. Endocrinol. £ P345-353-
Benacerraf B. & McDevitt H.O. (1972) Histocompatibility-linked
immune response genes. Science 175 p273-279.
Bendezu R., Wieland R.G., Jong P. & Levine B. (1977) Unusual
events preceding hyperthyroidism with diffuse goitre. Arch. Int.
Medicine £37 p1023-1025.
Bennett R.M., Peller J.S. & Merritt M.M. (1986) Defective DNA
receptor function in systemic lupus erythematosus and related
diseases: evidence for an autoantibody influencing cell physiology.
Lancet £ p 186-188.
Berrih S., Gaud C., Bach M-A., Le Brigand H., Binet J.B. & Bach J.OF.
(1981) Evaluation of T cell subsets in myasthenia gravis using
anti-T cell monoclonal antibodies. Clin. Exp. Immunol. 45. p1—8.
Bertouch J.V., Roberts-Thomson P.J. & Bradley J. ( 1 983) Diurnal
variation of lymphocyte subsets identified by monoclonal antibodies.
Brit. Med. J. 286 p1171-1172.
Biro, J. (1982). Thyroid stimulating antibodies in Graves' disease
and the effect of thyrotrophin binding globulins on their
determination. J. Endocrinol £2 175-184.
Blecher M., Lewis S., Hicks J.M. & Joseph S. (1984) Beta blocking
autoantibodies in pediatric bronchial asthma. J. Allergy Clin.
Immunol. 74. p246-251
Blichert-Toft M. , Jorgensen J., Hansen B.J., Watt-Boolsen S. ,
Christiansen C & Ibsen J. (1977) Long-term observation of thyroid
function after surgical treatment of thyrotoxicosis. Acta Chir.
Scand. £43 p221-227-
Bliddal, H., Bech, K. , Petersen, P.H., Siersbeck-Nielsen, K., &
Friis, T. (1982a) Evidence of a correlation between thyroid
adenylate cyclase activation by immunoglobulins in Graves' disease
before and during long-term antithyroid treatments. Acta
Endocrinol. (Copenh.) 101 p35-40.
Bliddal, H., Bech, K., Feldt-Rasmussen, U., Thomsen, M., Ryder, L.P.,
Hansen, J.M., Siersback-Nielsen, K., & Friis, T. (1982b).
Thyroid-stimulating immunoglobulins in Hashimoto's thyroiditis
measured by radioreceptor assay and adenylate cyclase stimulation
and their relationship to HLA-D alleles. J. Clin. Endocrinol.
Metab. 55 P995 - 998.
-352-
Bliddal H., Bech K., Siersbaek-Neilsen K. & Friis T. (1983) The
prognostic value of parallel of thyrotropin binding inhibitory
immunoglobulins (TBII) and thyroid adenylate cyclase stimulating
antibodies (TSAb) in Graves' disease after long term antithyroid drug
treatment. J. Endocrinol. Invest. ^ p259-262.
Blizzard R.M., Chee D. & Davis W. ( 1967) The incidence of adrenal
and other antibodies in the sera of patients with idiopathic adrenal
insufficiency (Addison's disease). Clin. Exp. Immunol. 2 p19-30.
Bluestein H.G., Green I., Maurer P.H. & Benacerraf B. (1972) Specific
immune response genes of the guinea pig V. Influence of the GA and GT
immune response genes on the specificity of cellular and humoral
immune responses to a terpolymer of L-glutamic acid, L-alanine and
L-tyrosine. J. Exp. Med. 135 p98-109.
Bodansky H.J., Wolf E., Cudworth A.G., Dean B.M., Nineham L.J.,
Bottazzo G.F., Matthews J.A., Kurtz A.B. & Kohner E.M. (1982)
Genetic and immunologic factors in microvascular disease in type I
insulin-dependent diabetes. Diabetes 3_1_ p70-74.
Bogner U., Hutterworth T.H., Kotulla P., Wenzel B., Finke R., Hopf U.
& Schleusener H. (1979) Circulating immune complexes (IC), TSH
receptor antibodies ((TSH-r-ab), thyroglobulin antibodies (Tab) and
thyroid microsomal antibodies ((Mab) in patients with Graves'
disease. Ann d'Endocrinologie 40 28A.
Bolk J.H., Bussemaker J.K., Elte J.W.F., Haak A. & van der Heide D.
(1972) Thyroid stimulating immunoglobulins do not cause
non-autonomous, autonomous or toxic multinodular goitres. Lancet 2
P61-63.
Borges, M. , Ingbar, J.C., Endo, K., Amir, S., Uchimura, H., Nagataki,
S., & Ingbar, S.H. ( 1 982). A new method for assessing the
thyrotrophin binding inhibitory activity in the immunoglobulins and
whole serum of patients with Graves' disease. J. Clin. Endocrinol.
Metab. 54 P552-558.
Bottazzo G.F., Cudworth A.G., Moul D.J., Doniach D. & Festenstein H.
(1978) Evidence for a primary autoimmune type of diabetes mellitus.
Brit. Med. J. 2 p1253-1255.
Bottazzo G.F., Pujol-Borrel R. & Hanafusa T. (1983) Role of
aberrant HLA-DR expression and antigen presentation in induction of
endocrine autoimmunity. Lancet 2 p1115—1118.
Bonnyns M., Bentin J., Devetter G. & Duchateau J. (1983)
Heterogeneity of immunoregulatory T cells in human thyroid
autoimmunity: influence of thyroid status. Clin. Exp. Immunol. 52
P629-634.
Boukis M.A., Koutras D.A., Souvatzoglou A., Evangelopolou A.,
Vrontakis M. & Moulopolous S.D. (1983) Thyroid hormone and
immunological studies in endemic goitre. J. Clin. Endocrinol.
Metab. 57 p859-862.
-353-
Bouma D.J., Kammer H. & Greer M.A. (1982) Follow-up comparison of
short-term versus 1-year antithyroid drug therapy for the
thyrotoxicosis of Graves' disease. J. Clin. Endocrinol. Metab. 55
pi 138-1142-
Boyd R.L., Cole R.K. & Wick G. (1983) Genetically controlled
severity of autoimmune thyroiditis in obese strain (OS) chickens is
expressed at both the humoral and cellular mechanism levels.
Immunol. Commun. J_2 p263-272.
Bremner W.J. & Griep R.J. (1976) Graves' thyrotoxicosis following
primary thyroid failure. J. American Med. Assoc. 235 p1361.
Breshnihan B. & Jasin H.E. (1977) Suppressor function of peripheral
blood mononuclear cells in normal individuals and in patients with
systemic lupus erythematosus. J. Clin. Invest. 59. p106-116.
Briones-Urbina R., Bear J.C. & Farid N.R. ( 1982) Association of
hypergammaglobulinaemia G with HLA-DR3 in Graves' disease. Tissue
Antigens _1j) p20-24.
Brohee D., Delespesse G. , Bebisschop M.J. & Bonnyns M. (1979)
Circulating immune complexes in various thyroid diseases. Clin.
Exp. Immunol. 36^ P379-383.
Brown R.S., Pohl S.L., Jackson I.M.D. & Reichlin S. (1978) Do
thyroid-stimulating immunoglobulins cause non-toxic and toxic
multinodular goitre? Lancet J_ p904-906.
Brown, R.S., Kertiles, L.P., & Reichlin, S. (1983). Partial
purification and characterization of thyrotropin binding inhibitory
immunoglobulins from normal human plasma. J. Clin. Endocrinol.
Metab. 56. p156—163-
Buchanan W.W., Alexander W.D., Crooks J., Koutras D.A., Wayne E.J.,
Anderson J.R. & Goudie R.B. (1961) Association of thyrotoxicosis
and autoimmune thyroiditis. Brit. Med. J. J_ p843-847.
Buchanan W.W., Koutras D.A., Crooks J., Alexander W.D., Brass W. ,
Anderson J.R., Goudie R.B. & Gray K.G. (1962) The clinical
significance of the complement fixation test in thyrotoxicosis. J.
Endocrinol. £4 p115-125.
Buchanan W.W., Koutras D.A., Crooks J. & Harden R.M. (1965) A
comparison of pretreatment with potassium perchlorate and
methyl-thiouracil on results of 131-1 therapy. Brit. J. Radiology
38 P536-540.
Budman D.R., Merchant E.B., Steinberg A.D., Doft B. , Gershwin M.E.,
Lizzio E. & Reeves J.P. (1977) Increased spontaneous activity of
antibody-forming cells in the peripheral blood of patients with
active SLE. Arch. Rheum. 20_ p829-833.
Burch P.R.J. & Rowell N.R. (1963) Autoimmunity. Aetiological
aspects of chronic discoid and systemic lupus erythematosus, systemic
sclerosis and Hashimoto's thyroiditis. Lancet 2 P507-513-
-354-
Burgi H. & Labhart A. (1974) The thyroid gland. In "Clinical
Endocrinology. Theory and Practice." Editor: A. Labhart.
Springer-Verlag. p135-283.
Burke G. (1967) Dissociation between thyroid injury and formation
of Long-Acting Thyroid Stimulator in thyrotoxicosis. Ann. Int. Med.
67 P349-355.
Burmester G.R., Yu D.T.Y., Irani A-M., Kunkel H.G. & Winchester R.J.
(1981) Ia+ T cells in synovial fluid and tissues of patients with
rheumatoid arthritis. Arthritis Rheum. 2U p1370—1376.
Burnet M. (1961) The mechanism of autoimmunity. Scientific
American 204 p58-67-
Burr W.A., Fitzgerald M.G. & Hoffenberg R. (1979) Relapse after
short-term antithyroid therapy of Graves' disease. New England J.
Med. 300 p200.
Buschard K. , Madsbad S. & Rygaard J. (198O) Depressed suppressor
cell activity in patients with newly diagnosed insulin dependent
diabetes mellitus. Clin. Exp. Immunol. 4j_ p25-32.
Buschard K., Ropke C., Madsbad S., Mehlsen J., Sorensen T.B. &
Rygaard J. (1983) Alterations of peripheral T-lymphocyte
subpopulations in patients with insulin-dependent (Type I) diabetes
mellitus. J. Clin. Lab. Immunol. JO. p 127—131.
Cahill G.F. & McDevitt H.O. ( 1 981) Insulin-dependent diabetes
mellitus: The initial lesion. New England J. Med. 304 p1454—1465-
Calder E.A., Penhale W.J., Barnes E.W. & Irvine W.J. (1973) Cytotoxic
lymphocytes in Hashimoto's thyroiditis. Clin. Exp. Immunol. _14_
P19-23.
Calder E.A., Penhale W.J., Barnes E.W. & Irvine W.J. (1974) Evidence
for circulating immune complexes in thyroid diseases. Brit. Med. J.
2 P30-31.
Calder E.A., Irvine W.J., Davidson N.M. & Wu F. (1976) T, B and K
cells in autoimmune thyroid disease. Clin. Exp. Immunol. 25. p17-22.
Canonica G.W., Bagnasco M., Corte G., Ferrrini S., Ferrini 0. &
Giordano G. (1982) Ciculating T lymphocytes in Hashimoto's disease.
Imbalance of subsets and presence of activated cells. Clin.
Immunol. Immunopathol. 23_ p616-625.
Canonica G.W., Bagnasco M., Ferrini S., Biassoni P., Giordano G. &
Corte G. (1983) Circulating T-cell subsets in Graves' disease:
differences between patients with active disease and in remission
after 1311 therapy. Clin. Immunol. Immunopathol. .28 p265-271.
Carneiro, L., Dorrington, K.J., & Munro, D.S. (1966). Relation
between Long-Acting Thyroid Stimulator and thyroid function in
thyrotoxicosis. Lancet £ p878 - 880.
-355-
Carpenter J.L., Van Obberghen E., Gorden P. & Orci L. (1981) Binding,
membrane redistribution, internalization and lysosomal association of
[125-1] anti-insulin receptor antibody in Im-9 cultured human
lymphocytes. Exp. Cell Res. 134 p8l-92.
Caruso C., Lio D., Palmeri P. & Cillari E. (1984) HLA-DR phenotypes
and blood levels of T cell subsets. Tissue Antigens £4 p320-322.
Caruso C., Cillari E., Palmeri P., Lio D. & Salerno A. (1985) 0KT4+
and 0KT8+ cell subset values and HLA-DR phenotypes. J. Clin. Lab
Immunol. _1jj. P91-92.
Casali P., Bossus A., Carpentier N.A.O & Lambert P.H. (1977) Solid
phase enzyme immunoassay or radioimmunoassay for the detection of
immune complexes based on their recognition by conglutinin:
conglutinin-binding test. Clin. Exp. Immunol. 2£ p342-354.
Cassidy C.E. & VanderLaan W.P. ( 1960) Thyroid suppression test in
the prognosis of hyperthyroidism treated with antithyroid drugs.
New England J. Med. 262 p1228-1229.
Cassidy C.E. (1965) Use of thyroid suppression test as a guide to
prognosis of hyperthyroidism treated with antithyroid drugs. J.
Clin. Endocrinol. Metab. 25 p155-156.
Cattogio L.J., Bernstein R.M., Black C.M., Hughes G.R.V. & Maddison
P.J. (1983) Serological markers in progressive systemic sclerosis:
clinical correlations. Ann. Rheum. Diseases _42 p23-27.
Cevallos J.L., Hagen G.A., Maloof F. & Chapman E.M. (1974)
Low-dosage 131—I therapy of thyrotoxicosis (diffuse goitres). A five
year follow-up study. New England J. Med. 290 p141 — 143-
Champion B.R., Varey A.M., Katz D., Cooke A. & Roitt I.M. (1985)
Autoreactive T-cell lines specific for mouse thyroglobulin.
Immunology 54. p513—519.
Charon D.J., Englemman E.G., Benike C.J. & McDevitt H.O. (1980) la
antigens on alloreactive T cells in man detected by monoclonal
antibodies. J. Exp. Med. J_52p 1275-1283.
Charreire J. (1982) Syngeneic sensitization of mouse lymphocytes on
monolayers of thyroid epithelial cells. Eur. J. Immunol. 12
P416-421.
Charreire J. & Michel-Bechet M. (1982) Syngeneic sensitization of
mouse lymphocytes on monolayers of thyroid epithelial cells III.
Induction of thyroiditis by thyroid sensitized T lymphoblasts. Eur.
J. Immunol. J_2 p421-426.
Chiovato L., Macchia E., Mariotti S., Vitti P., Fenzi G.F. & Pinchera
A. (1978) Thyroid antibody levels during antithyroid drug therapy
of Graves' disease. Annals d'Endocrinologie _39 p21A Abstr. 36.
Chiovato L., Vitti P., Lombardi A., Kohn L.D. & Pinchera A. (1985)
Expression of the microsomal antigen on the surface of continuously
cultured rat thyroid cells is modulated by thyrotropin. J. Clin.
Endocrinol. Metab. 6j_ p 12—16.
-356-
Chopra J.J., Solomon D.H., Chopra U., Yoshihara E., Terasaki P.I. &
Smith F. (1977) Abnormalities in thyroid function in relatives of
patients with Graves' disease and Hashimoto's thyroiditis: Lack of
correlation with inheritance of HLA-B8. J. Clin. Endocrinol. Metab.
45 p45-54.
Christensen L.K. & Binder V. (1962) A case of hyperthyroidism
developed in spite of previous hypophysectomy. Acta Med. Scand. 172
P285-288.
Clagget J.A., Wilson C.B. & Weigle W.O. (1974) Interstitial immune
complex thyroiditis in mice. The role of autoantibody to
thyroglobulin. J. Exp. Med. 140 p1439—1456.
Clague, R., Mukhtar, E., Pyle, G., Nutt, J., Clark, F., Scott, M.,
Evered, D., Rees-Smith, B., &I Hall, R. (1976). Thyroid stimulating
immunoglobulins and the control of thyroid function. J. Clin.
Endocrinol. Metab. 43 p550 - 556.
Codaccioni J.L., Depieds R., Jean R., Henry C.L. & Lebreuil G. (1971)
Bilan de la recherche des auto-anticorps thyroidiens par
immuno-fluorescence indirecte chez 317 subjects. Confrontations
histopathologiques dans 102 cas . Annales d'Endocrinologie 32
p172-182.
Compston D.A.S., Vincent A., Newsom-Davies J. & Batchelor J.R. (1980)
Clinical, pathological, HLA antigen and immunological evidence for
disease heterogeneity in myasthenia gravis. Brain 103 P579-601.
Copping, S., Byfield, P.G.H., & Himsworth, R.L. (1985). An
autoantibody to hTSH interfering with assay for thyrotrophin receptor
antibodies. Fourth joint meeting of British Endocrine Society. J.
Endocrinol. 104 (Supplement), Abstract 124, p78.
Corte G., Mingari M.C., Morretta A., Damiani G., Morretta L. &
Bargellesi A. (1982) Human T cell subpopulations defined by a
monoclonal antibody. I. A small subset is responsible for
proliferation to allogeneic cells or to soluble antigens and for
helper activity for B cell differentiation. J. Immunol. 128 p16—19-
Cotner T., Williams J.M., Christensen L., Shapiro H.M., Strom T.B. &
Strorainger J. (1983) Simultaneous flow cytometric analysis of
human T cell activation antigen expression and DNA content. J. Exp.
Med. _157 P461-472.
Cotter S.M. (1979) Uncommon disorders in the cat. American Animal
Hospital Association Annual Meeting Proceedings 1979. p115-117.
Creemers P., Rose N.R. & Kong Y.C.M. (1983) Experimental autoimmune
thyroiditis. In vitro cytotoxic effect of T cells for the
development of spontaneous autoimmune thyroiditis in obese strain
(OS) chickens. J. Immunol. 126 P750-753.
Crooks J., Murray I.P.D. & Wayne E.J. (1959) Statistical methods
applied to the clinical diagnosis of thyrotoxicosis. Quart. J. Med.
28 p211-234.
-357-
Crooks J., Buchanan W.W., Wayne E.J. & McDonald E. (1960) Effect of
pretreatment with methylthiouraoil on results of 131-1 therapy.
Brit. Med. J. ± p151-154 -
Cudworth A.G., Bottazzo G.F. & Doniach D. (1980) Genetic and
immunological factors in Type I diabetes. In "Immunology of
Diabetes." Editor: W.J. Irvine. Teviot Scientific Publications.
P67-99.
Dailey M.E., Lindsay S. & Miller E.R. (1953) Histologic lesions in
the thyroid glands of patients receiving radioiodine for
hyperthyroidism. J. Clin. Endocrinol. _1_3 p 1513—1529-
Dahlberg P. A., Holmund G., Karlsson F.A. & Safwenberg J. (1981)
HLA-A, -B, -C and -DR antigens in patients with Graves' disease and
their correlation with signs and clinical course. Acta Endocrinol.
97 p42-47.
Dambuyant C. , Thivolet J., Viala J-J., Ville D. & Boyer J. (1982)
Clearance mediated by splenic macrophage membrane receptors for
immune complexes in cutaneous vasculitis. J. Invest. Dermatol. 78
pi 9^-199.
Dausset J. (1954) Leuco-agglutinins. IV. Leuco-agglutinins and
blood transfusion. Vox Sang. _4 p 190—198.
Davidson S., Soodak M., Neary J.T., Strout H.V., Kieffer J.D., Mover
H. & Maloof F. ( 1978) The irreversible inactivation of thyroid
peroxidase by methylmercaptoimidazole, thiouracil and proylthiouracil
in vitro and its relationship to in vitro findings. Endocrinology
103 p871-882.
Davies T.F. , Evered D.C., Smith B.R., Yeo P.P.B., Clark F. & Hall
R. (1977) Value of thyroid-stimulating immunoglobulins in
predicting short-term thyrotoxic relapse in Graves' disease. Lancet
J_ p1181-1182.
Davies, T.F. (19 81). Autoantibodies to the human thyrotropin
receptor are not species specific. J. Clin. Endocrinol. Metab. 52,
426 - 430.
Davies, T.F. , Platzer, M., & Farid, N.R. ( 1982). Prediction of
therapeutic response to radioactive iodine in Graves' disease using
TSH-receptor antibodies and HLA status. Clin. Endocrinol. (Oxf) 16,
183-191.
Davies, T.F., Platzer, M., Schwartz, A., & Friedman, E. (1983).
Functionality of thyroid-stimulating antibodies assessed by
cryopreserved human thyroid cell bioassay. J. Clin. Endocrinol.
Metab. 57, 1021-1027.
Dawes P.J.D., Petersen V.B., Rees Smith B. & Hall R. (1978)
Solubilization and partial characterization of human and porcine
thyrotrophin receptors. J. Endocrinol. 78 p89-102.
-358-
De Bruin, T.W.A., Van der Heide, D. & Querido, A. (1982).
Thyrotrophin binding inhibition by antithyrotrophin receptor
antibodies in Graves' disease which is not reflected by 1.6 m
ammonium sulphate precipitates. Clin. Endocrinol. (Oxf) 17, 77-84.
De Bruin, T.W.A., Van der Heide, D., Querido, A., & Krol, M.C.
(1984). Direct and quantitative measurement by immunoprecipitation
assay of anti-thyrotrophin receptor antibodies in sera of patients
with Graves' disease. Clin. Endocrinol. (Oxf) 80^, 143-151.
De Carvalho L.P.C., Wick G. & Roitt I.M. (1981) Requirement of T
cells for the development of spontaneous autoimmune thyroiditis in
the obese strain (OS) chicken. J Immunol. 126 P750-753-
De Carvalho L.C.P. & Roitt I.M. (1982) The nature of the
autoantibody response to thyroglobulin in murine strains with high
or low susceptibility to the experimental induction of autoimmune
thyroiditis. Clin. Exp. Immunol. 4B p519-526.
De Carvalho L.C.P., Templeman J., Wick G. & Roitt I.M. (1982) The
role of self-antigen in the development of autoimmunity in obese
strain chickens with spontaneous autoallergic thyroiditis. J. Exp.
Med. p1255-1266.
De Groot L.J. ( 1977) Short-term antithyroid drug therapy. New
England J. Med. 297 p212-213-
De Kruyft R.H., Kim Y.T., Siskind G.W. & Weksler M.E. (1980) Age
related changes in the in vitro immune response: Increased suppressor
activity in immature and aged mice. J. Immunol. 125 p142—147.
Dickmeiss E., Soeberg B. & Svejgaard A. (1977) Human cell-mediated
cytotoxicity against modified target cells is restricted by HLA.
Nature 270 p526-528.
Di Mario U., Iavicoli M. & Andreani D. (1980) Circulating immune
complexes in diabetes. Diabetologia J_9 p89-92.
Di Mario U., Ventriglia L., Iavicoli M., Guy K. & Andreani D. (1983)
The correlation between insulin antibodies and circulating immune
complexes in diabetics with and without microangiopathy. Clin. Exp.
Immunol. 52 p575-580.
Di Mario U., Iavicoli M. & Andreani D. (1984) Immunological aspects
of diabetic microangiopathy. In "Immunology in Diabetes". Editors:
Andreani D., Di Mario U., Federlin K.F. & Heding L.G., Kimpton
Medical Publications.
Di Mario U. & Guy K. (1984) Evaluation of class II antigen
positive T cells: A simple double staining method using monoclonal
antibodies. J. Clin. Lab. Immunol. VS P203-204.
Dixon F.J., Feldman J.D. & Vasquez J.J. (1961) Experimental
glomerulonephritis. The pathogenesis of a laboratory model resembling
the spectrum of human glomerulonephritis. J. Exp. Med. 113
p899-920.
-359-
Docter R. , Bos G., Visser T.J. & Henneman G. (1980) Thyrotrophin
binding inhibiting immunoglobulins in Graves' disease before, during
and after antithyroid therapy and its relation to Long Acting Thyroid
Stimulator. Clin. Endocrinol. T2 p143—153.
Doniach D. & Roitt I.M. (1957) Autoimmunioty in Hashimoto's disease
and its implications. J. Clin. Endocrinol. J_7 p1293-1303.
Doniach D., Hudson R.V. & Roitt I.M. (1960) Human autoimmune
thyroiditis: Clinical studies. Brit. Med. J. J_ P365-372.
Doniach, D. (1981). Hashimoto's thyroiditis and primary myxoedema
viewed as separate entities. Eur. J. Clin. Invest. JJ_, 245 - 247.
Doniach D. & Bottazzo G.F. ( 1983) Early detection of autoimmune
endocrine disorders. Hospital Update 9^ p1145—1149-
Dorrington, K.J., Carneiro, L. & Munro, D.S. (1966). The protealysis
of immunoglobulin G with Long-Acting Thyroid Stimulating activity.
Biochem. J. £8 p858-86l.
Drachman D.B., Angus C.W., Adams R.N./, Michelson J.D. & Hoffman G.J.
(1978) Myasthenic antibodies cross-link acetylcholine receptors to
accelerate degeneration. New England J. Med. 298 p1116-1122.
Drexhage, H.A., Bottazzo, G.F., Doniach D., Bitensky, L. & Chagen,
J. (1980) Evidence for thyroid-growth-stimulating immunoglobulins
in some goitrous thyroid diseases. Lancet _2 p287-292.
Duke 0., Panayi G.S., Janossy G. & Poulter L.W. (1982) An
immunohistochemical analysis of lymphocyte subpopulations and their
microenvironment in the synovial membranes of patients with
rheumatoid arthritis using monoclonal antibodies. Clin. Exp.
Immunol. 4£ p22-30.
Dunn J.T. & Chapman E.M. (1964) Rising incidence of hypothyroidism
after radioiodine therapy of thyrotoxicosis. New England J. Med.
271 P1037-1042.
Dutton R.W. (1972) Inhibitory and stimulatory effects of
concanavalin A on the response of mouse spleen cell suspensions to
antigen. J. Exp. Med. 136 p1445—1460.
Dwyer D.S., Bradley R.J., Urquhart C.K. & Kearney J.F. (1983)
Naturally occuring anti-idiotype antibodies in myasthenia gravis
patients. Nature 301 p611-614.
Eason J. (1928) The correlations of Graves' disease and
thyroiditis. Edinburgh Med. J. 2 p169-181.
Editorial (1979) Four controversies about the cause of
hyperthyroidism. Lancet £ p78-80.
Einhorn J. & Saterborg N.E. (1962) Propylthiouracil and 131-1 in
the treatment of thyrotoxicosis. Acta Radiologica 58^ pl6l—166.
-360-
Einhorn J., Fagraeus A. & Jonsson J. ( 1965) Thyroid antibodies
after 131-1 treatment for hyperthyroidism. J. Clin. Endocrinol.
Metab. 25 P1218-1224.
Einhorn J., Fagraeus A. & Jonsson J. (1966) Thyroid antibodies in
euthyroid subjects after iodine-131 therapy. Radiation Research 28
P296-301.
Einhorn N., Packalen T. & Wasserman J. (1971) Lymphocyte
stimulation after local irradiation of the thyroid gland in Man. Acta
Radiol. Ther. Phys. £0 p481-487.
Eisenbarth G., Wilson P., Ward F. & Lebovitz H.E. (1978) HLA-type
and occurrence of disease in familial polyglandular failure. New
England J. Med. 298 p92-94.
Eisenbarth G.S., Haynes B.F., Schroer J.A. & Fauci A.S. (1980)
Production of monoclonal antibodies reacting with peripheral blood
mononuclear cell surface differentiation antigens. J. Immunol. 124
P1237-1244.
El Kabir D.J., Benhamou-Glynn N., Doniach D. & Roitt I.M. (1966)
Absorption of thyroid-stimulating globulin from thyrotoxic sera by
organ homogenates. Nature 210 p319—321.
Elwald R.W. & Schubart A.F. ( 1966) Agglutinating activity of the
complement component C1q in the F11 latex fixation test. J.
Immunol. £7 p100-105.
Endo, K., Kasogi, K., Konishi, J., Ikekubo, K., Okuno, T., Takeda,
Y., Mori, T., & Torizuka, K. (1978). Detection and properties of TSH
binding inhibitor immunoglobulins in patients with Graves' disease
and Hashimoto's thyroiditis. J. Clin. Endocrinol. Metab. 4J5
P734-739.
Endo Y., Aratake Y., Yamamoto I., Nakagawa H., Kuribyashi T. & Ohtaki
S. (1983) Peripheral K cells in Graves' disease and Hashimoto's
thyroiditis in relation to circulating immune complexes. Clin.
Endocrinol. J_8 p 187-194.
Engel A.G., Tsujihata M. , Lambert E.H., Lindstrom J. & Lennon V.A.
(1976) Experimental autoimmune myasthenia gravis: A sequential and
quantitative study of the neuromuscular junction ultrastructure and
electrophysiologic correlations. J. Neuropathol. Exp. Neurol. 35.
P569-576.
Engel A.G., Sakakibara H., Sahashi K. , Lindstrom J., Lambert E.H. &
Lennon V.A. (1979) Passively transferred experimental autoimmune
myasthenia gravis. Sequential and quantitative study of the motor end
plate fine structure and ultrastructural localization of immune
complexes (IgG & C3) of the acetylcholine receptor. Neurology 29
pi 79-185.
Engel A.G. & Fumagalli G. ( 1982) Mechanisms of acetylcholine
receptor loss from the neuromuscular junction, in "Receptors,
Antibodies and Disease" (Ciba Foundation Symposium 90) p197-224.
-361-
Espinoza L.R., Bridgeford P., Lowenstein M., Bocanegra T.S., Vasey
F.B. & Germain B.F. (1982) Polymyalgia rheumatioa and giant cell
arteritis: Circulating immune complexes. J. Rheumatol. £ p556-560.
Esquivel P.S., Kong Y.M. & Rose N.R. ( 1978) Evidence for
thyroglobulin-reactive T cells in good responder mice. Cellular
Immunol. 37. pi4—19-
Etienne-Decerf J. & Winand R.J. (1981) A sensitive technique for
determination of thyroid-stimulating immunoglobulins (TSI) in
unfractionated serum. Clin. Endocrinol. J_4 p83-91.
Evans R.L., Faldetta T.J., Humphreys R.E., Pratt D.M., Yunis E.J. &
Schlossman S.F. (1978) Peripheral human T cells sensitized in mixed
lymphocyte culture synthesize and express la-like antigens. J. Exp.
Med. 148 P1440-1445.
Evered D., Young E.T., Tunbridge W.M.G., Ormston B.J., Green E.,
Petersen V.B. & Dickinson P.H. (1975) Thyroid function after
subtotal thyroidectomy for hyperthyroidism. Brit. Med. J. £ p25-27.
Fais S., Pallon F., Squarcia 0., Boirivant M. & Pozzilli P. (1985) T
cell early activation antigens expressed by peripheral lymphocytes in
Crohn's disease. J. Clin. Lab. Immunol. J_6 P75-76.
Fajans S.S. ( 1958) Hyperthyroidism in a patient with post partum
necrosis of the pituitary. Case report and implications. J. Clin.
Endocrinol. J_8 p271-277.
Farid N.R., Munro R.E., Row V.V. & Volpe R. (1973) Peripheral
thymus dependent (T) lymophocytes in Graves' disease and Hashimoto's
thyroiditis. New England J. Med. 288 p1313—1317-
Farid N.R., Munro R.E., Row V.V. & Volpe R. (1974) The use of the
E-rosette as a test for remission in Graves' disease treated with
antithyroid drugs. Clin. Endocrinol. 3 p55-6l.
Farid N.R., Barnard J., Kutas C., Noel E.P. & Marshall W.H. ( 1975)
HLA antigens in Graves' disease and Hashimoto's thyroiditis. Int.
Arch. Allergy Appl. Immunol. 49 p837-84l.
Farid N.R., Barnard J. & Marshall W.H. ( 1976) The association of
HLA with autoimmune thyroid disease in Newfoundland. The influence of
HLA homozygosity in Graves' disease. Tissue Antigens 8 pl8l—186.
Farid N.R., Sampson L., Noel E.P., Barnard J.M., Mandeville R.,
Larsen B., Marshall W.H. & Carter N.D. (1979) A study of human
leucocyte D locus related antigens in Graves' disease. J. Clin.
Invest. 63. P108-113-
Farid N.R., Stone E. & Johnson G. (1980a) Graves' disease and HLA:
Clinical and epidemiologic associations. Clin. Endocrinol. 13
P535-544.
Farid N.R., Larsen B., Payne R., Noel E.P. & Sampson L. (1980b)
Polyglandular autoimmune disease and HLA. Tissue Antigens 16
P23-29.
-362-
Farid N.R., Sampson L., Moens H. & Barnard J.M. (1980c) The
association of goitrous thyroiditis with HLA-DR5. Clin. Res. 28
672A.
Farid N.R., Moens H., Larsen B., Fifield F. , Saltman K. & Ingram D.W.
( 1980d) HLA haplotypes in familial Graves' disease. Tissue
Antigens _1_5 p492-500.
Farid N.R. & Bear J.C. (1981) The human major histocompatibility
complex and endocrine disease. Endocrine Reviews 2 p50-86.
Farid N.R., Sampson L., Moens H. & Barnard J.M. (1981) Goitrous
autoimmune thyroiditis is associated with HLA-DR5. Tissue Antigens
117 P265-268.
Farid N.R., Hawe B.S. & Walfish P.G. (1983) Increased frequency of
HLA-DR3 and 5 in the syndromes of painless thyroiditis with transient
thyrotoxicosis: Evidence for an autoimmune aetiology. Clin.
Endocrinol. p699-704.
Fatourechi V., McConahey W.M. & Woolner L.B. (1971) Hyperthyroidism
associated with histologic Hashimoto's thyroiditis. Mayo Clinic
Procs. 46^ p682-689-
Fauci A.S. ( 1980) Immunoregulation in autoimmunity. J. Allergy
Clin. Immunol. 6^6 p5-17.
Feldman E.C. In "Textbook of Veterinary Internal Medicine."
Diseases of the dog and cat Volume 2. Ettinger S.T. (Ed.), W.B.
Saunders. Philadelphia.
Feldman J-L., Becker M.J., Moutsopoulos H., Fye K., Blackman M. ,
Epstein W.V. & Talal N. (1976) Antibody-dependent cell-mediated
cytotoxicity in selected autoimmune diseases. J. Clin. Invest. 58
P173-179.
Feldt-Rasmussen U. , Bech K., Date J., Pedersen P.H., Johansen K. &
Madsen S.N. (1982) Thyroid stimulating antibodies, thyroglobulin
antibodies and serum proteins during treatment of Graves' disease
with radioiodine or propylthiouracil. Allergy 37^ P161—167-
Fenzi G.F., Bartalena L., Macchia E., Monzani F. & Checchi M. (1978)
Interference of thyroglobulin in TSAb detection by the radioreceptor
assay. J. Endocrinol. Invest. _1_ p221-222.
Fenzi G.F., Hashizume K., Roudebush C.P. & DeGroot L.J. (1979)
Changes in thyroid-stimulating immunoglobulins during antithyroid
therapy. J. Clin. Endocrinol. Metab. 4£ P572-576.
Fenzi G.F., Macchia E., Bartalena L., Mazzanti F., Baschieri L. &
DeGroot L.J. (1978) Radioreceptor assay of TSH: its use to detect
thyroid-stimulating immunoglobulins. J. Endocrinol. Invest.
P17-24.
Flier J.S., Kahn C.R., Jarrett D.B. & Roth J. (1975) Antibodies
that impair insulin receptor binding in an unusual diabetic syndrome
with severe insulin resistance. Science 190 p63-65.
-363-
Fraser K.J. (1969) IgA immunoglobulin deficiency and autoimmunity.
Lancet 2 p804-805.
Fraser C.M., Venter J.G. & Kaliner M. (1981) Autonomic
abnormalities and autoantibodies to beta adrenergic receptors. New
England J. Med. 305 p1165-1170.
French M.A.H., Harrison G., Penning C.A., Cunningham J., Hughes P. &
Rowel N.R. (1985) Serum immune complexes in systemic sclerosis:
Relationship with precipitating nuclear antibodies. Ann. Rheum.
Dis. 44 p89-92.
Friedman J.M. & Fialkow P.J. (1978) The genetics of Graves'
disease. Clinics in Endocrinology and Metabolism ]_ p47-65.
Fu S.M., Chiorazzi N., Wang C.Y., Montazeri G., Kunbel H.G., Ko H.S.
& Gottlieb A.B> (1978) la-bearing T lymphocytes in man. their
identification and role in the generation of allogeneic helper
activity. J. Exp. Med. 148 P1423-1427.
Fumagalli G., Engel A.G. & Lindstrom J. ( 1 981) Ultrastuctural
apsects of acetylcholine recpetor turnover at the normal and
myasthenic motor end-plate. J. Neuropathol. Exp. Neurol. 4j)
P301-310.
Furth E.D., Becker D.V., Ray B.S. & Kane J.W. (1962) Appearance of
unilateral infiltrative exophthalmos of Graves' disease after the
successful treatment of the same process in the contralateral eye by
apparently total surgical hypophysectomy. J. Clin. Endocrinol. 22
P518-524.
Garry R. & Hall R. (1979) Stimulation of mitosis in rat thyroid
by long-acting thyroid stimulator. Lancet p693-695.
Gavras I. & Thomson J.A. (1972) Late thyrotoxicosis complicating
autoimmune thyroiditis. Acta Endocrinol. 69_ p4l-45.
Gilman A.G., Goodman L.S. & Gilman A. ( 1 980) The pharmacological
basis of therapeutics. 6^h Edition. McMillan Publishing Co. Inc.
P1409.
Ginsberg J., Shewring G. & Rees-Smith B. (1983) TSH receptor
binding and thyroid stimulation by sera from patients with Graves'
disease. Clin. Endocrinol. _19 P305-311.
Glennon J.A., Gordon E.S. & Sawin C.T. (1972) Hypothyroidism after
low-dose 131 —I treatment of hyperthyroidism. Ann. Int. Med. 7j5
P721-723.
Gonzalez R.L., Dau P.C. & Spitler L.E. (1979) Altered regulation of
mitogen responsiveness by suppressor cells in multiple sclerosis.
Clin. Exp. Immunol. 36. p78-84.
Goodwin J.S. & Williams R.C. ( 1979) Suppressor cells - a recent
conceptual epidemic. J. Clin. Lab. Immunol. 2 p89-91.
-364-
Goodwin J.F., Steinberg H. & Wilson A. (1954) Long-term therapy of
thyrotoxicosis with thiouracil compounds. Brit. Med. J.
p422-425.
Goolden A.W.G. & Fraser T.R. ( 1969a) Treatment of thyrotoxicosis
with low doses of radioactive iodine. Brit. Med. J. 3. p442-443.
Goolden A.W.G. & Fraser T.R. (1969b) Effect of pretreatment with
carbimazole in patients with thyrotoxicosis subsequently treated with
radioactive iodine. Brit. Med. J. _1_ p443-444.
Goolden A.W.G., Davidson M. & Hoffenberg R. (1971) Myxoedema
preceding hyperthyroidism. Lancet 2 p268.
Gordin A. (1973) Serum thyrotrophin and circulating thyroglobulin
antibodies in subjects with non-toxic goitre and in euthyroid
subjects who had undergone subtotal thyroidectomy or radioiodine
therapy. Acta Endocrinol. 74 p283-295.
Gordin A., Wagar G. & Hernberg C.A. (1973) Serum thyrotrophin and
response to thyrotrophin-releasing hormone in patients who are
euthyroid after radioiodine treatment for hyperthyroidism. Acta
Med. Scand. P335-340.
Gordin A., Maenpaa J., Makinen T., Totterman T.H. & Tiilikainen A.
(1979) Immunological and genetic markers in a family with
Hashimoto's disease. Clin. Endocrinol. J_1_ p425-435.
Gossage A.A.R., Byfield P.G.H., Copping S. & Himsworth R.L. (1981)
A comparative study of the binding of Graves' immunoglobulins by the
patient's own and other thyroid membranes. Clin. Endocrinol. 14
P301-310.
Gossage A.A.R., Crawley J.C.W., Copping S., Hinge D. & Himsworth R.L.
(1983) Thyroid function and immunological activity during and
after medical treatment of Graves' disease. Clin. Endocrinol J_9
p87-96.
Gosselin S.J., Capen C.C. & Martin S.L. (1981 ) Histologic and
ultrastructural evaluation of thyroid lesions associated with
hypothyroidism in dogs. Veterinary Pathol. JJ3 p299-309.
Gosselin S.J., Capen C.C., Martin S.L. & Krakowka S. Induced
lymphocytic thyroiditis in dogs: Effect of intrathyroidal injection
of thyroid autoantibodies. American Journal of Veterinary Research
42 p1565-1572.
Goto M., Tanimoto K., Chinara T. & Horiuchi Y. (1981 ) Natural
cell-mediated cytotxicity in Sjogren's syndrome and rheumatoid
arthritis. Arthritis Rheum. 24_ p1377—1382.
Goudie R.B., Anderson J.R. & Gray K.G. ( 1959) Complement-fixing
antithyroid antibodies in hospital patients with asymptomatic thyroid
lesions. J. Path. Bact. 77 P389-400.
Goudie R.B., Anderson J.R., Gray K.K. & Whyte W.G. (1966)
Autoantibodies in Addison's disease. Lancet J_ p1173—1176.
-365-
Greaves M.F., Verbi W., Festenstein H. , Papasteriadis C., Jaraquemada
D. & Hayward A. (1979) "la-like" antigens on human T cells. Eur.
J. Immunol.£ p356-362.
Green M. & Wilson G.M. (1964) Thyrotoxicosis treated by surgery or
iodine-131- With special reference to development of hypothyroidism.
Brit. Med. J. 1 p1005-1010.
Greene R. ( 1950) The significance of lymphadenoid changes in the
thyroid gland. J. Endocrinol. ]_ p 1 —6 .
Greenwood R.M., Daly J.G. & Himsworth R.L. (1985) Hyperthyroidism
and the impalpable thyroid gland. Clin. Endocrinol. 2_2 p583-587.
Greer M.A., Kammer H. & Bouma D.J. (1977) Short-term antithyroid
therapy for the thyrotoxicosis of Graves' disease. New England J.
Med. 297 p173-176.
Greig W.R., Boyle J.A., Buchanan W.W. & Fulton S. (1965) Clinical
and radiobiological observations on latent effects of X-irradiation
on the thyroid gland. J. Clin. Endocrinol. Metab .25 p1009-10l4.
Griffiths N.J., Murley R.S., Gulin R.f Simpson R.D., Woods T.F. &
Burnett D. (1974) Thyroid function following partial thyroidectomy.
Brit. J. Surgery 6j_ p626-632.
Grinblat J., Shohat B., Lewitus Z. & Joshua H. (1979) Quantitative
and functional assessment of peripheral T lymphocytes in thyroid
diseases. Acta Endocrinol. 90 P52-61.
Grinden C.B. & Johnson K.H. ( 1983) Systemic lupus erythematosus:
Literature review and report of 42 new canine cases. J. American
Animal Hospital Association _1_9 p489-503.
Grumet F.C., Konishi J., Payne R.D. & Kriss J.P. (1973) Association
of Graves' disease with HL-A8. Clin. Res. 2_1_ p493 (Abstr).
Grumet F.C., Payne R.O., Konishi J. & Kriss J.P. ( 1974) HLA
antigens as markers for disease susceptibility and autoimmunity in
Graves' disease. J. Clin. Endocrinol. Metab. 39 p1115—1119-
Grumet F.C., Payne R.O., Konishi J., Mori J. & Kriss J.P. (1975) HLA
antigens in Japanese patients with Graves' disease. Tissue Antigens
6 P347-352.
Gupta R.C., McDuffie F.C., Huston K.A., Tappeiner G., Meurer M. ,
Jordon R.E., Luthra H.S., Hunder G.G. & Ilstrup D. (1979) Comparison
of three immunoassays for immune complexes in rheumatoid arthritis.
Arth. Rheum. 22 p433-439.
Guy K. , Van Heyningen V., Cohen B.B., Deane D.l. & Steel C.M. (1982)
Differential expression and serologically distinct subpopulations of
human la antigens detected with monoclonal antibodies to la alpha and
beta chains. Eur. J. Immunol. J_2 p942-947.
Hagen G.A., Ouellette R.P. & Chapman E.M. (1967) Comparison of high
and low dosage levels of 1311 in the treatment of thyrotoxicosis.
New England J. Med. 277 P559-562.
-366-
Hales I., Stiel J., Reeve T., Heap T. & Myhill J. (1969) Prediction
of the long-term results of antithyroid therapy for thyrotoxicosis.
J. Clin. Endocrinol. Metab. 2£ P998-1001.
Hall R., Turner-Warwick M. & Doniach D. ( 1 966) Autoantibodies in
iodide goitre and asthma. Clin. exp. Immunol. p285-296.
Hall R., Smith B.R. & Mukhtar E.D. (1975) Thyroid stimulators in
health and disease. Clin. Endocrinol. p 213-230.
Halla J.T., Volanakis J.E. & Schrohenloher R.E. (1979a) Immune
complexes in rheumatoid arthritis sera and synovial fluids. A
comparison of three methods. Arth. Rheum. 2£ p440-448.
Halla J.T., Volanakis J.E. & Schrohenloher R.E. (1979b) Circulating
immune complexes in mixed connective tissue disease. Arth. Rheum. 22
p484-489.
Hallengren B., Forsgren A. & Melander A. (1980) Effects of
antithyroid drugs on lymphocyte function in vitro. J. Clin.
Endocrinol. Metab. 5J_ p298-301.
Hallgren H.M. & Yunis E.S. (1977) Suppressor lymphocytes in young
and aged humans. J. Immunol. 118 p2004-2008.
Hamilton R.D., Mayberry W.E., McConahey W.M. & Hanson K.C. ( 1967)
Ophthalmopathy of Graves' disease: A comparison between patients
treated surgically and patients treated with radioiodine. Mayo
Clin. Proc. 42 p8l2-818.
Hanafusa T., Pujol-Borrell R.P., Chiovato L., Russell R.C.G., Doniach
D. & Bottazzo G.F. (1983) Aberrant expression of HLA-DR antigen on
thyrocytes in Graves' disease: Relevance for autoimmunity. Lancet 2^
p1111-1115.
Hanafusa T., Pujol-Borrell R.P., Chiovato L., Doniach D. & Bottazzo
G.F. (1983) In vitro and in vivo reversal of thyroid epithelial
polarity: its relevance for autoimmune thyroid disease. Clin. Exp.
Immunol. 5(3 p639-646.
Hardisty C.A., Hanford L., Humphries H. & Munro D.S. (1981a)
Long-acting thyroid stimulator (LATS) and long-acting thyroid
stimulator protector (LATS-P) in untreated thyrotoxicosis. Clin.
Endocrinol. 14 p631-639>
Hardisty C.A., Hanford L. & Munro D.S. (1981b) The prediction of
relapse after drug treatment of Graves' disease by assay of long
acting thyroid stimulator protector (LATS-P). Clin. Endocrinol. 14
P509-517.
Hardisty C.A., Talbot C.H. & Munro D.S. (1981c) The effect of
partial thyroidectomy for Graves' disease on serum long-acting
thyroid stimulator-protector (LATS-P). Clin. Endocrinol. 14
pl8l—188.
Hardisty C.A., Kendall-Taylor P., Atkinson S., Humphries H. & Munro
D.S. (1983) The assay of Graves' immunoglobulins: a comparison of
different methods. Clin. Endocrinol. 2(3 p637-644.
-367-
Hardisty, C.A., Fowles A. & Munro D.S. (1984a) Serum long acting
thyroid stimulator (LATS) and LATS-Protector (LATS-P) in Graves'
disease associated with localized myxoedema. J. Endocrinol. Invest.
7 P151 -155 -
Hardisty C.A., Fowles A. & Munro D.S. (1984b) The effect of
radioiodine and antithyroid drugs on serum long acting thyroid
stimulator protector. A three year prospective study. Clin.
Endocrinol. 20 p597-605.
Hashizume K. , Fenzi G. & DeGroot L.J. ( 1978) Thyroglobulin
inhibition of thyrotropin binding to thyroid plasma membrane. J.
Clin. Endocrinol. Metab. 48^ p679-685.
Haspel M.V., Onodera T., Prabhaker B.S., McClintock P.R., Essani K.,
Ray U.R., Yagihashi S. & Notkins A.L. (1983) Multiple
organ-reactive monoclonal antibodies. Nature 304 p73-76.
Hawkins B.R., Ma J.J.C., Lam K.S.L., Wang C.C.L. & Yeung R.T.T.
(1985) Association of HLA antigens with thyrotoxic Graves' disease
and periodic paralysis in Hong Kong Chinese. Clin. Endocrinol. ,23
P245-252.
Hay F.C., Nineham L. J. & Roitt I.M. ( 1976) Routine assay for the
detection of immune complexes of known immunoglobulin class using
solid phase C1q. Clin. Exp. Immunol. 24. p396-400.
Haynes B.F., Hemler M.E., Mann D.L., Eisenbarth G.S., Shelhamer J.,
Mostowski H.S., Thomas C.A., Strominger J.L. & Fauci A.S. (1981)
Characterisation of a monoclonal antibody (4F2) that binds to human
monocytes and to a subset of activated lymphocytes. J. Immunol. 126
pi 409-1415.
Hedley A.J., Flemming C.J., Chesters M.I., Michie W. & Crooks J.
(1970) Surgical teatment of thyrotoxicosis. Brit. Med. J. J_
P519-523.
Hedley A.J., Hall R., Amos J., Michie W. & Crooks J. (1971) Serum
thyrotropin levels after subtotal thyroidectomy for Graves' disease.
Lancet p455-458.
Hegedus L., Perrild H., Poulsen L.R., Andersen J.R., Holm B., Schnor
P., Jensen G. & Hansen J.M. ( 1983a) The determination of thyroid
volume by ultrasound and its relationship to body weight, age and sex
in normal subjects. J. Clin. Endocrinol. Metab. 5j6 p260-263.
Hegedus L., Hansen J.M. & Karstrup S. ( 1983b) High incidence of
normal thyroid gland volume in patients with Graves' disease. Clin.
Endocrinol. T9_ p603-607.
Heiman P. (1962) Atoxic and toxic goitre. Endemiology,
symptomatology and surgical treatment. Acta Chir. Scand. 289
[Suppl.] p923-924.
Heinemann S., Bevan S., Kullberg R., Lindstrom J. & Rice R.J. (1977)
Modulation of the acetylcholine receptor by anti-receptor antibody.
Procs. Nat. Acad. Sciences 74. P3090-3097.
-368-
Hensen J., Kotulla P., Finke R., Bogner U., Baddenhoop K., Meinhold
H. & Schleusener H. (1984) Methodological aspects and clinical
results of an assay for thyroid-stimulating antibodies: correlation
with thyrotropin binding inhibiting antibodies. J. Clin. Endocrinol.
Metab. 58 p980-987.
Henson J., Kotulla P., Finke R., Badenhoop K., Koppenhagen K. ,
Meinhold H. & Schleusener H. (1984) 10 years experience with
consecutive measurement of thyrotropin binding inhibiting
immunoglobulins. J. Endocrinol. Invest. 7. p215-220.
Herberman R.B. & Ortaldo J.R. (1981) Natural killer cells: Their
role in defences against disease. Science 214 p24-30.
Hersey P., Lawrence S., Prendergast D., Bindon C., Benson W. & Valk
P. (1983) Association of Sjogren's syndrome with C4 deficiency,
defective reticuloendothelial function and circulating immune
complexes. Clin. Exp. Immunol. 52 p551-560.
Hershman J.M., Givens J.R., Cassidy C.E. & Astwood E.B. (1966)
Long-term outcome of hyperthyroidism treated with antithyroid drugs.
J. Clin. Endocrinol. 26^ p803-807.
Hertz K.G., Gazze L.A., Kirkpatrick C.H. & Katz S.I. (1977)
Autoimmune vitiligo. Detection of antibodies to melanin-producing
cells. New England J. Med. 297 p634-637.
Hijmans W., Doniach D., Roitt I.M. & Holborow E.J. (1961) Serological
overlap between lupus erythematosus, rheumatoid arthritis and
thyroid autoimmune disease. Brit. Med. J. 2 P909-914.
Hodes R., Hathcock K. & Singer A. (1980) Major histocompatibility
complex restricted self recognition. J. Exp. med. 152 p1779—1794.
Hoenig M., Goldschmidt M.H., Ferguson D.C., Koch K. & Eymontt M.J.
(1982) Toxic nodular goitre in the cat. J. Small Animal Practice 23
p 1 — 12.
Holzworth J., Theran P., Carpenter J.L., Harpster N.K. & Todoroff
R.J. (1980) Hyperthyroidism in the cat: Ten cases. J. American
Veterinary Medical Association 176 P345-353.
Horowitz S.D., Borcherding W. & Bargman G.J. ( 1977) Suppressor T
cell function in diabetes mellitus. Lancet 2 p1291 •
Hsu C.C.S., Chen Y. & Patterson R. (1976) Peripheral blood
lymphocyte abnormalities associated with hyperthyroidism of Graves'
disease. Clin. Exp. Immunol. 2l5 p431-440.
Hurley C.K., Nunez G., Winchester R.,Finn O.J., Levy R. & Capra J.D.
(1982) The human HLA-DR antigens are encoded by multiple beta chain
loci. J. Immunol. 129 p2103-2108.
Iavicoli M. , Di Mario U., Pozzilli P., Canalese J., Venriglia L.,
Galfo C. & Andreani D. (1982) Impaired phagocyte function and
increased immune complexes in diabetics with microangiopathy.
Diabetes 31 p7—11.
-369-
Iida Y. , Konishi J., Kasagi K. , Kuma K. & Torizuka K. ( 1982)
Detection of TSH-binding inhibitor immunoglobulins by using the
Triton-solubilized receptor from human thyroid membranes.
Endocrinol. Japon. 29_ p227-231.
Imamura N. , Fujimura K. & Kuramoto A. ( 1984 ) Lymphocyte
subpopulations in pernicious anaemia. New England J. Med. 311 p56.
Inada Y., Kamiyama M., Kanemitsu T., Hyman C.L. & Clark W.S. (1982)
Studies on immune adherence (C3b) receptor activity of human
erythrocytes: relationship between receptor activity and presence of
immune complexes in serum. Clin. Exp. Immunol. 50_ p189—197•
Inada Y., Kamiyama M., Kanemitsu T. & Clark W.S. (1983) Studies on
immune adherence (C3b) receptor activity on human erythrocytes:
Relationship between receptor activity and membrane osmotic
fragility. J. Clin. Lab. Immunol. _12^ p97-103.
Ingbar S.H. (1985) The thyroid gland. In "Williams Textbook of
Endocrinology." Editors: J.D. Wilson & D.W. Foster. W.B. Saunders.
P682-815.
Inman R.D. (1982) Immune complexes in SLE. Clinics in Rheumatic
Diseases 8^ p49-62.
Irvine W.J., MacGregor A.G. & Stuart A.E. (1962) The prognostic
significance of thyroid antibodies in the management of
thyrotoxicosis. Lancet 2 p843-847.
Irvine W.J. (1964) Thyroid autoimmunity as a disorder of immune
tolerance. Quart. J. Exp. Physiol. 49 P324-337.
Irvine W.J. & Stewart A.G. (1967) Prognostic significance of
thyroid antibodies in the management of thyrotoxicosis. In
"Thyrotoxicosis" (W.J. Irvine, Editor). Livingston. Edinburgh &
London, pill—112.
Irvine W.J., Stewart A.G. & Scarth L. (1967) A clinical and
immunological study of adrenocortical insufficiency (Addison's
disease). Clin. Exp. Immunol. 2 p31-69-
Irvine W.J. & Barnes E.W. (1972) Adrenocortical insufficiency.
Clinics in Endocrinology and Metabolism _1_ p549-594.
Irvine W.J., Gray R.S., Morris P.J. & Ting A (1977a) Correlation of
HLA and thyroid antibodies with clinical course of thyrotoxicosis
treated with antithyroid drugs. Lancet 2 p898-890.
Irvine W.J., Al-Khateeb S.F., Di Mario U., Feek C.M., Gray R.S.,
Edmond B. & Duncan L.J.P. (1977b) Soluble immune complexes in the
sera of newly diagnosed insulin-dependent diabetics and in treated
diabetics. Clin. Exp. Immunol. 30 p16—21.
Irvine W.J., Gray R.S., Morris P.J. & Ting A. (1978) HLA in primary
atrophic hypothyroidism and Hashimoto goitre. J. Clin. Lab.
Immunol. J_ p 193-195.
-370-
Irvine W.J., Lamberg B-A., Cullen D.R. & Gordin R. (1979) Primary
hypothyroidism preceding thyrotoxicosis: A report of two cases and a
review of the literature. J. Clin. Lab. Immunol. 2^ P349-352.
Irvine W.J. (1980a) Immunological aspects of Diabetes mellitus.
In "Immunolgy of Diabetes", Editor: W.J. Irvine. Teviot Scientific
Publications. p1-54.
Irvine W.J., Di Mario U., Guy K. & Borsey D.Q. (1980b) Immune
complexes in type I diabetics with persistent islet cell antibodies.
J. Clin. Lab. Immunol. 4^ p87-89.
Irvine W.J., Di Mario U., Guy K., Feek C.M., Gray R.S. & Duncan
L.J.P. (1980c) Immune complexes in newly diagnosed insulin
dependent (type I) diabetics. In "Immunology of Diabetes", Editor:
W.J. Irvine. Teviot Scientific Publications. p219-227.
Iwatani Y., Amino N., Asari S., Izumiguchi Y., Kumahara Y. & Miyai K.
(1983) T lymphocyte subsets in autoimmune thyroid diseases and
subacute thyroiditis detected with monoclonal antibodies. J. Clin.
Endocrinol. Metab. 56 p251-254.
Izui S., McConahey P.J. & Dixon F.J. (1978) Increased polyclonal
activation of B lymphocytes in mice with spontaneous autoimmune
disease. J. Immunol. 121 p2213-2219.
Izzard L.L., van Wyk H.A., Potgieter N., Brighton S. & Anderson R.
(1983) An evaluation of nephelometry and complement-based tests for
the detection of circulating immnune complexes. South African Med.
J. 63 p244-250.
Jackson I. ( 1975) Hyperthyroiditis - a diagnostic pitfall. New
England J. Med. 293 p661-662.
Jackson R.A., Bowring M. & Morris M.A. (1981) Increased circulating
la positive T cells in recent onset Graves' disease and insulin
dependent diabetes. 63r<* Annual Meeting of the Endocrine Society,
Cincinnati. Abstr 450.
Jackson R.A., Morris M.A., Haynes B.F. & Eisenbarth G.S. (1982)
Increased circulating la antigen bearing T cells in type I diabetes
mellitus. New England J. Med. 306 p785-788.
Jackson R.A., Haynes B.F., Burch W.M., Shimizu I., Bowring M.A. &
Eisenbarth G.S. ( 1984) T cells in new onset Graves' disease. J.
Clin. Endocrinol. Metab. 59. pl87-190.
Jansen F.K. (1982) The possible relationships between viral
infection and autoimmunity. In "Immunology of Diabetes", W.J. Irvine
(Editor). Teviot Scientific Publications Ltd., Edinburgh. p243-254.
James K.W. (1971) Myxoedema preceding hyperthyroidism. Lancet 2
P156.
Jansson R., Dahlberg P.A., Johansson H. & Lindstrom B. (1983)
Intrathyroidal concentrations of methimazole in patients with Graves'
disease. J. Clin. Endocrinol. Metab. 57 p129-132.
-371-
Janson R., Karlsson A. & Forsum U. (1984) Intrathyroidal HLA-DR
expression and T lymphocyte phenotypes in Graves' thyrotoxicosis,
Hashimoto's thyroiditis and nodular colloid goitre. Clin. Exp.
Immunol. 58^ p264-272.
Jerne N.K. (1973) The immune system. Scientific American 229
P52-60.
Joassoo A., Robertson P. & Murray I.P.C. (1975) Viral antibodies in
thyrotoxicosis. Lancet 2 p124.
Jones B.R. & Johnstone A.C. (1981) Hyperthyroidism in an aged cat.
New Zealand Veterinary Journal 29 p70-72.
Jones B.M., Teng C.S. & Yeung R.T.T. (1982) Evaluation of B cell,
T-helper cell and T-suppressor cell function in patients with Graves'
disease before and after treatment with antithyroid drugs. Clin.
Immunol. Immunopathol. £5 p232-242.
Jonsson J., Einhorn N., Fagraeus A. & Einhorn J. (1968) Organ
antibodies after local irradiation. Radiology 90 p536-540.
Joplin G.F. & Fraser R. (1959) Thyrotoxicosis developing in
recurrent nodular goitre with focal thyroiditis. Proc. Roy. Soc.
Medicine 52 p177-178.
Kahn C.R., Kasuga M., King G.L. & Grunfeld C. (1982) Autoantibodies
to insulin receptors in man: immunological determinants and mechanism
of action. In "Receptors, Antibodies and Disease", Ciba Foundation
Symposium 90, p91—113.
Kajita Y., Nakajima Y., Ishida M., Ochi Y., Miyaaki T., Nacchiya T.
& Ijichi H. ( 1983) Characteristics of auto-antibodies to bovine
TSH in the serum of two patients with Graves' disease. Acta.
Endocrinol (Copenh) 104 p423-430.
Kalderon A.E., Bogaars H.A. & Diamond I. (1973) Ultrastructural
alterations of the follicular basement membrane in Hashimoto's
thyroiditis. American J. Med.. 55_ p485-491.
Kalderon A.E. & Bogaars H.A. (1977) Immune complex deposits in
Graves' disease and Hashimoto's thyroiditis. American J. Med. 63.
P729-734.
Karlsson F. A. & Dahlberg P.A. (1981) Thyroid stimulating
antibodies (TSAb) in patients with Graves' disease undergoing
antithyroid drug treatment: indicators of activity of the disease.
Clin. Endocrinol. J_44 p579-585.
Katz D.V., Kite J.H. & Albini B. (1981) Immune complexes in tissues
of obese strain (OS) chickens. J. Immunol. 126 p2296-2301.
Kawa A., Nakamura S., Nakazawa M., Sakaguchi S. , Kawabata T., Maeda
Y. & Kanehisa T. (1977) HLA-Bw35 and B5 in Japanese patients with
Graves' disease. Acta Endocrinol. 86^ P754-757.
-372-
Keast D. , Rennie D. , Weetman A.P., Foord S. & Hall R. (1981) The
influence of methimazole on autoimmune thyroid disease in the rat.
Ann. d'Endocrinologie 66A p112.
Kendall-Taylor P. Are antithyroid drugs immunosuppressive? Brit.
Med. J. 288 p509-510.
Kennedy R., Di Mario U., Pozzilli P., Guy K., Leonardi M., Sensi M. &
Andreani D. (1985) Activated T cells in Graves' disease before
treatment. Clin. Exp. Immunol. 59 P377-382.
Kenny F.M. & Holliday M.A. (1964) Hypoparathyroidism, moniliasis,
Addison's disease and Hashimoto's disease. Hypercalcaemia treated
with intravenously administered sodium sulphate. American J. Med.
34 p856-860
Khoury E.L., Bottazzo G.F., de Carvalho P.L.C., Wick G. & Roitt I.M.
(1982) Predisposition to organ-specific autoimunity in obese strain
(OS) chickens: Reactivity to thyroid, gastric, adrenal and pancreatic
antigens. Clin. Exp. Immunol. 4£ p273-282.
Kiessling W. R., Finke R., Kotulla P. & Schleusener H. (1982)
Circulating TSH-binding inhibitory immunoglobulins in myasthenia
gravis. Acta Endocrinol 101 p4l-46.
Kirk R.W. (Ed.) In "Current veterinary therapy VIII. Small animal
practice." W.B. Saunders. Philadelphia. Chapter 67 p1592—1614.
Kite J.H., Argue H. & Rose N.R. (1966) Experimental thyroiditis in
the Rhesus monkey I. Cytotoxic, mixed agglutinating and
complement-fixing antibodies. Clin. Exp. Immunol. _1_ p 139-157.
Kiy Y., Rezkallah-Iwasso M.T., Peracoli M.T.S. & Mota N.G.S. (1981)
Immunological studies in toxic multinodular goitre and active Graves'
disease. Clin. Endocrinol. 16 p11-17.
Klareskog L., Forsum U., Wigren A. & Wigzell H. (1982) Relationships
between HLA-DR expressing cells and T lymphocytes of different
subsets in rheumatoid synovial tissue. Scand. J. Immunol. 1_5
P501-507.
Klouda P.T., Acheson E.J., Goldby F.S., Lawler W., Manos J., Dyer
P.A., Harris R. & Mallick N.P. ( 1979) Strong association between
idiopathic membranous nephropathy and HLA-DRw3. Lancet 2 p770-772.
Kodama K., Sikorska H., Bandy-Dafoe P., Bayly R. & Wall J.R. (1982)
Demonstration of a circulating autoantibody against a soluble eye
muscle antigen in Graves' ophthalmopathy. Lancet ,2 p1353-1356.
Kofler H., Kofler R., Wolf H. & Wick G. ( 1983) Immunofluorescence
studies on the codistribution of immune deposits and complement in
the thyroid glands of obese strain (OS) chickens. Immunobiol. 164
P390-401.
Kohn L.D., Valente W.A., Laccetti P., Cohen J.L., Aloj S.M. &
Grollman E.F. ( 1983) Multicomponent structure of the thyrotropin
receptor: Relationship to Graves* disease. Life Sciences 32 p15-30.
-373-
Kong Y.C.M., David C.S., Giraldo A.A., Eirehewy M. & Rose N.R. (1979)
Regulation of mouse response to thyroglobulin: influence of H-2D end
genes. J. Immunol. 123 p15—18.
Kong Y.C.M., Okayasu I., Giraldo A.A., Beisel K.W., Sundick R.S.,
Rose N.R., David C.S., Audiberc F. & Chedid L. (1982) Tolerance to
thyroglobulin by activating suppressor mechanisms. Ann. N.Y. Acad.
Sci. 392 p191-207
Konishi J., Herman M.M. & Kriss J.P. (1974) Binding of
thyroglobulin and thyroglobulin-antithyroglobulin immune complex to
extraocular membrane. Endocrinology 95 p434-446.
Konishi J., Iiday Y., Endo K., Misaki T., Nohara Y., Matsuura N.,
Muri T. & Torizuka K. ( 1983) Inhibition of thyrotropin-induced
adenosine 3'5'-monophosphate increase by immunoglobulins from
patients with primary myxoederaa. J. Clin. Endocrinol. Metab. 57
P5H4-549.
Kotulla P. & Schleusener H. (1981) Solubilised TSH receptor: its
usefulness for the radioligand assay. J. Endocrinol. Invest. 4_
p155-160.
Kowalczyk D. & Zembala M. (1978) Migration inhibition of T
lymphocytes from human peripheral blood by specific antigen and
lymphokines. Clin. Exp. Immunol. 32 P333-338.
Kriss J.P., Pieshnakov V. & Chien J.R. (1964) Isolation and
identification of the long-acting thyroid stimulator and its relation
to hyperthyroidism and circumscribed pretibial myxoedema. J. Clin.
Endocrinol. Metab. 24^ p 1005-1028.
Kriss J. P., Pleshakov V., Rosenblum A.L., Holderness M. , Sharp G. &
Utiger R. (1967) Studies on the pathogenesis of the ophthalmopathy
of Graves' disease. J. Clin. Endocrinol. 27 P582-593-
Kruth S.A. (1980) Hyperthyroidism in the cat. California
Veterinarian 8^ p25.
Kuzuya N., Chiu S., Ikeda H., Uchimura M., Ito K. & Nagataki S.
(1979) Correlation between thyroid stimulators and 3> 5,
3'-triiodothyronine suppressibility in patients during treatment for
hyperthyroidism with thionamide drugs: comparison of assays by
thyroid stimulating and thyrotropin displacing activities. J. Clin.
Endocrinol. Metab. 48 p706-711.
Lachman P.J. ( 1967) Conglutinin and immunoconglutinins. Adv.
Immunol. 6^ p479-527-
Lam D.C.C. & Lindsay R.H. (1979) Accumulation of 2-(14c)
propylthiouracil in human polymorphonuclear leukocytes. Biochem.
Pharmacol. 28 p2289-2296.
Lambert P.H., Dixon F.J., Zubler R.H., Agnello V. et al (1978) A
WHO collaborative study for the evaluation of eighteen methods for
detecting immune complexes in serum. J. Clin. Lab. Immunol.
p 1 — 15.
-374-
Lamki L. , Row V.V. & Volpe R. (1973) Cell mediated immunity in
Graves' disease and in Hashimoto's thyroiditis as shown by the
demonstration of migration inhibition factor (MIF). J. Clin.
Endocrinol. Metab. ^6 p358-364.
Lampert I.A. (1984) Expression of HLA-DR (la like) antigen on
epidermal keratinocytes in human dermatoses. Clin. Exp. Immunol. 5J
p93-100.
Larsson E.L. & Coutinho A. (1979) The role of mitogenic lectins in
T cell triggering. Nature 280 p239-24l.
Lampson L.A. & Levy R. (1980) Two populations of la like molecules
on a human B cell line. J. Immunol. 125 p293-299.
Laurberg P. & Weeke J. (1975) T3 release from thyroid slices as an
assay for thyroid stimulators. Scan. J. Clin. Lab. Invest.
35 P723-727.
Laurberg P., Hansen P.E.B., Iversen E., Jensen S.E. & Weeke J. (1986)
Goitre size and outcome of medical treatment of Graves' disease. Acta
Endocrinol. 111 p39-43-
Lawley T.J., Hall R.P., Fauci A.S., Katz S.I., Hamburger M.I. & Frank
M.M. (1981) defective Fc receptor functions associated with the HLA
B8/DR3 haplotype. Studies in patients with dermatitis herpetiformis
and normal subjects. New England J. Med. 304 p185-192.
Lazarus J.H., Marchant B., Alexander W.D. & Clark D.H. (1975)
35s-antithyroid drug concentration and organic binding of iodine in
the human thyroid. Clin. Endocrinol. 4^ p609-6l5.
Leav I., Schiller A.L., Rijnberk A., Legg M.A. & der Kindern P.J.
(1976) Adenomas and carcinomas of the canine and feline thyroid.
Amer. J. Pathol. 83 P94-101
Leclere J., Bene M.C., Duprez A., Faure G., Thomas J.L., Vignaud
J.M. & Burlet C. (1984) Behaviour of thyroid tissue from patients
with Graves' disease in nude mice. J. Clin. Endocrinol. Metab. 59.
p175-177.
Lederman M.M., Ellner J.J. & Rodman H.M. (1981) Defective
suppressor cell generation in juvenile onset diabetes. J. Immunol.
127 p2051-2055.
Levey G.S. & Pastan I. (1970) Activation of thyroid adenyl cyclase
by long-acting thyroid stimulator. Lite. Sci. 9_ p67-73-
Levitt T. (1951) Evolution of the toxic thyroid gland. A clinical
and pathological study based on 2114 thyroidectomies. Lancet 2
P957-965.
Lewis E.J. & Roberts J.L. ( 19 8 0) Is autoimmunity a common
denominator in immune complex diseases? Lancet J_ p178-180.
Liddle G.W., Heyssel R.M. & McKenzie J.M. (1965) Graves* disease
without hyperthyroidism. Amer. J. Med. 39. p845-848.
-375-
Lillehoj H.S. & Rose N.R. (1975) Humoral and cellular immune
response to thyroglobulin in different rat strains. Clin. Exp.
Immunol. p661—
Lillehoj H.S., Beisel K. & Rose N.R. (1981) Genetic factors
controlling the susceptibility to experimental autoimmune thyroiditis
in inbred rat strains. J. Immunol. 127 p654-659.
Lilly F., Boyse E.A. & Old L.J. ( 1 964) Genetic basis of
susceptibility to viral leukaemogenesis. Lancet 2 p1207-1209.
Lindemann J. & Klein P.A. ( 1967) Viral oncolysis: Increased
immunogenicity of host cell antigen associated with influenza virus.
J. Exp. Med. J26 p93-108.
Lindstrom J., Campbell M. & Nare B. ( 1978) Specificities of
antibodies to acetylcholine receptors Muscle and Nerve _1_ p 140-145.
Lipman L.M., Green D.E., Snyder N.J., Nelson J.C. & Solomon D.H.
(1967) Relationship of long-acting thyroid stimulator to the
clinical features and course of Graves' disease. Am. J. Med 43
P486-498.
Livezey M.D., Sundick R.S. & Rose N.R. (1981) Spontaneous
autoiimmune thyroiditis in chicks II. Evidence for autoresponsive
thymocytes. J. Immunol. 127 P1469-1472.
London L., Perussia B. & Trincheri G. (1985) Induction of
proliferation in vitro of resting human natural killer cells:
expression of surfacer activation antigens. J. Immunol. 134
P718-727.
Long D.A. & Shewell J. (1955) The influence of the thyroid gland
on the production of antitoxin in the guinea pig. Brit. J. Exper.
Pathol. 36 p153-356.
Loriaux D.L. (1985) The polyendocrine deficiency syndromes. New
England J. Med. 312 p 1568-1569.
Lowry R.C., Lowe D. , Hadden D.R., Montgomery D.A.D. & Weaver J.A.
(1971) Thyroid suppressibility: Follow-up for two years after
antithyroid treatment. Brit. Med. J. p19-22.
Lucke V.M. ( 1964) An histological study of thyroid abnormalities
in the domestic cat. J. Small Animal Practice 5 P351-358.
Ludgate M.E., McGregor A.M., Weetman A.P., Ratanachaiyarong S.,
Lazarus J.H., Hall R. & Middleton G.W. ( 1984) Analysis of the T
cell subsets in Graves' disease: alterations associated with
carbimazole. Brit. Med. J. 288 p526-530.
Lundell G. & Jonsson J. (1973) Thyroid antibodies and
hypothyroidism in 131-I therapy for hyperthyroidism. Acta
Radiologica V2. p443-453-
Lundell G. , Wasserman J., Granberg P-0. & Blomgren H. ( 1976)
Lymphocyte populations in peripheral blood in hyperthyroid and
euthyroid subjects. Clin. Exp. Immunol. 23. P33-39.
-376-
Lundstrom B., Hed J., Johansen K.E. & Norrby K. (1977) Thyroid
function after subtotal thyroidectomy for hyperthyroidism related to
some morphological and immunological features. Acta Chir. Scand.
143 P215-220.
Lundstrom B., Gillquist J., Karlberg B., Kegedal B. & Tegler L.
(1978) Thyroid function after subtotal resection for
hyperthyroidism: a prospective study. Eur. J. Clin. Invest. (3
p47-52.
McCullagh E.P., Humphrey D.C., McGarry C.J. & Sundgren V. (1951)
Results of propylthiouracil treatment for hyperthyroidism. J.
American Med. Assoc. 147 p106-110.
McCullagh E.P. & Cassidy C.E. ( 1953) Propylthiouracil. 4-6 year
follow-up of selected patients with Graves' disease. J. Clin.
Endocrinol. 13 p1507-1512.
McCullagh E.P., Reynolds C.W. & McKenzie J.M. (1960) Hyperthyroidism
after section of the pituitary stalk for malignant exophthalmos. J.
Clin. Endocrinol. 20 p 1029-1033.
McDevitt H.O. Chinitz A. (1969) Genetic control of antibody
response: relationship between immune response and histocompatibility
(H-2) type. Science 163 p1207-1209.
McDougal J.S., Hubbard M., McDuffie F.C., Strobel P.L., Smith S.J.,
Bass., Goldman J.A., Hartman S., Myerson G., Miller S., Morales R. &
Wilson C.H. (1982) Comparison of five assays for immune complexes in
the rheumatic diseases. An assessment of their validity for
rheumatoid arthritis. Arth. Rheum. 25 p1156-1157.
McGregor A.M., Petersen M.M., Capiferri R., Evered D.C., Smith B.R.
& Hall R. (1979a) Effects of radioiodine on thyrotropin binding
inhibiting immunoglobulins in Graves' disease. Clin. Endocrinol. 11
p437-444.
McGregor A.M., Smith B.R., McLachlan S.M. & Hall R. (1979b) Effect
of irradiation on thyroid autoantibody production. Lancet 2
p442-443.
McGregor A.M., Petersen M., McLachlan S., Hunter M.P., Clark F. &
Evered D.C. (1979c) Irradiation and the immune response in
autoimmune thyroid disease. Ann. d'Endocrinologie 4£ p42A
Abstr. 77.
McGregor A.M., Smith B.R., Hall R., Petersen M.M., Miller M. & Dewar
P.J. (1980a) Prediction of relapse in hyperthyroid Graves' disease.
Lancet _1_ p 1101 -1103 -
McGregor A.M., Petersen M.M., McLachlan S.M., Rooke P., Smith B.R. &
Hall R. (1980b) Carbimazole and the autoimmune response in Graves'
disease. New England J. Med. 303 P302-307.
McGregor A.M., Smith B.R., Hall R., Collins P.N., Bottazzo G.F. &
Petersen M.M. (1982) Specificity of the immunosuppressive action
of carbimazole in Graves' disease. Brit. Med. J. 284 p1750-1751.
-377-
McKenna R., Kearns M., Sugrue D., Drury M.I. & McCarthy C.F. (1982)
HLA and hyperthyroidism in Ireland. Tissue antigens _1_9 P97-99.
McKenzie J.M. (1958) The bioassay of thyrotropin in serum.
Endocrinology 63 P372-377.
McKenzie J.M. (1961) Studies on the thyroid activator of
hyperthyroidism. J. Clin. Endocrinol. 2_1^ p635-647.
McKenzie J.M. (1962a) Fractionation of plasma containing the long
acting thyroid stimulator. J. Biol. Chem. 237 P3571-3572.
McKenzie J.M. (1962b) The pituitary and Graves disease. Proc.
Royal Soc. Med. 55 p539-540.
McKenzie J.M. (1965) Review: Pathogenesis of Graves' disease - role
of the long-acting thyroid stimulator. J. Clin. Endocrinol. 25.
p424-431.
McKenzie J.M. & McCullagh E.P. (1968) Observations against a causal
relationship between the Long-Acting Thyroid Stimulator and
ophthalmopathy in Graves' disease. J. Clin. Endocrinol. 2_8
p1177-1182.
McKenzie J.M. & Zakarija M. (1976) A reconsideration of
thyroid-stimulating immunoglobulin as the cause of hyperthyroidism in
Graves' disease. J. Clin. Endorinol. Metab. j\2 p778-784.
McKenzie J.M. & Zakarija M. (1977) LATS in Graves' disease. Recent
Progress in Hormone Research 33. p29-59.
McLachlan S.M., McGregor A.M., Smith B.R. & Hall R. (1979) Thyroid
autoantibody synthesis by Hashimoto thyroid lymphocytes. Lancet _1_
p162-163-
McLachlan S.M., Wee S.L., McGregor A.M., Smith B.R. & Hall R. (1980)
In vitro studies on the control of thyroid autoantibody synthesis. J.
Clin. Lab. Immunol. 3. p 15-21.
McLarty D.G., Brownlie B.E.W., Alexander W.D., Papupetrou P.D. &
Horton P. (1973) Remission of thyrotoxicosis during treatment with
propranolol. Brit. Med. J. 2 p332-334.
McMicheal A.J., Ting A., Zweerink H.J. & Askonas B.A. ( 1977) HLA
restriction of cell-mediated lysis of influenza virus infected human
cells. Nature 270 p524-526.
McMillan F.D. & Sherding R.G. (1981) Feline hyperthyroidism.
Treatment of four cases. Feline Practice J_1_ p25-32.
McMullan N.M. & Smyth P.P.A. ( 1984) In vitro generation of NADPH
as an index of thyroid stimulating immunoglobulins (TSI) in goitrous
disease. Clin. Endocrinol. (Oxf) 20_ p269-280.
McNeill A. D. & Thomson J.A. ( 1 968) Long-term follow-up of
surgically treated thyrotoxic patients. Brit. Med. J. 3. p643- 647.
-378-
Macchia E., Fenzi G.F., Monzani F., Lippi F. , Vitti P., Grasso L.,
Bartalena L., Baschieri L. & Pinchera A. (1981) Comparison between
thyroid stimulating and TSH-binding inhibiting immunoglobulins of
Graves' disease. Clin. Endocrinol. 15 P175-182.
Maciel R.M.B., Miki S.S., Nicolau W. & Mendes N.F. (1976) Peripheral
blood T and B lymphocytes, in vitro stimulation with
phytohaemagglutinin and sensitization with 2,4-dinitrochlorobenzene
in Graves' disease. J. Clin. Endocrinol. Metab. 42 p583-587.
Major P.W. & Munro D.S. (1962) Observations on the stimulation of
thyroid function in mice by the injection of serum from normal
subjects and from patients with thyroid disorders. Clin. Sci. 23
p463-475.
Malone J.F. & Cullen M.J. (1976) Two mechanisms for hypothyroidism
after 131-1 therapy. Lancet _1_ p73-75.
Mangkornkanok M., Marcowitz A.S. & Battitora H.A. ( 1972) Chronic
thyroiditis in the rabbit induced with homologous thyroid
microsomes. Science 178 p316-320
Mann D.L. & Sharrow S.O. (1979) B-cell alloantigens on
T-lymphocytes . Transplant. Procs. J_1_ p 1774-1775.
Mannik M., Haakenstad A.O. & Arend W.P. ( 1974) The fate and
detection of circulating immune complexes. Prog. Immunol. 5_
p91—101.
Manson D.I. (1953) Late results of treatment of thyrotoxicosis
with thiouracil compounds. Edinburgh Med. J. 6£ p321-330.
Marchant B., Alexander W.D., Lazarus J.H., Lees J. & Clark D.H.
(1972) The accumulation of 35g-antithyroid drugs by the thyroid
gland. J. Clin. Endocrinol. Metab. 34. p847-851.
Marcocci C., Valente W.A. Pinchera A., Aloj S.M., Kohn L.D. &
Grollman E.F. (1983) Graves' IgG stimulation of iodide uptake in
FRTL-5 at thyroid cells: a clinical assay complementing FRTL- 5
assays measuring adenylate cyclase and growth stimulating antibodies
in autoimmune thyroid disease. J. Endocrinol. Invest 6_ p463-471.
Mariotti S., Pinchera A., Marcocci C., Vitti P., Urbano C., Chiovato
L. , Tosi M. & Baschieri L. (1979) Solubilization of human thyroid
microsomal antigen. J. Clin. Endocrinol. Metab. 48^ p207-212.
Martin F.I.R., Larkins R.G., Alford F.P., Andrews J.T., Greenberg
P.B., Melick R.A. & Penington J.S. (1972) LATS and the results of
131-1 treatment of thyrotoxicosis. Australia and New Zealand
Journal of medicine. 2 p168-172.
Maruyama N., Furukawa F., Nakai Y. , Sasaki Y. , Ohta K., Ozaki S.,
Hirose S. & Shirai T. (1983) Genetic studies of autoimmunity in New
Zealand mice IV. Contribution of NZB and NZW genes to the spontaneous
occurrence of retroviral gp70 immune complexes in (NZB x NZW) F-|
hybrid and the correlation to renal disease. J. Immunol. 130
P740-746.
-379-
Mason D.W., Dallman M. & Barclay A.N. (1981) Graft-versus-host
disease induces expression of la antigen in rat epidermal cells and
gut epithelium. Nature 293 P149-150.
Mather B.A., Roberts D.F., Scanlon M.F., Mukhtar E.D., Davies T.F.,
Rees Smith B. & Hall R. (1980) HLA antigens and thyroid antibodies
in patients with Graves' disease and their first degree relatives.
Clin. Endocrinol. L2 p 155-163.
Mazzaferri E.L., Reynolds J.C., Young R.L., Thomas C.N. & Parisi F.
(1976) Propranolol as primary therapy for thyrotoxicosis: Results
of a long-term prospective study. Arch. Int. Med. 136 p50-56.
Meek J.C., Jones A.E., Lewis U.J., & Vander-laan W.P. (1964)
Isolation and characterization of the long-acting thyroid stimulator
of Graves' disease. J. Clin. Invest. 4_3 p1258-1259.
Michie W.J.C., Beck R.G., Mahaffy E.F., Honein J.L. & Fowler G.B.
(1967) Quantitative, radiological and histological studies of the
thymus in thyroid disease. Lancet _1_ p691-695.
Michie W., Pegg C.A.S. & Bewsher P.D. (1972) Prediction of
hypothyroidism after partial thyroidectomy for thyrotoxicosis.
Brit. Med. J. J_ p 13-17.
Michie W. (1975) Whither thyrotoxicosis. Brit. J. Surgery 62_
P673-682.
Migliorini P., Aiuti F. , Balestieri G. et al (1984) Comparison of
pathologic and normal sera by immune complex determination: Five
disease groups within 190 samples are discriminated by computer
selected combinations of 13 methods. Clin. Immunol. Immunopathol.
32 p298-315.
Miller A.E., Hudson J. & Tindall R.S.A. (1982) Immune regulation in
myasthenia gravis. Evidence for an increased suppressor T cell
population. Ann. Neurol. 1_2 p341-347.
Mittag T., Massa T., Kornfeld P., Papatestas A., Bender A. & Genkins
G. (1981) Multiple forms of acetylcholine recptor antibody in
myasthenia gravis. Ann. New York Acad. Sciences 377 P342-359.
Mittler R.S., Rao P.E., Talle M.A., Look R. & Goldstein G. (1983)
Cell membrane perturbation of resting T cells and thymocytes causes
display of activation antigens. J. Exp. Med. 158 p99—111.
Mischak R.P. & Dau P.C. (1981) Lymphocyte binding antibodies and
suppressor cell activity in myasthenia gravis. Ann. New York Acad.
Sciences 377 p436-446.
Mizejewski G.J., Baron J. & Poissant G. (1971) Immunologic
investigations of naturally occurring canine thyroiditis. J.
Immunol. _107 p 1152-1160.
Moens H. & Farid N.R. (1978) Hashimoto's thyroiditis is associated
with HLA-DRw3. New England J. Med. 299 P133-134.
-380-
Moens H., Barnard J.M., Bear J. & Farid N.R. (1979) The association
of HLA-B8 with atrophic thyroiditis. Tissue Antigens _1_3 p3^2—348.
Moretta L., Webb S.R. & Grossi C.E. (1977) Functional analysis of
two human T cell subpopulations: Help and suppression of B cell
responses by T cells bearing receptors for IgM and IgG. J. Exp.
Med. 146 p184—190.
Moretta L., Mingari M.C. & Romanzi C.A. (1978) Loss of Fc receptors
for IgG from human lymphocytes exposed to IgG immune complexes.
Nature 272 p6l8-620.
Moretta A., Mingari M.C.C. & Santoli D. (1979) Human T lymphocyte
subpopulations: Alterations in systemic lupus erythematosus. Scan.
J. Immunol. J_0 p223-229.
Moretta A., Corte G., Mingari M.C. & Moretta L. (1982) Human T cell
subpopulations defined by monoclonal antibody. II. Evidence for cell
cooperation in the response to alloantigen and generation of
cytolytic cells. J. Immunol. 128 p20-23.
Montgomery D.A.D. & Welbourn R.B. (1975) The thyroid gland. In
"Medical and Surgical Endocrinology". Edward Arnold. p258-344.
Morgan D.A., Ruscetti F.W. & Gallo R. (1976) Science 193 p1008-1012
Morgans M.E., Oldham A.K. & Trotter W.R. (1952) The effect of
exogenous thyroxine on radioiodine uptake in normal subjects and in
cases of thyrotoxicosis in remission. J. Endocrinol. Q p250- 253-
Mori T. & Kriss J.P. (1971) Measurements by competitive binding
radioassay of serum anti-microsomal and anti-thyroglobulin antibodies
in Graves' disease and other thyroid disorders. J. Clin.
Endocrinol. Metab. 33. p688-698.
Mori H., Amino N., Iwatani Y. , Kabutomori 0., Asari S., Motoi S.,
Miyai K. & Kumahara Y. (1980) Increase of peripheral B lymphocytes
in Graves' disease. Clin. Exp. Immunol. 42^ P33-40.
Morimoto C., Abe T., Hara M. & Homma M. ( 1977) In vitro
TNP-specific antibody formation by peripheral lymphocytes from
patients with systemic lupus erythematosus. Scand. J. Immunol. 6^
P575-581.
Morimoto C., Reinherz E.L., Abe T., Homma M. & Schlossman S.F.
(1980a) Characteristics of anti-T cell antibodies in systemic lupus
erythematosus: Evidence for selective reactivity with normal
suppressor cells defined by monoclonal antibodies. Clin. Immunol.
Immunopathol. _1_6 p474-484.
Morimoto C., Reinhertz E.L., Schlossman S.F., Schur P.H., Mills J.A.
& Steinberg A.D. (1980b) Alterations in immunoregulatory T cell
subsets in active systemic lupus erythematosus. J. Clin. Invest. 66
p1171-1174.
-381-
Morimoto C., Reinherz E.L., Borel Y., Mantzouranis E., Steinberg A.D.
& Schlossman S.F. (1981) Autoantibody to an immunoregulatory
inducer population in patients with juvenile rheumatoid arthritis. J.
Clin. Invest. 6j_ P753-761.
Morse W.I., Cochrane W.A. & Landrigan P.L. (1961) Familial
hypoparathyroidism with pernicious anaemia, steatorrhoea and
adrenocortical insufficiency. A variant of mucoviscidosis. New
England J. Med. 26^ p1021.
Mota N.G.S., Kiy Y., Rezkallah-Iwasso M.T. & Peracoli M.T.S. (1980)
Humoral and cell-mediated immunity in large non-toxic multinodular
goitre. Clin. Endocrinol. 13 p173-180.
Mueller G.H., Kirk R.W. & Scott D.W. (1983) Cutaneous
endocrinology. In "Small animal dermatology" W.B. Saunders.
Philadelphia. p548.
Mukhtar E.D., Smith B.R., Pyle G.A., Hall R. & Vice P. (1975)
Relation of thyroid-stimulating immunoglobulins to thyroid function
and effects of surgery, radioiodine and antithyroid drugs. Lancet
1 p713-715.
Mulaisho C., Abdou N.I. & Utiger R.D. (1975) Lack of T cell immune
abnormalities in peripheral blood in patients with Graves' disease or
hypothyroidism. J. Clin. Endocrinol. Metab. p266-270.
Muller G.H., Kirk R.W. & Scott D.W. (1983) In "Small animal
dermatology" Third edition W.B. Saunders. Philadelphia.
Nair M.P.N. & Schwartz S.A. (1981) Suppression of natural killer
activity and antibody-dependent cellular cytotoxicity by cultured
human lymphocytes. J. Immunol. 126 p2221-2229.
Nakoo Y., Kishihara M., Baba Y., Kuma K., Fukunushi T. & Imura K.
( 1978) HLA antigens in autoimmune diseases. Arch. Int. Med. 138
P567-570.
Nelson J.C. & Palmer E.J. (1975) A remission of goitrous
hypothyroidism during pregnancy. J. Clin. Endocrinol. Metab. 4_0
P383-386
Neville M.E. & Lischner H.W. (1981) Activation of Fc receptor
bearing lymphocytes by immune complexes: II. Killer lymphocytes
mediate Fc ligand induced lymphokine production. J. Exp. Med. 154
P1868-1876.
Neufeld M. , Blizzard R.M. & McLaren N. ( 1979) Two types of
autoimmune Addison's disease. Clin. Res. 27 812A.
Newsom-Davis J., Pinching A.J., Vincent A. & Wilson S.G. (1978)
Function of circulating antibody to acetylcholine receptor in
myasthenia gravis investigated by plasma exchange. Neurology 28
P266-272.
-382-
Newsom-Davies J., Vincent A. & Willcox N. (1982) Acetylcholine
receptor antibody: Clinical and experimental aspects. In
"Receptors, Antibodies and Disease". Ciba Foundation Symposium 90.
Pitman. p225-247.
Neylan D. & Smyth P.P.A. (1982) Dose-response relationships in a
cytochemical section bioassay for thyroid stimulators. Clin.
Endocrinol. p479-487.
Nofal M.M., Beierwaltes W.H. & Patno M.E. (1966) Treatment of
hyperthyroidism with sodium iodide 1*131. j. American Med Assoc. 197
P605-610.
Nydegger U.E., Lambert P.H., Gerber H. & Miescher P.A. (1974)
Circulating immune complexes in the serum in systemic lupus
erythematosus and in carriers of hepatitis B antigen. J. Clin.
Invest. 54 p297-309.
O'Brien S.E. & Riley J.H. (1980) Unilateral thyroid neoplasm in a
cat. Veterinary Record 107 p199-200.
O'Donnel J., Trokoudes K., Silverberg J., Row V. & Volpe R. (1978)
Throtropin displacement activity of serum immunoglobulins from
patients with Graves' disease. J. Clin Endocrinol Metab. 4j5
P770-777.
O'Gorman P., Stafforth J.S. & Ballantyne M.R. (1964) Antibody
response to thyroid irradiation. J. Clin. Endocrinol. 2_4
P1072-1075.
Okabe N., Inoue R. & Mori R. (1983) Analysis of peripheral T
lymphocyte subpopulations in Graves' disease. J. Clin. Lab.
Immunol. JJ) p91-95.
Okayasu I., Kong Y.M., Rose N.R. & David C.S. (1980) Induction of
tolerance in experimental autoimmune thyroiditis with soluble mouse
thyroglobulin. Feder. Proc. 3£ p667-668.
Okita N., Topliss D., Lewis M., Row V.V. & Volpe R. (1981a)
T-lymphocyte sensitization in Graves' and Hashimoto's diseases
confirmed by an indirect migration inhibition factor test. J. Clin.
Endocrinol. Metab. 5£ P523-527.
Okita N., Row V.V. & Volpe R. (1981b) Suppressor T-lymphocyte
deficiency in Graves' disease and Hashimoto's thyroiditis J. Clin.
Endocrinol. Metab. 52 p528-533-
Olczak S., McCulloch A.J. & Clark F. (1978) Thyrotoxic Graves'
disease after primary hypothyroidism. Brit. Med. J. 3. p666.
Oldstone M.B.A., Tishon A. & Buchmeier M.J. ( 1 983) Virus-induced
immune complex disease: genetic control of C1q binding complexes in
the circulation of mice persistently infected with lymphocytic
chriomeningitis virus. J. Immunol. 130 P912-918.
Openheim J.J. & Gery I. (1982) Interleukin I is more than an
interleukin. Immunology Today 3. p113—119-
-383-
Orgiazzi J., Williams D.E., Chopra I.J. & Solomon D.H. (1976) Human
thyroid adenyl cyclase stimulating activity in immunoglobulin G of
patients with Graves' disease. J. Clin. Endocrinol. Metab 4_2
P341-353.
Ozawa Y. , Maciel R.M., Chupra I.J. Solomon D.H. & Beal G.N. (1979)
Relationships among immunoglobulin markers in Graves' disease. J.
Clin. Endocrinol. Metab. 4f3 p381-387.
Pacini F., Sridama V., Pressendo J., De Groot L.J. & Medof M.E.
(1983) Binding of immunoglobulin G from patients with thyroid
autoimmune disease to normal T lymphocytes. Clin Endocrinol. J_8
P29-37.
Parker C.W. (1981) Autoantibodies and beta adrenergic receptors.
New England J. Med. 305 p1212-1213.
Patrick J. & Lindstrom J. (1973) Autoimmune response to
acetylcholine receptor. Science 180 p871-872.
Payne R. (1957) Leukocyte agglutinins in human sera. Arch. Int.
Med. 99 P587-606.
Penhale W.J., Farmer A., McKenna R.P. & Irvine W.J. (1973)
Spontaneous thyroiditis in thymectomised and irradiated Wistar rats.
Clin. Exp. Immunol. J_5 p225-231 .
Penhale W.J., Farmer A. & Irvine W.J. (1975) Thyroiditis in T
cell-depleted rats. Influence of strain, radiation dose, adjuvants
and antilymphocyte serum. Clin. Exp Immunol. T\_ p362-375.
Penhale W.J., Irvine W.J., Inglis J.R. & Farmer A. (1976) Thyroiditis
in T cell-depleted rats: Suppression of the autoallergic response by
reconstitutiion with normal lymphoid cells. Clin. Exp. Immunol. 25
P6-16.
Penner E., Albini B., Glurich I., Andres G.A. & Milgrom F. (1982)
Dissociation of immune complexes in tissue sections by excess of
antigen. Int. Archs. Allergy Appl. Immunol. 67. p245-253.
Pequegnat E.P., Mayberry W.E., McConahey W.M. & Wyse E.P. (1967)
Large doses of radioiodine in Graves' disease. Effect on
ophthalmopathy and Long-Acting Thyroid Stimulator. Mayo Clin.
Proc. 42 p802-8l 1 .
Petersen V., Rees-Smith B. & Hall R. (1975) A study of thyroid
stimulating activity in human serum with the highly sensitive
cytochemical bioassay. J. Clin. Endocrinol. Metab. 4_1^ p199-202.
Peterson M.E., Johnson G.F. & Anderson L. K. ( 1979) Spontaneous
hyperthyroidism in the cat. American College of Veterinary Internal
Medicine Procs. 1979, p108, Abstr. 61.
Peterson M.E., Becker D.V. & Hurley J.R. (1980) Feline
hyperthyroidism: Further definition. American College of Veterinary
Inernal Medicine Procs. 1980, p124, Abstr.
-384-
Peterson M.E. ( 1982) Propylthiouracil in the treatment of feline
hyperthyoidism. J. American Veterinary Association 179 p485-487.
Peterson M.E. & Becker D.V. (1983) Spontaneous hyperthyroidism in
the cat: An animal model for toxic nodular goitre. Procs. American
Thyroid Association 59th meeting.
Peterson M.E., Kintzer P.P., Cavanagh P.G., Fox P.R., Ferguson D.C.
& Johnson G.F. (1983) Feline hyperthyroidism: Pretreatment clinical
and laboratory evaluation of 131 cases. J. American Veterinary
Medical Association 183 p103—110.
Peterson M.E. & Becker D.V. (1984) Radionuclide imaging in 135
cats with hyperthyroidism. Veterinary Radiology 2!5 p23-25.
Peterson M.E., Hurvitz A.I., Leib M.S., Cavanagh P.G. & Button R.E.
(1984) Propylthiouracil-associated haemolytic anaemia,
thrombocytopenia and antinuclear antibody in cats with
hyperthyroidism. J. American Veterinary Medical Association 184
p806-808.
Phillips D.I.W., Barker D.J.P., Smith B.R., Didcote S. & Morgan D.
(1985) The geographical distribution of thyrotoxicosis according to
the presence or absence of TSH receptor antibodies. Clin.
Endocrinol. 23 p283-287.
Pimstone B., Joffe B., Pimstone N., Bonnici F. & Jackson W.P.U.
(1969) Clinical response to long-term propranolol therapy in
hyperthyroidism. S. African Med. J. j43 p1203-1205.
Pinchera A., Pinchera M.G. & Stanbury J.B. (1965) Thyrotropin and
Long-Acting Thyroid Stimulator assays in thyroid disease. J. Clin.
Endocrinol. 25 pl89-208.
Pinchera A., Liberti P., Martino E., Fenzi G.F., Grasso L., Rovis L.,
Baschieri L. & Doria G. (1969) Effects of antithyroid therapy on
the Long-Acting Thyroid Stimulator and antithyroglobulin antibodies.
J. Clin. Endocrinol. Metab. 29. p231-238.
Pincus S.H., Clegg D.O. & Ward J.R. ( 1985) Characterisation of T
cells bearing HLA-DR antigens in rheumatoid arthritis. Arthritis
Rheum. 2J3 p8-15.
Pirskanen R. (1976) Genetic associations between myasthenia gravis
and the HLA system. J. Neurol., Neurosurg. & Psychiatry 39 p23-33«
Ploth D.W., Fitz A., Schnetzler D., Seidenfeld J & Wilson C.B. (1978)
Thyroglobulin-anti-thyroglobulin immune complex glomerulonephritis
complicating radioiodine therapy. Clin. Immunol. Immunopathol. 9_
P327-332.
Poskitt J.R. & Poskitt P.K.F. (1985) Lack of association of
rheumatoid factor with either circulating immune complexes or tumour
burden in cancer patients. Cancer J55 p1507-1509.
Pozzilli P., Sensi M., Gorsuch A., Bottazzo G.F. & Cudworth A.G.
(1979) Evidence for raised K-cell levels in Type I diabetes.
Lancet 2 p173-175.
-385-
Pozzilli P., Sensi M. & Andreani D. (1981) A likely protective role
of serum factors on K cell activity in Type I diabetes.
Diabetologia 2J_ p317 (Abstr.).
Pozzilli P., Sensi M. & Andreani D. (1982) Inhibition of killer
cell cytotoxicity by carbimazole in vitro. J. Endocrinol. Invest. 5
pi 49-152.
Pozzilli P. & Andreani D. (1982) Increased killer cells in Graves'
disease. Hormone Metab. Research 14 p56.
Pujol-Borrell R., Hanafusa T., Chiovato L. & Bottazzo G.F. ( 1983)
Lectin-induced expression of DR antigen on human cultured follicular
thyroid cells. Nature 304 p71—73-
Rapoport B., Caplan R. & DeGroot L.J. (1973) Low-dose sodium iodide
131-1 therapy in Graves' disease. J. American Med. Assoc. 244
p1610-1613-
Reeback J.S., Silman A.J., Holborow E.J., Maini R.N. & Hay F.C.
(1985) Circulating immune complexes and rheumatoid arthritis: a
comparison of different assay methods and their early predictive
value for disease activity and outcome. Ann. Rheum. Dis. 44^ p79-82.
Rees A.J., Peters D.K., Compston D.A.S. & Batchelor J.R. (1978)
Strong association between HLA-DR2 and antibody-mediated
Goodpasture's syndrome. Lancet p967-968.
Rees Smith B. & Hall R. (1974) Thyroid-stimulating immunoglobulins
in Graves' disease. Lancet 2 p427-431.
Rees Smith B. & Hall R. (1981) Measurement of thyrotropin receptor
antibodies. Methods in Enzymology 7£ p405-420.
Rennie D.P., McGregor A.M., Keast D., Weetman A.P., Foord S., Diegez
C., Williams E.D. & Hall R. (1983) The influence of methimazole on
thyroglobulin-induced thyroiditis in the rat. Endocrinology 112
P326-330.
Reinherz E.L., Rubinstein A., Geha R.S., Strelkausus A.J., Rosen F.S.
& Schlossman S.F. (1979) Abnormalities of immunoregulatory T cells
in disorders of immune function. New England J. Med. 301 p10l8-1022
Reveno W.S. & Rosenbaum H. (1964) Observations on the use of
antithyroid drugs. Ann. Int. Med. j50 p982-989.
Ritchie A.W.S., Oswald I. & Micklem H.S. (1983) Circadian variation
of lymphocyte subpopulations: A study with monoclonal antibodies.
Brit. Med. J. 286 p1773- 1775.
Ritzman S.E. & Daniels J.C. (1982) Immune complexes:
Characteristics, clinical correlations and interpretive approaches in
the clinical laboratory. Clinical Chemistry 2f) p1259—1271 .
Rodey G.E., Luehrman L.K. & Thomas D.W. (1979) In vitro primary
immunization of human peripheral blood lymphocytes to KLH: Evidence
for HLA-D region restriction. J. Immunol. 123 p250-2254.
-386-
Roitt I.M & Doniach D. ( 1960) Thyroid autoimmunity. Brit. Med.
Bulletin jl6 p152-158.
Roitt I.M. & de Carvalho L.C. ( 1982) The immunological basis of
autoimmune disease. In "Receptors, Antibodies and Disease", Ciba
Foundation Symposium 90, Pitman, London. p22-34.
Rose Pleszczynski M. & Blanchard R. (1981) Abnormal suppressor cell
function in atopic dermatitis. J. Invest, dermatol. 76 p279-283.
Rose N.R., Kong Y.C.M., Okayasu I., Giraldo A.A., Beisel K. & Sundick
R.S. (1981) T cell regulation in autoimmune thyroiditis.
Immunol. Reviews 55_ p299—31 ^-
Rossen R.D., Brewer E.J., Person D.A., Templeton J.W. & Lidsky M.D.
(1977) Circulating immune complexes and antinuclear antibodies in
juvenile rheumatoid arthritis. Arth. Rheum. 20_ p 1485-1490.
Roudebush C.P., Hoye K.E. & DeGroot L.J. (1977) Compensated
low-dose 131-1 therapy of Graves' disease. Ann. Int. Med. 87.
P441-U43.
Sakane T. & Greene I. ( 1977) Human suppressor T cells induced by
concanavalin A: Suppressor T cells belong to distinctive T cell
subclasses. J. Immunol. 119 p1169—1178.
Samarut C.H. & Revillard J.P. (1979) Human T-lymphocyte receptors
for IgM: Control by IgG binding lymphocytes. Eur. J. Immunol. 9_
p4l5-420.
Sanker A.J., Sundick R.S. & Brown T.R. (1983) Analysis of the serum
concentrations and antigenic determinants of thyroglobulin in
chickens susceptible to autoimmune thyroiditis. J. Immunol. 131
P1252-1256.
Sasazuki T., Kohno Y., Iwanoto I. & Tanimura M. (1978) Association
between HLA haplotype and low responsiveness to tetanus toxoid in
man. Nature 272 P359-361.
Sasazuki T., Nishimura Y. , Muto M. & Ohta N. ( 1983) HLA-linked
genes controlling immune response and disease susceptibility.
Immunol. Rev. 70 p51-75.
Sauvezie B. , Miyaska N., Charron D. , Kielich C. , Loeb J., Daniels
T.E. & Talal N. (1982) An increase in peripheral blood la-positive
cells in Sjogren's syndrome correlates with a decrease in the
autologous mixed lymphocyte response. Clin. Exp. Immunol. 4j)
P50-58.
Schade R.O.K., Owen S.G., Smart G.A. & Hall R. (1960) The relation
of thyroid autoimmunity to round-celled infiltration of the thyroid
gland. J. Clin. Path. J_3 p499-501.
Schandene L., Vanden Steen F., Romasco F. & Wybran J. (1983) Active
T rosettes, human autologous T rosettes, 0KT8 and 0KT4 cells,
con-A induced suppressive activity and autoantibodies: Clinical
correlations. Clin. Immunol. Immunopathol. 28 p147—154.
-387-
Schernthaner G. , Ludwig H., Scleusener H., Finke R., Kotulla P. &
Mayr W.R. (1979) TSH receptor antibodies, HLA-B8, and thyroid
autoantibodies in patients with Graves' disease in therapeutically
induced euthyroidism. Experientia 35^ p1408—1413.
Schernthaner G., Schleusener H., Kotulla P., Finke R., Wenzel B. &
Mayr W.R. (1980) Prediction of relapse or long-term remission in
hyperthyroid Graves' disease. Lancet 2 p373-374.
Schleusener H., Finke R., Kotulla P., Wenzel K.W., Meinhold H. &
Roedler H.D. (1978) Determination of thyroid stimulating
immunoglobulins (TSI) during the course of Graves' disease. A
reliable indicator for remission and persistence of the disease. J.
Endocrinol. Invest. 2 p155-161.
Schleusener H., Schernthaner G. , Mayr W.R., Kotulla P., Bogner U. ,
Finke R., Meinhold H., Koppenhagen K. & Wenzel K.W. (1983) HLA-DR3
and HLA-DR5 associated thyrotoxicosis - two different types of toxic
diffuse goitre. J. Clin. Endocrinol. Metab. 56 P781-785.
Schneider J., Chin W., Friou G.J., Cooper S.M., Harding B., Hill R.L.
& Quismoro F.P. ( 1975) Reduced antibody-dependent cell-mediated
cytotoxicity in systemic lupus erythematosus. Clin. Exp. Immunol.
20 P187-192.
Scott D.W. (1981) J. American Animal Hospital Association 17
p83-86.
Seibold J.R., Rodman G.P., Medsger J.A. & Winkelstein A. (1982)
Circulating immune complexes in eosinophilic fasciitis. Arth.
Rheum. 25 p1180-1185.
Selby W.S., Janossy G., Mason D.Y. & Jewell D.P. (1983) Expression
of HLA-DR antigens by colonic epithelium in inflammatory bowel
disease. Clin. Exp. Immunol. 53. p614—618.
Seybold M. & Lindstrom J. (1981) Patterns of acetylcholine receptor
antibody fluctuation in myasthenia gravis. Ann. New York Acad.
Sciences 377 p292-306.
Shecter Y. , Maron R., Elias D. & Cohen I.R. (1982) Autoantibodies
to the insulin receptor spontaneously develop as anti-idiotypes in
mice immunized with insulin. Science 216 p542-546.
Shewring G.A. & Rees Smith B. ( 1982) An improved radioreceptor
assay for TSH receptor antibodies. Clin. Endocrinol. YJ_ p409-4l7.
Shinomiya N., Yata J. & Sasazuki T. (1984) T-cell subsets
regulating anti-acetylcholine receptor antibody formation in
myasthenia gravis and characterisation of suppressor T cell factors
involved. Clin. Immunol. Immunopathol. 33. p182-190.
Shinozawa T., Villadolid M.C. & Ingbar S.H. (1986a) Detection and
measurement of fat cell binding immunoglobulins: A new method
applicable to the diagnosis and study of Graves' disease. J. Clin.
Endocrinol. Metab. 632 p1-9.
-388-
Shinozawa T., Villadolid M.C. & Ingbar S.H. (1986b) A new
serum-based assay for fat cell binding immunoglobulins: Application
to the detection of the thyrotropin receptor antibodies of Graves'
disease. J. Clin. Endocrinol. Metab. 62 p10-15.
Shishiba Y., Solomon D.H. & Beall G.N. (1967) Comparison of early
effects of thyrotropin and long-acting thyroid stimulator on
thyroidal secretion. Endocrinology 8(1 P957-961 .
Shishiba Y., Solomon D.H. & Davison W.D. (1970) Comparison of the
effect of thyrotropin and long-acting thyroid stimulator on glucose
oxidation and endocytosis in canine thyroid slices. Endocrinology
86 p183—190.
Shishiba Y., Shimizu T., Yoshimura S. & Shizume K. (1972) Discrepancy
between inactivation by thyroid particulate fraction and thyroid
stimulating activity of long-acting thyroid stimulator. J. Clin.
Endocrinol. Metab. 3J+ p7-12.
Shishiba Y. , Shimizu T., Yoshimura S. & Shizume K. (1973) Direct
evidence for human thyroidal stimulation by LATS-Protector. J. Clin.
Endocrinol. Metab. 36_ p517-520.
Shishiba Y., Ozawa Y., Ohtsuki N. & Shimizu T. (1982) Discrepancy
between thyroid-stimulating and thyrotrophin binding inhibitory
activities of Graves' immunoglobulin Gs assessed in the mouse. J.
Clin. Endocrinol. Metab. 54_ p858-862.
Shou L., Schwartz S.A. & Good R.A. (1976) Suppressor cell activity
after concanavalin A treatment of lymphocytes from normal donors.
J. Exp. Med. 1+3 pi 100-1110.
Signore A., Pozzilli P., Di Mario U., Sensi M., Beales P. & Andreani
D. (1985) Inhibition of the receptor for interleukin-2 induced by
carbimazole:relevance for the therapy of autoimmune thyroid disease.
Clin. Exp. Immunol. 60 pi 11-116.
Siminovitch K. , Klein M. , Prusanski W. , Wilkinson S., Lee P., Yoon
S-J. & Keystone E. (1982) Circulating immune complexes in patients
with progressive systemic sclerosis. Arth. Rheum. 2J5 p 1174— 1179«
Skolnik P.R., Lisak R.P. & Zweiman B. (1982) Monclonal antibody
analysis of blood T cell subsets in myasthenia gravis. Ann. Neurol.
H p170-176.
Slater L.M., Murray S.L., Kershnar A. & Mosier M. ( 1980)
Immunological suppressor cell activity in insulin dependent diabetes
mellitus. J. Clin. Lab. Immunol. 3. p105-109.
Slaughter L.A., Carson D.A., Jensen F.C., Holbrook T.L. & Vaughan
J.H. In vitro effects of Epstein-Barr virus on peripheral blood
mononuclear cells from patients with rheumatoid arthritis and normal
subjects. J. Exp. Med. 1+8 P1429-1434.
Slingerland D.W., Hershman J.M., Dell E.S. & Burrows B.A. (1972)
Thyrotropin and PBI in radioiodine-treated hyperthyroid patients.
J. Clin. Endocrinol. 35^ p912—9 17-
-389-
Slingerland D.W. & Burrows B.A. (1979) Long-term antithyroid
treatment in hyperthyroidism. J. American Med. Assoc. 3_0
p2408-24l0.
Smeds S., Anderberg B., Boeryd B., Ericson L.E., Gillquist J. &
Persilden J. (1981) The nude mouse. A possible experimental model for
investigation of human thyroid tissue. J. Endocrinol. Invest. _4
p 11 — 16.
Smith B.R., Rickards C.R., Jones E.D., Kajita Y., Buckland P.R.,
Creagh F.M., Howells R.D., Hashim F., Parkes A.B. & Petersen V.B.
( 1985) The thyrotropin receptor and its role in Graves' disease.
J. Endocrinol. Invest. p175-l82.
Smith R.N. & Wilson G.M. (1967) Clinical trial of different doses
of 131-1 in treatment of thyrotoxicosis. Brit. Med. J. p129—132.
Smyth P.P.A., McMullen N.M., Grubeck-Loebenstein B., McKenna T.J. &
O'Donovan D.K. ( 1985) Immunologic stimulators in goitre. 4th
Joint Meeting of BES, J. Endocrinol. 104 p60 Abstr 87.
Smyth P.P.A., Neylan D. & O'Donovan D.K. ( 1 983) Association of
thryoid-stimulating immunoglobulins and thyrotropin-releasing hormone
responsiveness in women with euthyroid goitre. J. Clin. Endocrinol.
Metab. 57 p1001-1006.
Solomon D.H., Beck J.C., Vanderlaan W.P. & Astwood E.B. (1953)
Prognosis of hyperthyroidism treated by antithyroid drugs. J.
American Med. Assoc. 152 p201-205.
Solomon D.H., Chopra I.H., Chopra U. & Smith F.J. (1977)
Identification of subgroups of euthyroid Graves' ophthalmopathy.
New England J. Med. 296 p181 — 185-
Solomon N., Carpenter C.C.J., Bennett I.L. & Harvey A.M. (1965)
Schmidt's syndrome (thyroid and adrenal insufficiency) and coexistent
diabetes mellitus. Diabetes J_4 p300-304.
Southgate K., Creagh F., Teece M., Kingswood C. & Rees Smith B.
(1984) A receptor assay for the measurement of TSH receptor
antibodies in unextracted serum. Clin. Endocrinol. J_0 p539-543-
Sridama V., Pacini F. & DeGroot L.J. (1982) Decreased suppressor T-
lymphocytes in autoimmune thyroid diseases detected by monoclonal
antibodies. J. Clin. Endocrinol. Metab. 54 p316—319-
Steensgaard J. & Johansen A. (1980) Biochemical aspects of immune
complex formation and immune complex diseases. Allergy 35. p457-472.
Stenszky V., Balazs C.S., Kozma L., Rochlitz S.Z., Bear J.C. & Farid
N.R. (1983) Identification of subsets of Graves' disease by cluster
analysis. Clin. Endocrinol. 18 P335-345.
Strakosh C., Joyner D. & Wall J.R. (1978) Thyroid-stimulating
antibodies in patients with autoimmune thyroid disorders. J. Clin.
Endocrinol. Metab. 47 p361—365.
-390-
Strakosh C.R., Wenzel B.E., Row V.V. & Volpe R. (1982) Immunology
of autoimmune thyroid disease. New England J. Med. 307 p1499—1507-
Studer H., Hunziker H.R. & Ruchti C. (1978) Morphological and
functional substrate of thyrotoxicosis caused by nodular goitres.
Amer. J. Med. 65 p227-234.
Sugenoya A., Kidd A., Row V. & Volpe R. (1979) Correlation between
thyrotropin dispacing activity and human thyroid stimulating activity
by immunoglobulins from patients with Graves' disease and other
thyroid disorders. J. Clin. Endocrinol. Metab. 49. P398-402.
Sugrue D., McEvoy M., Feely J. Drury M.I. ( 1980) Hyperthyroidism in
the land of Graves'. Results of treatment by surgery, radio-iodine
and carbimazole in 837 cases. Quart. J. Med. 49. p51—61.
Sundick R.S. & Wick G. (1976) Increased iodine uptake by obese
strain thyroid glands transplanted to normal chick embryos. J.
Immunol. JM6 p 131 9-1323.
Sundick R.S., Bagchi N., Livezey M.D., Brown T.R. & Mack R.E. (1979)
Abnormal thyroid regulation in chickens with thyroiditis.
Endocrinology 105 p493-498.
Svejgaard A., Jersild C., Nielsen L.S. & Bodmer W.F. (1974) HLA
antigens and disease. Statistical and genetical considerations.
Tissue Antigens 4. p95-105.
Svejgaard A., Platz P. & Ryder L.P. (1983) HLA and disease 1982 - a
survey. Immunol. Rev. 70 p193-2l8.
Takeda Y. & Kriss J. (1977) Radiometric measurement of
thyroglobulin-anti-thyroglobulin immune complex in human sera. J.
Clin. Endocrinol. Metab. 44 p46—51.
Tamai H., Suematsu H., Ikemi Y., Kuma K., Matsuzuka F., Kumagai L.F.,
Shizume K. & Nagataki S. (1978) Responses to TRH and suppression
in euthyroid subjects with a family history of Graves' disease. J.
Clin. Endocrinol. Metab. 47 p475-479.
Tamai H., Nakagawa T., Fukino 0., Ohsako N., Shinzato H., Suematsu
H., Kumak , Matsuzuka F. & Nagataki S. (1980) Thionamide therapy
in Graves' disease: relation of relapse rate to duration of therapy.
Ann. Int. Med. 92 p488-490.
Teng C.S. & Yeung R.T.T. ( 1980) Changes in thyroid-stimulating
antibody activity in Graves' disease treated with antithyroid drug
and its relationship with relapse: a prospective study. J. Clin.
Endocrinol. Metab. 50 p144—147.
Teng C.S., Yeung R.T.T., Khoo R.K.K. & Alugaratnam T.T. (1980) A
prospective study of the changes in thyrotropin binding inhibitory
immunoglobulins in Graves' disease treated by subtotal thyroidectomy
or radioactive iodine. Clin. Endocrinol. 5(3 p 1005-1012.
Terasaki P.I. & McLelland J.D. (1964) Microdroplet assay of human
serum cytotoxins. Nature 204 p998-1000.
-391-
Theophilopoulos A.N. (1980) Evaluation and clinical significance of
circulating immune complexes. Progress in Clinical Immunology
p63-106.
Thielemans C., Vanhaelst L., de Waele M. , Jonckheer M. & van Camp B.
(1981) Autoimmune thyroiditis: A condition related to a decrease in
T-suppressor cells. Clin. Endocrinol. 15 p259-263.
Thoday K.L., Seth J. & Elton R. (1984) Radioimmunoassay of total
thyroxine and triiodothyronine in healthy cats: Assay methodology and
effects of age, sex, breed, heredity and environment. J. Small
Animal Practice 2!5 p457-472.
Thomsen M., Platz P., Christy M., Nerup J., Ryder L.P. & Svejgaard A.
(1979) HLA-D associated resistance and susceptibility to insulin
dependent diabetes mellitus. Transplant. Proc. V\_ p1307—1312.
Thorsby E., Svejgaard E., Solem J.H. & Kornstad L. (1975) The
frequency of major histocompatibility antigens (SD & LD) in
thyrotoxicosis. Tissue antigens J5 p54-55.
Thorsby E., Berle E. & Braathen L. (1983) Role of HLA-D region
molecules in T-cell activation by antigen. Transplant. Proc. J_5
p282-284.
Todd I., Pu jol-Borrell R., Hammond L. , Bottazzo G.F. & Feldmann M.
(1984) Interferon-gamma induces HLA-DR expression by thyroid
epithelium. Ann. Endocrinol. (Paris) 45 p39.
Toft A.D., Irvine W.J., Seth J., Hunter W.M. & Cameron E.H.D. (1975)
Thyroid function in the long-term follow-up of patients treated with
iodine-131 for thyrotoxicosis Lancet 2 p576-591.
Toft A.D., Irvine W.J., Sinclair I., Mcintosh D., Seth J. & Cameron
E.H.D. (1978) Thyroid function after surgical treatment of
thyrotoxicosis: a report of 100 cases terated with propranolol before
operation. New England J. Med. 298 p643-647.
Tomazic V. & Rose N.R. (1975) Autoimmune murine thyroiditis VII.
Induction of the thyroid lesions by passive transfer of immune serum.
Clin. Immunol. Immunopathol. 4^ p511 —516.
Topliss D., How J., Lewis M. & Row V. (1983) Evidence for cell
mediated immunity and specific suppressor T lymphocyte dysfunction in
Graves' disease and diabetes mellitus. J. Clin. Endocrinol. Metab.
57 P700-705.
Torok-Storb B., Nepom G.T., Nepom B.S. & Hanson J.A. (1983) HLA-DR
antigens on lymphoid cells differ from those on myeloid cells. Nature
305 P541-543.
Tosi R., Visraara D. , Tanigaki N. , Ferrara G.B., Cicimarra F.,
Buffolano W., Folio D. & Auricchio S. (1983) Evidence that coeliac
disease is primarily associated with a DC locus allelic specificity.
Clin. Immunol. Immunopathol. 28 p395-404.
Trotter W.R. (1961) Treatment of thyrotoxicosis. Proc. Roy. Soc.
Med. 54 p869-871 •
-392-
Tung K.S.K., De Horatius R.J. & Williams R.C. (1981) Study of
circulating immune complex size in systemic lupus erythematosus.
Clin. Exp. Immunol. 43. p615-625.
Turner-Warwick M. & Haslam P.L. Smooth muscle antibody in bronchial
asthma. Clin. Exp. Immunol. 7 P31-38.
Urbaniak S.J., Penhale W.J. & Irvine W.J. (1974) Peripheral blood T
and B lymphocytes in patients with thyrotoxicosis and Hashimoto's
thyroiditis and in normal subjects. A comparison of lymphocyte
separation methods. Clin. Exp. Immunol. J_8 p449-459-
Valente W.A., Vitti P., Rotella C.M., Vaughan M.M., Alaj S.M.,
Grollman E.F., Abesi-Impiombato F.S. & Kohn L.D. (1983)
Growth-promoting antibodies in autoimmune thyroid disease: a
distinct population of thyroid-stimulating antibodies. New Engl. J.
Med. 304 p1028-1034.
Van Berkhout F.T., Croughs R.J.M., Kater L. , Schuurman H.J., Meyling
F.J.H.G., Kooyman C.D., van der Gaag R.D., Jolink D. & Drexhage H.A.
( 1986) Familial Cushing's syndrome due to nodular adrenocortical
hyperplasia: A putative receptor antibody disease. Clin.
Endocrinol. 24_ p299-310.
VanderLaan W.P. (1957) Results of administration of desiccated
thyroid to subjects in remission from hyperthyroidism after treatment
with antithyroid drugs. New England J. Med. 256 p511-513-
Van der Heide D., Bolk J.H., de Bruin T.W.A., van Es L.A., Daha M.R.,
Bussemaker J.K., Goslings B.M. & Querido A. ( 1980) Circulating
immune complexes and thyroid-stimulating immunoglobulins before,
during and after antithyroid drug therapy in patients with Graves'
disease. Lancet p 1376—1380.
Van Herle A.J., Uller R.P., Matthews N.L. & Brown J. (1973)
Radioimmunoassay for measurement of thyroglobulin in human serum.
J. Clin. Invest. 52 p1320-1327-
Van Heyningen V., Guy K., Newman R. & Steel C.M. (1982) Human MHC
class II molecules as differentiation markers. Immunogenetics 16
p459_465.
van Welsum M., Feltkamp T.E.W., de Vries M.J., Docter R., van Zijl J.
& Henneman G. (1974) Hypothyroidism after thyroidectomy for
Graves' disease: a search for an explanation. Brit. Med. J.
P755-756.
Venter J.C., Fraser C.M. & Harrison L.C. (1980) Autoantibodies to
beta2-adrenergic receptors: a possible cause of beta-adrenergic
hyporesponsiveness in allergic rhinitis and asthma. Science 207
P1361-1363.
Vickerman C.E. (1979) Soluble immune complex disease associated
with antigen heterogeneity: an HLA-related disorder. Medical
Hypotheses 5 p635-640.
-393-
Vitti P., Rotella C.M., Valente W.A., Cohen J., Aloj S.M., Laccetti
P. Ambesi-Impiombato F.S., Grollman E.F., Pinchera A., Toccafondi R.
& Kohn L.D. ( 1983) Characterization of the optimal stimulatory
effects of Graves' monoclonal and serum immunoglobulin G on Adenosine
3'5 monophosphate production in FRTL-5 thyroid cells: a potential
clinical assay. J. Clin. Endocrinol. Metab 57_ p782-789
Vladutiu A.O. & Rose N.R. (1971) Autoimmune murine thyroiditis:
Relation to histocompatibility (H-2) type. Science 174 p1137— 1139.
Vladutiu A.O. & Rose N.R. (1975) Cellular basis of the genetic
control of immune responsiveness to murine thyroglobulin in mice.
Cellular Immunol. V7 p106—113-
Vladutiu A.O. (1982) Autoimmune thyroiditis: Conversion of low
responder mice to high responder by cyclophosphamide. Clin. Exp.
Immunol. 47 p683-689.
Volpe R., Desbarats-Schonbaum M-L, Schonbaum E., Row V.V. & Ezrin C.
(1969) The effect of radioablation of the thyroid gland in Graves'
disease with high levels of Long-Acting Thyroid Stimulator. American
J. Med. 46 p217-225.
Volpe R., Edmonds M. , Lamki L., Clark P.V. & Row V.V. (1972) The
pathogenesis of Graves' disease. A disorder of delayed
hypersensitivity? Mayo Clin. Proc. 47. p824-834.
Volpe R., Farid N.R., von Westarp C. & Row V.V. ( 1974) The
pathogenesis of Graves' disease and Hashimoto's thyroiditis. Clin.
Endocrinol. 3,p239-26l.
Wall J.R., Gray B. & Greenwood D.M. (1977) Total and "activated"
peripheral blood T lymphocytes in patients with thyroid disorders.
Acta Endocrinol. 85_ p753-759.
Wall J.R. & Chartier B. (1981) Blood mononuclear cells with
suppressor activity in patients with thyroid disorders: Increased
levels of T-gamma cells in subacute thyroiditis. J. Clin. Lab.
Immunol. §_ p 115—119-
Wall J.R., Baur R., Schleusener H. & Bandy-Dafoe P. (1983)
Peripheral blood and intrathyroidal mononuclear cell populations in
patients with autoimmune thyroid disorders enumerated using
monoclonal antibodies. J. Clin. Lab. Immunol. 56 p164—169.
Wasserman N.H., Penn A.S., Freimuth P.I., Treptow N., Wentzel S.,
Cleveland W.L. & Erlanger B.F. (1982) Anti-idiotypic route to
anti-acetylcholine receptor antibodies and experimental myasthenia
gravis. Proc. Nat. Acad. Sciences 79. p48l0-4814.
Weetman A.P., Gunn C.A., Rennie D.P., Hall R. & McGregor A.M. (1985a)
The production and characterisation of monoclonal antibodies to the
human thyroid microsome. J. Endocrinol. 105 p47-52.
Weetman A.P., Volkman D.J., Burman K.D., Gerrard T.L. & Fauci A.S.
(1985b) The in vitro regulation of human thyrocyte HLA-DR antigen
expression. J. Clin. Endocrinol. Metab. 6j_ p8l7-824.
-394-
Weissel M. , Hofer R., Zasmet A.H. & Mayr W.R. (1980) HLA-DR and
Hashimoto's thyroiditis. Tissue Antigens J_6 p256-257.
Werner S.C., Wegelius 0., Fierer J.A. & Hsu K.C. (1972)
Immunoglobulins and complement in the connective tissues of the
thyroid in Graves' disease. New England J. Med. 287 p421-425.
Whittingham S., Morris P.J. & Martin F.I.R. (1975) HLA-8: A genetic
link with thyrotoxicosis. Tissue Antigens J5 p23-27.
Williams D., Block M. & Hershman J. (1974) Graves' hyperthyroidism
following myxoedema in a patient with recurrent carcinoma of the
colon. Clin. Res. 22 169A.
Willcox H.N.A., Newsom-Davis J. & Calder L.R. (1984) Cell types
required for anti-acetylcholine receptor antibody synthesis by
cultured thymocytes and blood lymphocytes in myasthenia gravis.
Clin. Exp. Immunol. 5f) p97-106.
Williams R.C. (1981) Immune complexes in human diseases. Ann.
Rev. Med. 32 p13-28.
Witebsky E., Rose N.R., Terplan K. , Paine J.R. & Egan R.W. (1957)
Chronic thyroiditis and autoimmunization. J. American Med. Assoc.
164 p1439-1446.
Wuepper K.D. (1969) Immunological aspects of adrenocortical
insufficiency. American J. Med. 4j5 p206-2l6.
Yamamoto T. & Sakamoto H. (1978) Spontaneous remission from primary
hypothyroidism. Ann. Int. Med. 88^ p808-809-
Yonemasu K. & Stroud R.M. (1971) C1q: Rapid purification method for
preparation of monospecific antisera and for biochemical studies.
J. Immunol. 106 P304-313.
Young E.T., Kendall-Taylor P., Steel N., Stephenson A. & Stratton A.
(1985) HLA typing and Graves' disease. Endocrinol. 104 [suppl.]
p82.
Yu D.T.Y., Winchester R.J., Fu S.M., Gibefsky A., Ko H.S. & Kunkel
H.G. (1980a) Peripheral blood la positive cells. Increased in
certain diseases and after immunzation. J. Exp. Med. 151 p91-100.
Yu D.T.Y., McClune J.M., Fu S.M., Winchester R.J. & Kunkel H.G.
(1980b) Two types of la positive T cells: synthesis and exchange of
la antigens. J. Exp. med. 152 p895-
Zimmerman R., Ozer H., De Wolf W.C., Evans R.L., Yunis E.J. &
Schlossman S.F. (1979) The detection of la-like and Drw antigens on
activated T cells. Transplant. Proc. J_1_ p 1770-1773-
Zubler R.H., Lange G., Lambert P.H. & Miescher P.A. ( 1976)
Detection of immune complexes in unheated sera by a modified 125i_dq
binding test. J. Immunol. 116 p232-235.
-395-
SUPPLEMENTARY REFERENCES
Wilkin T.J., Su/anson Beck J., Gunn A., A1 Mossah M., Isles T.E. & Crooks J.
(1980) Autoantibodies in thyrotoxicosis: a quantitative study of their
behaviour in relation to the course and outcome of treatment. J. Endocrin.
Invest. 2 p5-14.
Wise P.H., Marion M. & Pain R.W. (1973) Single-dose, "block-replace"
drug therapy in hyperthyroidism. Brit. Med. J. 4 pl43-145.
Wise P.H., Marion M. & Pain R.W. (1979) Mode of action of carbimazole
in Graves' disease. Clin. Endocrino], _10 p655-664.
Zakarija M., McKenzie J.M. & Banovac K. (1980) Clinical significance of
thyroid stimulating antibody in Graves' disease. Ann. Int. Med. 93
p28-32.
